bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
adenosine deaminase is a Gene/protein/RNA, CD26 is a Individual_protein	678_task0	Sentence: The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein	[ "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.	[ "The", "adenosine", "deaminase", "-", "binding", "region", "is", "distinct", "from", "major", "anti", "-", "CD26", "mAb", "epitopes", "on", "the", "human", "dipeptidyl", "peptidase", "IV(CD26", ")", "molecule", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
adenosine deaminase is a Gene/protein/RNA, CD26 is a Individual_protein	678_task1	Sentence: The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. Instructions: please typing these entity words according to sentence: adenosine deaminase, CD26 Options: Gene/protein/RNA, Individual_protein	[ "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.	[ "The", "adenosine", "deaminase", "-", "binding", "region", "is", "distinct", "from", "major", "anti", "-", "CD26", "mAb", "epitopes", "on", "the", "human", "dipeptidyl", "peptidase", "IV(CD26", ")", "molecule", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
adenosine deaminase, CD26	678_task2	Sentence: The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. Instructions: please extract entity words from the input sentence	[ "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.	[ "The", "adenosine", "deaminase", "-", "binding", "region", "is", "distinct", "from", "major", "anti", "-", "CD26", "mAb", "epitopes", "on", "the", "human", "dipeptidyl", "peptidase", "IV(CD26", ")", "molecule", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
sequence - specific HMG box is a DNA_domain_or_region, lymphocyte transcriptional activator is a protein_family_or_group, Sox-4 is a protein_molecule	100643_task0	Sentence: Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, protein_family_or_group, protein_molecule	[ "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O" ]	Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4.	[ "Solution", "structure", "of", "the", "sequence", "-", "specific", "HMG", "box", "of", "the", "lymphocyte", "transcriptional", "activator", "Sox-4", "." ]	[ "protein_family_or_group", "DNA_domain_or_region", "protein_domain_or_region", "other_name", "protein_substructure", "peptide", "protein_molecule", "(AND protein_substructure protein_substructure)", "DNA_family_or_group", "DNA_substructure", "polynucleotide", "" ]
sequence - specific HMG box is a DNA_domain_or_region, lymphocyte transcriptional activator is a protein_family_or_group, Sox-4 is a protein_molecule	100643_task1	Sentence: Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4. Instructions: please typing these entity words according to sentence: sequence - specific HMG box, lymphocyte transcriptional activator, Sox-4 Options: DNA_domain_or_region, protein_family_or_group, protein_molecule	[ "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O" ]	Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4.	[ "Solution", "structure", "of", "the", "sequence", "-", "specific", "HMG", "box", "of", "the", "lymphocyte", "transcriptional", "activator", "Sox-4", "." ]	[ "protein_family_or_group", "DNA_domain_or_region", "protein_domain_or_region", "other_name", "protein_substructure", "peptide", "protein_molecule", "(AND protein_substructure protein_substructure)", "DNA_family_or_group", "DNA_substructure", "polynucleotide", "" ]
sequence - specific HMG box, lymphocyte transcriptional activator, Sox-4	100643_task2	Sentence: Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O" ]	Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4.	[ "Solution", "structure", "of", "the", "sequence", "-", "specific", "HMG", "box", "of", "the", "lymphocyte", "transcriptional", "activator", "Sox-4", "." ]	[ "protein_family_or_group", "DNA_domain_or_region", "protein_domain_or_region", "other_name", "protein_substructure", "peptide", "protein_molecule", "(AND protein_substructure protein_substructure)", "DNA_family_or_group", "DNA_substructure", "polynucleotide", "" ]
R1306W is a ProteinMutation	825_task0	Sentence: A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ProteinMutation	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O" ]	A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.	[ "A", "first", "Taiwanese", "Chinese", "family", "of", "type", "2B", "von", "Willebrand", "disease", "with", "R1306W", "mutation", "." ]	[ "ProteinMutation" ]
R1306W is a ProteinMutation	825_task1	Sentence: A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation. Instructions: please typing these entity words according to sentence: R1306W Options: ProteinMutation	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O" ]	A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.	[ "A", "first", "Taiwanese", "Chinese", "family", "of", "type", "2B", "von", "Willebrand", "disease", "with", "R1306W", "mutation", "." ]	[ "ProteinMutation" ]
R1306W	825_task2	Sentence: A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O" ]	A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.	[ "A", "first", "Taiwanese", "Chinese", "family", "of", "type", "2B", "von", "Willebrand", "disease", "with", "R1306W", "mutation", "." ]	[ "ProteinMutation" ]
Streptococcus infantarius is a Microorganism, ability to ferment lactose is a Phenotype, CJ18 is a Microorganism	116_task0	Sentence: Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O" ]	Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42].	[ "Further", "study", "of", "the", "gene", "content", "of", "the", "two", "Western", "African", "Streptococcus", "infantarius", " ", "strains", "showed", "that", "these", "strains", "had", "acquired", "the", "ability", "to", "ferment", " ", "lactose", "through", "the", "LacZS", "system", ",", "as", "previously", "described", "for", "Eastern", " ", "African", "strain", "CJ18", "[", "42", "]", "." ]	[ "Phenotype", "Microorganism" ]
Streptococcus infantarius is a Microorganism, ability to ferment lactose is a Phenotype, CJ18 is a Microorganism	116_task1	Sentence: Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42]. Instructions: please typing these entity words according to sentence: Streptococcus infantarius, ability to ferment lactose, CJ18 Options: Microorganism, Phenotype	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O" ]	Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42].	[ "Further", "study", "of", "the", "gene", "content", "of", "the", "two", "Western", "African", "Streptococcus", "infantarius", " ", "strains", "showed", "that", "these", "strains", "had", "acquired", "the", "ability", "to", "ferment", " ", "lactose", "through", "the", "LacZS", "system", ",", "as", "previously", "described", "for", "Eastern", " ", "African", "strain", "CJ18", "[", "42", "]", "." ]	[ "Phenotype", "Microorganism" ]
Streptococcus infantarius, ability to ferment lactose, CJ18	116_task2	Sentence: Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42]. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O" ]	Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42].	[ "Further", "study", "of", "the", "gene", "content", "of", "the", "two", "Western", "African", "Streptococcus", "infantarius", " ", "strains", "showed", "that", "these", "strains", "had", "acquired", "the", "ability", "to", "ferment", " ", "lactose", "through", "the", "LacZS", "system", ",", "as", "previously", "described", "for", "Eastern", " ", "African", "strain", "CJ18", "[", "42", "]", "." ]	[ "Phenotype", "Microorganism" ]
ages is a Person, 7 and 75 years is a Value, disability is a Condition, primary is a Qualifier, generalized or segmental is a Scope, dystonia is a Condition, optimal is a Qualifier, pharmacologic treatment is a Procedure, disease duration is a Measurement, at least 5 years is a Value	NCT01497639_inc_task0	Sentence: ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement	[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O" ]	ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years.	[ "ages", "of", "7", "and", "75", "years", "\n", "marked", "disability", "owing", "to", "primary", "generalized", "or", "segmental", "dystonia", ",", "despite", "optimal", "pharmacologic", "treatment", "\n", "disease", "duration", "of", "at", "least", "5", "years", ".", "\n" ]	[ "Scope", "Procedure", "Measurement", "Value", "Qualifier", "Condition", "Person" ]
ages is a Person, 7 and 75 years is a Value, disability is a Condition, primary is a Qualifier, generalized or segmental is a Scope, dystonia is a Condition, optimal is a Qualifier, pharmacologic treatment is a Procedure, disease duration is a Measurement, at least 5 years is a Value	NCT01497639_inc_task1	Sentence: ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years. Instructions: please typing these entity words according to sentence: ages, 7 and 75 years, disability, primary, generalized or segmental, dystonia, optimal, pharmacologic treatment, disease duration, at least 5 years Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement	[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O" ]	ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years.	[ "ages", "of", "7", "and", "75", "years", "\n", "marked", "disability", "owing", "to", "primary", "generalized", "or", "segmental", "dystonia", ",", "despite", "optimal", "pharmacologic", "treatment", "\n", "disease", "duration", "of", "at", "least", "5", "years", ".", "\n" ]	[ "Scope", "Procedure", "Measurement", "Value", "Qualifier", "Condition", "Person" ]
ages, 7 and 75 years, disability, primary, generalized or segmental, dystonia, optimal, pharmacologic treatment, disease duration, at least 5 years	NCT01497639_inc_task2	Sentence: ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years. Instructions: please extract entity words from the input sentence	[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O" ]	ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years.	[ "ages", "of", "7", "and", "75", "years", "\n", "marked", "disability", "owing", "to", "primary", "generalized", "or", "segmental", "dystonia", ",", "despite", "optimal", "pharmacologic", "treatment", "\n", "disease", "duration", "of", "at", "least", "5", "years", ".", "\n" ]	[ "Scope", "Procedure", "Measurement", "Value", "Qualifier", "Condition", "Person" ]
epileptology is an umlsterm, epilepsy is an umlsterm, surgery is an umlsterm, Classification is an umlsterm, Epileptic Seizures is an umlsterm, classification is an umlsterm, epileptic seizures is an umlsterm, seizure is an umlsterm, seizure is an umlsterm, classification is an umlsterm	DerNervenarzt.80690117.eng.abstr_task0	Sentence: Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed .	[ "Recent", "advances", "in", "epileptology", "and", "epilepsy", "surgery", "require", "revision", "of", "the", "currently", "used", "International", "Classification", "of", "Epileptic", "Seizures", ",", "which", "was", "published", "1981", ".", "We", "present", "a", "classification", "of", "epileptic", "seizures", "which", "is", "based", "purely", "on", "the", "clinical", "seizure", "semiology", ".", "The", "advantages", "of", "a", "semiological", "seizure", "classification", "are", "stressed", "." ]	[ "umlsterm" ]
epileptology is an umlsterm, epilepsy is an umlsterm, surgery is an umlsterm, Classification is an umlsterm, Epileptic Seizures is an umlsterm, classification is an umlsterm, epileptic seizures is an umlsterm, seizure is an umlsterm, seizure is an umlsterm, classification is an umlsterm	DerNervenarzt.80690117.eng.abstr_task1	Sentence: Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed . Instructions: please typing these entity words according to sentence: epileptology, epilepsy, surgery, Classification, Epileptic Seizures, classification, epileptic seizures, seizure, seizure, classification Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed .	[ "Recent", "advances", "in", "epileptology", "and", "epilepsy", "surgery", "require", "revision", "of", "the", "currently", "used", "International", "Classification", "of", "Epileptic", "Seizures", ",", "which", "was", "published", "1981", ".", "We", "present", "a", "classification", "of", "epileptic", "seizures", "which", "is", "based", "purely", "on", "the", "clinical", "seizure", "semiology", ".", "The", "advantages", "of", "a", "semiological", "seizure", "classification", "are", "stressed", "." ]	[ "umlsterm" ]
epileptology, epilepsy, surgery, Classification, Epileptic Seizures, classification, epileptic seizures, seizure, seizure, classification	DerNervenarzt.80690117.eng.abstr_task2	Sentence: Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed .	[ "Recent", "advances", "in", "epileptology", "and", "epilepsy", "surgery", "require", "revision", "of", "the", "currently", "used", "International", "Classification", "of", "Epileptic", "Seizures", ",", "which", "was", "published", "1981", ".", "We", "present", "a", "classification", "of", "epileptic", "seizures", "which", "is", "based", "purely", "on", "the", "clinical", "seizure", "semiology", ".", "The", "advantages", "of", "a", "semiological", "seizure", "classification", "are", "stressed", "." ]	[ "umlsterm" ]
Allergy is a Condition, porphyrins and analogues is a Scope, Photosensitivity is a Condition, Porphyria is a Condition, Allergic constitution is a Condition, Scar diathesis is a Condition	NCT03181984_exc_task0	Sentence: Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition	[ "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators	[ "Allergy", "to", "porphyrins", "and", "analogues", ";", "Photosensitivity", ";", "Porphyria", ";", "Allergic", "constitution", ";", "\n", "Scar", "diathesis", ";", "\n", "Pregnancy", "or", "unwilling", "to", "adopt", "reliable", "contraceptive", "measures", "during", "the", "month", "after", "drug", "application", ";", "\n", "Be", "judged", "not", "suitable", "to", "participate", "the", "study", "by", "the", "investigators", "\n" ]	[ "Scope", "Condition", "Drug" ]
Allergy is a Condition, porphyrins and analogues is a Scope, Photosensitivity is a Condition, Porphyria is a Condition, Allergic constitution is a Condition, Scar diathesis is a Condition	NCT03181984_exc_task1	Sentence: Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators Instructions: please typing these entity words according to sentence: Allergy, porphyrins and analogues, Photosensitivity, Porphyria, Allergic constitution, Scar diathesis Options: Scope, Condition	[ "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators	[ "Allergy", "to", "porphyrins", "and", "analogues", ";", "Photosensitivity", ";", "Porphyria", ";", "Allergic", "constitution", ";", "\n", "Scar", "diathesis", ";", "\n", "Pregnancy", "or", "unwilling", "to", "adopt", "reliable", "contraceptive", "measures", "during", "the", "month", "after", "drug", "application", ";", "\n", "Be", "judged", "not", "suitable", "to", "participate", "the", "study", "by", "the", "investigators", "\n" ]	[ "Scope", "Condition", "Drug" ]
Allergy, porphyrins and analogues, Photosensitivity, Porphyria, Allergic constitution, Scar diathesis	NCT03181984_exc_task2	Sentence: Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators Instructions: please extract entity words from the input sentence	[ "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators	[ "Allergy", "to", "porphyrins", "and", "analogues", ";", "Photosensitivity", ";", "Porphyria", ";", "Allergic", "constitution", ";", "\n", "Scar", "diathesis", ";", "\n", "Pregnancy", "or", "unwilling", "to", "adopt", "reliable", "contraceptive", "measures", "during", "the", "month", "after", "drug", "application", ";", "\n", "Be", "judged", "not", "suitable", "to", "participate", "the", "study", "by", "the", "investigators", "\n" ]	[ "Scope", "Condition", "Drug" ]
interleukin-5 is a Protein, interleukin-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-2 receptor is a Entity, IL-2R is a Entity, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, gene segment is a Entity, 5 ' upstream is a Entity, activation - inducible enhancer elements is a Entity, AP-1 is a Entity, NF - kappaB is a Entity, NF - kappaB is a Entity, IL-2 is a Protein, IL-5 is a Protein, CD4 is a Protein, IL-5 is a Protein	510_task0	Sentence: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis.	[ "Two", "distinct", "pathways", "of", "interleukin-5", "synthesis", "in", "allergen", "-", "specific", "human", "T", "-", "cell", "clones", "are", "suppressed", "by", "glucocorticoids", ".", "\n", "Glucocorticoids", "(", "GC", ")", "have", "long", "been", "used", "as", "the", "most", "effective", "agents", "for", "the", "treatment", "of", "allergic", "diseases", "accompanied", "by", "eosinophilia", "such", "as", "chronic", "asthma", "and", "atopic", "dermatitis", ".", "The", "development", "of", "chronic", "eosinophilic", "inflammation", "is", "dependent", "on", "interleukin-5", "(", "IL-5", ")", ",", "a", "selective", "eosinophil", "-", "activating", "factor", ",", "produced", "by", "helper", "T", "cells", ".", "To", "delineate", "the", "regulatory", "mechanisms", "of", "human", "IL-5", "synthesis", ",", "we", "established", "allergen", "-", "specific", "CD4", "+", "T", "-", "cell", "clones", "from", "asthmatic", "patients", ".", "GC", "efficiently", "suppressed", "IL-5", "synthesis", "of", "T", "-", "cell", "clones", "activated", "via", "either", "T", "-", "cell", "receptor", "(", "TCR", ")", "or", "IL-2", "receptor", "(", "IL-2R", ")", ".", "Induction", "of", "IL-5", "mRNA", "upon", "TCR", "and", "IL-2R", "stimulation", "was", "totally", "inhibited", "by", "dexamethasone", ".", "Human", "IL-5", "promoter", "/", "enhancer", "-", "luciferase", "gene", "construct", "transfected", "to", "T", "-", "cell", "clones", "was", "transcribed", "on", "either", "TCR", "or", "IL-2R", "stimulation", "and", "was", "clearly", "downregulated", "by", "dexamethasone", ",", "indicating", "that", "the", "approximately", "500-bp", "human", "IL-5", "gene", "segment", "located", "5", "'", "upstream", "of", "the", "coding", "region", "contains", "activation", "-", "inducible", "enhancer", "elements", "responsible", "for", "the", "regulation", "by", "GC", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "suggested", "that", "AP-1", "and", "NF", "-", "kappaB", "are", "among", "the", "possible", "targets", "of", "GC", "actions", "on", "TCR", "-", "stimulated", "T", "cells", ".", "NF", "-", "AT", "and", "NF", "-", "kappaB", "were", "not", "significantly", "induced", "by", "IL-2", "stimulation", ".", "Our", "results", "showing", "that", "GC", "suppressed", "IL-5", "production", "by", "human", "CD4", "+", "T", "cells", "activated", "by", "two", "distinct", "stimuli", ",", "TCR", "and", "IL-2R", "stimulation", ",", "underscore", "the", "efficacy", "of", "GC", "in", "the", "treatment", "of", "allergic", "diseases", "via", "suppression", "of", "T", "-", "cell", "IL-5", "synthesis", ".", "\n" ]	[ "Entity", "Protein" ]
interleukin-5 is a Protein, interleukin-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-2 receptor is a Entity, IL-2R is a Entity, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, gene segment is a Entity, 5 ' upstream is a Entity, activation - inducible enhancer elements is a Entity, AP-1 is a Entity, NF - kappaB is a Entity, NF - kappaB is a Entity, IL-2 is a Protein, IL-5 is a Protein, CD4 is a Protein, IL-5 is a Protein	510_task1	Sentence: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis. Instructions: please typing these entity words according to sentence: interleukin-5, interleukin-5, IL-5, IL-5, IL-5, IL-2 receptor, IL-2R, IL-5, IL-5, IL-5, gene segment, 5 ' upstream, activation - inducible enhancer elements, AP-1, NF - kappaB, NF - kappaB, IL-2, IL-5, CD4, IL-5 Options: Entity, Protein	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis.	[ "Two", "distinct", "pathways", "of", "interleukin-5", "synthesis", "in", "allergen", "-", "specific", "human", "T", "-", "cell", "clones", "are", "suppressed", "by", "glucocorticoids", ".", "\n", "Glucocorticoids", "(", "GC", ")", "have", "long", "been", "used", "as", "the", "most", "effective", "agents", "for", "the", "treatment", "of", "allergic", "diseases", "accompanied", "by", "eosinophilia", "such", "as", "chronic", "asthma", "and", "atopic", "dermatitis", ".", "The", "development", "of", "chronic", "eosinophilic", "inflammation", "is", "dependent", "on", "interleukin-5", "(", "IL-5", ")", ",", "a", "selective", "eosinophil", "-", "activating", "factor", ",", "produced", "by", "helper", "T", "cells", ".", "To", "delineate", "the", "regulatory", "mechanisms", "of", "human", "IL-5", "synthesis", ",", "we", "established", "allergen", "-", "specific", "CD4", "+", "T", "-", "cell", "clones", "from", "asthmatic", "patients", ".", "GC", "efficiently", "suppressed", "IL-5", "synthesis", "of", "T", "-", "cell", "clones", "activated", "via", "either", "T", "-", "cell", "receptor", "(", "TCR", ")", "or", "IL-2", "receptor", "(", "IL-2R", ")", ".", "Induction", "of", "IL-5", "mRNA", "upon", "TCR", "and", "IL-2R", "stimulation", "was", "totally", "inhibited", "by", "dexamethasone", ".", "Human", "IL-5", "promoter", "/", "enhancer", "-", "luciferase", "gene", "construct", "transfected", "to", "T", "-", "cell", "clones", "was", "transcribed", "on", "either", "TCR", "or", "IL-2R", "stimulation", "and", "was", "clearly", "downregulated", "by", "dexamethasone", ",", "indicating", "that", "the", "approximately", "500-bp", "human", "IL-5", "gene", "segment", "located", "5", "'", "upstream", "of", "the", "coding", "region", "contains", "activation", "-", "inducible", "enhancer", "elements", "responsible", "for", "the", "regulation", "by", "GC", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "suggested", "that", "AP-1", "and", "NF", "-", "kappaB", "are", "among", "the", "possible", "targets", "of", "GC", "actions", "on", "TCR", "-", "stimulated", "T", "cells", ".", "NF", "-", "AT", "and", "NF", "-", "kappaB", "were", "not", "significantly", "induced", "by", "IL-2", "stimulation", ".", "Our", "results", "showing", "that", "GC", "suppressed", "IL-5", "production", "by", "human", "CD4", "+", "T", "cells", "activated", "by", "two", "distinct", "stimuli", ",", "TCR", "and", "IL-2R", "stimulation", ",", "underscore", "the", "efficacy", "of", "GC", "in", "the", "treatment", "of", "allergic", "diseases", "via", "suppression", "of", "T", "-", "cell", "IL-5", "synthesis", ".", "\n" ]	[ "Entity", "Protein" ]
interleukin-5, interleukin-5, IL-5, IL-5, IL-5, IL-2 receptor, IL-2R, IL-5, IL-5, IL-5, gene segment, 5 ' upstream, activation - inducible enhancer elements, AP-1, NF - kappaB, NF - kappaB, IL-2, IL-5, CD4, IL-5	510_task2	Sentence: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]	Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis.	[ "Two", "distinct", "pathways", "of", "interleukin-5", "synthesis", "in", "allergen", "-", "specific", "human", "T", "-", "cell", "clones", "are", "suppressed", "by", "glucocorticoids", ".", "\n", "Glucocorticoids", "(", "GC", ")", "have", "long", "been", "used", "as", "the", "most", "effective", "agents", "for", "the", "treatment", "of", "allergic", "diseases", "accompanied", "by", "eosinophilia", "such", "as", "chronic", "asthma", "and", "atopic", "dermatitis", ".", "The", "development", "of", "chronic", "eosinophilic", "inflammation", "is", "dependent", "on", "interleukin-5", "(", "IL-5", ")", ",", "a", "selective", "eosinophil", "-", "activating", "factor", ",", "produced", "by", "helper", "T", "cells", ".", "To", "delineate", "the", "regulatory", "mechanisms", "of", "human", "IL-5", "synthesis", ",", "we", "established", "allergen", "-", "specific", "CD4", "+", "T", "-", "cell", "clones", "from", "asthmatic", "patients", ".", "GC", "efficiently", "suppressed", "IL-5", "synthesis", "of", "T", "-", "cell", "clones", "activated", "via", "either", "T", "-", "cell", "receptor", "(", "TCR", ")", "or", "IL-2", "receptor", "(", "IL-2R", ")", ".", "Induction", "of", "IL-5", "mRNA", "upon", "TCR", "and", "IL-2R", "stimulation", "was", "totally", "inhibited", "by", "dexamethasone", ".", "Human", "IL-5", "promoter", "/", "enhancer", "-", "luciferase", "gene", "construct", "transfected", "to", "T", "-", "cell", "clones", "was", "transcribed", "on", "either", "TCR", "or", "IL-2R", "stimulation", "and", "was", "clearly", "downregulated", "by", "dexamethasone", ",", "indicating", "that", "the", "approximately", "500-bp", "human", "IL-5", "gene", "segment", "located", "5", "'", "upstream", "of", "the", "coding", "region", "contains", "activation", "-", "inducible", "enhancer", "elements", "responsible", "for", "the", "regulation", "by", "GC", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "suggested", "that", "AP-1", "and", "NF", "-", "kappaB", "are", "among", "the", "possible", "targets", "of", "GC", "actions", "on", "TCR", "-", "stimulated", "T", "cells", ".", "NF", "-", "AT", "and", "NF", "-", "kappaB", "were", "not", "significantly", "induced", "by", "IL-2", "stimulation", ".", "Our", "results", "showing", "that", "GC", "suppressed", "IL-5", "production", "by", "human", "CD4", "+", "T", "cells", "activated", "by", "two", "distinct", "stimuli", ",", "TCR", "and", "IL-2R", "stimulation", ",", "underscore", "the", "efficacy", "of", "GC", "in", "the", "treatment", "of", "allergic", "diseases", "via", "suppression", "of", "T", "-", "cell", "IL-5", "synthesis", ".", "\n" ]	[ "Entity", "Protein" ]
neurologic is a Anatomical_system, brain is a Organ	PMID-8102531_task0	Sentence: Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Anatomical_system, Organ	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O" ]	Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored.	[ "Epilepsy", "in", "Down", "syndrome", ":", "clinical", "aspects", "and", "possible", "mechanisms", ".", "\n", "Although", "epilepsy", "is", "more", "common", "in", "persons", "with", "trisomy", "21", "(", "Down", "syndrome", ")", "than", "in", "the", "general", "population", ",", "the", "mechanisms", "by", "which", "seizures", "are", "generated", "in", "this", "population", "have", "received", "little", "attention", ".", "It", "is", "likely", "that", "this", "increased", "seizure", "susceptibility", "is", "due", "to", "a", "combination", "of", "medical", "risk", "factors", "and", "inherent", "neurologic", "abnormalities", "characteristic", "of", "Down", "syndrome", ".", "In", "this", "review", "clinical", "aspects", "of", "seizures", "among", "individuals", "with", "Down", "syndrome", "were", "described", "and", "possible", "mechanisms", "by", "which", "the", "trisomy", "21", "brain", "may", "generate", "seizures", "were", "explored", ".", "\n" ]	[ "Anatomical_system", "Organ" ]
neurologic is a Anatomical_system, brain is a Organ	PMID-8102531_task1	Sentence: Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored. Instructions: please typing these entity words according to sentence: neurologic, brain Options: Anatomical_system, Organ	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O" ]	Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored.	[ "Epilepsy", "in", "Down", "syndrome", ":", "clinical", "aspects", "and", "possible", "mechanisms", ".", "\n", "Although", "epilepsy", "is", "more", "common", "in", "persons", "with", "trisomy", "21", "(", "Down", "syndrome", ")", "than", "in", "the", "general", "population", ",", "the", "mechanisms", "by", "which", "seizures", "are", "generated", "in", "this", "population", "have", "received", "little", "attention", ".", "It", "is", "likely", "that", "this", "increased", "seizure", "susceptibility", "is", "due", "to", "a", "combination", "of", "medical", "risk", "factors", "and", "inherent", "neurologic", "abnormalities", "characteristic", "of", "Down", "syndrome", ".", "In", "this", "review", "clinical", "aspects", "of", "seizures", "among", "individuals", "with", "Down", "syndrome", "were", "described", "and", "possible", "mechanisms", "by", "which", "the", "trisomy", "21", "brain", "may", "generate", "seizures", "were", "explored", ".", "\n" ]	[ "Anatomical_system", "Organ" ]
neurologic, brain	PMID-8102531_task2	Sentence: Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O" ]	Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored.	[ "Epilepsy", "in", "Down", "syndrome", ":", "clinical", "aspects", "and", "possible", "mechanisms", ".", "\n", "Although", "epilepsy", "is", "more", "common", "in", "persons", "with", "trisomy", "21", "(", "Down", "syndrome", ")", "than", "in", "the", "general", "population", ",", "the", "mechanisms", "by", "which", "seizures", "are", "generated", "in", "this", "population", "have", "received", "little", "attention", ".", "It", "is", "likely", "that", "this", "increased", "seizure", "susceptibility", "is", "due", "to", "a", "combination", "of", "medical", "risk", "factors", "and", "inherent", "neurologic", "abnormalities", "characteristic", "of", "Down", "syndrome", ".", "In", "this", "review", "clinical", "aspects", "of", "seizures", "among", "individuals", "with", "Down", "syndrome", "were", "described", "and", "possible", "mechanisms", "by", "which", "the", "trisomy", "21", "brain", "may", "generate", "seizures", "were", "explored", ".", "\n" ]	[ "Anatomical_system", "Organ" ]
regulation of gene expression is a Relation_Trigger	4262_task0	Sentence: RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Relation_Trigger	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]	RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals.	[ "RNA", "editing", "by", "adenosine", "deamination", "is", "a", "posttranscriptional", "mechanism", "for", "the", "regulation", "of", "gene", "expression", "and", "is", "particularly", "widespread", "in", "mammals", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species" ]
regulation of gene expression is a Relation_Trigger	4262_task1	Sentence: RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals. Instructions: please typing these entity words according to sentence: regulation of gene expression Options: Relation_Trigger	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]	RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals.	[ "RNA", "editing", "by", "adenosine", "deamination", "is", "a", "posttranscriptional", "mechanism", "for", "the", "regulation", "of", "gene", "expression", "and", "is", "particularly", "widespread", "in", "mammals", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species" ]
regulation of gene expression	4262_task2	Sentence: RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]	RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals.	[ "RNA", "editing", "by", "adenosine", "deamination", "is", "a", "posttranscriptional", "mechanism", "for", "the", "regulation", "of", "gene", "expression", "and", "is", "particularly", "widespread", "in", "mammals", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species" ]
facial nerve palsy is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, patients is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, blood - peripheral is an umlsterm, nerve - barrier is an umlsterm, regeneration is an umlsterm, facial nerve is an umlsterm, palsy is an umlsterm	DerRadiologe.60360890.eng.abstr_task0	Sentence: In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]	In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy .	[ "In", "inflammatory", "peripheral", "facial", "nerve", "palsy", "pathologically", "intense", ",", "linear", "and", "smooth", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "always", "be", "observed", "on", "T1-w-", "SE-", "MR", "sequences", ".", "The", "other", "nerve", "segments", "often", "present", "with", "a", "pathological", "enhancement", "as", "well", ".", "On", "T2-w-", "SE", "sequences", ",", "a", "thickening", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "observed", ".", "The", "pathological", "enhancement", "persists", "over", "weeks", "and", "months", ";", "even", "in", "patients", "with", "complete", "clinical", "recovery", ",", "a", "persistent", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "demonstrated", ".", "No", "correlation", "can", "be", "established", "between", "the", "intensity", "of", "the", "enhancement", ",", "the", "clinical", "condition", "and", "the", "electrophysiological", "data", "on", "electroneurography", ".", "The", "persistent", "enhancement", "of", "the", "different", "nerve", "segments", "is", "due", "to", "a", "long", "-", "lasting", "breakdown", "of", "the", "blood", "-", "peripheral", "nerve", "-", "barrier", "related", "to", "the", "process", "of", "degeneration", "and", "regeneration", "of", "the", "facial", "nerve", "in", "inflammatory", "palsy", "." ]	[ "umlsterm" ]
facial nerve palsy is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, patients is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, blood - peripheral is an umlsterm, nerve - barrier is an umlsterm, regeneration is an umlsterm, facial nerve is an umlsterm, palsy is an umlsterm	DerRadiologe.60360890.eng.abstr_task1	Sentence: In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy . Instructions: please typing these entity words according to sentence: facial nerve palsy, nerve, nerve, nerve, patients, nerve, nerve, blood - peripheral, nerve - barrier, regeneration, facial nerve, palsy Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]	In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy .	[ "In", "inflammatory", "peripheral", "facial", "nerve", "palsy", "pathologically", "intense", ",", "linear", "and", "smooth", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "always", "be", "observed", "on", "T1-w-", "SE-", "MR", "sequences", ".", "The", "other", "nerve", "segments", "often", "present", "with", "a", "pathological", "enhancement", "as", "well", ".", "On", "T2-w-", "SE", "sequences", ",", "a", "thickening", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "observed", ".", "The", "pathological", "enhancement", "persists", "over", "weeks", "and", "months", ";", "even", "in", "patients", "with", "complete", "clinical", "recovery", ",", "a", "persistent", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "demonstrated", ".", "No", "correlation", "can", "be", "established", "between", "the", "intensity", "of", "the", "enhancement", ",", "the", "clinical", "condition", "and", "the", "electrophysiological", "data", "on", "electroneurography", ".", "The", "persistent", "enhancement", "of", "the", "different", "nerve", "segments", "is", "due", "to", "a", "long", "-", "lasting", "breakdown", "of", "the", "blood", "-", "peripheral", "nerve", "-", "barrier", "related", "to", "the", "process", "of", "degeneration", "and", "regeneration", "of", "the", "facial", "nerve", "in", "inflammatory", "palsy", "." ]	[ "umlsterm" ]
facial nerve palsy, nerve, nerve, nerve, patients, nerve, nerve, blood - peripheral, nerve - barrier, regeneration, facial nerve, palsy	DerRadiologe.60360890.eng.abstr_task2	Sentence: In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]	In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy .	[ "In", "inflammatory", "peripheral", "facial", "nerve", "palsy", "pathologically", "intense", ",", "linear", "and", "smooth", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "always", "be", "observed", "on", "T1-w-", "SE-", "MR", "sequences", ".", "The", "other", "nerve", "segments", "often", "present", "with", "a", "pathological", "enhancement", "as", "well", ".", "On", "T2-w-", "SE", "sequences", ",", "a", "thickening", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "observed", ".", "The", "pathological", "enhancement", "persists", "over", "weeks", "and", "months", ";", "even", "in", "patients", "with", "complete", "clinical", "recovery", ",", "a", "persistent", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "demonstrated", ".", "No", "correlation", "can", "be", "established", "between", "the", "intensity", "of", "the", "enhancement", ",", "the", "clinical", "condition", "and", "the", "electrophysiological", "data", "on", "electroneurography", ".", "The", "persistent", "enhancement", "of", "the", "different", "nerve", "segments", "is", "due", "to", "a", "long", "-", "lasting", "breakdown", "of", "the", "blood", "-", "peripheral", "nerve", "-", "barrier", "related", "to", "the", "process", "of", "degeneration", "and", "regeneration", "of", "the", "facial", "nerve", "in", "inflammatory", "palsy", "." ]	[ "umlsterm" ]
Progesterone receptor is a GENE-Y	17169175_task0	Sentence: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation.	[ "Progesterone", "receptor", "requires", "a", "co", "-", "chaperone", "for", "signalling", "in", "uterine", "biology", "and", "implantation", "." ]	[ "GENE-Y", "CHEMICAL" ]
Progesterone receptor is a GENE-Y	17169175_task1	Sentence: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Instructions: please typing these entity words according to sentence: Progesterone receptor Options: GENE-Y	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation.	[ "Progesterone", "receptor", "requires", "a", "co", "-", "chaperone", "for", "signalling", "in", "uterine", "biology", "and", "implantation", "." ]	[ "GENE-Y", "CHEMICAL" ]
Progesterone receptor	17169175_task2	Sentence: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation.	[ "Progesterone", "receptor", "requires", "a", "co", "-", "chaperone", "for", "signalling", "in", "uterine", "biology", "and", "implantation", "." ]	[ "GENE-Y", "CHEMICAL" ]
non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors is a Intervention_Pharmacological, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . is a Intervention_Pharmacological, 1397 is a Participant_Sample-size, antiretroviral - treatment - naive is a Participant_Condition, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; is a Intervention_Pharmacological, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; is a Intervention_Pharmacological, or a three - class strategy ( PI plus NNRTI plus NRTI ; is a Intervention_Pharmacological, AIDS - defining event is a Outcome_Physical, death is a Outcome_Mortality, CD4 cell count decline is a Outcome_Physical, change in CD4 cell count is a Outcome_Physical, composite endpoint is a Outcome_Other, 388 is a Participant_Sample-size, 302 is a Participant_Sample-size, 188 is a Participant_Sample-size, HRs is a Outcome_Other, AIDS or death is a Outcome_Mortality, virological failure is a Outcome_Physical, Mean change in CD4 cell count is a Outcome_Physical, HIV is a Participant_Condition, discontinue treatment is a Outcome_Other, toxic effects is a Outcome_Adverse-effects, NNRTI - based regimen is a Intervention_Pharmacological, PI - based regimen is a Intervention_Pharmacological	29145_task0	Sentence: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV .	[ "A", "comparison", "of", "three", "highly", "active", "antiretroviral", "treatment", "strategies", "consisting", "of", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitors", ",", "protease", "inhibitors", ",", "or", "both", "in", "the", "presence", "of", "nucleoside", "reverse", "transcriptase", "inhibitors", "as", "initial", "therapy", "(", "CPCRA", "058", "FIRST", "Study", ")", ":", "a", "long", "-", "term", "randomised", "trial", ".", "BACKGROUND", "Long", "-", "term", "data", "from", "randomised", "trials", "on", "the", "consequences", "of", "treatment", "with", "a", "protease", "inhibitor", "(", "PI", ")", ",", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", ",", "or", "both", "are", "lacking", ".", "Here", ",", "we", "report", "results", "from", "the", "FIRST", "trial", ",", "which", "compared", "initial", "treatment", "strategies", "for", "clinical", ",", "immunological", ",", "and", "virological", "outcomes", ".", "METHODS", "Between", "1999", "and", "2002", ",", "1397", "antiretroviral", "-", "treatment", "-", "naive", "patients", ",", "presenting", "at", "18", "clinical", "trial", "units", "with", "80", "research", "sites", "in", "the", "USA", ",", "were", "randomly", "assigned", "in", "a", "ratio", "of", "1:1:1", "to", "a", "protease", "inhibitor", "(", "PI", ")", "strategy", "(", "PI", "plus", "nucleoside", "reverse", "transcriptase", "inhibitor", "[", "NRTI", "]", ";", "n=470", ")", ",", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", "strategy", "(", "NNRTI", "plus", "NRTI", ";", "n=463", ")", ",", "or", "a", "three", "-", "class", "strategy", "(", "PI", "plus", "NNRTI", "plus", "NRTI", ";", "n=464", ")", ".", "Primary", "endpoints", "were", "a", "composite", "of", "an", "AIDS", "-", "defining", "event", ",", "death", ",", "or", "CD4", "cell", "count", "decline", "to", "less", "than", "200", "cells", "per", "mm3", "for", "the", "PI", "versus", "NNRTI", "comparison", ",", "and", "average", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "comparison", ".", "Analyses", "were", "by", "intention", "-", "to", "-", "treat", ".", "This", "study", "is", "registered", "ClinicalTrials.gov", ",", "number", "NCT00000922", ".", "FINDINGS", "1397", "patients", "were", "assessed", "for", "the", "composite", "endpoint", ".", "A", "total", "of", "388", "participants", "developed", "the", "composite", "endpoint", ",", "302", "developed", "AIDS", "or", "died", ",", "and", "188", "died", ".", "NNRTI", "versus", "PI", "hazard", "ratios", "(", "HRs", ")", "for", "the", "composite", "endpoint", ",", "for", "AIDS", "or", "death", ",", "for", "death", ",", "and", "for", "virological", "failure", "were", "1.02", "(", "95", "%", "CI", "0.79", "-", "1.31", ")", ",", "1.07", "(", "0.80", "-", "1.41", ")", ",", "0.95", "(", "0.66", "-", "1.37", ")", ",", "and", "0.66", "(", "0.56", "-", "0.78", ")", ",", "respectively", ".", "1196", "patients", "were", "assessed", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "primary", "endpoint", ".", "Mean", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "was", "+234", "cells", "per", "mm3", "and", "+227", "cells", "per", "mm3", "for", "the", "three", "-", "class", "and", "the", "combined", "two", "-", "class", "strategies", "(", "p=0.62", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "and", "virological", "failure", "were", "1.15", "(", "0.91", "-", "1.45", ")", "and", "0.87", "(", "0.75", "-", "1.00", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "were", "similar", "for", "participants", "with", "baseline", "CD4", "cell", "counts", "of", "200", "cells", "per", "mm3", "or", "less", "and", "of", "more", "than", "200", "cells", "per", "mm3", "(", "p=0.38", "for", "interaction", ")", ",", "and", "for", "participants", "with", "baseline", "HIV", "RNA", "concentrations", "less", "than", "100", "000", "copies", "per", "mL", "and", "100,000", "copies", "per", "mL", "or", "more", "(", "p=0.26", "for", "interaction", ")", ".", "Participants", "assigned", "the", "three", "-", "class", "strategy", "were", "significantly", "more", "likely", "to", "discontinue", "treatment", "because", "of", "toxic", "effects", "than", "were", "those", "assigned", "to", "the", "two", "-", "class", "strategies", "(", "HR", "1.58", ";", "p", "<", "0.0001", ")", ".", "INTERPRETATION", "Initial", "treatment", "with", "either", "an", "NNRTI", "-", "based", "regimen", "or", "a", "PI", "-", "based", "regimen", ",", "but", "not", "both", "together", ",", "is", "a", "good", "strategy", "for", "long", "-", "term", "antiretroviral", "management", "in", "treatment", "-", "naive", "patients", "with", "HIV", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Outcome_Mortality", "Outcome_Adverse-effects", "Participant_Sample-size" ]
non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors is a Intervention_Pharmacological, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . is a Intervention_Pharmacological, 1397 is a Participant_Sample-size, antiretroviral - treatment - naive is a Participant_Condition, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; is a Intervention_Pharmacological, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; is a Intervention_Pharmacological, or a three - class strategy ( PI plus NNRTI plus NRTI ; is a Intervention_Pharmacological, AIDS - defining event is a Outcome_Physical, death is a Outcome_Mortality, CD4 cell count decline is a Outcome_Physical, change in CD4 cell count is a Outcome_Physical, composite endpoint is a Outcome_Other, 388 is a Participant_Sample-size, 302 is a Participant_Sample-size, 188 is a Participant_Sample-size, HRs is a Outcome_Other, AIDS or death is a Outcome_Mortality, virological failure is a Outcome_Physical, Mean change in CD4 cell count is a Outcome_Physical, HIV is a Participant_Condition, discontinue treatment is a Outcome_Other, toxic effects is a Outcome_Adverse-effects, NNRTI - based regimen is a Intervention_Pharmacological, PI - based regimen is a Intervention_Pharmacological	29145_task1	Sentence: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV . Instructions: please typing these entity words according to sentence: non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking ., 1397, antiretroviral - treatment - naive, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ;, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ;, or a three - class strategy ( PI plus NNRTI plus NRTI ;, AIDS - defining event, death, CD4 cell count decline, change in CD4 cell count, composite endpoint, 388, 302, 188, HRs, AIDS or death, virological failure, Mean change in CD4 cell count, HIV, discontinue treatment, toxic effects, NNRTI - based regimen, PI - based regimen Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV .	[ "A", "comparison", "of", "three", "highly", "active", "antiretroviral", "treatment", "strategies", "consisting", "of", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitors", ",", "protease", "inhibitors", ",", "or", "both", "in", "the", "presence", "of", "nucleoside", "reverse", "transcriptase", "inhibitors", "as", "initial", "therapy", "(", "CPCRA", "058", "FIRST", "Study", ")", ":", "a", "long", "-", "term", "randomised", "trial", ".", "BACKGROUND", "Long", "-", "term", "data", "from", "randomised", "trials", "on", "the", "consequences", "of", "treatment", "with", "a", "protease", "inhibitor", "(", "PI", ")", ",", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", ",", "or", "both", "are", "lacking", ".", "Here", ",", "we", "report", "results", "from", "the", "FIRST", "trial", ",", "which", "compared", "initial", "treatment", "strategies", "for", "clinical", ",", "immunological", ",", "and", "virological", "outcomes", ".", "METHODS", "Between", "1999", "and", "2002", ",", "1397", "antiretroviral", "-", "treatment", "-", "naive", "patients", ",", "presenting", "at", "18", "clinical", "trial", "units", "with", "80", "research", "sites", "in", "the", "USA", ",", "were", "randomly", "assigned", "in", "a", "ratio", "of", "1:1:1", "to", "a", "protease", "inhibitor", "(", "PI", ")", "strategy", "(", "PI", "plus", "nucleoside", "reverse", "transcriptase", "inhibitor", "[", "NRTI", "]", ";", "n=470", ")", ",", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", "strategy", "(", "NNRTI", "plus", "NRTI", ";", "n=463", ")", ",", "or", "a", "three", "-", "class", "strategy", "(", "PI", "plus", "NNRTI", "plus", "NRTI", ";", "n=464", ")", ".", "Primary", "endpoints", "were", "a", "composite", "of", "an", "AIDS", "-", "defining", "event", ",", "death", ",", "or", "CD4", "cell", "count", "decline", "to", "less", "than", "200", "cells", "per", "mm3", "for", "the", "PI", "versus", "NNRTI", "comparison", ",", "and", "average", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "comparison", ".", "Analyses", "were", "by", "intention", "-", "to", "-", "treat", ".", "This", "study", "is", "registered", "ClinicalTrials.gov", ",", "number", "NCT00000922", ".", "FINDINGS", "1397", "patients", "were", "assessed", "for", "the", "composite", "endpoint", ".", "A", "total", "of", "388", "participants", "developed", "the", "composite", "endpoint", ",", "302", "developed", "AIDS", "or", "died", ",", "and", "188", "died", ".", "NNRTI", "versus", "PI", "hazard", "ratios", "(", "HRs", ")", "for", "the", "composite", "endpoint", ",", "for", "AIDS", "or", "death", ",", "for", "death", ",", "and", "for", "virological", "failure", "were", "1.02", "(", "95", "%", "CI", "0.79", "-", "1.31", ")", ",", "1.07", "(", "0.80", "-", "1.41", ")", ",", "0.95", "(", "0.66", "-", "1.37", ")", ",", "and", "0.66", "(", "0.56", "-", "0.78", ")", ",", "respectively", ".", "1196", "patients", "were", "assessed", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "primary", "endpoint", ".", "Mean", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "was", "+234", "cells", "per", "mm3", "and", "+227", "cells", "per", "mm3", "for", "the", "three", "-", "class", "and", "the", "combined", "two", "-", "class", "strategies", "(", "p=0.62", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "and", "virological", "failure", "were", "1.15", "(", "0.91", "-", "1.45", ")", "and", "0.87", "(", "0.75", "-", "1.00", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "were", "similar", "for", "participants", "with", "baseline", "CD4", "cell", "counts", "of", "200", "cells", "per", "mm3", "or", "less", "and", "of", "more", "than", "200", "cells", "per", "mm3", "(", "p=0.38", "for", "interaction", ")", ",", "and", "for", "participants", "with", "baseline", "HIV", "RNA", "concentrations", "less", "than", "100", "000", "copies", "per", "mL", "and", "100,000", "copies", "per", "mL", "or", "more", "(", "p=0.26", "for", "interaction", ")", ".", "Participants", "assigned", "the", "three", "-", "class", "strategy", "were", "significantly", "more", "likely", "to", "discontinue", "treatment", "because", "of", "toxic", "effects", "than", "were", "those", "assigned", "to", "the", "two", "-", "class", "strategies", "(", "HR", "1.58", ";", "p", "<", "0.0001", ")", ".", "INTERPRETATION", "Initial", "treatment", "with", "either", "an", "NNRTI", "-", "based", "regimen", "or", "a", "PI", "-", "based", "regimen", ",", "but", "not", "both", "together", ",", "is", "a", "good", "strategy", "for", "long", "-", "term", "antiretroviral", "management", "in", "treatment", "-", "naive", "patients", "with", "HIV", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Outcome_Mortality", "Outcome_Adverse-effects", "Participant_Sample-size" ]
non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking ., 1397, antiretroviral - treatment - naive, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ;, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ;, or a three - class strategy ( PI plus NNRTI plus NRTI ;, AIDS - defining event, death, CD4 cell count decline, change in CD4 cell count, composite endpoint, 388, 302, 188, HRs, AIDS or death, virological failure, Mean change in CD4 cell count, HIV, discontinue treatment, toxic effects, NNRTI - based regimen, PI - based regimen	29145_task2	Sentence: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV .	[ "A", "comparison", "of", "three", "highly", "active", "antiretroviral", "treatment", "strategies", "consisting", "of", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitors", ",", "protease", "inhibitors", ",", "or", "both", "in", "the", "presence", "of", "nucleoside", "reverse", "transcriptase", "inhibitors", "as", "initial", "therapy", "(", "CPCRA", "058", "FIRST", "Study", ")", ":", "a", "long", "-", "term", "randomised", "trial", ".", "BACKGROUND", "Long", "-", "term", "data", "from", "randomised", "trials", "on", "the", "consequences", "of", "treatment", "with", "a", "protease", "inhibitor", "(", "PI", ")", ",", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", ",", "or", "both", "are", "lacking", ".", "Here", ",", "we", "report", "results", "from", "the", "FIRST", "trial", ",", "which", "compared", "initial", "treatment", "strategies", "for", "clinical", ",", "immunological", ",", "and", "virological", "outcomes", ".", "METHODS", "Between", "1999", "and", "2002", ",", "1397", "antiretroviral", "-", "treatment", "-", "naive", "patients", ",", "presenting", "at", "18", "clinical", "trial", "units", "with", "80", "research", "sites", "in", "the", "USA", ",", "were", "randomly", "assigned", "in", "a", "ratio", "of", "1:1:1", "to", "a", "protease", "inhibitor", "(", "PI", ")", "strategy", "(", "PI", "plus", "nucleoside", "reverse", "transcriptase", "inhibitor", "[", "NRTI", "]", ";", "n=470", ")", ",", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", "strategy", "(", "NNRTI", "plus", "NRTI", ";", "n=463", ")", ",", "or", "a", "three", "-", "class", "strategy", "(", "PI", "plus", "NNRTI", "plus", "NRTI", ";", "n=464", ")", ".", "Primary", "endpoints", "were", "a", "composite", "of", "an", "AIDS", "-", "defining", "event", ",", "death", ",", "or", "CD4", "cell", "count", "decline", "to", "less", "than", "200", "cells", "per", "mm3", "for", "the", "PI", "versus", "NNRTI", "comparison", ",", "and", "average", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "comparison", ".", "Analyses", "were", "by", "intention", "-", "to", "-", "treat", ".", "This", "study", "is", "registered", "ClinicalTrials.gov", ",", "number", "NCT00000922", ".", "FINDINGS", "1397", "patients", "were", "assessed", "for", "the", "composite", "endpoint", ".", "A", "total", "of", "388", "participants", "developed", "the", "composite", "endpoint", ",", "302", "developed", "AIDS", "or", "died", ",", "and", "188", "died", ".", "NNRTI", "versus", "PI", "hazard", "ratios", "(", "HRs", ")", "for", "the", "composite", "endpoint", ",", "for", "AIDS", "or", "death", ",", "for", "death", ",", "and", "for", "virological", "failure", "were", "1.02", "(", "95", "%", "CI", "0.79", "-", "1.31", ")", ",", "1.07", "(", "0.80", "-", "1.41", ")", ",", "0.95", "(", "0.66", "-", "1.37", ")", ",", "and", "0.66", "(", "0.56", "-", "0.78", ")", ",", "respectively", ".", "1196", "patients", "were", "assessed", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "primary", "endpoint", ".", "Mean", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "was", "+234", "cells", "per", "mm3", "and", "+227", "cells", "per", "mm3", "for", "the", "three", "-", "class", "and", "the", "combined", "two", "-", "class", "strategies", "(", "p=0.62", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "and", "virological", "failure", "were", "1.15", "(", "0.91", "-", "1.45", ")", "and", "0.87", "(", "0.75", "-", "1.00", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "were", "similar", "for", "participants", "with", "baseline", "CD4", "cell", "counts", "of", "200", "cells", "per", "mm3", "or", "less", "and", "of", "more", "than", "200", "cells", "per", "mm3", "(", "p=0.38", "for", "interaction", ")", ",", "and", "for", "participants", "with", "baseline", "HIV", "RNA", "concentrations", "less", "than", "100", "000", "copies", "per", "mL", "and", "100,000", "copies", "per", "mL", "or", "more", "(", "p=0.26", "for", "interaction", ")", ".", "Participants", "assigned", "the", "three", "-", "class", "strategy", "were", "significantly", "more", "likely", "to", "discontinue", "treatment", "because", "of", "toxic", "effects", "than", "were", "those", "assigned", "to", "the", "two", "-", "class", "strategies", "(", "HR", "1.58", ";", "p", "<", "0.0001", ")", ".", "INTERPRETATION", "Initial", "treatment", "with", "either", "an", "NNRTI", "-", "based", "regimen", "or", "a", "PI", "-", "based", "regimen", ",", "but", "not", "both", "together", ",", "is", "a", "good", "strategy", "for", "long", "-", "term", "antiretroviral", "management", "in", "treatment", "-", "naive", "patients", "with", "HIV", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Outcome_Mortality", "Outcome_Adverse-effects", "Participant_Sample-size" ]
dysgenesis is an umlsterm, oligohydramnios is an umlsterm, congenital is an umlsterm, anuria is an umlsterm, stillbirth is an umlsterm, death is an umlsterm, respiratory failure is an umlsterm, diagnosis is an umlsterm, histology is an umlsterm, proximal tubule is an umlsterm, family is an umlsterm, consanguinity is an umlsterm, Lectin is an umlsterm, proximal tubule is an umlsterm, findings is an umlsterm, vein thrombosis is an umlsterm, morphological is an umlsterm, disorder is an umlsterm, pathogenesis is an umlsterm	DerPathologe.50160143.eng.abstr_task0	Sentence: Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed .	[ "Renal", "tubular", "dysgenesis", "is", "a", "rarely", "recognized", "condition", "characterized", "by", "oligohydramnios", ",", "Potter", "'s", "sequence", "and", "congenital", "anuria", "leading", "to", "stillbirth", "or", "neonatal", "death", "from", "respiratory", "failure", ".", "It", "is", "thought", "to", "be", "inherited", "in", "an", "autosomal", "recessive", "manner", ".", "Definitive", "diagnosis", "is", "based", "on", "renal", "histology", ",", "revealing", "the", "lack", "of", "proximal", "tubule", "differentiation", ".", "Two", "additional", "cases", "of", "affected", "sibs", "in", "a", "family", "with", "parental", "consanguinity", "are", "reported", ".", "Lectin", "and", "immunohistochemical", "studies", "confirmed", "structural", "and", "functional", "immaturity", "of", "the", "proximal", "tubule", ".", "Further", "findings", "include", "bilateral", "renal", "vein", "thrombosis", ".", "The", "clinical", "and", "morphological", "parameters", "defining", "this", "disorder", "and", "the", "possible", "mechanisms", "of", "pathogenesis", "are", "discussed", "." ]	[ "umlsterm" ]
dysgenesis is an umlsterm, oligohydramnios is an umlsterm, congenital is an umlsterm, anuria is an umlsterm, stillbirth is an umlsterm, death is an umlsterm, respiratory failure is an umlsterm, diagnosis is an umlsterm, histology is an umlsterm, proximal tubule is an umlsterm, family is an umlsterm, consanguinity is an umlsterm, Lectin is an umlsterm, proximal tubule is an umlsterm, findings is an umlsterm, vein thrombosis is an umlsterm, morphological is an umlsterm, disorder is an umlsterm, pathogenesis is an umlsterm	DerPathologe.50160143.eng.abstr_task1	Sentence: Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed . Instructions: please typing these entity words according to sentence: dysgenesis, oligohydramnios, congenital, anuria, stillbirth, death, respiratory failure, diagnosis, histology, proximal tubule, family, consanguinity, Lectin, proximal tubule, findings, vein thrombosis, morphological, disorder, pathogenesis Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed .	[ "Renal", "tubular", "dysgenesis", "is", "a", "rarely", "recognized", "condition", "characterized", "by", "oligohydramnios", ",", "Potter", "'s", "sequence", "and", "congenital", "anuria", "leading", "to", "stillbirth", "or", "neonatal", "death", "from", "respiratory", "failure", ".", "It", "is", "thought", "to", "be", "inherited", "in", "an", "autosomal", "recessive", "manner", ".", "Definitive", "diagnosis", "is", "based", "on", "renal", "histology", ",", "revealing", "the", "lack", "of", "proximal", "tubule", "differentiation", ".", "Two", "additional", "cases", "of", "affected", "sibs", "in", "a", "family", "with", "parental", "consanguinity", "are", "reported", ".", "Lectin", "and", "immunohistochemical", "studies", "confirmed", "structural", "and", "functional", "immaturity", "of", "the", "proximal", "tubule", ".", "Further", "findings", "include", "bilateral", "renal", "vein", "thrombosis", ".", "The", "clinical", "and", "morphological", "parameters", "defining", "this", "disorder", "and", "the", "possible", "mechanisms", "of", "pathogenesis", "are", "discussed", "." ]	[ "umlsterm" ]
dysgenesis, oligohydramnios, congenital, anuria, stillbirth, death, respiratory failure, diagnosis, histology, proximal tubule, family, consanguinity, Lectin, proximal tubule, findings, vein thrombosis, morphological, disorder, pathogenesis	DerPathologe.50160143.eng.abstr_task2	Sentence: Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed .	[ "Renal", "tubular", "dysgenesis", "is", "a", "rarely", "recognized", "condition", "characterized", "by", "oligohydramnios", ",", "Potter", "'s", "sequence", "and", "congenital", "anuria", "leading", "to", "stillbirth", "or", "neonatal", "death", "from", "respiratory", "failure", ".", "It", "is", "thought", "to", "be", "inherited", "in", "an", "autosomal", "recessive", "manner", ".", "Definitive", "diagnosis", "is", "based", "on", "renal", "histology", ",", "revealing", "the", "lack", "of", "proximal", "tubule", "differentiation", ".", "Two", "additional", "cases", "of", "affected", "sibs", "in", "a", "family", "with", "parental", "consanguinity", "are", "reported", ".", "Lectin", "and", "immunohistochemical", "studies", "confirmed", "structural", "and", "functional", "immaturity", "of", "the", "proximal", "tubule", ".", "Further", "findings", "include", "bilateral", "renal", "vein", "thrombosis", ".", "The", "clinical", "and", "morphological", "parameters", "defining", "this", "disorder", "and", "the", "possible", "mechanisms", "of", "pathogenesis", "are", "discussed", "." ]	[ "umlsterm" ]
limb is an umlsterm, amputation is an umlsterm, emergency service is an umlsterm, personnel is an umlsterm, treatment is an umlsterm, limbs is an umlsterm, replantation is an umlsterm, prosthesis is an umlsterm, functions is an umlsterm, limb is an umlsterm	Notfall+Rettungsmedizin.90020141.eng.abstr_task0	Sentence: Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting .	[ "Prehospital", "management", "of", "the", "acute", "limb", "amputation", "places", "great", "demands", "on", "the", "emergency", "service", "personnel", ".", "The", "initial", "treatment", "of", "amputated", "limbs", "often", "determines", "the", "success", "of", "later", "clinical", "attempts", "of", "replantation", ".", "So", "far", "no", "kind", "of", "prosthesis", "could", "ever", "take", "the", "place", "and", "the", "original", "biomechanical", "functions", "of", "the", "original", "limb", "in", "the", "prehospital", "setting", "." ]	[ "umlsterm" ]
limb is an umlsterm, amputation is an umlsterm, emergency service is an umlsterm, personnel is an umlsterm, treatment is an umlsterm, limbs is an umlsterm, replantation is an umlsterm, prosthesis is an umlsterm, functions is an umlsterm, limb is an umlsterm	Notfall+Rettungsmedizin.90020141.eng.abstr_task1	Sentence: Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting . Instructions: please typing these entity words according to sentence: limb, amputation, emergency service, personnel, treatment, limbs, replantation, prosthesis, functions, limb Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting .	[ "Prehospital", "management", "of", "the", "acute", "limb", "amputation", "places", "great", "demands", "on", "the", "emergency", "service", "personnel", ".", "The", "initial", "treatment", "of", "amputated", "limbs", "often", "determines", "the", "success", "of", "later", "clinical", "attempts", "of", "replantation", ".", "So", "far", "no", "kind", "of", "prosthesis", "could", "ever", "take", "the", "place", "and", "the", "original", "biomechanical", "functions", "of", "the", "original", "limb", "in", "the", "prehospital", "setting", "." ]	[ "umlsterm" ]
limb, amputation, emergency service, personnel, treatment, limbs, replantation, prosthesis, functions, limb	Notfall+Rettungsmedizin.90020141.eng.abstr_task2	Sentence: Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting .	[ "Prehospital", "management", "of", "the", "acute", "limb", "amputation", "places", "great", "demands", "on", "the", "emergency", "service", "personnel", ".", "The", "initial", "treatment", "of", "amputated", "limbs", "often", "determines", "the", "success", "of", "later", "clinical", "attempts", "of", "replantation", ".", "So", "far", "no", "kind", "of", "prosthesis", "could", "ever", "take", "the", "place", "and", "the", "original", "biomechanical", "functions", "of", "the", "original", "limb", "in", "the", "prehospital", "setting", "." ]	[ "umlsterm" ]
CpG is a compound, ERalpha is a protein	DS.d1277_task0	Sentence: In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O" ]	In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e.	[ "In", "the", "present", "study", ",", "the", "mRNA", "expression", "and", "promoter", "CpG", "methylation", "of", "ERalpha", "isoforms", "(", "i.e", "." ]	[ "protein", "compound" ]
CpG is a compound, ERalpha is a protein	DS.d1277_task1	Sentence: In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e. Instructions: please typing these entity words according to sentence: CpG, ERalpha Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O" ]	In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e.	[ "In", "the", "present", "study", ",", "the", "mRNA", "expression", "and", "promoter", "CpG", "methylation", "of", "ERalpha", "isoforms", "(", "i.e", "." ]	[ "protein", "compound" ]
CpG, ERalpha	DS.d1277_task2	Sentence: In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O" ]	In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e.	[ "In", "the", "present", "study", ",", "the", "mRNA", "expression", "and", "promoter", "CpG", "methylation", "of", "ERalpha", "isoforms", "(", "i.e", "." ]	[ "protein", "compound" ]
Dysphagia is an umlsterm, surgical is an umlsterm, oral cavity is an umlsterm, hypopharynx is an umlsterm, postoperative is an umlsterm, Videofluoroscopy is an umlsterm, visualization is an umlsterm, deglutition is an umlsterm, morphology is an umlsterm, videofluoroscopy is an umlsterm, therapeutic is an umlsterm, pathology is an umlsterm, deglutition is an umlsterm, patients is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, hypopharynx is an umlsterm, deglutition is an umlsterm, deglutition is an umlsterm	DerRadiologe.80380117.eng.abstr_task0	Sentence: Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases .	[ "Dysphagia", "is", "a", "common", "complaint", "following", "surgical", "intervention", "in", "the", "oral", "cavity", "and", "hypopharynx", ",", "often", "leading", "to", "prolonged", "postoperative", "recovery", ".", "Videofluoroscopy", "allows", "detailed", "visualization", "of", "deglutition", ",", "demonstrating", "the", "morphology", "as", "well", "as", "the", "functional", "aspects", ".", "Therefore", ",", "videofluoroscopy", "provides", "the", "basis", "for", "further", "therapeutic", "management", ".", "We", "discuss", "the", "pathology", "of", "deglutition", "in", "19", "patients", "recovering", "from", "tumor", "surgery", "of", "the", "oro-", "and", "hypopharynx", ".", "In", "most", "cases", "the", "results", "demonstrated", "severe", "impairment", "of", "both", "the", "oral", "and", "pharyngeal", "phase", "of", "deglutition", ".", "Our", "data", "emphasize", "the", "importance", "of", "the", "oral", "phase", "of", "deglutition", "for", "preparation", "and", "initiation", "of", "the", "following", "phases", "." ]	[ "umlsterm" ]
Dysphagia is an umlsterm, surgical is an umlsterm, oral cavity is an umlsterm, hypopharynx is an umlsterm, postoperative is an umlsterm, Videofluoroscopy is an umlsterm, visualization is an umlsterm, deglutition is an umlsterm, morphology is an umlsterm, videofluoroscopy is an umlsterm, therapeutic is an umlsterm, pathology is an umlsterm, deglutition is an umlsterm, patients is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, hypopharynx is an umlsterm, deglutition is an umlsterm, deglutition is an umlsterm	DerRadiologe.80380117.eng.abstr_task1	Sentence: Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases . Instructions: please typing these entity words according to sentence: Dysphagia, surgical, oral cavity, hypopharynx, postoperative, Videofluoroscopy, visualization, deglutition, morphology, videofluoroscopy, therapeutic, pathology, deglutition, patients, tumor, surgery, hypopharynx, deglutition, deglutition Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases .	[ "Dysphagia", "is", "a", "common", "complaint", "following", "surgical", "intervention", "in", "the", "oral", "cavity", "and", "hypopharynx", ",", "often", "leading", "to", "prolonged", "postoperative", "recovery", ".", "Videofluoroscopy", "allows", "detailed", "visualization", "of", "deglutition", ",", "demonstrating", "the", "morphology", "as", "well", "as", "the", "functional", "aspects", ".", "Therefore", ",", "videofluoroscopy", "provides", "the", "basis", "for", "further", "therapeutic", "management", ".", "We", "discuss", "the", "pathology", "of", "deglutition", "in", "19", "patients", "recovering", "from", "tumor", "surgery", "of", "the", "oro-", "and", "hypopharynx", ".", "In", "most", "cases", "the", "results", "demonstrated", "severe", "impairment", "of", "both", "the", "oral", "and", "pharyngeal", "phase", "of", "deglutition", ".", "Our", "data", "emphasize", "the", "importance", "of", "the", "oral", "phase", "of", "deglutition", "for", "preparation", "and", "initiation", "of", "the", "following", "phases", "." ]	[ "umlsterm" ]
Dysphagia, surgical, oral cavity, hypopharynx, postoperative, Videofluoroscopy, visualization, deglutition, morphology, videofluoroscopy, therapeutic, pathology, deglutition, patients, tumor, surgery, hypopharynx, deglutition, deglutition	DerRadiologe.80380117.eng.abstr_task2	Sentence: Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases .	[ "Dysphagia", "is", "a", "common", "complaint", "following", "surgical", "intervention", "in", "the", "oral", "cavity", "and", "hypopharynx", ",", "often", "leading", "to", "prolonged", "postoperative", "recovery", ".", "Videofluoroscopy", "allows", "detailed", "visualization", "of", "deglutition", ",", "demonstrating", "the", "morphology", "as", "well", "as", "the", "functional", "aspects", ".", "Therefore", ",", "videofluoroscopy", "provides", "the", "basis", "for", "further", "therapeutic", "management", ".", "We", "discuss", "the", "pathology", "of", "deglutition", "in", "19", "patients", "recovering", "from", "tumor", "surgery", "of", "the", "oro-", "and", "hypopharynx", ".", "In", "most", "cases", "the", "results", "demonstrated", "severe", "impairment", "of", "both", "the", "oral", "and", "pharyngeal", "phase", "of", "deglutition", ".", "Our", "data", "emphasize", "the", "importance", "of", "the", "oral", "phase", "of", "deglutition", "for", "preparation", "and", "initiation", "of", "the", "following", "phases", "." ]	[ "umlsterm" ]
interferon - gamma is a protein_molecule, gene expression is an other_name	22106_task0	Sentence: Regulation of interferon-gamma gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, protein_molecule	[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "B-other_name", "I-other_name", "O" ]	Regulation of interferon-gamma gene expression.	[ "Regulation", "of", "interferon", "-", "gamma", "gene", "expression", "." ]	[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "protein_N/A", "RNA_molecule", "DNA_domain_or_region", "body_part" ]
interferon - gamma is a protein_molecule, gene expression is an other_name	22106_task1	Sentence: Regulation of interferon-gamma gene expression. Instructions: please typing these entity words according to sentence: interferon - gamma, gene expression Options: other_name, protein_molecule	[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "B-other_name", "I-other_name", "O" ]	Regulation of interferon-gamma gene expression.	[ "Regulation", "of", "interferon", "-", "gamma", "gene", "expression", "." ]	[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "protein_N/A", "RNA_molecule", "DNA_domain_or_region", "body_part" ]
interferon - gamma, gene expression	22106_task2	Sentence: Regulation of interferon-gamma gene expression. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "B-other_name", "I-other_name", "O" ]	Regulation of interferon-gamma gene expression.	[ "Regulation", "of", "interferon", "-", "gamma", "gene", "expression", "." ]	[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "protein_N/A", "RNA_molecule", "DNA_domain_or_region", "body_part" ]
Histamine is an other_organic_compound, c - fos is a DNA_domain_or_region, cyclic AMP production is an other_name, H2 receptor is a protein_complex, human promonocytic cell line U937 is a cell_line	61791_task0	Sentence: Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, other_name, cell_line, DNA_domain_or_region, protein_complex	[ "B-other_organic_compound", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_complex", "I-protein_complex", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937.	[ "Histamine", "modulates", "the", "expression", "of", "c", "-", "fos", "through", "cyclic", "AMP", "production", "via", "the", "H2", "receptor", "in", "the", "human", "promonocytic", "cell", "line", "U937", "." ]	[ "protein_family_or_group", "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region)", "other_name", "other_organic_compound", "protein_molecule", "", "nucleotide", "DNA_family_or_group", "protein_complex", "RNA_molecule", "DNA_domain_or_region" ]
Histamine is an other_organic_compound, c - fos is a DNA_domain_or_region, cyclic AMP production is an other_name, H2 receptor is a protein_complex, human promonocytic cell line U937 is a cell_line	61791_task1	Sentence: Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. Instructions: please typing these entity words according to sentence: Histamine, c - fos, cyclic AMP production, H2 receptor, human promonocytic cell line U937 Options: other_organic_compound, other_name, cell_line, DNA_domain_or_region, protein_complex	[ "B-other_organic_compound", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_complex", "I-protein_complex", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937.	[ "Histamine", "modulates", "the", "expression", "of", "c", "-", "fos", "through", "cyclic", "AMP", "production", "via", "the", "H2", "receptor", "in", "the", "human", "promonocytic", "cell", "line", "U937", "." ]	[ "protein_family_or_group", "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region)", "other_name", "other_organic_compound", "protein_molecule", "", "nucleotide", "DNA_family_or_group", "protein_complex", "RNA_molecule", "DNA_domain_or_region" ]
Histamine, c - fos, cyclic AMP production, H2 receptor, human promonocytic cell line U937	61791_task2	Sentence: Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. Instructions: please extract entity words from the input sentence	[ "B-other_organic_compound", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_complex", "I-protein_complex", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937.	[ "Histamine", "modulates", "the", "expression", "of", "c", "-", "fos", "through", "cyclic", "AMP", "production", "via", "the", "H2", "receptor", "in", "the", "human", "promonocytic", "cell", "line", "U937", "." ]	[ "protein_family_or_group", "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region)", "other_name", "other_organic_compound", "protein_molecule", "", "nucleotide", "DNA_family_or_group", "protein_complex", "RNA_molecule", "DNA_domain_or_region" ]
FGEYRSLESDNEE is a peptide, TGN38 is a protein, AP-2 is a protein-complex	1.0alpha7.train.1235_task0	Sentence: We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: peptide, protein, protein-complex	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-peptide", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b).	[ "We", "have", "shown", "previously", ",", "using", "an", "in", "vitro", "peptide", "competition", "assay", ",", "that", "the", "peptide", "FGEYRSLESDNEE", "blocks", "binding", "of", "a", "biotin", "-", "labeled", "TGN38", "peptide", "to", "AP-2", "purified", "from", "rat", "brain", "(", "Kamiguchi", "et", "al", ".", ",", "1998b", ")", "." ]	[ "peptide", "protein", "protein-complex" ]
FGEYRSLESDNEE is a peptide, TGN38 is a protein, AP-2 is a protein-complex	1.0alpha7.train.1235_task1	Sentence: We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b). Instructions: please typing these entity words according to sentence: FGEYRSLESDNEE, TGN38, AP-2 Options: peptide, protein, protein-complex	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-peptide", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b).	[ "We", "have", "shown", "previously", ",", "using", "an", "in", "vitro", "peptide", "competition", "assay", ",", "that", "the", "peptide", "FGEYRSLESDNEE", "blocks", "binding", "of", "a", "biotin", "-", "labeled", "TGN38", "peptide", "to", "AP-2", "purified", "from", "rat", "brain", "(", "Kamiguchi", "et", "al", ".", ",", "1998b", ")", "." ]	[ "peptide", "protein", "protein-complex" ]
FGEYRSLESDNEE, TGN38, AP-2	1.0alpha7.train.1235_task2	Sentence: We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-peptide", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b).	[ "We", "have", "shown", "previously", ",", "using", "an", "in", "vitro", "peptide", "competition", "assay", ",", "that", "the", "peptide", "FGEYRSLESDNEE", "blocks", "binding", "of", "a", "biotin", "-", "labeled", "TGN38", "peptide", "to", "AP-2", "purified", "from", "rat", "brain", "(", "Kamiguchi", "et", "al", ".", ",", "1998b", ")", "." ]	[ "peptide", "protein", "protein-complex" ]
aim is an umlsterm, techniques is an umlsterm, cataract surgery is an umlsterm, postoperative is an umlsterm, astigmatism is an umlsterm, visual acuity is an umlsterm	DerOpthalmologe.80950427.eng.abstr_task0	Sentence: Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity .	[ "Purpose", ":", "The", "aim", "was", "to", "compare", "the", "different", "techniques", "of", "cataract", "surgery", "regarding", "early", "postoperative", "astigmatism", "and", "visual", "acuity", "." ]	[ "umlsterm" ]
aim is an umlsterm, techniques is an umlsterm, cataract surgery is an umlsterm, postoperative is an umlsterm, astigmatism is an umlsterm, visual acuity is an umlsterm	DerOpthalmologe.80950427.eng.abstr_task1	Sentence: Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity . Instructions: please typing these entity words according to sentence: aim, techniques, cataract surgery, postoperative, astigmatism, visual acuity Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity .	[ "Purpose", ":", "The", "aim", "was", "to", "compare", "the", "different", "techniques", "of", "cataract", "surgery", "regarding", "early", "postoperative", "astigmatism", "and", "visual", "acuity", "." ]	[ "umlsterm" ]
aim, techniques, cataract surgery, postoperative, astigmatism, visual acuity	DerOpthalmologe.80950427.eng.abstr_task2	Sentence: Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity .	[ "Purpose", ":", "The", "aim", "was", "to", "compare", "the", "different", "techniques", "of", "cataract", "surgery", "regarding", "early", "postoperative", "astigmatism", "and", "visual", "acuity", "." ]	[ "umlsterm" ]
Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural is a MORFOLOGIA_NEOPLASIA, afectación meníngea is a MORFOLOGIA_NEOPLASIA, angiomiolipoma is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, lesiones intraparenquimatosas is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma seroso G3 is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, masa residual retroperitoneal is a MORFOLOGIA_NEOPLASIA, masa mesentérica is a MORFOLOGIA_NEOPLASIA, implante tumoral is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA	205_task0	Sentence: Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16).	[ "Anamnesis", "\n", "Mujer", "68", "años", ".", "\n", "-", "Alergia", "a", "amoxicilina", "y", "moxifloxacino", "(", "con", "estudio", "por", "alergología", ")", ".", "\n", "-", "No", "hábitos", "tóxicos", ".", "\n", "-", "No", "factores", "de", "riesgo", "cardiovascular", ".", "\n\n", "-", "Hipotiroidismo", ".", "\n", "-", "Antecedentes", "quirúrgicos", ":", "histerectomía", "sin", "anexectomía", "con", "41", "años", ".", "\n", "-", "Tratamiento", "habitual", ":", "Levotiroxina", ",", "Guayana", "en", "comprimidos", ".", "\n\n", "", "", "HISTORIA", "ONCOLÓGICA", ":", "\n", "-", "Diagnóstico", "en", "Mayo/2015", "de", "Adenocarcinoma", "seroso", "de", "ovario", "G3", "estadio", "IV", "por", "afectación", "pleural", ".", "Inicia", "tratamiento", "con", "quimioterapia", "(", "QT", ")", "según", "esquema", "Carboplatino", "(", "AUC", "5", "cada", "3", "semanas", ")", "-", "Paclitaxel", "(", "175", "mg", "/", "m2", "cada", "3", "semanas", ")", "-", "Bevacizumab", "(", "15", "mg", "/", "kg", ")", ",", "del", "que", "recibe", "un", "total", "de", "4", "ciclos", ",", "último", "el", "07/08/15", "con", "reducción", "10", "%", "en", "4º", "ciclo", "por", "astenia", "G3", ".", "Respuesta", "parcial", "bioquímica", "(", "descenso", "importante", "del", "Ca", "125", ")", "y", "por", "imagen", ".", "\n\n", "", "", "22/08/16", ":", "Paciente", "con", "clínica", "de", "1", "mes", "aproximadamente", "de", "duración", "(", "tras", "3º", "ciclo", "de", "QT", "el", "14/07/15", ")", "consistente", "en", "cuadro", "de", "desorientación", ".", "Tras", "4º", "ciclo", "de", "QT", "el", "07/08/15", ",", "con", "mala", "tolerancia", "al", "mismo", ",", "presenta", "empeoramiento", "del", "cuadro", "neurológico", "con", "crisis", "convulsiva", "el", "22/08/15", "por", "lo", "que", "es", "traída", "a", "urgencias", "por", "sus", "familiares", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "118", "mEq", "/", "L.", "Se", "realiza", "TAC", "craneal", "sin", "hallazgos", "patológicos", "y", "sin", "hacer", "referencia", "a", "existencia", "de", "edema", "cerebral", ",", "y", "se", "inicia", "correción", "hidroelectrolítica", "con", "mejoria", "rápida", "del", "cuadro", ",", "aunque", "no", "resolución", "completa", ".", "Es", "dada", "de", "alta", "tras", "24", "horas", "en", "observación", "y", "con", "cifra", "de", "Na", "133", "mEq", "/", "L.", "\n", "El", "28/08/15", "en", "valorada", "en", "hospital", "de", "día", "de", "Oncología", "para", "5º", "cliclo", ",", "que", "se", "suspende", "por", "persitencia", "de", "cuadro", "neurológico", "a", "pesar", "de", "Na", "corregido", "(", "134", "mEq", "/", "L", ")", ",", "mala", "tolerancia", "al", "4º", "ciclo", "y", "episodio", "de", "fiebre", "puntual", "el", "26/08/15", "secundario", "a", "fístula", "perianal", "en", "tratamiento", "con", "Eritromicina", ".", "En", "dicha", "consulta", ",", "debido", "a", "persistencia", "del", "cuadro", "neurologico", ",", "se", "solicita", "RMN", "craneal", "a", "fin", "de", "descartar", "afectación", "meníngea", "que", "pudiera", "explicar", "el", "cuadro", ".", "\n", "El", "31/08/16", "consulta", "nuevamente", "en", "urgencias", "por", "episodio", "convulsivo", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "112", "mEq", "/", "L", ",", "por", "lo", "que", "se", "inicia", "corrección", "de", "la", "misma", "con", "mejoría", "rápida", "del", "cuadro", "en", "24", "horas", "y", "posteriormente", "trasladada", "a", "planta", "de", "Oncología", "para", "continuidad", "de", "cuidados", ".", "\n\n", "Exploración", "física", "\n", "AL", "INGRESO", "EN", "ONCOLOGÍA", "MÉDICA", "\n", "PS", "4", ".", "Glasgow", "11", "(", "apertura", "espontánea", "de", "ojos", ",", "retira", "al", "dolor", ",", "no", "obedece", "órdenes", ",", "lenguaje", "incomprensible", ")", ".", "\n", "Pupilas", "isocóricas", "normorreactivas", ".", "Moviliza", "4", "miembros", ".", "\n", "Auscultación", "Cardio", "-", "Respiratoria", ":", "Normal", ".", "Abdomen", "normal", ".", "\n", "Miembros", "Inferiores", "sin", "edema", "ni", "signos", "Trombosis", "Venosa", "Profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "PRUEBAS", "DE", "LABORATORIO", "\n\n", "-", "Analítica", "31/08/15", ":", "\n", "", "Hemograma", ":", "Hb", "99", "g", "/", "l", ",", "resto", "normal", ".", "\n", "", "BioquÍmica", "sérica", ":", "Na", "112", "mEq", "/", "L", ",", "K", "3.2", "mEq", "/", "L", ",", "resto", "normal", ".", "\n", "", "Coagulación", ":", "Normal", ".", "\n", "-", "Gasometría", "Venosa", "31/05/15", ":", "EVOLUCIÓN", ".", "\n", "", "Na", ":", "111", "(", "15.00pm", ")", "-", ">", "113", "(", "16.00pm", ")", "-", ">", "116", "(", "17.00pm", ")", "-", ">", "116", "(", "18.45pm", ")", "\n", "", "Osm", ":", "229", "-", ">", "233", "-", ">", "237-", ">", "237", ".", "\n", "-", "IONES", "ORINA", ":", "Na", "110", "mEq", "/", "L", "(", "elevado", ")", ",", "K", "10", "mEq", "/", "L.", "Proteinuria", ".", "\n", "-", "Marcadores", "tumorales", "01/09/16", ":", "CEA", "5,1", "ng", "/", "ml", "(", "descenso", ",", "al", "diagnóstico", "de", "7.9", "ng", "/", "ml", ")", ".", "CA", "125", "977", "U", "/", "ml", "(", "franco", "descenso", ",", "al", "diagnóstico", "de", "46852", "U", "/", "ml", ")", ".", "\n", "-", "Analítica", "10/09/16", "(", "PREVIA", "AL", "ALTA", "):", "\n", "", "Bioquímica", ":", "Urea", "45", "mg", "/", "dl", ",", "proteinas", "totales", "6", "gr", "/", "dl", ",", "fósforo", "inorgánico", "2,55", "mg", "/", "dl", ".", "Sodio", "normal", "(", "139", "mEq", "/", "L", ")", ".", "\n", "*", "Hemograma", ":", "Hemoglobina", "98", "gr", "/", "L.", "Series", "blanca", "y", "paquetaria", "normales", ".", "\n\n", "PRUEBAS", "IMAGEN", "\n", "-", "TAC", "de", "tórax", "y", "abdomen", "(", "3/09/2015", ")", ".", "Nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "sin", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "pleural", ".", "Han", "desaparecido", "los", "engrosamientos", "pleurales", ".", "En", "hígado", "sigue", "apreciándose", "pequeño", "nódulo", "de", "8", "mm", "en", "periferia", "subdiafragmática", "del", "segmento", "VIII", "de", "contenido", "predominantemente", "graso", "(", "angiomiolipoma", "hepático", "?", ")", ".", "Pequeña", "lesión", "focal", "hipodensa", "en", "periferia", "del", "segmento", "VII", "de", "6", "mm", "de", "diámetro", ",", "indeterminada", ".", "Masa", "mesentérica", "de", "72", "x", "27", "x", "34", "mm", "de", "mayor", "tamaño", "que", "en", "la", "TC", "previa", ",", "con", "cápsula", "periférica", "bien", "definida", "y", "con", "contenido", "interno", "graso", "con", "polos", "sólidos", "de", "aspecto", "tumoral", "y", "de", "extirpe", "histológica", "diferente", "al", "tumor", "ovárico", ".", "Persisten", "masas", "tumorales", "pélvicas", "que", "rodean", "el", "rectosigma", ",", "útero", "y", "ocupan", "ambas", "fosas", "anexiales", "que", "se", "han", "reducido", "notablemente", "de", "tamaño", "respecto", "a", "la", "TC", "previa", ".", "Ha", "desaparecido", "la", "ascitis", ".", "Con", "ventana", "de", "hueso", "no", "se", "han", "apreciado", "imágenes", "sugestivas", "enfermedad", "metastásica", "ósea", ".", "\n\n", "-", "RM", "cerebral", "(", "7/09/2015", ")", ".", "No", "existen", "lesiones", "intraparenquimatosas", "ni", "que", "afecten", "a", "las", "meninges", ".", "\n\n", "INTERVENCIONISMO", "\n\n", "-", "Anatomía", "patológica", "biopsia", "core", "masa", "abdominal", "residual", "(", "con", "control", "ecográfico", ")", "11/09/16", ":", "\n", "BIOPSIA", "INSUFICIENTE", "PARA", "DIAGNÓSTICO", "CONSTITUIDA", "POR", "TEJIDO", "FIBROADIPOSO", ",", "CON", "PRESENCIA", "DE", "MACRÓFAGOS", "Y", "CAMBIOS", "INFLAMATORIOS", ".", "Comentario", ":", "No", "se", "han", "identificado", "signos", "morfológicos", "de", "malignidad", ".", "\n\n", "Diagnóstico", "\n", "-", "INGRESO", "EN", "PLANTA", "POR", ":", "\n", "1", ".", "Hiponatremia", "profunda", ",", "sintomáticamente", "severa", "y", "de", "carácter", "crónico", "y", "dos", "episodios", "graves", "documentados", "de", "somnolencia", ",", "confusión", "y", "convulsiones", ",", "por", "probable", "SIADH", "asociado", "a", "carboplatino", ".", "\n", "2", ".", "Proteinuria", "y", "tendencia", "a", "la", "hipertensión", "arterial", "seguramente", "secundaria", "a", "toxicidad", "por", "Bevacizumab", ".", "\n", "3", ".", "Masa", "abdominal", "de", "unos", "8", "-", "9", "cms", "de", "densidad", "grasa", "en", "raíz", "de", "mesenterio", "que", "ha", "crecido", "de", "forma", "aislada", "y", "que", "parece", "de", "etiología", "diferente", "al", "adenocarcinoma", "diagnosticado", "previamente", ".", "\n", "-", "PATOLOGÍA", "BASAL", ":", "Adenocarcinoma", "seroso", "G3", "de", "ovario", "estadio", "IV", "en", "RP", "tras", "4", "ciclos", "de", "Carbo", "-", "Taxol", "-", "Beva", "(", "corroborada", "en", "TAC", "de", "reevaluación", "y", "con", "descenso", "muy", "importante", "de", "marcadores", "séricos", ")", ".", "\n\n", "Tratamiento", "\n", "TRATAMIENTO", "AL", "ALTA", "DE", "PLANTA", "\n", "-", "Dieta", "normal", ".", "\n", "-", "Retirada", "de", "tratamiento", "de", "primera", "línea", "con", "Carbo", "-", "Paclitaxel", "-", "Bevacizumab", ".", "\n", "-", "Ingesta", "de", "líquidos", "sin", "restricciones", "(", "no", "tomar", "mas", "de", "2", "litros", "diarios", ")", "\n", "-", "Tratamiento", "hipotensor", "con", "Losartán", "50", ":", "1", "-", "0", "-", "0", "y", "si", "presiste", "TA", "elevadas", "(", ">", "160/80", "mmHg", ")", ",", "añadir", "manidipino", "10", ":", "0", "-", "0", "-", "1", ".", "\n", "-", "Omeprazol", "20", "mgrs", "al", "día", "vía", "oral", ".", "\n", "-", "Dexametasona", "4", "mgrs", "cada", "12", "horas", "vía", "oral", ".", "Seguir", "pauta", "descendente", ".", "\n", "-", "Lorazepam", "2", "mgrs", "por", "las", "noches", ".", "\n", "-", "Levotiroxina", "50", "mcgrs", "al", "día", "(", "por", "las", "mañans", ")", ".", "\n", "-", "No", "precisa", "tratamiento", "con", "Tolvaptán", ".", "\n\n", "Evolución", "\n", "La", "evolución", "de", "la", "paciente", "durante", "el", "ingreso", "fue", ",", "al", "principio", ",", "bastante", "tórpida", "por", "persistencia", "del", "estado", "de", "sopor", "y", "de", "bajo", "nivel", "de", "conciencia", "y", "por", "presentar", "episodios", "de", "agitación", "intermitentes", "a", "pesar", "de", "la", "normalización", "progresiva", "y", "lenta", "de", "los", "nivels", "de", "sodio", "sérico", ".", "Si", "bien", "lo", "anterior", ",", "no", "presentó", "en", "más", "ocasiones", "crisis", "convulsivas", ",", "manteniéndose", "en", "todo", "momento", "afebril", "y", "sin", "otros", "déficits", "neurológicos", ".", "Además", "poliuria", "con", "natriuresis", "normal", "y", "con", "creatinina", "sérica", "y", "ácido", "úrico", "normales", ".", "Por", "fin", ",", "tras", "elevación", "de", "la", "osmolalidad", "plasmática", "progresiva", "y", "tratamiento", "con", "dosis", "moderadas", "de", "dexametasona", "además", "de", "restricción", "de", "aporte", "liquidos", ",", "mejoró", "de", "forma", "ostensible", "a", "nivel", "neurológico", ",", "permaneciendo", "en", "los", "últimos", "días", "del", "ingreso", "consciente", "y", "cada", "vez", "más", "orientada", "y", "alerta", ",", "mejorando", "progresivamene", "su", "estado", "general", ".", "No", "obstante", ",", "durante", "su", "ingreso", "se", "ha", "objetivado", "de", "forma", "progresiva", "tendencia", "a", "la", "hipertensió", "arterial", "ademá", "de", "proteinuria", "discreta", ",", "siendo", "bien", "controladas", "con", "Losartán", ".", "Al", "alta", "de", "con", "sodio", "plasmático", "normal", "y", "con", "estado", "general", "conservado", ",", "afebril", "y", "tolerando", "dieta", "oral", "ademas", "de", "ausenxcia", "de", "deficits", "neurologicos", ".", "\n", "En", "cuanto", "a", "la", "causa", "de", "la", "hiponatremia", ",", "la", "pacinete", "fue", "valorado", "por", "Nefrología", "(", "continúa", "en", "sus", "consultas", ")", ",", "siendo", "diagnosticada", "de", "SIADH", "en", "relación", "a", "Carboplatino", "(", "diagnóstico", "de", "exclusión", ")", "vs", "SIADH", "como", "síndrome", "paraneoplásico", "en", "relación", "al", "tumor", ".", "Inicia", "nueva", "línea", "de", "QT", "con", "adriamicina", "liposomal", "en", "Noviembre/15", "(", "recibe", "únicamente", "1", "ciclo", ")", ".", "Dado", "que", "el", "SIADH", "se", "relaciona", "poco", "con", "un", "adenocarcinoma", "de", "pulmón", ",", "se", "decidió", "tomar", "muestra", "de", "la", "masa", "residual", "retroperitoneal", "(", "dado", "que", "parecía", "de", "una", "estirpe", "diferente", ")", ",", "por", "lo", "que", "la", "paciente", "se", "comentó", "en", "Comité", "de", "Tumores", ".", "Se", "decide", "resección", "de", "la", "masa", ":", "Intervención", "Quirúrgica", "(", "Enero/16", "):", "exéresis", "de", "la", "masa", "mesentérica", ",", "ooforectomía", "bilateral", ",", "omentectomía", "con", "implante", "tumoral", "peritoneal", ".", "\n", "Anatomía", "patológica", "de", "adenocarcinoma", "de", "origen", "ovárico", ".", "Posteriormente", "continúa", "con", "QT", "basada", "en", "adriamicina", "liposomal", ",", "y", "recibe", "un", "total", "de", "3", "ciclos", "(", "contando", "con", "el", "previo", "a", "la", "cirugía", ")", ",", "decidiéndose", "STOP", "en", "Abril/15", "por", "astenia", "importante", ".", "En", "la", "reevaluación", "de", "Mayo/15", "se", "objetiva", "respuesta", "completa", "por", "imagen", "y", "por", "marcadores", ".", "Desde", "la", "retirada", "del", "carboplatino", ",", "no", "ha", "vuelto", "a", "presentar", "hiponatremia", ".", "\n", "-", "TC", "tórax", "-", "abdomen", "Mayo/15", ":", "Tórax", ":", "Persiste", "nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "estable", "respecto", "al", "estudios", "previos", ",", "asi", "como", "en", "segmento", "laterobasal", "del", "LID", ",", "sin", "cambios", "también", ".", "No", "hay", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "ni", "engrosamiento", "pleural", ".", "Múltiples", "nódulos", "calcificados", "en", "ambas", "mamas", ".", "Resto", "del", "tórax", "sin", "hallazgos", "de", "interés", ".", "Abdomen", ":", "Hígado", "de", "tamaño", "normal", "y", "contorno", "liso", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "pequeño", "tamaño", "ya", "conocida", ".", "Vía", "biliar", "intra", "y", "extrahepática", "de", "calibre", "normal", ".", "Vesícula", "biliar", "sin", "alteraciones", ".", "\n", "Bazo", ",", "pancreas", ",", "adrenales", "y", "riñones", "sin", "hallazgos", "de", "interés", ".", "Estómago", ",", "asas", "de", "intestino", "delgado", "y", "colon", "sin", "dilataciones", "ni", "engrosamientos", "murales", ".", "\n", "Vejiga", "urinaria", "bien", "replecionada", "sin", "engrosamiento", "de", "la", "pared", ".", "Histerectomizada", "con", "doble", "anexectomía", ",", "sin", "imágenes", "de", "recidiva", ".", "Resto", "del", "abdomen", "sin", "hallazgos", "de", "interés", ".", "Conclusión", ":", "Nódulos", "pulmonares", "estables", ".", "Nódulos", "mamarios", "calcificados", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "estable", ".", "Ausencia", "quirúrgica", "de", "genitales", "internos", ".", "\n", "-", "Evolución", "de", "Ca", "125", ":", "46852", "U", "/", "ml", "(", "diagnóstico", ")", "--", ">", "19.4", "U", "/", "ml", "(", "Mayo/16", ")", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural is a MORFOLOGIA_NEOPLASIA, afectación meníngea is a MORFOLOGIA_NEOPLASIA, angiomiolipoma is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, lesiones intraparenquimatosas is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma seroso G3 is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, masa residual retroperitoneal is a MORFOLOGIA_NEOPLASIA, masa mesentérica is a MORFOLOGIA_NEOPLASIA, implante tumoral is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA	205_task1	Sentence: Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16). Instructions: please typing these entity words according to sentence: Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural, afectación meníngea, angiomiolipoma, tumoral, tumor, tumorales, metastásica, lesiones intraparenquimatosas, malignidad, adenocarcinoma, Adenocarcinoma seroso G3, tumor, adenocarcinoma, masa residual retroperitoneal, masa mesentérica, implante tumoral, adenocarcinoma Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16).	[ "Anamnesis", "\n", "Mujer", "68", "años", ".", "\n", "-", "Alergia", "a", "amoxicilina", "y", "moxifloxacino", "(", "con", "estudio", "por", "alergología", ")", ".", "\n", "-", "No", "hábitos", "tóxicos", ".", "\n", "-", "No", "factores", "de", "riesgo", "cardiovascular", ".", "\n\n", "-", "Hipotiroidismo", ".", "\n", "-", "Antecedentes", "quirúrgicos", ":", "histerectomía", "sin", "anexectomía", "con", "41", "años", ".", "\n", "-", "Tratamiento", "habitual", ":", "Levotiroxina", ",", "Guayana", "en", "comprimidos", ".", "\n\n", "", "", "HISTORIA", "ONCOLÓGICA", ":", "\n", "-", "Diagnóstico", "en", "Mayo/2015", "de", "Adenocarcinoma", "seroso", "de", "ovario", "G3", "estadio", "IV", "por", "afectación", "pleural", ".", "Inicia", "tratamiento", "con", "quimioterapia", "(", "QT", ")", "según", "esquema", "Carboplatino", "(", "AUC", "5", "cada", "3", "semanas", ")", "-", "Paclitaxel", "(", "175", "mg", "/", "m2", "cada", "3", "semanas", ")", "-", "Bevacizumab", "(", "15", "mg", "/", "kg", ")", ",", "del", "que", "recibe", "un", "total", "de", "4", "ciclos", ",", "último", "el", "07/08/15", "con", "reducción", "10", "%", "en", "4º", "ciclo", "por", "astenia", "G3", ".", "Respuesta", "parcial", "bioquímica", "(", "descenso", "importante", "del", "Ca", "125", ")", "y", "por", "imagen", ".", "\n\n", "", "", "22/08/16", ":", "Paciente", "con", "clínica", "de", "1", "mes", "aproximadamente", "de", "duración", "(", "tras", "3º", "ciclo", "de", "QT", "el", "14/07/15", ")", "consistente", "en", "cuadro", "de", "desorientación", ".", "Tras", "4º", "ciclo", "de", "QT", "el", "07/08/15", ",", "con", "mala", "tolerancia", "al", "mismo", ",", "presenta", "empeoramiento", "del", "cuadro", "neurológico", "con", "crisis", "convulsiva", "el", "22/08/15", "por", "lo", "que", "es", "traída", "a", "urgencias", "por", "sus", "familiares", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "118", "mEq", "/", "L.", "Se", "realiza", "TAC", "craneal", "sin", "hallazgos", "patológicos", "y", "sin", "hacer", "referencia", "a", "existencia", "de", "edema", "cerebral", ",", "y", "se", "inicia", "correción", "hidroelectrolítica", "con", "mejoria", "rápida", "del", "cuadro", ",", "aunque", "no", "resolución", "completa", ".", "Es", "dada", "de", "alta", "tras", "24", "horas", "en", "observación", "y", "con", "cifra", "de", "Na", "133", "mEq", "/", "L.", "\n", "El", "28/08/15", "en", "valorada", "en", "hospital", "de", "día", "de", "Oncología", "para", "5º", "cliclo", ",", "que", "se", "suspende", "por", "persitencia", "de", "cuadro", "neurológico", "a", "pesar", "de", "Na", "corregido", "(", "134", "mEq", "/", "L", ")", ",", "mala", "tolerancia", "al", "4º", "ciclo", "y", "episodio", "de", "fiebre", "puntual", "el", "26/08/15", "secundario", "a", "fístula", "perianal", "en", "tratamiento", "con", "Eritromicina", ".", "En", "dicha", "consulta", ",", "debido", "a", "persistencia", "del", "cuadro", "neurologico", ",", "se", "solicita", "RMN", "craneal", "a", "fin", "de", "descartar", "afectación", "meníngea", "que", "pudiera", "explicar", "el", "cuadro", ".", "\n", "El", "31/08/16", "consulta", "nuevamente", "en", "urgencias", "por", "episodio", "convulsivo", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "112", "mEq", "/", "L", ",", "por", "lo", "que", "se", "inicia", "corrección", "de", "la", "misma", "con", "mejoría", "rápida", "del", "cuadro", "en", "24", "horas", "y", "posteriormente", "trasladada", "a", "planta", "de", "Oncología", "para", "continuidad", "de", "cuidados", ".", "\n\n", "Exploración", "física", "\n", "AL", "INGRESO", "EN", "ONCOLOGÍA", "MÉDICA", "\n", "PS", "4", ".", "Glasgow", "11", "(", "apertura", "espontánea", "de", "ojos", ",", "retira", "al", "dolor", ",", "no", "obedece", "órdenes", ",", "lenguaje", "incomprensible", ")", ".", "\n", "Pupilas", "isocóricas", "normorreactivas", ".", "Moviliza", "4", "miembros", ".", "\n", "Auscultación", "Cardio", "-", "Respiratoria", ":", "Normal", ".", "Abdomen", "normal", ".", "\n", "Miembros", "Inferiores", "sin", "edema", "ni", "signos", "Trombosis", "Venosa", "Profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "PRUEBAS", "DE", "LABORATORIO", "\n\n", "-", "Analítica", "31/08/15", ":", "\n", "", "Hemograma", ":", "Hb", "99", "g", "/", "l", ",", "resto", "normal", ".", "\n", "", "BioquÍmica", "sérica", ":", "Na", "112", "mEq", "/", "L", ",", "K", "3.2", "mEq", "/", "L", ",", "resto", "normal", ".", "\n", "", "Coagulación", ":", "Normal", ".", "\n", "-", "Gasometría", "Venosa", "31/05/15", ":", "EVOLUCIÓN", ".", "\n", "", "Na", ":", "111", "(", "15.00pm", ")", "-", ">", "113", "(", "16.00pm", ")", "-", ">", "116", "(", "17.00pm", ")", "-", ">", "116", "(", "18.45pm", ")", "\n", "", "Osm", ":", "229", "-", ">", "233", "-", ">", "237-", ">", "237", ".", "\n", "-", "IONES", "ORINA", ":", "Na", "110", "mEq", "/", "L", "(", "elevado", ")", ",", "K", "10", "mEq", "/", "L.", "Proteinuria", ".", "\n", "-", "Marcadores", "tumorales", "01/09/16", ":", "CEA", "5,1", "ng", "/", "ml", "(", "descenso", ",", "al", "diagnóstico", "de", "7.9", "ng", "/", "ml", ")", ".", "CA", "125", "977", "U", "/", "ml", "(", "franco", "descenso", ",", "al", "diagnóstico", "de", "46852", "U", "/", "ml", ")", ".", "\n", "-", "Analítica", "10/09/16", "(", "PREVIA", "AL", "ALTA", "):", "\n", "", "Bioquímica", ":", "Urea", "45", "mg", "/", "dl", ",", "proteinas", "totales", "6", "gr", "/", "dl", ",", "fósforo", "inorgánico", "2,55", "mg", "/", "dl", ".", "Sodio", "normal", "(", "139", "mEq", "/", "L", ")", ".", "\n", "*", "Hemograma", ":", "Hemoglobina", "98", "gr", "/", "L.", "Series", "blanca", "y", "paquetaria", "normales", ".", "\n\n", "PRUEBAS", "IMAGEN", "\n", "-", "TAC", "de", "tórax", "y", "abdomen", "(", "3/09/2015", ")", ".", "Nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "sin", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "pleural", ".", "Han", "desaparecido", "los", "engrosamientos", "pleurales", ".", "En", "hígado", "sigue", "apreciándose", "pequeño", "nódulo", "de", "8", "mm", "en", "periferia", "subdiafragmática", "del", "segmento", "VIII", "de", "contenido", "predominantemente", "graso", "(", "angiomiolipoma", "hepático", "?", ")", ".", "Pequeña", "lesión", "focal", "hipodensa", "en", "periferia", "del", "segmento", "VII", "de", "6", "mm", "de", "diámetro", ",", "indeterminada", ".", "Masa", "mesentérica", "de", "72", "x", "27", "x", "34", "mm", "de", "mayor", "tamaño", "que", "en", "la", "TC", "previa", ",", "con", "cápsula", "periférica", "bien", "definida", "y", "con", "contenido", "interno", "graso", "con", "polos", "sólidos", "de", "aspecto", "tumoral", "y", "de", "extirpe", "histológica", "diferente", "al", "tumor", "ovárico", ".", "Persisten", "masas", "tumorales", "pélvicas", "que", "rodean", "el", "rectosigma", ",", "útero", "y", "ocupan", "ambas", "fosas", "anexiales", "que", "se", "han", "reducido", "notablemente", "de", "tamaño", "respecto", "a", "la", "TC", "previa", ".", "Ha", "desaparecido", "la", "ascitis", ".", "Con", "ventana", "de", "hueso", "no", "se", "han", "apreciado", "imágenes", "sugestivas", "enfermedad", "metastásica", "ósea", ".", "\n\n", "-", "RM", "cerebral", "(", "7/09/2015", ")", ".", "No", "existen", "lesiones", "intraparenquimatosas", "ni", "que", "afecten", "a", "las", "meninges", ".", "\n\n", "INTERVENCIONISMO", "\n\n", "-", "Anatomía", "patológica", "biopsia", "core", "masa", "abdominal", "residual", "(", "con", "control", "ecográfico", ")", "11/09/16", ":", "\n", "BIOPSIA", "INSUFICIENTE", "PARA", "DIAGNÓSTICO", "CONSTITUIDA", "POR", "TEJIDO", "FIBROADIPOSO", ",", "CON", "PRESENCIA", "DE", "MACRÓFAGOS", "Y", "CAMBIOS", "INFLAMATORIOS", ".", "Comentario", ":", "No", "se", "han", "identificado", "signos", "morfológicos", "de", "malignidad", ".", "\n\n", "Diagnóstico", "\n", "-", "INGRESO", "EN", "PLANTA", "POR", ":", "\n", "1", ".", "Hiponatremia", "profunda", ",", "sintomáticamente", "severa", "y", "de", "carácter", "crónico", "y", "dos", "episodios", "graves", "documentados", "de", "somnolencia", ",", "confusión", "y", "convulsiones", ",", "por", "probable", "SIADH", "asociado", "a", "carboplatino", ".", "\n", "2", ".", "Proteinuria", "y", "tendencia", "a", "la", "hipertensión", "arterial", "seguramente", "secundaria", "a", "toxicidad", "por", "Bevacizumab", ".", "\n", "3", ".", "Masa", "abdominal", "de", "unos", "8", "-", "9", "cms", "de", "densidad", "grasa", "en", "raíz", "de", "mesenterio", "que", "ha", "crecido", "de", "forma", "aislada", "y", "que", "parece", "de", "etiología", "diferente", "al", "adenocarcinoma", "diagnosticado", "previamente", ".", "\n", "-", "PATOLOGÍA", "BASAL", ":", "Adenocarcinoma", "seroso", "G3", "de", "ovario", "estadio", "IV", "en", "RP", "tras", "4", "ciclos", "de", "Carbo", "-", "Taxol", "-", "Beva", "(", "corroborada", "en", "TAC", "de", "reevaluación", "y", "con", "descenso", "muy", "importante", "de", "marcadores", "séricos", ")", ".", "\n\n", "Tratamiento", "\n", "TRATAMIENTO", "AL", "ALTA", "DE", "PLANTA", "\n", "-", "Dieta", "normal", ".", "\n", "-", "Retirada", "de", "tratamiento", "de", "primera", "línea", "con", "Carbo", "-", "Paclitaxel", "-", "Bevacizumab", ".", "\n", "-", "Ingesta", "de", "líquidos", "sin", "restricciones", "(", "no", "tomar", "mas", "de", "2", "litros", "diarios", ")", "\n", "-", "Tratamiento", "hipotensor", "con", "Losartán", "50", ":", "1", "-", "0", "-", "0", "y", "si", "presiste", "TA", "elevadas", "(", ">", "160/80", "mmHg", ")", ",", "añadir", "manidipino", "10", ":", "0", "-", "0", "-", "1", ".", "\n", "-", "Omeprazol", "20", "mgrs", "al", "día", "vía", "oral", ".", "\n", "-", "Dexametasona", "4", "mgrs", "cada", "12", "horas", "vía", "oral", ".", "Seguir", "pauta", "descendente", ".", "\n", "-", "Lorazepam", "2", "mgrs", "por", "las", "noches", ".", "\n", "-", "Levotiroxina", "50", "mcgrs", "al", "día", "(", "por", "las", "mañans", ")", ".", "\n", "-", "No", "precisa", "tratamiento", "con", "Tolvaptán", ".", "\n\n", "Evolución", "\n", "La", "evolución", "de", "la", "paciente", "durante", "el", "ingreso", "fue", ",", "al", "principio", ",", "bastante", "tórpida", "por", "persistencia", "del", "estado", "de", "sopor", "y", "de", "bajo", "nivel", "de", "conciencia", "y", "por", "presentar", "episodios", "de", "agitación", "intermitentes", "a", "pesar", "de", "la", "normalización", "progresiva", "y", "lenta", "de", "los", "nivels", "de", "sodio", "sérico", ".", "Si", "bien", "lo", "anterior", ",", "no", "presentó", "en", "más", "ocasiones", "crisis", "convulsivas", ",", "manteniéndose", "en", "todo", "momento", "afebril", "y", "sin", "otros", "déficits", "neurológicos", ".", "Además", "poliuria", "con", "natriuresis", "normal", "y", "con", "creatinina", "sérica", "y", "ácido", "úrico", "normales", ".", "Por", "fin", ",", "tras", "elevación", "de", "la", "osmolalidad", "plasmática", "progresiva", "y", "tratamiento", "con", "dosis", "moderadas", "de", "dexametasona", "además", "de", "restricción", "de", "aporte", "liquidos", ",", "mejoró", "de", "forma", "ostensible", "a", "nivel", "neurológico", ",", "permaneciendo", "en", "los", "últimos", "días", "del", "ingreso", "consciente", "y", "cada", "vez", "más", "orientada", "y", "alerta", ",", "mejorando", "progresivamene", "su", "estado", "general", ".", "No", "obstante", ",", "durante", "su", "ingreso", "se", "ha", "objetivado", "de", "forma", "progresiva", "tendencia", "a", "la", "hipertensió", "arterial", "ademá", "de", "proteinuria", "discreta", ",", "siendo", "bien", "controladas", "con", "Losartán", ".", "Al", "alta", "de", "con", "sodio", "plasmático", "normal", "y", "con", "estado", "general", "conservado", ",", "afebril", "y", "tolerando", "dieta", "oral", "ademas", "de", "ausenxcia", "de", "deficits", "neurologicos", ".", "\n", "En", "cuanto", "a", "la", "causa", "de", "la", "hiponatremia", ",", "la", "pacinete", "fue", "valorado", "por", "Nefrología", "(", "continúa", "en", "sus", "consultas", ")", ",", "siendo", "diagnosticada", "de", "SIADH", "en", "relación", "a", "Carboplatino", "(", "diagnóstico", "de", "exclusión", ")", "vs", "SIADH", "como", "síndrome", "paraneoplásico", "en", "relación", "al", "tumor", ".", "Inicia", "nueva", "línea", "de", "QT", "con", "adriamicina", "liposomal", "en", "Noviembre/15", "(", "recibe", "únicamente", "1", "ciclo", ")", ".", "Dado", "que", "el", "SIADH", "se", "relaciona", "poco", "con", "un", "adenocarcinoma", "de", "pulmón", ",", "se", "decidió", "tomar", "muestra", "de", "la", "masa", "residual", "retroperitoneal", "(", "dado", "que", "parecía", "de", "una", "estirpe", "diferente", ")", ",", "por", "lo", "que", "la", "paciente", "se", "comentó", "en", "Comité", "de", "Tumores", ".", "Se", "decide", "resección", "de", "la", "masa", ":", "Intervención", "Quirúrgica", "(", "Enero/16", "):", "exéresis", "de", "la", "masa", "mesentérica", ",", "ooforectomía", "bilateral", ",", "omentectomía", "con", "implante", "tumoral", "peritoneal", ".", "\n", "Anatomía", "patológica", "de", "adenocarcinoma", "de", "origen", "ovárico", ".", "Posteriormente", "continúa", "con", "QT", "basada", "en", "adriamicina", "liposomal", ",", "y", "recibe", "un", "total", "de", "3", "ciclos", "(", "contando", "con", "el", "previo", "a", "la", "cirugía", ")", ",", "decidiéndose", "STOP", "en", "Abril/15", "por", "astenia", "importante", ".", "En", "la", "reevaluación", "de", "Mayo/15", "se", "objetiva", "respuesta", "completa", "por", "imagen", "y", "por", "marcadores", ".", "Desde", "la", "retirada", "del", "carboplatino", ",", "no", "ha", "vuelto", "a", "presentar", "hiponatremia", ".", "\n", "-", "TC", "tórax", "-", "abdomen", "Mayo/15", ":", "Tórax", ":", "Persiste", "nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "estable", "respecto", "al", "estudios", "previos", ",", "asi", "como", "en", "segmento", "laterobasal", "del", "LID", ",", "sin", "cambios", "también", ".", "No", "hay", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "ni", "engrosamiento", "pleural", ".", "Múltiples", "nódulos", "calcificados", "en", "ambas", "mamas", ".", "Resto", "del", "tórax", "sin", "hallazgos", "de", "interés", ".", "Abdomen", ":", "Hígado", "de", "tamaño", "normal", "y", "contorno", "liso", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "pequeño", "tamaño", "ya", "conocida", ".", "Vía", "biliar", "intra", "y", "extrahepática", "de", "calibre", "normal", ".", "Vesícula", "biliar", "sin", "alteraciones", ".", "\n", "Bazo", ",", "pancreas", ",", "adrenales", "y", "riñones", "sin", "hallazgos", "de", "interés", ".", "Estómago", ",", "asas", "de", "intestino", "delgado", "y", "colon", "sin", "dilataciones", "ni", "engrosamientos", "murales", ".", "\n", "Vejiga", "urinaria", "bien", "replecionada", "sin", "engrosamiento", "de", "la", "pared", ".", "Histerectomizada", "con", "doble", "anexectomía", ",", "sin", "imágenes", "de", "recidiva", ".", "Resto", "del", "abdomen", "sin", "hallazgos", "de", "interés", ".", "Conclusión", ":", "Nódulos", "pulmonares", "estables", ".", "Nódulos", "mamarios", "calcificados", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "estable", ".", "Ausencia", "quirúrgica", "de", "genitales", "internos", ".", "\n", "-", "Evolución", "de", "Ca", "125", ":", "46852", "U", "/", "ml", "(", "diagnóstico", ")", "--", ">", "19.4", "U", "/", "ml", "(", "Mayo/16", ")", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural, afectación meníngea, angiomiolipoma, tumoral, tumor, tumorales, metastásica, lesiones intraparenquimatosas, malignidad, adenocarcinoma, Adenocarcinoma seroso G3, tumor, adenocarcinoma, masa residual retroperitoneal, masa mesentérica, implante tumoral, adenocarcinoma	205_task2	Sentence: Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16).	[ "Anamnesis", "\n", "Mujer", "68", "años", ".", "\n", "-", "Alergia", "a", "amoxicilina", "y", "moxifloxacino", "(", "con", "estudio", "por", "alergología", ")", ".", "\n", "-", "No", "hábitos", "tóxicos", ".", "\n", "-", "No", "factores", "de", "riesgo", "cardiovascular", ".", "\n\n", "-", "Hipotiroidismo", ".", "\n", "-", "Antecedentes", "quirúrgicos", ":", "histerectomía", "sin", "anexectomía", "con", "41", "años", ".", "\n", "-", "Tratamiento", "habitual", ":", "Levotiroxina", ",", "Guayana", "en", "comprimidos", ".", "\n\n", "", "", "HISTORIA", "ONCOLÓGICA", ":", "\n", "-", "Diagnóstico", "en", "Mayo/2015", "de", "Adenocarcinoma", "seroso", "de", "ovario", "G3", "estadio", "IV", "por", "afectación", "pleural", ".", "Inicia", "tratamiento", "con", "quimioterapia", "(", "QT", ")", "según", "esquema", "Carboplatino", "(", "AUC", "5", "cada", "3", "semanas", ")", "-", "Paclitaxel", "(", "175", "mg", "/", "m2", "cada", "3", "semanas", ")", "-", "Bevacizumab", "(", "15", "mg", "/", "kg", ")", ",", "del", "que", "recibe", "un", "total", "de", "4", "ciclos", ",", "último", "el", "07/08/15", "con", "reducción", "10", "%", "en", "4º", "ciclo", "por", "astenia", "G3", ".", "Respuesta", "parcial", "bioquímica", "(", "descenso", "importante", "del", "Ca", "125", ")", "y", "por", "imagen", ".", "\n\n", "", "", "22/08/16", ":", "Paciente", "con", "clínica", "de", "1", "mes", "aproximadamente", "de", "duración", "(", "tras", "3º", "ciclo", "de", "QT", "el", "14/07/15", ")", "consistente", "en", "cuadro", "de", "desorientación", ".", "Tras", "4º", "ciclo", "de", "QT", "el", "07/08/15", ",", "con", "mala", "tolerancia", "al", "mismo", ",", "presenta", "empeoramiento", "del", "cuadro", "neurológico", "con", "crisis", "convulsiva", "el", "22/08/15", "por", "lo", "que", "es", "traída", "a", "urgencias", "por", "sus", "familiares", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "118", "mEq", "/", "L.", "Se", "realiza", "TAC", "craneal", "sin", "hallazgos", "patológicos", "y", "sin", "hacer", "referencia", "a", "existencia", "de", "edema", "cerebral", ",", "y", "se", "inicia", "correción", "hidroelectrolítica", "con", "mejoria", "rápida", "del", "cuadro", ",", "aunque", "no", "resolución", "completa", ".", "Es", "dada", "de", "alta", "tras", "24", "horas", "en", "observación", "y", "con", "cifra", "de", "Na", "133", "mEq", "/", "L.", "\n", "El", "28/08/15", "en", "valorada", "en", "hospital", "de", "día", "de", "Oncología", "para", "5º", "cliclo", ",", "que", "se", "suspende", "por", "persitencia", "de", "cuadro", "neurológico", "a", "pesar", "de", "Na", "corregido", "(", "134", "mEq", "/", "L", ")", ",", "mala", "tolerancia", "al", "4º", "ciclo", "y", "episodio", "de", "fiebre", "puntual", "el", "26/08/15", "secundario", "a", "fístula", "perianal", "en", "tratamiento", "con", "Eritromicina", ".", "En", "dicha", "consulta", ",", "debido", "a", "persistencia", "del", "cuadro", "neurologico", ",", "se", "solicita", "RMN", "craneal", "a", "fin", "de", "descartar", "afectación", "meníngea", "que", "pudiera", "explicar", "el", "cuadro", ".", "\n", "El", "31/08/16", "consulta", "nuevamente", "en", "urgencias", "por", "episodio", "convulsivo", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "112", "mEq", "/", "L", ",", "por", "lo", "que", "se", "inicia", "corrección", "de", "la", "misma", "con", "mejoría", "rápida", "del", "cuadro", "en", "24", "horas", "y", "posteriormente", "trasladada", "a", "planta", "de", "Oncología", "para", "continuidad", "de", "cuidados", ".", "\n\n", "Exploración", "física", "\n", "AL", "INGRESO", "EN", "ONCOLOGÍA", "MÉDICA", "\n", "PS", "4", ".", "Glasgow", "11", "(", "apertura", "espontánea", "de", "ojos", ",", "retira", "al", "dolor", ",", "no", "obedece", "órdenes", ",", "lenguaje", "incomprensible", ")", ".", "\n", "Pupilas", "isocóricas", "normorreactivas", ".", "Moviliza", "4", "miembros", ".", "\n", "Auscultación", "Cardio", "-", "Respiratoria", ":", "Normal", ".", "Abdomen", "normal", ".", "\n", "Miembros", "Inferiores", "sin", "edema", "ni", "signos", "Trombosis", "Venosa", "Profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "PRUEBAS", "DE", "LABORATORIO", "\n\n", "-", "Analítica", "31/08/15", ":", "\n", "", "Hemograma", ":", "Hb", "99", "g", "/", "l", ",", "resto", "normal", ".", "\n", "", "BioquÍmica", "sérica", ":", "Na", "112", "mEq", "/", "L", ",", "K", "3.2", "mEq", "/", "L", ",", "resto", "normal", ".", "\n", "", "Coagulación", ":", "Normal", ".", "\n", "-", "Gasometría", "Venosa", "31/05/15", ":", "EVOLUCIÓN", ".", "\n", "", "Na", ":", "111", "(", "15.00pm", ")", "-", ">", "113", "(", "16.00pm", ")", "-", ">", "116", "(", "17.00pm", ")", "-", ">", "116", "(", "18.45pm", ")", "\n", "", "Osm", ":", "229", "-", ">", "233", "-", ">", "237-", ">", "237", ".", "\n", "-", "IONES", "ORINA", ":", "Na", "110", "mEq", "/", "L", "(", "elevado", ")", ",", "K", "10", "mEq", "/", "L.", "Proteinuria", ".", "\n", "-", "Marcadores", "tumorales", "01/09/16", ":", "CEA", "5,1", "ng", "/", "ml", "(", "descenso", ",", "al", "diagnóstico", "de", "7.9", "ng", "/", "ml", ")", ".", "CA", "125", "977", "U", "/", "ml", "(", "franco", "descenso", ",", "al", "diagnóstico", "de", "46852", "U", "/", "ml", ")", ".", "\n", "-", "Analítica", "10/09/16", "(", "PREVIA", "AL", "ALTA", "):", "\n", "", "Bioquímica", ":", "Urea", "45", "mg", "/", "dl", ",", "proteinas", "totales", "6", "gr", "/", "dl", ",", "fósforo", "inorgánico", "2,55", "mg", "/", "dl", ".", "Sodio", "normal", "(", "139", "mEq", "/", "L", ")", ".", "\n", "*", "Hemograma", ":", "Hemoglobina", "98", "gr", "/", "L.", "Series", "blanca", "y", "paquetaria", "normales", ".", "\n\n", "PRUEBAS", "IMAGEN", "\n", "-", "TAC", "de", "tórax", "y", "abdomen", "(", "3/09/2015", ")", ".", "Nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "sin", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "pleural", ".", "Han", "desaparecido", "los", "engrosamientos", "pleurales", ".", "En", "hígado", "sigue", "apreciándose", "pequeño", "nódulo", "de", "8", "mm", "en", "periferia", "subdiafragmática", "del", "segmento", "VIII", "de", "contenido", "predominantemente", "graso", "(", "angiomiolipoma", "hepático", "?", ")", ".", "Pequeña", "lesión", "focal", "hipodensa", "en", "periferia", "del", "segmento", "VII", "de", "6", "mm", "de", "diámetro", ",", "indeterminada", ".", "Masa", "mesentérica", "de", "72", "x", "27", "x", "34", "mm", "de", "mayor", "tamaño", "que", "en", "la", "TC", "previa", ",", "con", "cápsula", "periférica", "bien", "definida", "y", "con", "contenido", "interno", "graso", "con", "polos", "sólidos", "de", "aspecto", "tumoral", "y", "de", "extirpe", "histológica", "diferente", "al", "tumor", "ovárico", ".", "Persisten", "masas", "tumorales", "pélvicas", "que", "rodean", "el", "rectosigma", ",", "útero", "y", "ocupan", "ambas", "fosas", "anexiales", "que", "se", "han", "reducido", "notablemente", "de", "tamaño", "respecto", "a", "la", "TC", "previa", ".", "Ha", "desaparecido", "la", "ascitis", ".", "Con", "ventana", "de", "hueso", "no", "se", "han", "apreciado", "imágenes", "sugestivas", "enfermedad", "metastásica", "ósea", ".", "\n\n", "-", "RM", "cerebral", "(", "7/09/2015", ")", ".", "No", "existen", "lesiones", "intraparenquimatosas", "ni", "que", "afecten", "a", "las", "meninges", ".", "\n\n", "INTERVENCIONISMO", "\n\n", "-", "Anatomía", "patológica", "biopsia", "core", "masa", "abdominal", "residual", "(", "con", "control", "ecográfico", ")", "11/09/16", ":", "\n", "BIOPSIA", "INSUFICIENTE", "PARA", "DIAGNÓSTICO", "CONSTITUIDA", "POR", "TEJIDO", "FIBROADIPOSO", ",", "CON", "PRESENCIA", "DE", "MACRÓFAGOS", "Y", "CAMBIOS", "INFLAMATORIOS", ".", "Comentario", ":", "No", "se", "han", "identificado", "signos", "morfológicos", "de", "malignidad", ".", "\n\n", "Diagnóstico", "\n", "-", "INGRESO", "EN", "PLANTA", "POR", ":", "\n", "1", ".", "Hiponatremia", "profunda", ",", "sintomáticamente", "severa", "y", "de", "carácter", "crónico", "y", "dos", "episodios", "graves", "documentados", "de", "somnolencia", ",", "confusión", "y", "convulsiones", ",", "por", "probable", "SIADH", "asociado", "a", "carboplatino", ".", "\n", "2", ".", "Proteinuria", "y", "tendencia", "a", "la", "hipertensión", "arterial", "seguramente", "secundaria", "a", "toxicidad", "por", "Bevacizumab", ".", "\n", "3", ".", "Masa", "abdominal", "de", "unos", "8", "-", "9", "cms", "de", "densidad", "grasa", "en", "raíz", "de", "mesenterio", "que", "ha", "crecido", "de", "forma", "aislada", "y", "que", "parece", "de", "etiología", "diferente", "al", "adenocarcinoma", "diagnosticado", "previamente", ".", "\n", "-", "PATOLOGÍA", "BASAL", ":", "Adenocarcinoma", "seroso", "G3", "de", "ovario", "estadio", "IV", "en", "RP", "tras", "4", "ciclos", "de", "Carbo", "-", "Taxol", "-", "Beva", "(", "corroborada", "en", "TAC", "de", "reevaluación", "y", "con", "descenso", "muy", "importante", "de", "marcadores", "séricos", ")", ".", "\n\n", "Tratamiento", "\n", "TRATAMIENTO", "AL", "ALTA", "DE", "PLANTA", "\n", "-", "Dieta", "normal", ".", "\n", "-", "Retirada", "de", "tratamiento", "de", "primera", "línea", "con", "Carbo", "-", "Paclitaxel", "-", "Bevacizumab", ".", "\n", "-", "Ingesta", "de", "líquidos", "sin", "restricciones", "(", "no", "tomar", "mas", "de", "2", "litros", "diarios", ")", "\n", "-", "Tratamiento", "hipotensor", "con", "Losartán", "50", ":", "1", "-", "0", "-", "0", "y", "si", "presiste", "TA", "elevadas", "(", ">", "160/80", "mmHg", ")", ",", "añadir", "manidipino", "10", ":", "0", "-", "0", "-", "1", ".", "\n", "-", "Omeprazol", "20", "mgrs", "al", "día", "vía", "oral", ".", "\n", "-", "Dexametasona", "4", "mgrs", "cada", "12", "horas", "vía", "oral", ".", "Seguir", "pauta", "descendente", ".", "\n", "-", "Lorazepam", "2", "mgrs", "por", "las", "noches", ".", "\n", "-", "Levotiroxina", "50", "mcgrs", "al", "día", "(", "por", "las", "mañans", ")", ".", "\n", "-", "No", "precisa", "tratamiento", "con", "Tolvaptán", ".", "\n\n", "Evolución", "\n", "La", "evolución", "de", "la", "paciente", "durante", "el", "ingreso", "fue", ",", "al", "principio", ",", "bastante", "tórpida", "por", "persistencia", "del", "estado", "de", "sopor", "y", "de", "bajo", "nivel", "de", "conciencia", "y", "por", "presentar", "episodios", "de", "agitación", "intermitentes", "a", "pesar", "de", "la", "normalización", "progresiva", "y", "lenta", "de", "los", "nivels", "de", "sodio", "sérico", ".", "Si", "bien", "lo", "anterior", ",", "no", "presentó", "en", "más", "ocasiones", "crisis", "convulsivas", ",", "manteniéndose", "en", "todo", "momento", "afebril", "y", "sin", "otros", "déficits", "neurológicos", ".", "Además", "poliuria", "con", "natriuresis", "normal", "y", "con", "creatinina", "sérica", "y", "ácido", "úrico", "normales", ".", "Por", "fin", ",", "tras", "elevación", "de", "la", "osmolalidad", "plasmática", "progresiva", "y", "tratamiento", "con", "dosis", "moderadas", "de", "dexametasona", "además", "de", "restricción", "de", "aporte", "liquidos", ",", "mejoró", "de", "forma", "ostensible", "a", "nivel", "neurológico", ",", "permaneciendo", "en", "los", "últimos", "días", "del", "ingreso", "consciente", "y", "cada", "vez", "más", "orientada", "y", "alerta", ",", "mejorando", "progresivamene", "su", "estado", "general", ".", "No", "obstante", ",", "durante", "su", "ingreso", "se", "ha", "objetivado", "de", "forma", "progresiva", "tendencia", "a", "la", "hipertensió", "arterial", "ademá", "de", "proteinuria", "discreta", ",", "siendo", "bien", "controladas", "con", "Losartán", ".", "Al", "alta", "de", "con", "sodio", "plasmático", "normal", "y", "con", "estado", "general", "conservado", ",", "afebril", "y", "tolerando", "dieta", "oral", "ademas", "de", "ausenxcia", "de", "deficits", "neurologicos", ".", "\n", "En", "cuanto", "a", "la", "causa", "de", "la", "hiponatremia", ",", "la", "pacinete", "fue", "valorado", "por", "Nefrología", "(", "continúa", "en", "sus", "consultas", ")", ",", "siendo", "diagnosticada", "de", "SIADH", "en", "relación", "a", "Carboplatino", "(", "diagnóstico", "de", "exclusión", ")", "vs", "SIADH", "como", "síndrome", "paraneoplásico", "en", "relación", "al", "tumor", ".", "Inicia", "nueva", "línea", "de", "QT", "con", "adriamicina", "liposomal", "en", "Noviembre/15", "(", "recibe", "únicamente", "1", "ciclo", ")", ".", "Dado", "que", "el", "SIADH", "se", "relaciona", "poco", "con", "un", "adenocarcinoma", "de", "pulmón", ",", "se", "decidió", "tomar", "muestra", "de", "la", "masa", "residual", "retroperitoneal", "(", "dado", "que", "parecía", "de", "una", "estirpe", "diferente", ")", ",", "por", "lo", "que", "la", "paciente", "se", "comentó", "en", "Comité", "de", "Tumores", ".", "Se", "decide", "resección", "de", "la", "masa", ":", "Intervención", "Quirúrgica", "(", "Enero/16", "):", "exéresis", "de", "la", "masa", "mesentérica", ",", "ooforectomía", "bilateral", ",", "omentectomía", "con", "implante", "tumoral", "peritoneal", ".", "\n", "Anatomía", "patológica", "de", "adenocarcinoma", "de", "origen", "ovárico", ".", "Posteriormente", "continúa", "con", "QT", "basada", "en", "adriamicina", "liposomal", ",", "y", "recibe", "un", "total", "de", "3", "ciclos", "(", "contando", "con", "el", "previo", "a", "la", "cirugía", ")", ",", "decidiéndose", "STOP", "en", "Abril/15", "por", "astenia", "importante", ".", "En", "la", "reevaluación", "de", "Mayo/15", "se", "objetiva", "respuesta", "completa", "por", "imagen", "y", "por", "marcadores", ".", "Desde", "la", "retirada", "del", "carboplatino", ",", "no", "ha", "vuelto", "a", "presentar", "hiponatremia", ".", "\n", "-", "TC", "tórax", "-", "abdomen", "Mayo/15", ":", "Tórax", ":", "Persiste", "nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "estable", "respecto", "al", "estudios", "previos", ",", "asi", "como", "en", "segmento", "laterobasal", "del", "LID", ",", "sin", "cambios", "también", ".", "No", "hay", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "ni", "engrosamiento", "pleural", ".", "Múltiples", "nódulos", "calcificados", "en", "ambas", "mamas", ".", "Resto", "del", "tórax", "sin", "hallazgos", "de", "interés", ".", "Abdomen", ":", "Hígado", "de", "tamaño", "normal", "y", "contorno", "liso", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "pequeño", "tamaño", "ya", "conocida", ".", "Vía", "biliar", "intra", "y", "extrahepática", "de", "calibre", "normal", ".", "Vesícula", "biliar", "sin", "alteraciones", ".", "\n", "Bazo", ",", "pancreas", ",", "adrenales", "y", "riñones", "sin", "hallazgos", "de", "interés", ".", "Estómago", ",", "asas", "de", "intestino", "delgado", "y", "colon", "sin", "dilataciones", "ni", "engrosamientos", "murales", ".", "\n", "Vejiga", "urinaria", "bien", "replecionada", "sin", "engrosamiento", "de", "la", "pared", ".", "Histerectomizada", "con", "doble", "anexectomía", ",", "sin", "imágenes", "de", "recidiva", ".", "Resto", "del", "abdomen", "sin", "hallazgos", "de", "interés", ".", "Conclusión", ":", "Nódulos", "pulmonares", "estables", ".", "Nódulos", "mamarios", "calcificados", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "estable", ".", "Ausencia", "quirúrgica", "de", "genitales", "internos", ".", "\n", "-", "Evolución", "de", "Ca", "125", ":", "46852", "U", "/", "ml", "(", "diagnóstico", ")", "--", ">", "19.4", "U", "/", "ml", "(", "Mayo/16", ")", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
dasatinib is a CHEMICAL, BMS-354825 is a CHEMICAL, kinase is a GENE-N, SRC is a GENE-Y, BCR is a GENE-Y, ABL is a GENE-Y	17429625_task0	Sentence: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O" ]	Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.	[ "Preclinical", "pharmacokinetics", "and", "in", "vitro", "metabolism", "of", "dasatinib", "(", "BMS-354825", "):", "a", "potent", "oral", "multi", "-", "targeted", "kinase", "inhibitor", "against", "SRC", "and", "BCR", "-", "ABL", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
dasatinib is a CHEMICAL, BMS-354825 is a CHEMICAL, kinase is a GENE-N, SRC is a GENE-Y, BCR is a GENE-Y, ABL is a GENE-Y	17429625_task1	Sentence: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Instructions: please typing these entity words according to sentence: dasatinib, BMS-354825, kinase, SRC, BCR, ABL Options: GENE-Y, GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O" ]	Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.	[ "Preclinical", "pharmacokinetics", "and", "in", "vitro", "metabolism", "of", "dasatinib", "(", "BMS-354825", "):", "a", "potent", "oral", "multi", "-", "targeted", "kinase", "inhibitor", "against", "SRC", "and", "BCR", "-", "ABL", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
dasatinib, BMS-354825, kinase, SRC, BCR, ABL	17429625_task2	Sentence: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O" ]	Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.	[ "Preclinical", "pharmacokinetics", "and", "in", "vitro", "metabolism", "of", "dasatinib", "(", "BMS-354825", "):", "a", "potent", "oral", "multi", "-", "targeted", "kinase", "inhibitor", "against", "SRC", "and", "BCR", "-", "ABL", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Rel / NF - kappaB is a Protein, Notch is a Protein, Jagged1 is a Ligand, ligand is a Ligand, Notch receptors is a Protein, Jagged1 is a Ligand, DSL family is a Ligand, ligands is a Ligand, Notch receptors is a Protein, cell lineages is a Cell, transcription factors is a TranscriptionFactor, Jagged1 is a Ligand, Rel / NF - kappaB is a Protein, gene is a Gene, c - Rel is a Protein, RelA is a Protein, jagged1 is a Ligand, jagged1 is a Ligand, transcripts is a Transcript, NF - kappaB is a Protein, dominant mutant is a MutantProtein, IkappaBalpha is a Protein, Cell surface is a CellComponent, Jagged1 is a Ligand, c - Rel is a Protein, cell is a Cell, lymphocytes is a Cell, Notch1 / TAN-1 receptor is a Protein, Notch is a Protein, HES-1 is a Protein, transcripts is a Transcript, T cells is a Cell, CD23 is a Protein, transcripts is a Transcript, B cells is a Cell, Rel / NF - kappaB is a Protein, Jagged1 is a Ligand, splenic is a Tissue, B cells is a Cell, c - Rel is a Protein, c - Rel is a Protein, Notch is a Protein, jagged1 is a Ligand, Jagged1 is a Ligand, B - cell is a Cell, Notch is a Protein, NF - kappaB is a Protein	50_task0	Sentence: Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, TranscriptionFactor, CellComponent, Gene, Transcript, Ligand, MutantProtein, Protein, Cell	[ "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "B-Ligand", "O", "O", "O", "B-Ligand", "I-Ligand", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Gene", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "B-Transcript", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "B-Cell", "I-Cell", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system.	[ "Rel", "/", "NF", "-", "kappaB", "can", "trigger", "the", "Notch", "signaling", "pathway", "by", "inducing", "the", "expression", "of", "Jagged1", ",", "a", "ligand", "for", "Notch", "receptors", ".", "Jagged1", "belongs", "to", "the", "DSL", "family", "of", "ligands", "for", "Notch", "receptors", "that", "control", "the", "proliferation", "and", "differentiation", "of", "various", "cell", "lineages", ".", "However", ",", "little", "is", "known", "about", "the", "transcription", "factors", "that", "regulate", "its", "expression", ".", "Here", ",", "we", "show", "that", "Jagged1", "is", "a", "Rel", "/", "NF", "-", "kappaB", "-", "responsive", "gene", ".", "Both", "c", "-", "Rel", "and", "RelA", "induced", "jagged1", "gene", "expression", ",", "whereas", "a", "mutant", "defective", "for", "transactivation", "did", "not", ".", "Importantly", ",", "jagged1", "transcripts", "were", "also", "upregulated", "by", "endogenous", "NF", "-", "kappaB", "activation", "and", "this", "effect", "was", "inhibited", "by", "a", "dominant", "mutant", "of", "IkappaBalpha", ",", "a", "physiological", "inhibitor", "of", "NF", "-", "kappaB.", "Cell", "surface", "expression", "of", "Jagged1", "in", "c", "-", "Rel", "-", "expressing", "cell", "monolayers", "led", "to", "a", "functional", "interaction", "with", "lymphocytes", "expressing", "the", "Notch1", "/", "TAN-1", "receptor", ".", "This", "correlated", "with", "the", "initiation", "of", "signaling", "downstream", "of", "Notch", ",", "as", "evidenced", "by", "increased", "levels", "of", "HES-1", "transcripts", "in", "co", "-", "cultivated", "T", "cells", "and", "of", "CD23", "transcripts", "in", "co", "-", "cultivated", "B", "cells", ".", "Consistent", "with", "its", "Rel", "/", "NF", "-", "kappaB", "-", "dependent", "induction", ",", "Jagged1", "was", "found", "to", "be", "highly", "expressed", "in", "splenic", "B", "cells", "where", "c", "-", "Rel", "is", "expressed", "constitutively", ".", "These", "results", "demonstrate", "that", "c", "-", "Rel", "can", "trigger", "the", "Notch", "signaling", "pathway", "in", "neighboring", "cells", "by", "inducing", "jagged1", "gene", "expression", ",", "and", "suggest", "a", "role", "for", "Jagged1", "in", "B", "-", "cell", "activation", ",", "differentiation", "or", "function", ".", "These", "findings", "also", "highlight", "the", "potential", "for", "an", "interplay", "between", "the", "Notch", "and", "NF", "-", "kappaB", "signaling", "pathways", "in", "the", "immune", "system", ".", "\n" ]	[ "TranscriptionFactor", "Protein", "MutantProtein", "Cell", "CellComponent", "Transcript", "Ligand", "Tissue", "Gene" ]
Rel / NF - kappaB is a Protein, Notch is a Protein, Jagged1 is a Ligand, ligand is a Ligand, Notch receptors is a Protein, Jagged1 is a Ligand, DSL family is a Ligand, ligands is a Ligand, Notch receptors is a Protein, cell lineages is a Cell, transcription factors is a TranscriptionFactor, Jagged1 is a Ligand, Rel / NF - kappaB is a Protein, gene is a Gene, c - Rel is a Protein, RelA is a Protein, jagged1 is a Ligand, jagged1 is a Ligand, transcripts is a Transcript, NF - kappaB is a Protein, dominant mutant is a MutantProtein, IkappaBalpha is a Protein, Cell surface is a CellComponent, Jagged1 is a Ligand, c - Rel is a Protein, cell is a Cell, lymphocytes is a Cell, Notch1 / TAN-1 receptor is a Protein, Notch is a Protein, HES-1 is a Protein, transcripts is a Transcript, T cells is a Cell, CD23 is a Protein, transcripts is a Transcript, B cells is a Cell, Rel / NF - kappaB is a Protein, Jagged1 is a Ligand, splenic is a Tissue, B cells is a Cell, c - Rel is a Protein, c - Rel is a Protein, Notch is a Protein, jagged1 is a Ligand, Jagged1 is a Ligand, B - cell is a Cell, Notch is a Protein, NF - kappaB is a Protein	50_task1	Sentence: Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system. Instructions: please typing these entity words according to sentence: Rel / NF - kappaB, Notch, Jagged1, ligand, Notch receptors, Jagged1, DSL family, ligands, Notch receptors, cell lineages, transcription factors, Jagged1, Rel / NF - kappaB, gene, c - Rel, RelA, jagged1, jagged1, transcripts, NF - kappaB, dominant mutant, IkappaBalpha, Cell surface, Jagged1, c - Rel, cell, lymphocytes, Notch1 / TAN-1 receptor, Notch, HES-1, transcripts, T cells, CD23, transcripts, B cells, Rel / NF - kappaB, Jagged1, splenic, B cells, c - Rel, c - Rel, Notch, jagged1, Jagged1, B - cell, Notch, NF - kappaB Options: Tissue, TranscriptionFactor, CellComponent, Gene, Transcript, Ligand, MutantProtein, Protein, Cell	[ "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "B-Ligand", "O", "O", "O", "B-Ligand", "I-Ligand", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Gene", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "B-Transcript", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "B-Cell", "I-Cell", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system.	[ "Rel", "/", "NF", "-", "kappaB", "can", "trigger", "the", "Notch", "signaling", "pathway", "by", "inducing", "the", "expression", "of", "Jagged1", ",", "a", "ligand", "for", "Notch", "receptors", ".", "Jagged1", "belongs", "to", "the", "DSL", "family", "of", "ligands", "for", "Notch", "receptors", "that", "control", "the", "proliferation", "and", "differentiation", "of", "various", "cell", "lineages", ".", "However", ",", "little", "is", "known", "about", "the", "transcription", "factors", "that", "regulate", "its", "expression", ".", "Here", ",", "we", "show", "that", "Jagged1", "is", "a", "Rel", "/", "NF", "-", "kappaB", "-", "responsive", "gene", ".", "Both", "c", "-", "Rel", "and", "RelA", "induced", "jagged1", "gene", "expression", ",", "whereas", "a", "mutant", "defective", "for", "transactivation", "did", "not", ".", "Importantly", ",", "jagged1", "transcripts", "were", "also", "upregulated", "by", "endogenous", "NF", "-", "kappaB", "activation", "and", "this", "effect", "was", "inhibited", "by", "a", "dominant", "mutant", "of", "IkappaBalpha", ",", "a", "physiological", "inhibitor", "of", "NF", "-", "kappaB.", "Cell", "surface", "expression", "of", "Jagged1", "in", "c", "-", "Rel", "-", "expressing", "cell", "monolayers", "led", "to", "a", "functional", "interaction", "with", "lymphocytes", "expressing", "the", "Notch1", "/", "TAN-1", "receptor", ".", "This", "correlated", "with", "the", "initiation", "of", "signaling", "downstream", "of", "Notch", ",", "as", "evidenced", "by", "increased", "levels", "of", "HES-1", "transcripts", "in", "co", "-", "cultivated", "T", "cells", "and", "of", "CD23", "transcripts", "in", "co", "-", "cultivated", "B", "cells", ".", "Consistent", "with", "its", "Rel", "/", "NF", "-", "kappaB", "-", "dependent", "induction", ",", "Jagged1", "was", "found", "to", "be", "highly", "expressed", "in", "splenic", "B", "cells", "where", "c", "-", "Rel", "is", "expressed", "constitutively", ".", "These", "results", "demonstrate", "that", "c", "-", "Rel", "can", "trigger", "the", "Notch", "signaling", "pathway", "in", "neighboring", "cells", "by", "inducing", "jagged1", "gene", "expression", ",", "and", "suggest", "a", "role", "for", "Jagged1", "in", "B", "-", "cell", "activation", ",", "differentiation", "or", "function", ".", "These", "findings", "also", "highlight", "the", "potential", "for", "an", "interplay", "between", "the", "Notch", "and", "NF", "-", "kappaB", "signaling", "pathways", "in", "the", "immune", "system", ".", "\n" ]	[ "TranscriptionFactor", "Protein", "MutantProtein", "Cell", "CellComponent", "Transcript", "Ligand", "Tissue", "Gene" ]
Rel / NF - kappaB, Notch, Jagged1, ligand, Notch receptors, Jagged1, DSL family, ligands, Notch receptors, cell lineages, transcription factors, Jagged1, Rel / NF - kappaB, gene, c - Rel, RelA, jagged1, jagged1, transcripts, NF - kappaB, dominant mutant, IkappaBalpha, Cell surface, Jagged1, c - Rel, cell, lymphocytes, Notch1 / TAN-1 receptor, Notch, HES-1, transcripts, T cells, CD23, transcripts, B cells, Rel / NF - kappaB, Jagged1, splenic, B cells, c - Rel, c - Rel, Notch, jagged1, Jagged1, B - cell, Notch, NF - kappaB	50_task2	Sentence: Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system. Instructions: please extract entity words from the input sentence	[ "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "B-Ligand", "O", "O", "O", "B-Ligand", "I-Ligand", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Gene", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "B-Transcript", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "B-Cell", "I-Cell", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system.	[ "Rel", "/", "NF", "-", "kappaB", "can", "trigger", "the", "Notch", "signaling", "pathway", "by", "inducing", "the", "expression", "of", "Jagged1", ",", "a", "ligand", "for", "Notch", "receptors", ".", "Jagged1", "belongs", "to", "the", "DSL", "family", "of", "ligands", "for", "Notch", "receptors", "that", "control", "the", "proliferation", "and", "differentiation", "of", "various", "cell", "lineages", ".", "However", ",", "little", "is", "known", "about", "the", "transcription", "factors", "that", "regulate", "its", "expression", ".", "Here", ",", "we", "show", "that", "Jagged1", "is", "a", "Rel", "/", "NF", "-", "kappaB", "-", "responsive", "gene", ".", "Both", "c", "-", "Rel", "and", "RelA", "induced", "jagged1", "gene", "expression", ",", "whereas", "a", "mutant", "defective", "for", "transactivation", "did", "not", ".", "Importantly", ",", "jagged1", "transcripts", "were", "also", "upregulated", "by", "endogenous", "NF", "-", "kappaB", "activation", "and", "this", "effect", "was", "inhibited", "by", "a", "dominant", "mutant", "of", "IkappaBalpha", ",", "a", "physiological", "inhibitor", "of", "NF", "-", "kappaB.", "Cell", "surface", "expression", "of", "Jagged1", "in", "c", "-", "Rel", "-", "expressing", "cell", "monolayers", "led", "to", "a", "functional", "interaction", "with", "lymphocytes", "expressing", "the", "Notch1", "/", "TAN-1", "receptor", ".", "This", "correlated", "with", "the", "initiation", "of", "signaling", "downstream", "of", "Notch", ",", "as", "evidenced", "by", "increased", "levels", "of", "HES-1", "transcripts", "in", "co", "-", "cultivated", "T", "cells", "and", "of", "CD23", "transcripts", "in", "co", "-", "cultivated", "B", "cells", ".", "Consistent", "with", "its", "Rel", "/", "NF", "-", "kappaB", "-", "dependent", "induction", ",", "Jagged1", "was", "found", "to", "be", "highly", "expressed", "in", "splenic", "B", "cells", "where", "c", "-", "Rel", "is", "expressed", "constitutively", ".", "These", "results", "demonstrate", "that", "c", "-", "Rel", "can", "trigger", "the", "Notch", "signaling", "pathway", "in", "neighboring", "cells", "by", "inducing", "jagged1", "gene", "expression", ",", "and", "suggest", "a", "role", "for", "Jagged1", "in", "B", "-", "cell", "activation", ",", "differentiation", "or", "function", ".", "These", "findings", "also", "highlight", "the", "potential", "for", "an", "interplay", "between", "the", "Notch", "and", "NF", "-", "kappaB", "signaling", "pathways", "in", "the", "immune", "system", ".", "\n" ]	[ "TranscriptionFactor", "Protein", "MutantProtein", "Cell", "CellComponent", "Transcript", "Ligand", "Tissue", "Gene" ]
old is an umlsterm, adult is an umlsterm, man is an umlsterm, rheumatoid factor is an umlsterm, person is an umlsterm, Africa is an umlsterm, history is an umlsterm, laboratory is an umlsterm, diseases is an umlsterm, person is an umlsterm, risk factors is an umlsterm, rheumatic diseases is an umlsterm, future is an umlsterm, rheumatoid factor is an umlsterm, immunizations is an umlsterm, rheumatoid factor is an umlsterm, risk factors is an umlsterm	ZfuerRheumatologie.00590086.eng.abstr_task0	Sentence: A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed .	[ "A", "forty", "year", "old", "healthy", "adult", "man", "was", "admitted", "to", "our", "out", "-", "patient", "department", "because", "of", "a", "highly", "elevanted", "rheumatoid", "factor", ".", "Since", "the", "person", "was", "planning", "an", "extended", "stay", "in", "Africa", ",", "we", "performed", "an", "extensive", "history", ",", "clinical", "and", "laboratory", "examination", "to", "rule", "out", "oligosymptomatic", "inflammatory", "diseases", ".", "We", "further", "analyzed", "if", "the", "person", "presented", "genetic", "risk", "factors", "to", "develop", "rheumatic", "diseases", "in", "the", "future", "or", "if", "the", "presence", "of", "the", "rheumatoid", "factor", "could", "be", "a", "reaction", "to", "multiple", "immunizations", ".", "Possible", "explanations", "for", "an", "elevated", "rheumatoid", "factor", "including", "the", "genetic", "risk", "factors", "are", "discussed", "." ]	[ "umlsterm" ]
old is an umlsterm, adult is an umlsterm, man is an umlsterm, rheumatoid factor is an umlsterm, person is an umlsterm, Africa is an umlsterm, history is an umlsterm, laboratory is an umlsterm, diseases is an umlsterm, person is an umlsterm, risk factors is an umlsterm, rheumatic diseases is an umlsterm, future is an umlsterm, rheumatoid factor is an umlsterm, immunizations is an umlsterm, rheumatoid factor is an umlsterm, risk factors is an umlsterm	ZfuerRheumatologie.00590086.eng.abstr_task1	Sentence: A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed . Instructions: please typing these entity words according to sentence: old, adult, man, rheumatoid factor, person, Africa, history, laboratory, diseases, person, risk factors, rheumatic diseases, future, rheumatoid factor, immunizations, rheumatoid factor, risk factors Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed .	[ "A", "forty", "year", "old", "healthy", "adult", "man", "was", "admitted", "to", "our", "out", "-", "patient", "department", "because", "of", "a", "highly", "elevanted", "rheumatoid", "factor", ".", "Since", "the", "person", "was", "planning", "an", "extended", "stay", "in", "Africa", ",", "we", "performed", "an", "extensive", "history", ",", "clinical", "and", "laboratory", "examination", "to", "rule", "out", "oligosymptomatic", "inflammatory", "diseases", ".", "We", "further", "analyzed", "if", "the", "person", "presented", "genetic", "risk", "factors", "to", "develop", "rheumatic", "diseases", "in", "the", "future", "or", "if", "the", "presence", "of", "the", "rheumatoid", "factor", "could", "be", "a", "reaction", "to", "multiple", "immunizations", ".", "Possible", "explanations", "for", "an", "elevated", "rheumatoid", "factor", "including", "the", "genetic", "risk", "factors", "are", "discussed", "." ]	[ "umlsterm" ]
old, adult, man, rheumatoid factor, person, Africa, history, laboratory, diseases, person, risk factors, rheumatic diseases, future, rheumatoid factor, immunizations, rheumatoid factor, risk factors	ZfuerRheumatologie.00590086.eng.abstr_task2	Sentence: A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed .	[ "A", "forty", "year", "old", "healthy", "adult", "man", "was", "admitted", "to", "our", "out", "-", "patient", "department", "because", "of", "a", "highly", "elevanted", "rheumatoid", "factor", ".", "Since", "the", "person", "was", "planning", "an", "extended", "stay", "in", "Africa", ",", "we", "performed", "an", "extensive", "history", ",", "clinical", "and", "laboratory", "examination", "to", "rule", "out", "oligosymptomatic", "inflammatory", "diseases", ".", "We", "further", "analyzed", "if", "the", "person", "presented", "genetic", "risk", "factors", "to", "develop", "rheumatic", "diseases", "in", "the", "future", "or", "if", "the", "presence", "of", "the", "rheumatoid", "factor", "could", "be", "a", "reaction", "to", "multiple", "immunizations", ".", "Possible", "explanations", "for", "an", "elevated", "rheumatoid", "factor", "including", "the", "genetic", "risk", "factors", "are", "discussed", "." ]	[ "umlsterm" ]
Fazialisparese is an umlsterm, Goldimplantate is an umlsterm, Platinimplantaten is an umlsterm	DerOpthalmologe.70940600.ger.abstr_task0	Sentence: Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen .	[ "Zur", "Verbesserung", "des", "Lidschlusses", "bei", "Lagophthalmus", "aufgrund", "einer", "Fazialisparese", "werden", "zur", "Lidbeschwerung", "haeufig", "Goldimplantate", "eingesetzt", ".", "Die", "Vertraeglichkeit", "des", "implantierten", "Materials", "entspricht", "nicht", "immer", "den", "Erwartungen", ".", "Wir", "untersuchten", "daher", ",", "ob", "mit", "den", "sehr", "gut", "vertraeglichen", "Platinimplantaten", "bessere", "Ergebnisse", "erzielt", "werden", "koennen", "." ]	[ "umlsterm" ]
Fazialisparese is an umlsterm, Goldimplantate is an umlsterm, Platinimplantaten is an umlsterm	DerOpthalmologe.70940600.ger.abstr_task1	Sentence: Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen . Instructions: please typing these entity words according to sentence: Fazialisparese, Goldimplantate, Platinimplantaten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen .	[ "Zur", "Verbesserung", "des", "Lidschlusses", "bei", "Lagophthalmus", "aufgrund", "einer", "Fazialisparese", "werden", "zur", "Lidbeschwerung", "haeufig", "Goldimplantate", "eingesetzt", ".", "Die", "Vertraeglichkeit", "des", "implantierten", "Materials", "entspricht", "nicht", "immer", "den", "Erwartungen", ".", "Wir", "untersuchten", "daher", ",", "ob", "mit", "den", "sehr", "gut", "vertraeglichen", "Platinimplantaten", "bessere", "Ergebnisse", "erzielt", "werden", "koennen", "." ]	[ "umlsterm" ]
Fazialisparese, Goldimplantate, Platinimplantaten	DerOpthalmologe.70940600.ger.abstr_task2	Sentence: Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen .	[ "Zur", "Verbesserung", "des", "Lidschlusses", "bei", "Lagophthalmus", "aufgrund", "einer", "Fazialisparese", "werden", "zur", "Lidbeschwerung", "haeufig", "Goldimplantate", "eingesetzt", ".", "Die", "Vertraeglichkeit", "des", "implantierten", "Materials", "entspricht", "nicht", "immer", "den", "Erwartungen", ".", "Wir", "untersuchten", "daher", ",", "ob", "mit", "den", "sehr", "gut", "vertraeglichen", "Platinimplantaten", "bessere", "Ergebnisse", "erzielt", "werden", "koennen", "." ]	[ "umlsterm" ]
Pyoderma is an umlsterm, skin ulceration is an umlsterm, aetiology is an umlsterm, trauma is an umlsterm, standards is an umlsterm, treatment is an umlsterm, pyoderma is an umlsterm, diseases is an umlsterm, drug is an umlsterm, side effects is an umlsterm, therapy is an umlsterm, Immunosuppressive is an umlsterm, patient is an umlsterm, pyoderma is an umlsterm, operation is an umlsterm, combination therapy is an umlsterm, intravenous immunoglobulins is an umlsterm, corticosteroids is an umlsterm, disease is an umlsterm	DerHautarzt.90500879.eng.abstr_task0	Sentence: Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days .	[ "Pyoderma", "gangraenosum", "is", "a", "rare", ",", "chronic", "type", "of", "skin", "ulceration", "of", "unknown", "aetiology", ".", "It", "occasionally", "appears", "following", "trauma", ".", "There", "are", "no", "set", "standards", "for", "the", "treatment", "of", "pyoderma", "gangraenosum", ".", "It", "is", "essential", "to", "consider", "acuteness", "of", "progression", "as", "well", "as", "underlying", "systemic", "diseases", "and", "possible", "drug", "side", "effects", "before", "initiating", "a", "therapy", ".", "Immunosuppressive", "as", "well", "as", "immunomodulating", "agents", "are", "most", "often", "used", ",", "with", "varying", "degrees", "of", "success", ".", "We", "report", "a", "45-year", "-", "old", "patient", "who", "suffered", "from", "an", "extensive", "posttraumatic", "pyoderma", "gangraenosum", "after", "cardiac", "bypass", "operation", ".", "With", "short", "-", "term", "combination", "therapy", "consisting", "of", "high", "dose", "intravenous", "immunoglobulins", "and", "systemic", "corticosteroids", ",", "the", "progression", "of", "the", "disease", "could", "be", "stopped", "within", "a", "few", "days", "." ]	[ "umlsterm" ]
Pyoderma is an umlsterm, skin ulceration is an umlsterm, aetiology is an umlsterm, trauma is an umlsterm, standards is an umlsterm, treatment is an umlsterm, pyoderma is an umlsterm, diseases is an umlsterm, drug is an umlsterm, side effects is an umlsterm, therapy is an umlsterm, Immunosuppressive is an umlsterm, patient is an umlsterm, pyoderma is an umlsterm, operation is an umlsterm, combination therapy is an umlsterm, intravenous immunoglobulins is an umlsterm, corticosteroids is an umlsterm, disease is an umlsterm	DerHautarzt.90500879.eng.abstr_task1	Sentence: Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days . Instructions: please typing these entity words according to sentence: Pyoderma, skin ulceration, aetiology, trauma, standards, treatment, pyoderma, diseases, drug, side effects, therapy, Immunosuppressive, patient, pyoderma, operation, combination therapy, intravenous immunoglobulins, corticosteroids, disease Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days .	[ "Pyoderma", "gangraenosum", "is", "a", "rare", ",", "chronic", "type", "of", "skin", "ulceration", "of", "unknown", "aetiology", ".", "It", "occasionally", "appears", "following", "trauma", ".", "There", "are", "no", "set", "standards", "for", "the", "treatment", "of", "pyoderma", "gangraenosum", ".", "It", "is", "essential", "to", "consider", "acuteness", "of", "progression", "as", "well", "as", "underlying", "systemic", "diseases", "and", "possible", "drug", "side", "effects", "before", "initiating", "a", "therapy", ".", "Immunosuppressive", "as", "well", "as", "immunomodulating", "agents", "are", "most", "often", "used", ",", "with", "varying", "degrees", "of", "success", ".", "We", "report", "a", "45-year", "-", "old", "patient", "who", "suffered", "from", "an", "extensive", "posttraumatic", "pyoderma", "gangraenosum", "after", "cardiac", "bypass", "operation", ".", "With", "short", "-", "term", "combination", "therapy", "consisting", "of", "high", "dose", "intravenous", "immunoglobulins", "and", "systemic", "corticosteroids", ",", "the", "progression", "of", "the", "disease", "could", "be", "stopped", "within", "a", "few", "days", "." ]	[ "umlsterm" ]
Pyoderma, skin ulceration, aetiology, trauma, standards, treatment, pyoderma, diseases, drug, side effects, therapy, Immunosuppressive, patient, pyoderma, operation, combination therapy, intravenous immunoglobulins, corticosteroids, disease	DerHautarzt.90500879.eng.abstr_task2	Sentence: Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days .	[ "Pyoderma", "gangraenosum", "is", "a", "rare", ",", "chronic", "type", "of", "skin", "ulceration", "of", "unknown", "aetiology", ".", "It", "occasionally", "appears", "following", "trauma", ".", "There", "are", "no", "set", "standards", "for", "the", "treatment", "of", "pyoderma", "gangraenosum", ".", "It", "is", "essential", "to", "consider", "acuteness", "of", "progression", "as", "well", "as", "underlying", "systemic", "diseases", "and", "possible", "drug", "side", "effects", "before", "initiating", "a", "therapy", ".", "Immunosuppressive", "as", "well", "as", "immunomodulating", "agents", "are", "most", "often", "used", ",", "with", "varying", "degrees", "of", "success", ".", "We", "report", "a", "45-year", "-", "old", "patient", "who", "suffered", "from", "an", "extensive", "posttraumatic", "pyoderma", "gangraenosum", "after", "cardiac", "bypass", "operation", ".", "With", "short", "-", "term", "combination", "therapy", "consisting", "of", "high", "dose", "intravenous", "immunoglobulins", "and", "systemic", "corticosteroids", ",", "the", "progression", "of", "the", "disease", "could", "be", "stopped", "within", "a", "few", "days", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Parakeratosis variegata is an umlsterm, Pityriasis lichenoides is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm, Analysen is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm	DerHautarzt.50460498.ger.abstr_task0	Sentence: Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O" ]	Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps .	[ "Es", "wird", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "dem", "seltenen", "Krankheitsbild", "einer", "Parakeratosis", "variegata", "berichtet", ",", "die", "nach", "einem", "Zeitraum", "von", "4", "Jahren", "nach", "einer", "Pityriasis", "lichenoides", "et", "varioliformis", "acuta", "auftrat", ".", "Um", "einem", "moeglichen", "pathogenetischen", "Bezug", "dieser", "Erkrankungen", "aus", "der", "Gruppe", "der", "Parapsoriasisveraenderungen", "untereinander", "und", "bzgl", ".", "ihrer", "Beziehung", "zum", "niedrigmalignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "zu", "untersuchen", ",", "fuehrten", "wir", "histologische", "immunhistochemische", "und", "molekulargenetische", "Analysen", ",", "durch", ".", "Waehrend", "beide", "Erkrankungen", "charakteristische", "histologische", "Veraenderungen", "sowie", "ein", "ueberwiegendes", "lymphozytaeres", "epidermotropes", "T", "-", "Zellinfiltrat", "aufwiesen", ",", "konnte", "ein", "monoklonales", "Rearrangement", "des", "T", "-", "Zell", "-", "Rezeptors", "innerhalb", "beider", "Veraenderungen", "nicht", "gesichert", "werden", ".", "Somit", "interpretieren", "wir", "beide", "Erkrankungen", "als", "eigene", "Entitaeten", "und", "in", "diesem", "Fall", "ohne", "Bezug", "zum", "niedrig", "malignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Parakeratosis variegata is an umlsterm, Pityriasis lichenoides is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm, Analysen is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm	DerHautarzt.50460498.ger.abstr_task1	Sentence: Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps . Instructions: please typing these entity words according to sentence: Patienten, Parakeratosis variegata, Pityriasis lichenoides, Non - Hodgkin - Lymphom, Analysen, Non - Hodgkin - Lymphom Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O" ]	Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps .	[ "Es", "wird", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "dem", "seltenen", "Krankheitsbild", "einer", "Parakeratosis", "variegata", "berichtet", ",", "die", "nach", "einem", "Zeitraum", "von", "4", "Jahren", "nach", "einer", "Pityriasis", "lichenoides", "et", "varioliformis", "acuta", "auftrat", ".", "Um", "einem", "moeglichen", "pathogenetischen", "Bezug", "dieser", "Erkrankungen", "aus", "der", "Gruppe", "der", "Parapsoriasisveraenderungen", "untereinander", "und", "bzgl", ".", "ihrer", "Beziehung", "zum", "niedrigmalignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "zu", "untersuchen", ",", "fuehrten", "wir", "histologische", "immunhistochemische", "und", "molekulargenetische", "Analysen", ",", "durch", ".", "Waehrend", "beide", "Erkrankungen", "charakteristische", "histologische", "Veraenderungen", "sowie", "ein", "ueberwiegendes", "lymphozytaeres", "epidermotropes", "T", "-", "Zellinfiltrat", "aufwiesen", ",", "konnte", "ein", "monoklonales", "Rearrangement", "des", "T", "-", "Zell", "-", "Rezeptors", "innerhalb", "beider", "Veraenderungen", "nicht", "gesichert", "werden", ".", "Somit", "interpretieren", "wir", "beide", "Erkrankungen", "als", "eigene", "Entitaeten", "und", "in", "diesem", "Fall", "ohne", "Bezug", "zum", "niedrig", "malignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "." ]	[ "umlsterm" ]
Patienten, Parakeratosis variegata, Pityriasis lichenoides, Non - Hodgkin - Lymphom, Analysen, Non - Hodgkin - Lymphom	DerHautarzt.50460498.ger.abstr_task2	Sentence: Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O" ]	Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps .	[ "Es", "wird", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "dem", "seltenen", "Krankheitsbild", "einer", "Parakeratosis", "variegata", "berichtet", ",", "die", "nach", "einem", "Zeitraum", "von", "4", "Jahren", "nach", "einer", "Pityriasis", "lichenoides", "et", "varioliformis", "acuta", "auftrat", ".", "Um", "einem", "moeglichen", "pathogenetischen", "Bezug", "dieser", "Erkrankungen", "aus", "der", "Gruppe", "der", "Parapsoriasisveraenderungen", "untereinander", "und", "bzgl", ".", "ihrer", "Beziehung", "zum", "niedrigmalignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "zu", "untersuchen", ",", "fuehrten", "wir", "histologische", "immunhistochemische", "und", "molekulargenetische", "Analysen", ",", "durch", ".", "Waehrend", "beide", "Erkrankungen", "charakteristische", "histologische", "Veraenderungen", "sowie", "ein", "ueberwiegendes", "lymphozytaeres", "epidermotropes", "T", "-", "Zellinfiltrat", "aufwiesen", ",", "konnte", "ein", "monoklonales", "Rearrangement", "des", "T", "-", "Zell", "-", "Rezeptors", "innerhalb", "beider", "Veraenderungen", "nicht", "gesichert", "werden", ".", "Somit", "interpretieren", "wir", "beide", "Erkrankungen", "als", "eigene", "Entitaeten", "und", "in", "diesem", "Fall", "ohne", "Bezug", "zum", "niedrig", "malignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "." ]	[ "umlsterm" ]
microRNA is a Non-Specific_miRNAs, rat is a Species, traumatic brain injury is a Diseases, microRNA is a Non-Specific_miRNAs, miR-21 is a Specific_miRNAs, TBI is a Diseases	2527_task0	Sentence: Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Specific_miRNAs, Species, Diseases, Non-Specific_miRNAs	[ "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Species", "O", "O", "O", "B-Diseases", "I-Diseases", "I-Diseases", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O", "O", "O" ]	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.	[ "Our", "microarray", "based", "analysis", "of", "microRNA", "expression", "in", "rat", "cerebral", "cortex", "after", "traumatic", "brain", "injury", "has", "shown", "that", "some", "microRNA", "such", "as", "miR-21", "could", "be", "involved", "in", "the", "intricate", "process", "of", "TBI", "course", ".", " " ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Specific_miRNAs", "Species" ]
microRNA is a Non-Specific_miRNAs, rat is a Species, traumatic brain injury is a Diseases, microRNA is a Non-Specific_miRNAs, miR-21 is a Specific_miRNAs, TBI is a Diseases	2527_task1	Sentence: Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. Instructions: please typing these entity words according to sentence: microRNA, rat, traumatic brain injury, microRNA, miR-21, TBI Options: Specific_miRNAs, Species, Diseases, Non-Specific_miRNAs	[ "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Species", "O", "O", "O", "B-Diseases", "I-Diseases", "I-Diseases", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O", "O", "O" ]	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.	[ "Our", "microarray", "based", "analysis", "of", "microRNA", "expression", "in", "rat", "cerebral", "cortex", "after", "traumatic", "brain", "injury", "has", "shown", "that", "some", "microRNA", "such", "as", "miR-21", "could", "be", "involved", "in", "the", "intricate", "process", "of", "TBI", "course", ".", " " ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Specific_miRNAs", "Species" ]
microRNA, rat, traumatic brain injury, microRNA, miR-21, TBI	2527_task2	Sentence: Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Species", "O", "O", "O", "B-Diseases", "I-Diseases", "I-Diseases", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O", "O", "O" ]	Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.	[ "Our", "microarray", "based", "analysis", "of", "microRNA", "expression", "in", "rat", "cerebral", "cortex", "after", "traumatic", "brain", "injury", "has", "shown", "that", "some", "microRNA", "such", "as", "miR-21", "could", "be", "involved", "in", "the", "intricate", "process", "of", "TBI", "course", ".", " " ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Specific_miRNAs", "Species" ]
Patients is a cohort-patient, Swedish is an ethnicity, Polyposis is a disease, 196 is a size, families is a cohort-patient, FAP is a disease, colorectal is a body-part, adenomas is a disease, FAP is a disease, Sixty - one is a size, families is a cohort-patient, 135 is a size, families is a cohort-patient, living disease - affected member is a cohort-patient, 315 is a size, disease is a disease, patients is a cohort-patient, Sweden is an ethnicity, patients is a cohort-patient, 96 is a size, families is a cohort-patient, mutations is a mutation, APC is a gene, Twenty - four of the remaining 39 is a size, families is a cohort-patient, APC is a gene, mutations is a mutation, 15 is a size, families is a cohort-patient, six of these is a size, patients is a cohort-patient, bi - allelic MUTYH mutations is a mutation, Probands is a cohort-patient, cases is a cohort-patient, family is a cohort-patient, patients is a cohort-patient, FAP is a disease, individuals is a cohort-patient, age of 50 is an age, FAP is a disease, age of 75 is an age, patients is a cohort-patient, index patients is a cohort-patient, families is a cohort-patient, Patients is a cohort-patient, mutation is a mutation, APC is a gene, MUTYH is a gene, DL is a disease, duodenal is a body-part, lesion is a disease, FGP is a disease, fundic gland is a body-part, polyps is a disease, polyps is a disease, polyps is a disease, Patient is a cohort-patient, C896 is a cohort-patient, adenomas is a disease, family history of FAP is a Disorder, Patient is a cohort-patient, C107 is a cohort-patient, her is a gender, intestinal bleeding is a Disorder, age 47 is an age, 10–20 small ( less than 10 mm ) is a Concepts_Ideas, polyps is a disease, colorectal is a body-part, Tubular is a Concepts_Ideas, tubulovillous is a Concepts_Ideas, adenomas is a disease, age 50 is an age, carcinoma is a disease, Dukes A is a Phenomena, valvula Bauhini is a body-part, adenomas is a disease, patient is a cohort-patient	63_task0	Sentence: IGNORE LINE IGNORE LINE IGNORE LINE Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ethnicity, Concepts_Ideas, Phenomena, disease, mutation, cohort-patient, body-part, gender, Disorder, size, gene, age	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "B-disease", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "B-size", "I-size", "I-size", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-size", "B-disease", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "B-mutation", "O", "O", "B-gene", "O", "O", "B-size", "I-size", "I-size", "I-size", "I-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "O", "O", "B-gene", "O", "B-mutation", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "B-cohort-patient", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "B-cohort-patient", "B-cohort-patient", "O", "B-gender", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "O", "B-age", "I-age", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-body-part", "O", "O", "B-Concepts_Ideas", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "O", "B-age", "I-age", "O", "B-disease", "O", "B-Phenomena", "I-Phenomena", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	IGNORE LINE IGNORE LINE IGNORE LINE Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33].	[ "", "", "IGNORE", "LINE", "", "", "\n", "", "", "IGNORE", "LINE", "", "", "\n", "", "", "IGNORE", "LINE", "", "", "\n", "Methods", "\n\n", "Patients", "\n\n", "Between", "1957", "and", "31", "December", "2004", "the", "Swedish", "Polyposis", "Registry", "included", "data", "on", "196", "families", "with", "verified", "FAP", "(", "defined", "as", "more", "than", "100", "colorectal", "adenomas", "or", "if", "less", "with", "a", "family", "history", "of", "FAP", ")", ".", "Sixty", "-", "one", "of", "these", "families", "are", "now", "extinct", "but", "135", "families", "with", "at", "least", "one", "living", "disease", "-", "affected", "member", "remain", ".", "Presently", ",", "315", "disease", "-", "affected", "living", "patients", "are", "included", "in", "the", "registry", ".", "The", "geographical", "catchment", "area", "comprises", "the", "whole", "of", "Sweden", ".", "Details", "of", "how", "patients", "have", "been", "eligible", "for", "accession", "into", "the", "registry", "are", "given", "in", "[", "30", "]", ".", "In", "this", "study", "we", "have", "analyzed", "96", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene", ".", "Twenty", "-", "four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", "families", "remain", "to", "be", "tested", ".", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi", "-", "allelic", "MUTYH", "mutations", "[", "31", "]", ".", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call", "-", "up", "patients", ",", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP", ".", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non", "-", "FAP", "related", "cause", "after", "the", "age", "of", "75", ".", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study", ".", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1", ".", "\n\n", "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH", "\n\n", "Age", ",", "age", "at", "diagnosis", ";", "DL", ",", "duodenal", "lesion", ";", "dom", ",", "dominant", ";", "FGP", ",", "fundic", "gland", "polyps", ";", "NA", ",", "no", "available", "data", ";", "NI", ",", "no", "inheritance", ";", "Number", "of", "polyps", ",", "number", "of", "polyps", "at", "diagnosis", ";", "rec", ",", "recessive", "\n\n", "Patient", "C896", ",", "with", "only", "five", "adenomas", ",", "was", "included", "because", "of", "a", "family", "history", "of", "FAP", ".", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47", ".", "At", "diagnosis", ",", "10–20", "small", "(", "less", "than", "10", "mm", ")", "polyps", "were", "found", "in", "most", "colorectal", "parts", ".", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly", ".", "At", "age", "50", ",", "carcinoma", "(", "Dukes", "A", ")", "was", "diagnosed", "4", "cm", "from", "valvula", "Bauhini", "in", "conjunction", "with", "several", "new", "adenomas", ".", "At", "that", "time", "the", "patient", "underwent", "total", "colectomy", "with", "ileorectal", "anastomosis", "(", "IRA", ")", ".", "\n\n", "DNA", ",", "RNA", "and", "cDNA", "preparation", "\n\n", "Genomic", "DNA", "was", "isolated", "from", "samples", "of", "venous", "blood", ",", "anti", "-", "coagulated", "in", "ethylenediaminetetraacetic", "acid", "(", "EDTA", ")", ".", "DNA", "purification", "was", "performed", "using", "the", "PuregeneR", "DNA", "Isolation", "Kit", "(", "Gentra", "Systems", ",", "Minneapolis", ",", "MN", ")", "according", "to", "the", "manufacturer", "'s", "recommendations", ".", "DNA", "was", "extracted", "from", "paraffin", "-", "embedded", "tissue", "as", "described", "previously", "[", "32", "]", ".", "Histopaque", "(", "Sigma", ",", "St", "Louis", ",", "MO", ")", "or", "Lymphoprep", "(", "Axis", "-", "Shield", "PoC", "AS", ",", "Oslo", ",", "Norway", ")", "was", "used", "for", "purification", "of", "the", "lymphocytes", ",", "and", "total", "RNA", "was", "extracted", "using", "RNA", "-", "Stat", "60", "(", "Tel", "-", "Test", ",", "Friendswood", ",", "TX", ")", ".", "cDNA", "was", "synthesized", "as", "described", "previously", "[", "33", "]", ".", "\n\n" ]	[ "size", "cohort-patient", "Concepts_Ideas", "mutation", "Disorder", "body-part", "disease", "age", "Phenomena", "ethnicity", "gene", "gender" ]
Patients is a cohort-patient, Swedish is an ethnicity, Polyposis is a disease, 196 is a size, families is a cohort-patient, FAP is a disease, colorectal is a body-part, adenomas is a disease, FAP is a disease, Sixty - one is a size, families is a cohort-patient, 135 is a size, families is a cohort-patient, living disease - affected member is a cohort-patient, 315 is a size, disease is a disease, patients is a cohort-patient, Sweden is an ethnicity, patients is a cohort-patient, 96 is a size, families is a cohort-patient, mutations is a mutation, APC is a gene, Twenty - four of the remaining 39 is a size, families is a cohort-patient, APC is a gene, mutations is a mutation, 15 is a size, families is a cohort-patient, six of these is a size, patients is a cohort-patient, bi - allelic MUTYH mutations is a mutation, Probands is a cohort-patient, cases is a cohort-patient, family is a cohort-patient, patients is a cohort-patient, FAP is a disease, individuals is a cohort-patient, age of 50 is an age, FAP is a disease, age of 75 is an age, patients is a cohort-patient, index patients is a cohort-patient, families is a cohort-patient, Patients is a cohort-patient, mutation is a mutation, APC is a gene, MUTYH is a gene, DL is a disease, duodenal is a body-part, lesion is a disease, FGP is a disease, fundic gland is a body-part, polyps is a disease, polyps is a disease, polyps is a disease, Patient is a cohort-patient, C896 is a cohort-patient, adenomas is a disease, family history of FAP is a Disorder, Patient is a cohort-patient, C107 is a cohort-patient, her is a gender, intestinal bleeding is a Disorder, age 47 is an age, 10–20 small ( less than 10 mm ) is a Concepts_Ideas, polyps is a disease, colorectal is a body-part, Tubular is a Concepts_Ideas, tubulovillous is a Concepts_Ideas, adenomas is a disease, age 50 is an age, carcinoma is a disease, Dukes A is a Phenomena, valvula Bauhini is a body-part, adenomas is a disease, patient is a cohort-patient	63_task1	Sentence: IGNORE LINE IGNORE LINE IGNORE LINE Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33]. Instructions: please typing these entity words according to sentence: Patients, Swedish, Polyposis, 196, families, FAP, colorectal, adenomas, FAP, Sixty - one, families, 135, families, living disease - affected member, 315, disease, patients, Sweden, patients, 96, families, mutations, APC, Twenty - four of the remaining 39, families, APC, mutations, 15, families, six of these, patients, bi - allelic MUTYH mutations, Probands, cases, family, patients, FAP, individuals, age of 50, FAP, age of 75, patients, index patients, families, Patients, mutation, APC, MUTYH, DL, duodenal, lesion, FGP, fundic gland, polyps, polyps, polyps, Patient, C896, adenomas, family history of FAP, Patient, C107, her, intestinal bleeding, age 47, 10–20 small ( less than 10 mm ), polyps, colorectal, Tubular, tubulovillous, adenomas, age 50, carcinoma, Dukes A, valvula Bauhini, adenomas, patient Options: ethnicity, Concepts_Ideas, Phenomena, disease, mutation, cohort-patient, body-part, gender, Disorder, size, gene, age	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "B-disease", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "B-size", "I-size", "I-size", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-size", "B-disease", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "B-mutation", "O", "O", "B-gene", "O", "O", "B-size", "I-size", "I-size", "I-size", "I-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "O", "O", "B-gene", "O", "B-mutation", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "B-cohort-patient", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "B-cohort-patient", "B-cohort-patient", "O", "B-gender", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "O", "B-age", "I-age", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-body-part", "O", "O", "B-Concepts_Ideas", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "O", "B-age", "I-age", "O", "B-disease", "O", "B-Phenomena", "I-Phenomena", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	IGNORE LINE IGNORE LINE IGNORE LINE Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33].	[ "", "", "IGNORE", "LINE", "", "", "\n", "", "", "IGNORE", "LINE", "", "", "\n", "", "", "IGNORE", "LINE", "", "", "\n", "Methods", "\n\n", "Patients", "\n\n", "Between", "1957", "and", "31", "December", "2004", "the", "Swedish", "Polyposis", "Registry", "included", "data", "on", "196", "families", "with", "verified", "FAP", "(", "defined", "as", "more", "than", "100", "colorectal", "adenomas", "or", "if", "less", "with", "a", "family", "history", "of", "FAP", ")", ".", "Sixty", "-", "one", "of", "these", "families", "are", "now", "extinct", "but", "135", "families", "with", "at", "least", "one", "living", "disease", "-", "affected", "member", "remain", ".", "Presently", ",", "315", "disease", "-", "affected", "living", "patients", "are", "included", "in", "the", "registry", ".", "The", "geographical", "catchment", "area", "comprises", "the", "whole", "of", "Sweden", ".", "Details", "of", "how", "patients", "have", "been", "eligible", "for", "accession", "into", "the", "registry", "are", "given", "in", "[", "30", "]", ".", "In", "this", "study", "we", "have", "analyzed", "96", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene", ".", "Twenty", "-", "four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", "families", "remain", "to", "be", "tested", ".", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi", "-", "allelic", "MUTYH", "mutations", "[", "31", "]", ".", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call", "-", "up", "patients", ",", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP", ".", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non", "-", "FAP", "related", "cause", "after", "the", "age", "of", "75", ".", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study", ".", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1", ".", "\n\n", "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH", "\n\n", "Age", ",", "age", "at", "diagnosis", ";", "DL", ",", "duodenal", "lesion", ";", "dom", ",", "dominant", ";", "FGP", ",", "fundic", "gland", "polyps", ";", "NA", ",", "no", "available", "data", ";", "NI", ",", "no", "inheritance", ";", "Number", "of", "polyps", ",", "number", "of", "polyps", "at", "diagnosis", ";", "rec", ",", "recessive", "\n\n", "Patient", "C896", ",", "with", "only", "five", "adenomas", ",", "was", "included", "because", "of", "a", "family", "history", "of", "FAP", ".", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47", ".", "At", "diagnosis", ",", "10–20", "small", "(", "less", "than", "10", "mm", ")", "polyps", "were", "found", "in", "most", "colorectal", "parts", ".", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly", ".", "At", "age", "50", ",", "carcinoma", "(", "Dukes", "A", ")", "was", "diagnosed", "4", "cm", "from", "valvula", "Bauhini", "in", "conjunction", "with", "several", "new", "adenomas", ".", "At", "that", "time", "the", "patient", "underwent", "total", "colectomy", "with", "ileorectal", "anastomosis", "(", "IRA", ")", ".", "\n\n", "DNA", ",", "RNA", "and", "cDNA", "preparation", "\n\n", "Genomic", "DNA", "was", "isolated", "from", "samples", "of", "venous", "blood", ",", "anti", "-", "coagulated", "in", "ethylenediaminetetraacetic", "acid", "(", "EDTA", ")", ".", "DNA", "purification", "was", "performed", "using", "the", "PuregeneR", "DNA", "Isolation", "Kit", "(", "Gentra", "Systems", ",", "Minneapolis", ",", "MN", ")", "according", "to", "the", "manufacturer", "'s", "recommendations", ".", "DNA", "was", "extracted", "from", "paraffin", "-", "embedded", "tissue", "as", "described", "previously", "[", "32", "]", ".", "Histopaque", "(", "Sigma", ",", "St", "Louis", ",", "MO", ")", "or", "Lymphoprep", "(", "Axis", "-", "Shield", "PoC", "AS", ",", "Oslo", ",", "Norway", ")", "was", "used", "for", "purification", "of", "the", "lymphocytes", ",", "and", "total", "RNA", "was", "extracted", "using", "RNA", "-", "Stat", "60", "(", "Tel", "-", "Test", ",", "Friendswood", ",", "TX", ")", ".", "cDNA", "was", "synthesized", "as", "described", "previously", "[", "33", "]", ".", "\n\n" ]	[ "size", "cohort-patient", "Concepts_Ideas", "mutation", "Disorder", "body-part", "disease", "age", "Phenomena", "ethnicity", "gene", "gender" ]
Patients, Swedish, Polyposis, 196, families, FAP, colorectal, adenomas, FAP, Sixty - one, families, 135, families, living disease - affected member, 315, disease, patients, Sweden, patients, 96, families, mutations, APC, Twenty - four of the remaining 39, families, APC, mutations, 15, families, six of these, patients, bi - allelic MUTYH mutations, Probands, cases, family, patients, FAP, individuals, age of 50, FAP, age of 75, patients, index patients, families, Patients, mutation, APC, MUTYH, DL, duodenal, lesion, FGP, fundic gland, polyps, polyps, polyps, Patient, C896, adenomas, family history of FAP, Patient, C107, her, intestinal bleeding, age 47, 10–20 small ( less than 10 mm ), polyps, colorectal, Tubular, tubulovillous, adenomas, age 50, carcinoma, Dukes A, valvula Bauhini, adenomas, patient	63_task2	Sentence: IGNORE LINE IGNORE LINE IGNORE LINE Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33]. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "B-disease", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "B-size", "I-size", "I-size", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-size", "B-disease", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "B-mutation", "O", "O", "B-gene", "O", "O", "B-size", "I-size", "I-size", "I-size", "I-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "O", "O", "B-gene", "O", "B-mutation", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "B-cohort-patient", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "B-cohort-patient", "B-cohort-patient", "O", "B-gender", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "O", "B-age", "I-age", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-body-part", "O", "O", "B-Concepts_Ideas", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "O", "B-age", "I-age", "O", "B-disease", "O", "B-Phenomena", "I-Phenomena", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	IGNORE LINE IGNORE LINE IGNORE LINE Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33].	[ "", "", "IGNORE", "LINE", "", "", "\n", "", "", "IGNORE", "LINE", "", "", "\n", "", "", "IGNORE", "LINE", "", "", "\n", "Methods", "\n\n", "Patients", "\n\n", "Between", "1957", "and", "31", "December", "2004", "the", "Swedish", "Polyposis", "Registry", "included", "data", "on", "196", "families", "with", "verified", "FAP", "(", "defined", "as", "more", "than", "100", "colorectal", "adenomas", "or", "if", "less", "with", "a", "family", "history", "of", "FAP", ")", ".", "Sixty", "-", "one", "of", "these", "families", "are", "now", "extinct", "but", "135", "families", "with", "at", "least", "one", "living", "disease", "-", "affected", "member", "remain", ".", "Presently", ",", "315", "disease", "-", "affected", "living", "patients", "are", "included", "in", "the", "registry", ".", "The", "geographical", "catchment", "area", "comprises", "the", "whole", "of", "Sweden", ".", "Details", "of", "how", "patients", "have", "been", "eligible", "for", "accession", "into", "the", "registry", "are", "given", "in", "[", "30", "]", ".", "In", "this", "study", "we", "have", "analyzed", "96", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene", ".", "Twenty", "-", "four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", "families", "remain", "to", "be", "tested", ".", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi", "-", "allelic", "MUTYH", "mutations", "[", "31", "]", ".", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call", "-", "up", "patients", ",", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP", ".", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non", "-", "FAP", "related", "cause", "after", "the", "age", "of", "75", ".", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study", ".", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1", ".", "\n\n", "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH", "\n\n", "Age", ",", "age", "at", "diagnosis", ";", "DL", ",", "duodenal", "lesion", ";", "dom", ",", "dominant", ";", "FGP", ",", "fundic", "gland", "polyps", ";", "NA", ",", "no", "available", "data", ";", "NI", ",", "no", "inheritance", ";", "Number", "of", "polyps", ",", "number", "of", "polyps", "at", "diagnosis", ";", "rec", ",", "recessive", "\n\n", "Patient", "C896", ",", "with", "only", "five", "adenomas", ",", "was", "included", "because", "of", "a", "family", "history", "of", "FAP", ".", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47", ".", "At", "diagnosis", ",", "10–20", "small", "(", "less", "than", "10", "mm", ")", "polyps", "were", "found", "in", "most", "colorectal", "parts", ".", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly", ".", "At", "age", "50", ",", "carcinoma", "(", "Dukes", "A", ")", "was", "diagnosed", "4", "cm", "from", "valvula", "Bauhini", "in", "conjunction", "with", "several", "new", "adenomas", ".", "At", "that", "time", "the", "patient", "underwent", "total", "colectomy", "with", "ileorectal", "anastomosis", "(", "IRA", ")", ".", "\n\n", "DNA", ",", "RNA", "and", "cDNA", "preparation", "\n\n", "Genomic", "DNA", "was", "isolated", "from", "samples", "of", "venous", "blood", ",", "anti", "-", "coagulated", "in", "ethylenediaminetetraacetic", "acid", "(", "EDTA", ")", ".", "DNA", "purification", "was", "performed", "using", "the", "PuregeneR", "DNA", "Isolation", "Kit", "(", "Gentra", "Systems", ",", "Minneapolis", ",", "MN", ")", "according", "to", "the", "manufacturer", "'s", "recommendations", ".", "DNA", "was", "extracted", "from", "paraffin", "-", "embedded", "tissue", "as", "described", "previously", "[", "32", "]", ".", "Histopaque", "(", "Sigma", ",", "St", "Louis", ",", "MO", ")", "or", "Lymphoprep", "(", "Axis", "-", "Shield", "PoC", "AS", ",", "Oslo", ",", "Norway", ")", "was", "used", "for", "purification", "of", "the", "lymphocytes", ",", "and", "total", "RNA", "was", "extracted", "using", "RNA", "-", "Stat", "60", "(", "Tel", "-", "Test", ",", "Friendswood", ",", "TX", ")", ".", "cDNA", "was", "synthesized", "as", "described", "previously", "[", "33", "]", ".", "\n\n" ]	[ "size", "cohort-patient", "Concepts_Ideas", "mutation", "Disorder", "body-part", "disease", "age", "Phenomena", "ethnicity", "gene", "gender" ]
cartoon - based hostile attributional bias measure is a Intervention_Educational, urban African American boys is a Participant_Condition, cartoon - based adaptation is a Intervention_Educational, standard written hostile attributional bias vignette measure is a Outcome_Mental, psychometric properties is a Outcome_Mental, acceptability is a Outcome_Mental, test - retest reliability is a Outcome_Mental	51110_task0	Sentence: Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Participant_Condition, Outcome_Mental	[ "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys .	[ "Preliminary", "examination", "of", "a", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "for", "urban", "African", "American", "boys", ".", "The", "current", "study", "illustrates", "how", "researchers", "developed", "and", "validated", "a", "cartoon", "-", "based", "adaptation", "of", "a", "written", "hostile", "attributional", "bias", "measure", "for", "a", "sample", "of", "urban", ",", "low", "-", "income", ",", "African", "American", "boys", ".", "A", "series", "of", "studies", "were", "conducted", "to", "develop", "cartoon", "illustrations", "to", "accompany", "a", "standard", "written", "hostile", "attributional", "bias", "vignette", "measure", "(", "Study", "1", ")", ",", "to", "determine", "initial", "psychometric", "properties", "(", "Study", "2", ")", "and", "acceptability", "(", "Study", "3", ")", ",", "and", "to", "conduct", "a", "test", "-", "retest", "reliability", "trial", "of", "the", "adapted", "measure", "in", "a", "separate", "sample", "(", "Study", "4", ")", ".", "These", "studies", "utilize", "a", "participatory", "action", "research", "approach", "to", "measurement", "design", "and", "adaptation", ",", "and", "suggest", "that", "collaborations", "between", "researchers", "and", "key", "school", "stakeholders", "can", "lead", "to", "measures", "that", "are", "psychometrically", "strong", ",", "developmentally", "appropriate", ",", "and", "culturally", "sensitive", ".", "In", "addition", ",", "the", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "appears", "to", "have", "promise", "as", "an", "assessment", "and", "/", "or", "outcome", "measure", "for", "aggression", "and", "bullying", "prevention", "programs", "conducted", "with", "urban", "African", "American", "boys", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition" ]
cartoon - based hostile attributional bias measure is a Intervention_Educational, urban African American boys is a Participant_Condition, cartoon - based adaptation is a Intervention_Educational, standard written hostile attributional bias vignette measure is a Outcome_Mental, psychometric properties is a Outcome_Mental, acceptability is a Outcome_Mental, test - retest reliability is a Outcome_Mental	51110_task1	Sentence: Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys . Instructions: please typing these entity words according to sentence: cartoon - based hostile attributional bias measure, urban African American boys, cartoon - based adaptation, standard written hostile attributional bias vignette measure, psychometric properties, acceptability, test - retest reliability Options: Intervention_Educational, Participant_Condition, Outcome_Mental	[ "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys .	[ "Preliminary", "examination", "of", "a", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "for", "urban", "African", "American", "boys", ".", "The", "current", "study", "illustrates", "how", "researchers", "developed", "and", "validated", "a", "cartoon", "-", "based", "adaptation", "of", "a", "written", "hostile", "attributional", "bias", "measure", "for", "a", "sample", "of", "urban", ",", "low", "-", "income", ",", "African", "American", "boys", ".", "A", "series", "of", "studies", "were", "conducted", "to", "develop", "cartoon", "illustrations", "to", "accompany", "a", "standard", "written", "hostile", "attributional", "bias", "vignette", "measure", "(", "Study", "1", ")", ",", "to", "determine", "initial", "psychometric", "properties", "(", "Study", "2", ")", "and", "acceptability", "(", "Study", "3", ")", ",", "and", "to", "conduct", "a", "test", "-", "retest", "reliability", "trial", "of", "the", "adapted", "measure", "in", "a", "separate", "sample", "(", "Study", "4", ")", ".", "These", "studies", "utilize", "a", "participatory", "action", "research", "approach", "to", "measurement", "design", "and", "adaptation", ",", "and", "suggest", "that", "collaborations", "between", "researchers", "and", "key", "school", "stakeholders", "can", "lead", "to", "measures", "that", "are", "psychometrically", "strong", ",", "developmentally", "appropriate", ",", "and", "culturally", "sensitive", ".", "In", "addition", ",", "the", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "appears", "to", "have", "promise", "as", "an", "assessment", "and", "/", "or", "outcome", "measure", "for", "aggression", "and", "bullying", "prevention", "programs", "conducted", "with", "urban", "African", "American", "boys", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition" ]
cartoon - based hostile attributional bias measure, urban African American boys, cartoon - based adaptation, standard written hostile attributional bias vignette measure, psychometric properties, acceptability, test - retest reliability	51110_task2	Sentence: Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys .	[ "Preliminary", "examination", "of", "a", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "for", "urban", "African", "American", "boys", ".", "The", "current", "study", "illustrates", "how", "researchers", "developed", "and", "validated", "a", "cartoon", "-", "based", "adaptation", "of", "a", "written", "hostile", "attributional", "bias", "measure", "for", "a", "sample", "of", "urban", ",", "low", "-", "income", ",", "African", "American", "boys", ".", "A", "series", "of", "studies", "were", "conducted", "to", "develop", "cartoon", "illustrations", "to", "accompany", "a", "standard", "written", "hostile", "attributional", "bias", "vignette", "measure", "(", "Study", "1", ")", ",", "to", "determine", "initial", "psychometric", "properties", "(", "Study", "2", ")", "and", "acceptability", "(", "Study", "3", ")", ",", "and", "to", "conduct", "a", "test", "-", "retest", "reliability", "trial", "of", "the", "adapted", "measure", "in", "a", "separate", "sample", "(", "Study", "4", ")", ".", "These", "studies", "utilize", "a", "participatory", "action", "research", "approach", "to", "measurement", "design", "and", "adaptation", ",", "and", "suggest", "that", "collaborations", "between", "researchers", "and", "key", "school", "stakeholders", "can", "lead", "to", "measures", "that", "are", "psychometrically", "strong", ",", "developmentally", "appropriate", ",", "and", "culturally", "sensitive", ".", "In", "addition", ",", "the", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "appears", "to", "have", "promise", "as", "an", "assessment", "and", "/", "or", "outcome", "measure", "for", "aggression", "and", "bullying", "prevention", "programs", "conducted", "with", "urban", "African", "American", "boys", "." ]	[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition" ]
octreotide is a Intervention_Pharmacological, prochlorperazine is a Intervention_Pharmacological, migraine headache is a Outcome_Physical, octreotide ( OC ) is a Intervention_Pharmacological, prochlorperazine . is a Intervention_Pharmacological, median visual analog scale scores is a Outcome_Physical, pain is a Outcome_Pain, Restlessness consistent with akathisia is a Outcome_Physical, rescue medication is a Outcome_Physical, headache recurrence is a Outcome_Physical, clinical success rate is a Outcome_Other, restlessness is a Outcome_Physical, sedation is a Outcome_Pain	39965_task0	Sentence: Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Pain, Outcome_Other, Intervention_Pharmacological, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Pain", "O" ]	Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation .	[ "Randomized", "evaluation", "of", "octreotide", "vs", "prochlorperazine", "for", "ED", "treatment", "of", "migraine", "headache", ".", "UNLABELLED", "Patients", "with", "headaches", "account", "for", "approximately", "2", "%", "of", "all", "ED", "visits", ",", "with", "migraines", "being", "the", "most", "common", "defined", "primary", "headache", "syndrome", ".", "Our", "goals", "were", "to", "evaluate", "the", "efficacy", "of", "intravenous", "octreotide", "(", "OC", ")", "for", "the", "treatment", "of", "migraines", ",", "when", "compared", "to", "standard", "therapy", "with", "prochlorperazine", ".", "METHODS", "The", "study", "was", "conducted", "as", "a", "double", "-", "blinded", ",", "randomized", "controlled", "trial", ".", "Each", "subject", "received", "either", "100", "microg", "of", "octreotide", "or", "10", "mg", "of", "prochlorperazine", "intravenously", "for", "a", "2-minute", "period", ".", "RESULTS", "Comparison", "of", "the", "change", "in", "median", "visual", "analog", "scale", "scores", "for", "60", "minutes", "demonstrated", "that", "octreotide", "was", "less", "effective", "at", "reducing", "pain", "(", "P", "=", ".03", ")", "and", "producing", "clinical", "success", "(", "P", "<", ".01", ")", ".", "Restlessness", "consistent", "with", "akathisia", "was", "noted", "by", "35", "%", "of", "the", "PC", "group", "and", "8", "%", "of", "the", "OC", "group", "(", "P", "<", ".01", ")", ".", "At", "60", "minutes", ",", "rescue", "medication", "was", "required", "by", "48", "%", "of", "the", "patients", "in", "the", "OC", "group", ",", "whereas", "10", "%", "of", "the", "PC", "group", "required", "such", "therapy", "(", "P", "<", ".01", ")", ".", "All", "44", "patients", "were", "contacted", "for", "follow", "-", "up", "at", "48", "to", "72", "hours", "after", "enrollment", ".", "At", "that", "time", ",", "10", "%", "of", "the", "prochlorperazine", "and", "25", "%", "of", "the", "octreotide", "patients", "had", "experienced", "some", "headache", "recurrence", "(", "P", "=", ".1", ")", ".", "CONCLUSION", "Prochlorperazine", "was", "statistically", "superior", "to", "octreotide", "in", "clinical", "success", "rate", "and", "decrease", "in", "pain", "in", "migraine", "patients", "but", "caused", "more", "restlessness", "and", "sedation", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Pain" ]
octreotide is a Intervention_Pharmacological, prochlorperazine is a Intervention_Pharmacological, migraine headache is a Outcome_Physical, octreotide ( OC ) is a Intervention_Pharmacological, prochlorperazine . is a Intervention_Pharmacological, median visual analog scale scores is a Outcome_Physical, pain is a Outcome_Pain, Restlessness consistent with akathisia is a Outcome_Physical, rescue medication is a Outcome_Physical, headache recurrence is a Outcome_Physical, clinical success rate is a Outcome_Other, restlessness is a Outcome_Physical, sedation is a Outcome_Pain	39965_task1	Sentence: Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation . Instructions: please typing these entity words according to sentence: octreotide, prochlorperazine, migraine headache, octreotide ( OC ), prochlorperazine ., median visual analog scale scores, pain, Restlessness consistent with akathisia, rescue medication, headache recurrence, clinical success rate, restlessness, sedation Options: Outcome_Pain, Outcome_Other, Intervention_Pharmacological, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Pain", "O" ]	Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation .	[ "Randomized", "evaluation", "of", "octreotide", "vs", "prochlorperazine", "for", "ED", "treatment", "of", "migraine", "headache", ".", "UNLABELLED", "Patients", "with", "headaches", "account", "for", "approximately", "2", "%", "of", "all", "ED", "visits", ",", "with", "migraines", "being", "the", "most", "common", "defined", "primary", "headache", "syndrome", ".", "Our", "goals", "were", "to", "evaluate", "the", "efficacy", "of", "intravenous", "octreotide", "(", "OC", ")", "for", "the", "treatment", "of", "migraines", ",", "when", "compared", "to", "standard", "therapy", "with", "prochlorperazine", ".", "METHODS", "The", "study", "was", "conducted", "as", "a", "double", "-", "blinded", ",", "randomized", "controlled", "trial", ".", "Each", "subject", "received", "either", "100", "microg", "of", "octreotide", "or", "10", "mg", "of", "prochlorperazine", "intravenously", "for", "a", "2-minute", "period", ".", "RESULTS", "Comparison", "of", "the", "change", "in", "median", "visual", "analog", "scale", "scores", "for", "60", "minutes", "demonstrated", "that", "octreotide", "was", "less", "effective", "at", "reducing", "pain", "(", "P", "=", ".03", ")", "and", "producing", "clinical", "success", "(", "P", "<", ".01", ")", ".", "Restlessness", "consistent", "with", "akathisia", "was", "noted", "by", "35", "%", "of", "the", "PC", "group", "and", "8", "%", "of", "the", "OC", "group", "(", "P", "<", ".01", ")", ".", "At", "60", "minutes", ",", "rescue", "medication", "was", "required", "by", "48", "%", "of", "the", "patients", "in", "the", "OC", "group", ",", "whereas", "10", "%", "of", "the", "PC", "group", "required", "such", "therapy", "(", "P", "<", ".01", ")", ".", "All", "44", "patients", "were", "contacted", "for", "follow", "-", "up", "at", "48", "to", "72", "hours", "after", "enrollment", ".", "At", "that", "time", ",", "10", "%", "of", "the", "prochlorperazine", "and", "25", "%", "of", "the", "octreotide", "patients", "had", "experienced", "some", "headache", "recurrence", "(", "P", "=", ".1", ")", ".", "CONCLUSION", "Prochlorperazine", "was", "statistically", "superior", "to", "octreotide", "in", "clinical", "success", "rate", "and", "decrease", "in", "pain", "in", "migraine", "patients", "but", "caused", "more", "restlessness", "and", "sedation", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Pain" ]
octreotide, prochlorperazine, migraine headache, octreotide ( OC ), prochlorperazine ., median visual analog scale scores, pain, Restlessness consistent with akathisia, rescue medication, headache recurrence, clinical success rate, restlessness, sedation	39965_task2	Sentence: Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Pain", "O" ]	Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation .	[ "Randomized", "evaluation", "of", "octreotide", "vs", "prochlorperazine", "for", "ED", "treatment", "of", "migraine", "headache", ".", "UNLABELLED", "Patients", "with", "headaches", "account", "for", "approximately", "2", "%", "of", "all", "ED", "visits", ",", "with", "migraines", "being", "the", "most", "common", "defined", "primary", "headache", "syndrome", ".", "Our", "goals", "were", "to", "evaluate", "the", "efficacy", "of", "intravenous", "octreotide", "(", "OC", ")", "for", "the", "treatment", "of", "migraines", ",", "when", "compared", "to", "standard", "therapy", "with", "prochlorperazine", ".", "METHODS", "The", "study", "was", "conducted", "as", "a", "double", "-", "blinded", ",", "randomized", "controlled", "trial", ".", "Each", "subject", "received", "either", "100", "microg", "of", "octreotide", "or", "10", "mg", "of", "prochlorperazine", "intravenously", "for", "a", "2-minute", "period", ".", "RESULTS", "Comparison", "of", "the", "change", "in", "median", "visual", "analog", "scale", "scores", "for", "60", "minutes", "demonstrated", "that", "octreotide", "was", "less", "effective", "at", "reducing", "pain", "(", "P", "=", ".03", ")", "and", "producing", "clinical", "success", "(", "P", "<", ".01", ")", ".", "Restlessness", "consistent", "with", "akathisia", "was", "noted", "by", "35", "%", "of", "the", "PC", "group", "and", "8", "%", "of", "the", "OC", "group", "(", "P", "<", ".01", ")", ".", "At", "60", "minutes", ",", "rescue", "medication", "was", "required", "by", "48", "%", "of", "the", "patients", "in", "the", "OC", "group", ",", "whereas", "10", "%", "of", "the", "PC", "group", "required", "such", "therapy", "(", "P", "<", ".01", ")", ".", "All", "44", "patients", "were", "contacted", "for", "follow", "-", "up", "at", "48", "to", "72", "hours", "after", "enrollment", ".", "At", "that", "time", ",", "10", "%", "of", "the", "prochlorperazine", "and", "25", "%", "of", "the", "octreotide", "patients", "had", "experienced", "some", "headache", "recurrence", "(", "P", "=", ".1", ")", ".", "CONCLUSION", "Prochlorperazine", "was", "statistically", "superior", "to", "octreotide", "in", "clinical", "success", "rate", "and", "decrease", "in", "pain", "in", "migraine", "patients", "but", "caused", "more", "restlessness", "and", "sedation", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Pain" ]
adenoma is an umlsterm, lung is an umlsterm, benign tumor is an umlsterm, epithelial cells is an umlsterm, cells is an umlsterm, findings is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm, lung is an umlsterm, antibodies is an umlsterm, apoprotein is an umlsterm, human is an umlsterm, surfactant is an umlsterm, cells is an umlsterm, macrophages is an umlsterm, tissue is an umlsterm, cells is an umlsterm, findings is an umlsterm, surfactant is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm	DerPathologe.60170150.eng.abstr_task0	Sentence: The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma .	[ "The", "alveolar", "adenoma", "of", "the", "lung", "is", "a", "rare", "benign", "tumor", "in", "which", "the", "normal", "parenchymal", "architectur", "is", "imitated", "by", "a", "proliferation", "of", "both", "the", "alveolar", "epithelial", "cells", "and", "the", "mesenchymal", "septal", "cells", ".", "The", "first", "description", ",", "based", "on", "six", "cases", ",", "was", "published", "in", "1986", "by", "Yousem", "and", "Hochholzer", ".", "From", "their", "ultrastructural", "findings", "they", "presumed", "a", "type", "II", "pneumocytes", "differentiation", "of", "the", "epithelial", "cells", ".", "We", "investigated", "an", "alveolar", "adenoma", "of", "the", "lung", "immunhistochemical", "by", "means", "of", "antibodies", "against", "apoprotein", "B", "and", "C", "of", "human", "surfactant", ".", "Both", "the", "lining", "cells", "and", "the", "macrophages", "in", "the", "alveolar", "-", "like", "spaces", "were", "stained", ".", "The", "septal", "connection", "tissue", "cells", "did", "not", "react", ".", "These", "findings", "confirm", "the", "expression", "of", "surfactant", "constituants", "and", ",", "hence", ",", "the", "differentiation", "into", "type", "II", "pneumocytes", "of", "the", "epithelial", "cells", "of", "the", "alveolar", "adenoma", "." ]	[ "umlsterm" ]
adenoma is an umlsterm, lung is an umlsterm, benign tumor is an umlsterm, epithelial cells is an umlsterm, cells is an umlsterm, findings is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm, lung is an umlsterm, antibodies is an umlsterm, apoprotein is an umlsterm, human is an umlsterm, surfactant is an umlsterm, cells is an umlsterm, macrophages is an umlsterm, tissue is an umlsterm, cells is an umlsterm, findings is an umlsterm, surfactant is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm	DerPathologe.60170150.eng.abstr_task1	Sentence: The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma . Instructions: please typing these entity words according to sentence: adenoma, lung, benign tumor, epithelial cells, cells, findings, epithelial cells, adenoma, lung, antibodies, apoprotein, human, surfactant, cells, macrophages, tissue, cells, findings, surfactant, epithelial cells, adenoma Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma .	[ "The", "alveolar", "adenoma", "of", "the", "lung", "is", "a", "rare", "benign", "tumor", "in", "which", "the", "normal", "parenchymal", "architectur", "is", "imitated", "by", "a", "proliferation", "of", "both", "the", "alveolar", "epithelial", "cells", "and", "the", "mesenchymal", "septal", "cells", ".", "The", "first", "description", ",", "based", "on", "six", "cases", ",", "was", "published", "in", "1986", "by", "Yousem", "and", "Hochholzer", ".", "From", "their", "ultrastructural", "findings", "they", "presumed", "a", "type", "II", "pneumocytes", "differentiation", "of", "the", "epithelial", "cells", ".", "We", "investigated", "an", "alveolar", "adenoma", "of", "the", "lung", "immunhistochemical", "by", "means", "of", "antibodies", "against", "apoprotein", "B", "and", "C", "of", "human", "surfactant", ".", "Both", "the", "lining", "cells", "and", "the", "macrophages", "in", "the", "alveolar", "-", "like", "spaces", "were", "stained", ".", "The", "septal", "connection", "tissue", "cells", "did", "not", "react", ".", "These", "findings", "confirm", "the", "expression", "of", "surfactant", "constituants", "and", ",", "hence", ",", "the", "differentiation", "into", "type", "II", "pneumocytes", "of", "the", "epithelial", "cells", "of", "the", "alveolar", "adenoma", "." ]	[ "umlsterm" ]
adenoma, lung, benign tumor, epithelial cells, cells, findings, epithelial cells, adenoma, lung, antibodies, apoprotein, human, surfactant, cells, macrophages, tissue, cells, findings, surfactant, epithelial cells, adenoma	DerPathologe.60170150.eng.abstr_task2	Sentence: The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma .	[ "The", "alveolar", "adenoma", "of", "the", "lung", "is", "a", "rare", "benign", "tumor", "in", "which", "the", "normal", "parenchymal", "architectur", "is", "imitated", "by", "a", "proliferation", "of", "both", "the", "alveolar", "epithelial", "cells", "and", "the", "mesenchymal", "septal", "cells", ".", "The", "first", "description", ",", "based", "on", "six", "cases", ",", "was", "published", "in", "1986", "by", "Yousem", "and", "Hochholzer", ".", "From", "their", "ultrastructural", "findings", "they", "presumed", "a", "type", "II", "pneumocytes", "differentiation", "of", "the", "epithelial", "cells", ".", "We", "investigated", "an", "alveolar", "adenoma", "of", "the", "lung", "immunhistochemical", "by", "means", "of", "antibodies", "against", "apoprotein", "B", "and", "C", "of", "human", "surfactant", ".", "Both", "the", "lining", "cells", "and", "the", "macrophages", "in", "the", "alveolar", "-", "like", "spaces", "were", "stained", ".", "The", "septal", "connection", "tissue", "cells", "did", "not", "react", ".", "These", "findings", "confirm", "the", "expression", "of", "surfactant", "constituants", "and", ",", "hence", ",", "the", "differentiation", "into", "type", "II", "pneumocytes", "of", "the", "epithelial", "cells", "of", "the", "alveolar", "adenoma", "." ]	[ "umlsterm" ]
laminin is a Individual_protein, myosin heavy chain is a Individual_protein, MHC is a Individual_protein, alpha - skeletal actin is a Individual_protein	702_task0	Sentence: The effects of two adhesion substrates (serum and laminin) and time in culture on the expression of genes encoding myosin heavy chain (MHC) isoforms and alpha-skeletal actin were analysed in myocytes isolated from adult rat heart and maintained in serum-free culture. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effects of two adhesion substrates (serum and laminin) and time in culture on the expression of genes encoding myosin heavy chain (MHC) isoforms and alpha-skeletal actin were analysed in myocytes isolated from adult rat heart and maintained in serum-free culture.	[ "The", "effects", "of", "two", "adhesion", "substrates", "(", "serum", "and", "laminin", ")", "and", "time", "in", "culture", "on", "the", "expression", "of", "genes", "encoding", "myosin", "heavy", "chain", "(", "MHC", ")", "isoforms", "and", "alpha", "-", "skeletal", "actin", "were", "analysed", "in", "myocytes", "isolated", "from", "adult", "rat", "heart", "and", "maintained", "in", "serum", "-", "free", "culture", "." ]	[ "Individual_protein" ]

adenosine deaminase is a Gene/protein/RNA, CD26 is a Individual_protein

678_task0

Sentence: The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein

[ "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.

[ "The", "adenosine", "deaminase", "-", "binding", "region", "is", "distinct", "from", "major", "anti", "-", "CD26", "mAb", "epitopes", "on", "the", "human", "dipeptidyl", "peptidase", "IV(CD26", ")", "molecule", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

adenosine deaminase is a Gene/protein/RNA, CD26 is a Individual_protein

678_task1

Sentence: The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. Instructions: please typing these entity words according to sentence: adenosine deaminase, CD26 Options: Gene/protein/RNA, Individual_protein

[ "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.

[ "The", "adenosine", "deaminase", "-", "binding", "region", "is", "distinct", "from", "major", "anti", "-", "CD26", "mAb", "epitopes", "on", "the", "human", "dipeptidyl", "peptidase", "IV(CD26", ")", "molecule", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

adenosine deaminase, CD26

678_task2

Sentence: The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. Instructions: please extract entity words from the input sentence

[ "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.

[ "The", "adenosine", "deaminase", "-", "binding", "region", "is", "distinct", "from", "major", "anti", "-", "CD26", "mAb", "epitopes", "on", "the", "human", "dipeptidyl", "peptidase", "IV(CD26", ")", "molecule", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

sequence - specific HMG box is a DNA_domain_or_region, lymphocyte transcriptional activator is a protein_family_or_group, Sox-4 is a protein_molecule

100643_task0

Sentence: Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, protein_family_or_group, protein_molecule

[ "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O" ]

Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4.

[ "Solution", "structure", "of", "the", "sequence", "-", "specific", "HMG", "box", "of", "the", "lymphocyte", "transcriptional", "activator", "Sox-4", "." ]

[ "protein_family_or_group", "DNA_domain_or_region", "protein_domain_or_region", "other_name", "protein_substructure", "peptide", "protein_molecule", "(AND protein_substructure protein_substructure)", "DNA_family_or_group", "DNA_substructure", "polynucleotide", "" ]

sequence - specific HMG box is a DNA_domain_or_region, lymphocyte transcriptional activator is a protein_family_or_group, Sox-4 is a protein_molecule

100643_task1

Sentence: Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4. Instructions: please typing these entity words according to sentence: sequence - specific HMG box, lymphocyte transcriptional activator, Sox-4 Options: DNA_domain_or_region, protein_family_or_group, protein_molecule

[ "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O" ]

Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4.

[ "Solution", "structure", "of", "the", "sequence", "-", "specific", "HMG", "box", "of", "the", "lymphocyte", "transcriptional", "activator", "Sox-4", "." ]

[ "protein_family_or_group", "DNA_domain_or_region", "protein_domain_or_region", "other_name", "protein_substructure", "peptide", "protein_molecule", "(AND protein_substructure protein_substructure)", "DNA_family_or_group", "DNA_substructure", "polynucleotide", "" ]

sequence - specific HMG box, lymphocyte transcriptional activator, Sox-4

100643_task2

Sentence: Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O" ]

Solution structure of the sequence-specific HMG box of the lymphocyte transcriptional activator Sox-4.

[ "Solution", "structure", "of", "the", "sequence", "-", "specific", "HMG", "box", "of", "the", "lymphocyte", "transcriptional", "activator", "Sox-4", "." ]

[ "protein_family_or_group", "DNA_domain_or_region", "protein_domain_or_region", "other_name", "protein_substructure", "peptide", "protein_molecule", "(AND protein_substructure protein_substructure)", "DNA_family_or_group", "DNA_substructure", "polynucleotide", "" ]

R1306W is a ProteinMutation

825_task0

Sentence: A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ProteinMutation

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O" ]

A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.

[ "A", "first", "Taiwanese", "Chinese", "family", "of", "type", "2B", "von", "Willebrand", "disease", "with", "R1306W", "mutation", "." ]

[ "ProteinMutation" ]

R1306W is a ProteinMutation

825_task1

Sentence: A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation. Instructions: please typing these entity words according to sentence: R1306W Options: ProteinMutation

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O" ]

A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.

[ "A", "first", "Taiwanese", "Chinese", "family", "of", "type", "2B", "von", "Willebrand", "disease", "with", "R1306W", "mutation", "." ]

[ "ProteinMutation" ]

R1306W

825_task2

Sentence: A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinMutation", "O", "O" ]

A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.

[ "A", "first", "Taiwanese", "Chinese", "family", "of", "type", "2B", "von", "Willebrand", "disease", "with", "R1306W", "mutation", "." ]

[ "ProteinMutation" ]

Streptococcus infantarius is a Microorganism, ability to ferment lactose is a Phenotype, CJ18 is a Microorganism

116_task0

Sentence: Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O" ]

Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42].

[ "Further", "study", "of", "the", "gene", "content", "of", "the", "two", "Western", "African", "Streptococcus", "infantarius", " ", "strains", "showed", "that", "these", "strains", "had", "acquired", "the", "ability", "to", "ferment", " ", "lactose", "through", "the", "LacZS", "system", ",", "as", "previously", "described", "for", "Eastern", " ", "African", "strain", "CJ18", "[", "42", "]", "." ]

[ "Phenotype", "Microorganism" ]

Streptococcus infantarius is a Microorganism, ability to ferment lactose is a Phenotype, CJ18 is a Microorganism

116_task1

Sentence: Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42]. Instructions: please typing these entity words according to sentence: Streptococcus infantarius, ability to ferment lactose, CJ18 Options: Microorganism, Phenotype

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O" ]

Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42].

[ "Further", "study", "of", "the", "gene", "content", "of", "the", "two", "Western", "African", "Streptococcus", "infantarius", " ", "strains", "showed", "that", "these", "strains", "had", "acquired", "the", "ability", "to", "ferment", " ", "lactose", "through", "the", "LacZS", "system", ",", "as", "previously", "described", "for", "Eastern", " ", "African", "strain", "CJ18", "[", "42", "]", "." ]

[ "Phenotype", "Microorganism" ]

Streptococcus infantarius, ability to ferment lactose, CJ18

116_task2

Sentence: Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42]. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O" ]

Further study of the gene content of the two Western African Streptococcus infantarius strains showed that these strains had acquired the ability to ferment lactose through the LacZS system, as previously described for Eastern African strain CJ18 [42].

[ "Further", "study", "of", "the", "gene", "content", "of", "the", "two", "Western", "African", "Streptococcus", "infantarius", " ", "strains", "showed", "that", "these", "strains", "had", "acquired", "the", "ability", "to", "ferment", " ", "lactose", "through", "the", "LacZS", "system", ",", "as", "previously", "described", "for", "Eastern", " ", "African", "strain", "CJ18", "[", "42", "]", "." ]

[ "Phenotype", "Microorganism" ]

ages is a Person, 7 and 75 years is a Value, disability is a Condition, primary is a Qualifier, generalized or segmental is a Scope, dystonia is a Condition, optimal is a Qualifier, pharmacologic treatment is a Procedure, disease duration is a Measurement, at least 5 years is a Value

NCT01497639_inc_task0

Sentence: ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement

[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O" ]

ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years.

[ "ages", "of", "7", "and", "75", "years", "\n", "marked", "disability", "owing", "to", "primary", "generalized", "or", "segmental", "dystonia", ",", "despite", "optimal", "pharmacologic", "treatment", "\n", "disease", "duration", "of", "at", "least", "5", "years", ".", "\n" ]

[ "Scope", "Procedure", "Measurement", "Value", "Qualifier", "Condition", "Person" ]

ages is a Person, 7 and 75 years is a Value, disability is a Condition, primary is a Qualifier, generalized or segmental is a Scope, dystonia is a Condition, optimal is a Qualifier, pharmacologic treatment is a Procedure, disease duration is a Measurement, at least 5 years is a Value

NCT01497639_inc_task1

Sentence: ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years. Instructions: please typing these entity words according to sentence: ages, 7 and 75 years, disability, primary, generalized or segmental, dystonia, optimal, pharmacologic treatment, disease duration, at least 5 years Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement

[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O" ]

ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years.

[ "ages", "of", "7", "and", "75", "years", "\n", "marked", "disability", "owing", "to", "primary", "generalized", "or", "segmental", "dystonia", ",", "despite", "optimal", "pharmacologic", "treatment", "\n", "disease", "duration", "of", "at", "least", "5", "years", ".", "\n" ]

[ "Scope", "Procedure", "Measurement", "Value", "Qualifier", "Condition", "Person" ]

ages, 7 and 75 years, disability, primary, generalized or segmental, dystonia, optimal, pharmacologic treatment, disease duration, at least 5 years

NCT01497639_inc_task2

Sentence: ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years. Instructions: please extract entity words from the input sentence

[ "B-Person", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "O", "O", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "O", "B-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O" ]

ages of 7 and 75 years marked disability owing to primary generalized or segmental dystonia, despite optimal pharmacologic treatment disease duration of at least 5 years.

[ "ages", "of", "7", "and", "75", "years", "\n", "marked", "disability", "owing", "to", "primary", "generalized", "or", "segmental", "dystonia", ",", "despite", "optimal", "pharmacologic", "treatment", "\n", "disease", "duration", "of", "at", "least", "5", "years", ".", "\n" ]

[ "Scope", "Procedure", "Measurement", "Value", "Qualifier", "Condition", "Person" ]

epileptology is an umlsterm, epilepsy is an umlsterm, surgery is an umlsterm, Classification is an umlsterm, Epileptic Seizures is an umlsterm, classification is an umlsterm, epileptic seizures is an umlsterm, seizure is an umlsterm, seizure is an umlsterm, classification is an umlsterm

DerNervenarzt.80690117.eng.abstr_task0

Sentence: Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed .

[ "Recent", "advances", "in", "epileptology", "and", "epilepsy", "surgery", "require", "revision", "of", "the", "currently", "used", "International", "Classification", "of", "Epileptic", "Seizures", ",", "which", "was", "published", "1981", ".", "We", "present", "a", "classification", "of", "epileptic", "seizures", "which", "is", "based", "purely", "on", "the", "clinical", "seizure", "semiology", ".", "The", "advantages", "of", "a", "semiological", "seizure", "classification", "are", "stressed", "." ]

[ "umlsterm" ]

epileptology is an umlsterm, epilepsy is an umlsterm, surgery is an umlsterm, Classification is an umlsterm, Epileptic Seizures is an umlsterm, classification is an umlsterm, epileptic seizures is an umlsterm, seizure is an umlsterm, seizure is an umlsterm, classification is an umlsterm

DerNervenarzt.80690117.eng.abstr_task1

Sentence: Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed . Instructions: please typing these entity words according to sentence: epileptology, epilepsy, surgery, Classification, Epileptic Seizures, classification, epileptic seizures, seizure, seizure, classification Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed .

[ "Recent", "advances", "in", "epileptology", "and", "epilepsy", "surgery", "require", "revision", "of", "the", "currently", "used", "International", "Classification", "of", "Epileptic", "Seizures", ",", "which", "was", "published", "1981", ".", "We", "present", "a", "classification", "of", "epileptic", "seizures", "which", "is", "based", "purely", "on", "the", "clinical", "seizure", "semiology", ".", "The", "advantages", "of", "a", "semiological", "seizure", "classification", "are", "stressed", "." ]

[ "umlsterm" ]

epileptology, epilepsy, surgery, Classification, Epileptic Seizures, classification, epileptic seizures, seizure, seizure, classification

DerNervenarzt.80690117.eng.abstr_task2

Sentence: Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Recent advances in epileptology and epilepsy surgery require revision of the currently used International Classification of Epileptic Seizures , which was published 1981. We present a classification of epileptic seizures which is based purely on the clinical seizure semiology . The advantages of a semiological seizure classification are stressed .

[ "Recent", "advances", "in", "epileptology", "and", "epilepsy", "surgery", "require", "revision", "of", "the", "currently", "used", "International", "Classification", "of", "Epileptic", "Seizures", ",", "which", "was", "published", "1981", ".", "We", "present", "a", "classification", "of", "epileptic", "seizures", "which", "is", "based", "purely", "on", "the", "clinical", "seizure", "semiology", ".", "The", "advantages", "of", "a", "semiological", "seizure", "classification", "are", "stressed", "." ]

[ "umlsterm" ]

Allergy is a Condition, porphyrins and analogues is a Scope, Photosensitivity is a Condition, Porphyria is a Condition, Allergic constitution is a Condition, Scar diathesis is a Condition

NCT03181984_exc_task0

Sentence: Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition

[ "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators

[ "Allergy", "to", "porphyrins", "and", "analogues", ";", "Photosensitivity", ";", "Porphyria", ";", "Allergic", "constitution", ";", "\n", "Scar", "diathesis", ";", "\n", "Pregnancy", "or", "unwilling", "to", "adopt", "reliable", "contraceptive", "measures", "during", "the", "month", "after", "drug", "application", ";", "\n", "Be", "judged", "not", "suitable", "to", "participate", "the", "study", "by", "the", "investigators", "\n" ]

[ "Scope", "Condition", "Drug" ]

Allergy is a Condition, porphyrins and analogues is a Scope, Photosensitivity is a Condition, Porphyria is a Condition, Allergic constitution is a Condition, Scar diathesis is a Condition

NCT03181984_exc_task1

Sentence: Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators Instructions: please typing these entity words according to sentence: Allergy, porphyrins and analogues, Photosensitivity, Porphyria, Allergic constitution, Scar diathesis Options: Scope, Condition

[ "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators

[ "Allergy", "to", "porphyrins", "and", "analogues", ";", "Photosensitivity", ";", "Porphyria", ";", "Allergic", "constitution", ";", "\n", "Scar", "diathesis", ";", "\n", "Pregnancy", "or", "unwilling", "to", "adopt", "reliable", "contraceptive", "measures", "during", "the", "month", "after", "drug", "application", ";", "\n", "Be", "judged", "not", "suitable", "to", "participate", "the", "study", "by", "the", "investigators", "\n" ]

[ "Scope", "Condition", "Drug" ]

Allergy, porphyrins and analogues, Photosensitivity, Porphyria, Allergic constitution, Scar diathesis

NCT03181984_exc_task2

Sentence: Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators Instructions: please extract entity words from the input sentence

[ "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution; Scar diathesis; Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application; Be judged not suitable to participate the study by the investigators

[ "Allergy", "to", "porphyrins", "and", "analogues", ";", "Photosensitivity", ";", "Porphyria", ";", "Allergic", "constitution", ";", "\n", "Scar", "diathesis", ";", "\n", "Pregnancy", "or", "unwilling", "to", "adopt", "reliable", "contraceptive", "measures", "during", "the", "month", "after", "drug", "application", ";", "\n", "Be", "judged", "not", "suitable", "to", "participate", "the", "study", "by", "the", "investigators", "\n" ]

[ "Scope", "Condition", "Drug" ]

interleukin-5 is a Protein, interleukin-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-2 receptor is a Entity, IL-2R is a Entity, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, gene segment is a Entity, 5 ' upstream is a Entity, activation - inducible enhancer elements is a Entity, AP-1 is a Entity, NF - kappaB is a Entity, NF - kappaB is a Entity, IL-2 is a Protein, IL-5 is a Protein, CD4 is a Protein, IL-5 is a Protein

510_task0

Sentence: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis.

[ "Two", "distinct", "pathways", "of", "interleukin-5", "synthesis", "in", "allergen", "-", "specific", "human", "T", "-", "cell", "clones", "are", "suppressed", "by", "glucocorticoids", ".", "\n", "Glucocorticoids", "(", "GC", ")", "have", "long", "been", "used", "as", "the", "most", "effective", "agents", "for", "the", "treatment", "of", "allergic", "diseases", "accompanied", "by", "eosinophilia", "such", "as", "chronic", "asthma", "and", "atopic", "dermatitis", ".", "The", "development", "of", "chronic", "eosinophilic", "inflammation", "is", "dependent", "on", "interleukin-5", "(", "IL-5", ")", ",", "a", "selective", "eosinophil", "-", "activating", "factor", ",", "produced", "by", "helper", "T", "cells", ".", "To", "delineate", "the", "regulatory", "mechanisms", "of", "human", "IL-5", "synthesis", ",", "we", "established", "allergen", "-", "specific", "CD4", "+", "T", "-", "cell", "clones", "from", "asthmatic", "patients", ".", "GC", "efficiently", "suppressed", "IL-5", "synthesis", "of", "T", "-", "cell", "clones", "activated", "via", "either", "T", "-", "cell", "receptor", "(", "TCR", ")", "or", "IL-2", "receptor", "(", "IL-2R", ")", ".", "Induction", "of", "IL-5", "mRNA", "upon", "TCR", "and", "IL-2R", "stimulation", "was", "totally", "inhibited", "by", "dexamethasone", ".", "Human", "IL-5", "promoter", "/", "enhancer", "-", "luciferase", "gene", "construct", "transfected", "to", "T", "-", "cell", "clones", "was", "transcribed", "on", "either", "TCR", "or", "IL-2R", "stimulation", "and", "was", "clearly", "downregulated", "by", "dexamethasone", ",", "indicating", "that", "the", "approximately", "500-bp", "human", "IL-5", "gene", "segment", "located", "5", "'", "upstream", "of", "the", "coding", "region", "contains", "activation", "-", "inducible", "enhancer", "elements", "responsible", "for", "the", "regulation", "by", "GC", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "suggested", "that", "AP-1", "and", "NF", "-", "kappaB", "are", "among", "the", "possible", "targets", "of", "GC", "actions", "on", "TCR", "-", "stimulated", "T", "cells", ".", "NF", "-", "AT", "and", "NF", "-", "kappaB", "were", "not", "significantly", "induced", "by", "IL-2", "stimulation", ".", "Our", "results", "showing", "that", "GC", "suppressed", "IL-5", "production", "by", "human", "CD4", "+", "T", "cells", "activated", "by", "two", "distinct", "stimuli", ",", "TCR", "and", "IL-2R", "stimulation", ",", "underscore", "the", "efficacy", "of", "GC", "in", "the", "treatment", "of", "allergic", "diseases", "via", "suppression", "of", "T", "-", "cell", "IL-5", "synthesis", ".", "\n" ]

[ "Entity", "Protein" ]

interleukin-5 is a Protein, interleukin-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, IL-2 receptor is a Entity, IL-2R is a Entity, IL-5 is a Protein, IL-5 is a Protein, IL-5 is a Protein, gene segment is a Entity, 5 ' upstream is a Entity, activation - inducible enhancer elements is a Entity, AP-1 is a Entity, NF - kappaB is a Entity, NF - kappaB is a Entity, IL-2 is a Protein, IL-5 is a Protein, CD4 is a Protein, IL-5 is a Protein

510_task1

Sentence: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis. Instructions: please typing these entity words according to sentence: interleukin-5, interleukin-5, IL-5, IL-5, IL-5, IL-2 receptor, IL-2R, IL-5, IL-5, IL-5, gene segment, 5 ' upstream, activation - inducible enhancer elements, AP-1, NF - kappaB, NF - kappaB, IL-2, IL-5, CD4, IL-5 Options: Entity, Protein

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis.

[ "Two", "distinct", "pathways", "of", "interleukin-5", "synthesis", "in", "allergen", "-", "specific", "human", "T", "-", "cell", "clones", "are", "suppressed", "by", "glucocorticoids", ".", "\n", "Glucocorticoids", "(", "GC", ")", "have", "long", "been", "used", "as", "the", "most", "effective", "agents", "for", "the", "treatment", "of", "allergic", "diseases", "accompanied", "by", "eosinophilia", "such", "as", "chronic", "asthma", "and", "atopic", "dermatitis", ".", "The", "development", "of", "chronic", "eosinophilic", "inflammation", "is", "dependent", "on", "interleukin-5", "(", "IL-5", ")", ",", "a", "selective", "eosinophil", "-", "activating", "factor", ",", "produced", "by", "helper", "T", "cells", ".", "To", "delineate", "the", "regulatory", "mechanisms", "of", "human", "IL-5", "synthesis", ",", "we", "established", "allergen", "-", "specific", "CD4", "+", "T", "-", "cell", "clones", "from", "asthmatic", "patients", ".", "GC", "efficiently", "suppressed", "IL-5", "synthesis", "of", "T", "-", "cell", "clones", "activated", "via", "either", "T", "-", "cell", "receptor", "(", "TCR", ")", "or", "IL-2", "receptor", "(", "IL-2R", ")", ".", "Induction", "of", "IL-5", "mRNA", "upon", "TCR", "and", "IL-2R", "stimulation", "was", "totally", "inhibited", "by", "dexamethasone", ".", "Human", "IL-5", "promoter", "/", "enhancer", "-", "luciferase", "gene", "construct", "transfected", "to", "T", "-", "cell", "clones", "was", "transcribed", "on", "either", "TCR", "or", "IL-2R", "stimulation", "and", "was", "clearly", "downregulated", "by", "dexamethasone", ",", "indicating", "that", "the", "approximately", "500-bp", "human", "IL-5", "gene", "segment", "located", "5", "'", "upstream", "of", "the", "coding", "region", "contains", "activation", "-", "inducible", "enhancer", "elements", "responsible", "for", "the", "regulation", "by", "GC", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "suggested", "that", "AP-1", "and", "NF", "-", "kappaB", "are", "among", "the", "possible", "targets", "of", "GC", "actions", "on", "TCR", "-", "stimulated", "T", "cells", ".", "NF", "-", "AT", "and", "NF", "-", "kappaB", "were", "not", "significantly", "induced", "by", "IL-2", "stimulation", ".", "Our", "results", "showing", "that", "GC", "suppressed", "IL-5", "production", "by", "human", "CD4", "+", "T", "cells", "activated", "by", "two", "distinct", "stimuli", ",", "TCR", "and", "IL-2R", "stimulation", ",", "underscore", "the", "efficacy", "of", "GC", "in", "the", "treatment", "of", "allergic", "diseases", "via", "suppression", "of", "T", "-", "cell", "IL-5", "synthesis", ".", "\n" ]

[ "Entity", "Protein" ]

interleukin-5, interleukin-5, IL-5, IL-5, IL-5, IL-2 receptor, IL-2R, IL-5, IL-5, IL-5, gene segment, 5 ' upstream, activation - inducible enhancer elements, AP-1, NF - kappaB, NF - kappaB, IL-2, IL-5, CD4, IL-5

510_task2

Sentence: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O" ]

Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Glucocorticoids (GC) have long been used as the most effective agents for the treatment of allergic diseases accompanied by eosinophilia such as chronic asthma and atopic dermatitis. The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells. To delineate the regulatory mechanisms of human IL-5 synthesis, we established allergen-specific CD4+ T-cell clones from asthmatic patients. GC efficiently suppressed IL-5 synthesis of T-cell clones activated via either T-cell receptor (TCR) or IL-2 receptor (IL-2R). Induction of IL-5 mRNA upon TCR and IL-2R stimulation was totally inhibited by dexamethasone. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T-cell clones was transcribed on either TCR or IL-2R stimulation and was clearly downregulated by dexamethasone, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contains activation-inducible enhancer elements responsible for the regulation by GC. Electrophoretic mobility shift assay analysis suggested that AP-1 and NF-kappaB are among the possible targets of GC actions on TCR-stimulated T cells. NF-AT and NF-kappaB were not significantly induced by IL-2 stimulation. Our results showing that GC suppressed IL-5 production by human CD4+ T cells activated by two distinct stimuli, TCR and IL-2R stimulation, underscore the efficacy of GC in the treatment of allergic diseases via suppression of T-cell IL-5 synthesis.

[ "Two", "distinct", "pathways", "of", "interleukin-5", "synthesis", "in", "allergen", "-", "specific", "human", "T", "-", "cell", "clones", "are", "suppressed", "by", "glucocorticoids", ".", "\n", "Glucocorticoids", "(", "GC", ")", "have", "long", "been", "used", "as", "the", "most", "effective", "agents", "for", "the", "treatment", "of", "allergic", "diseases", "accompanied", "by", "eosinophilia", "such", "as", "chronic", "asthma", "and", "atopic", "dermatitis", ".", "The", "development", "of", "chronic", "eosinophilic", "inflammation", "is", "dependent", "on", "interleukin-5", "(", "IL-5", ")", ",", "a", "selective", "eosinophil", "-", "activating", "factor", ",", "produced", "by", "helper", "T", "cells", ".", "To", "delineate", "the", "regulatory", "mechanisms", "of", "human", "IL-5", "synthesis", ",", "we", "established", "allergen", "-", "specific", "CD4", "+", "T", "-", "cell", "clones", "from", "asthmatic", "patients", ".", "GC", "efficiently", "suppressed", "IL-5", "synthesis", "of", "T", "-", "cell", "clones", "activated", "via", "either", "T", "-", "cell", "receptor", "(", "TCR", ")", "or", "IL-2", "receptor", "(", "IL-2R", ")", ".", "Induction", "of", "IL-5", "mRNA", "upon", "TCR", "and", "IL-2R", "stimulation", "was", "totally", "inhibited", "by", "dexamethasone", ".", "Human", "IL-5", "promoter", "/", "enhancer", "-", "luciferase", "gene", "construct", "transfected", "to", "T", "-", "cell", "clones", "was", "transcribed", "on", "either", "TCR", "or", "IL-2R", "stimulation", "and", "was", "clearly", "downregulated", "by", "dexamethasone", ",", "indicating", "that", "the", "approximately", "500-bp", "human", "IL-5", "gene", "segment", "located", "5", "'", "upstream", "of", "the", "coding", "region", "contains", "activation", "-", "inducible", "enhancer", "elements", "responsible", "for", "the", "regulation", "by", "GC", ".", "Electrophoretic", "mobility", "shift", "assay", "analysis", "suggested", "that", "AP-1", "and", "NF", "-", "kappaB", "are", "among", "the", "possible", "targets", "of", "GC", "actions", "on", "TCR", "-", "stimulated", "T", "cells", ".", "NF", "-", "AT", "and", "NF", "-", "kappaB", "were", "not", "significantly", "induced", "by", "IL-2", "stimulation", ".", "Our", "results", "showing", "that", "GC", "suppressed", "IL-5", "production", "by", "human", "CD4", "+", "T", "cells", "activated", "by", "two", "distinct", "stimuli", ",", "TCR", "and", "IL-2R", "stimulation", ",", "underscore", "the", "efficacy", "of", "GC", "in", "the", "treatment", "of", "allergic", "diseases", "via", "suppression", "of", "T", "-", "cell", "IL-5", "synthesis", ".", "\n" ]

[ "Entity", "Protein" ]

neurologic is a Anatomical_system, brain is a Organ

PMID-8102531_task0

Sentence: Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Anatomical_system, Organ

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O" ]

Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored.

[ "Epilepsy", "in", "Down", "syndrome", ":", "clinical", "aspects", "and", "possible", "mechanisms", ".", "\n", "Although", "epilepsy", "is", "more", "common", "in", "persons", "with", "trisomy", "21", "(", "Down", "syndrome", ")", "than", "in", "the", "general", "population", ",", "the", "mechanisms", "by", "which", "seizures", "are", "generated", "in", "this", "population", "have", "received", "little", "attention", ".", "It", "is", "likely", "that", "this", "increased", "seizure", "susceptibility", "is", "due", "to", "a", "combination", "of", "medical", "risk", "factors", "and", "inherent", "neurologic", "abnormalities", "characteristic", "of", "Down", "syndrome", ".", "In", "this", "review", "clinical", "aspects", "of", "seizures", "among", "individuals", "with", "Down", "syndrome", "were", "described", "and", "possible", "mechanisms", "by", "which", "the", "trisomy", "21", "brain", "may", "generate", "seizures", "were", "explored", ".", "\n" ]

[ "Anatomical_system", "Organ" ]

neurologic is a Anatomical_system, brain is a Organ

PMID-8102531_task1

Sentence: Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored. Instructions: please typing these entity words according to sentence: neurologic, brain Options: Anatomical_system, Organ

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O" ]

Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored.

[ "Epilepsy", "in", "Down", "syndrome", ":", "clinical", "aspects", "and", "possible", "mechanisms", ".", "\n", "Although", "epilepsy", "is", "more", "common", "in", "persons", "with", "trisomy", "21", "(", "Down", "syndrome", ")", "than", "in", "the", "general", "population", ",", "the", "mechanisms", "by", "which", "seizures", "are", "generated", "in", "this", "population", "have", "received", "little", "attention", ".", "It", "is", "likely", "that", "this", "increased", "seizure", "susceptibility", "is", "due", "to", "a", "combination", "of", "medical", "risk", "factors", "and", "inherent", "neurologic", "abnormalities", "characteristic", "of", "Down", "syndrome", ".", "In", "this", "review", "clinical", "aspects", "of", "seizures", "among", "individuals", "with", "Down", "syndrome", "were", "described", "and", "possible", "mechanisms", "by", "which", "the", "trisomy", "21", "brain", "may", "generate", "seizures", "were", "explored", ".", "\n" ]

[ "Anatomical_system", "Organ" ]

neurologic, brain

PMID-8102531_task2

Sentence: Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Anatomical_system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O" ]

Epilepsy in Down syndrome: clinical aspects and possible mechanisms. Although epilepsy is more common in persons with trisomy 21 (Down syndrome) than in the general population, the mechanisms by which seizures are generated in this population have received little attention. It is likely that this increased seizure susceptibility is due to a combination of medical risk factors and inherent neurologic abnormalities characteristic of Down syndrome. In this review clinical aspects of seizures among individuals with Down syndrome were described and possible mechanisms by which the trisomy 21 brain may generate seizures were explored.

[ "Epilepsy", "in", "Down", "syndrome", ":", "clinical", "aspects", "and", "possible", "mechanisms", ".", "\n", "Although", "epilepsy", "is", "more", "common", "in", "persons", "with", "trisomy", "21", "(", "Down", "syndrome", ")", "than", "in", "the", "general", "population", ",", "the", "mechanisms", "by", "which", "seizures", "are", "generated", "in", "this", "population", "have", "received", "little", "attention", ".", "It", "is", "likely", "that", "this", "increased", "seizure", "susceptibility", "is", "due", "to", "a", "combination", "of", "medical", "risk", "factors", "and", "inherent", "neurologic", "abnormalities", "characteristic", "of", "Down", "syndrome", ".", "In", "this", "review", "clinical", "aspects", "of", "seizures", "among", "individuals", "with", "Down", "syndrome", "were", "described", "and", "possible", "mechanisms", "by", "which", "the", "trisomy", "21", "brain", "may", "generate", "seizures", "were", "explored", ".", "\n" ]

[ "Anatomical_system", "Organ" ]

regulation of gene expression is a Relation_Trigger

4262_task0

Sentence: RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Relation_Trigger

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]

RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals.

[ "RNA", "editing", "by", "adenosine", "deamination", "is", "a", "posttranscriptional", "mechanism", "for", "the", "regulation", "of", "gene", "expression", "and", "is", "particularly", "widespread", "in", "mammals", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species" ]

regulation of gene expression is a Relation_Trigger

4262_task1

Sentence: RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals. Instructions: please typing these entity words according to sentence: regulation of gene expression Options: Relation_Trigger

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]

RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals.

[ "RNA", "editing", "by", "adenosine", "deamination", "is", "a", "posttranscriptional", "mechanism", "for", "the", "regulation", "of", "gene", "expression", "and", "is", "particularly", "widespread", "in", "mammals", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species" ]

regulation of gene expression

4262_task2

Sentence: RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "O", "O", "O" ]

RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals.

[ "RNA", "editing", "by", "adenosine", "deamination", "is", "a", "posttranscriptional", "mechanism", "for", "the", "regulation", "of", "gene", "expression", "and", "is", "particularly", "widespread", "in", "mammals", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species" ]

facial nerve palsy is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, patients is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, blood - peripheral is an umlsterm, nerve - barrier is an umlsterm, regeneration is an umlsterm, facial nerve is an umlsterm, palsy is an umlsterm

DerRadiologe.60360890.eng.abstr_task0

Sentence: In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]

In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy .

[ "In", "inflammatory", "peripheral", "facial", "nerve", "palsy", "pathologically", "intense", ",", "linear", "and", "smooth", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "always", "be", "observed", "on", "T1-w-", "SE-", "MR", "sequences", ".", "The", "other", "nerve", "segments", "often", "present", "with", "a", "pathological", "enhancement", "as", "well", ".", "On", "T2-w-", "SE", "sequences", ",", "a", "thickening", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "observed", ".", "The", "pathological", "enhancement", "persists", "over", "weeks", "and", "months", ";", "even", "in", "patients", "with", "complete", "clinical", "recovery", ",", "a", "persistent", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "demonstrated", ".", "No", "correlation", "can", "be", "established", "between", "the", "intensity", "of", "the", "enhancement", ",", "the", "clinical", "condition", "and", "the", "electrophysiological", "data", "on", "electroneurography", ".", "The", "persistent", "enhancement", "of", "the", "different", "nerve", "segments", "is", "due", "to", "a", "long", "-", "lasting", "breakdown", "of", "the", "blood", "-", "peripheral", "nerve", "-", "barrier", "related", "to", "the", "process", "of", "degeneration", "and", "regeneration", "of", "the", "facial", "nerve", "in", "inflammatory", "palsy", "." ]

[ "umlsterm" ]

facial nerve palsy is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, patients is an umlsterm, nerve is an umlsterm, nerve is an umlsterm, blood - peripheral is an umlsterm, nerve - barrier is an umlsterm, regeneration is an umlsterm, facial nerve is an umlsterm, palsy is an umlsterm

DerRadiologe.60360890.eng.abstr_task1

Sentence: In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy . Instructions: please typing these entity words according to sentence: facial nerve palsy, nerve, nerve, nerve, patients, nerve, nerve, blood - peripheral, nerve - barrier, regeneration, facial nerve, palsy Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]

In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy .

[ "In", "inflammatory", "peripheral", "facial", "nerve", "palsy", "pathologically", "intense", ",", "linear", "and", "smooth", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "always", "be", "observed", "on", "T1-w-", "SE-", "MR", "sequences", ".", "The", "other", "nerve", "segments", "often", "present", "with", "a", "pathological", "enhancement", "as", "well", ".", "On", "T2-w-", "SE", "sequences", ",", "a", "thickening", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "observed", ".", "The", "pathological", "enhancement", "persists", "over", "weeks", "and", "months", ";", "even", "in", "patients", "with", "complete", "clinical", "recovery", ",", "a", "persistent", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "demonstrated", ".", "No", "correlation", "can", "be", "established", "between", "the", "intensity", "of", "the", "enhancement", ",", "the", "clinical", "condition", "and", "the", "electrophysiological", "data", "on", "electroneurography", ".", "The", "persistent", "enhancement", "of", "the", "different", "nerve", "segments", "is", "due", "to", "a", "long", "-", "lasting", "breakdown", "of", "the", "blood", "-", "peripheral", "nerve", "-", "barrier", "related", "to", "the", "process", "of", "degeneration", "and", "regeneration", "of", "the", "facial", "nerve", "in", "inflammatory", "palsy", "." ]

[ "umlsterm" ]

facial nerve palsy, nerve, nerve, nerve, patients, nerve, nerve, blood - peripheral, nerve - barrier, regeneration, facial nerve, palsy

DerRadiologe.60360890.eng.abstr_task2

Sentence: In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O" ]

In inflammatory peripheral facial nerve palsy pathologically intense , linear and smooth enhancement of the distal intrameatal nerve segment can always be observed on T1-w- SE- MR sequences . The other nerve segments often present with a pathological enhancement as well . On T2-w- SE sequences , a thickening of the distal intrameatal nerve segment can be observed . The pathological enhancement persists over weeks and months ; even in patients with complete clinical recovery , a persistent enhancement of the distal intrameatal nerve segment can be demonstrated . No correlation can be established between the intensity of the enhancement , the clinical condition and the electrophysiological data on electroneurography . The persistent enhancement of the different nerve segments is due to a long-lasting breakdown of the blood-peripheral nerve-barrier related to the process of degeneration and regeneration of the facial nerve in inflammatory palsy .

[ "In", "inflammatory", "peripheral", "facial", "nerve", "palsy", "pathologically", "intense", ",", "linear", "and", "smooth", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "always", "be", "observed", "on", "T1-w-", "SE-", "MR", "sequences", ".", "The", "other", "nerve", "segments", "often", "present", "with", "a", "pathological", "enhancement", "as", "well", ".", "On", "T2-w-", "SE", "sequences", ",", "a", "thickening", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "observed", ".", "The", "pathological", "enhancement", "persists", "over", "weeks", "and", "months", ";", "even", "in", "patients", "with", "complete", "clinical", "recovery", ",", "a", "persistent", "enhancement", "of", "the", "distal", "intrameatal", "nerve", "segment", "can", "be", "demonstrated", ".", "No", "correlation", "can", "be", "established", "between", "the", "intensity", "of", "the", "enhancement", ",", "the", "clinical", "condition", "and", "the", "electrophysiological", "data", "on", "electroneurography", ".", "The", "persistent", "enhancement", "of", "the", "different", "nerve", "segments", "is", "due", "to", "a", "long", "-", "lasting", "breakdown", "of", "the", "blood", "-", "peripheral", "nerve", "-", "barrier", "related", "to", "the", "process", "of", "degeneration", "and", "regeneration", "of", "the", "facial", "nerve", "in", "inflammatory", "palsy", "." ]

[ "umlsterm" ]

Progesterone receptor is a GENE-Y

17169175_task0

Sentence: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation.

[ "Progesterone", "receptor", "requires", "a", "co", "-", "chaperone", "for", "signalling", "in", "uterine", "biology", "and", "implantation", "." ]

[ "GENE-Y", "CHEMICAL" ]

Progesterone receptor is a GENE-Y

17169175_task1

Sentence: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Instructions: please typing these entity words according to sentence: Progesterone receptor Options: GENE-Y

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation.

[ "Progesterone", "receptor", "requires", "a", "co", "-", "chaperone", "for", "signalling", "in", "uterine", "biology", "and", "implantation", "." ]

[ "GENE-Y", "CHEMICAL" ]

Progesterone receptor

17169175_task2

Sentence: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation.

[ "Progesterone", "receptor", "requires", "a", "co", "-", "chaperone", "for", "signalling", "in", "uterine", "biology", "and", "implantation", "." ]

[ "GENE-Y", "CHEMICAL" ]

non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors is a Intervention_Pharmacological, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . is a Intervention_Pharmacological, 1397 is a Participant_Sample-size, antiretroviral - treatment - naive is a Participant_Condition, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; is a Intervention_Pharmacological, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; is a Intervention_Pharmacological, or a three - class strategy ( PI plus NNRTI plus NRTI ; is a Intervention_Pharmacological, AIDS - defining event is a Outcome_Physical, death is a Outcome_Mortality, CD4 cell count decline is a Outcome_Physical, change in CD4 cell count is a Outcome_Physical, composite endpoint is a Outcome_Other, 388 is a Participant_Sample-size, 302 is a Participant_Sample-size, 188 is a Participant_Sample-size, HRs is a Outcome_Other, AIDS or death is a Outcome_Mortality, virological failure is a Outcome_Physical, Mean change in CD4 cell count is a Outcome_Physical, HIV is a Participant_Condition, discontinue treatment is a Outcome_Other, toxic effects is a Outcome_Adverse-effects, NNRTI - based regimen is a Intervention_Pharmacological, PI - based regimen is a Intervention_Pharmacological

29145_task0

Sentence: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV .

[ "A", "comparison", "of", "three", "highly", "active", "antiretroviral", "treatment", "strategies", "consisting", "of", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitors", ",", "protease", "inhibitors", ",", "or", "both", "in", "the", "presence", "of", "nucleoside", "reverse", "transcriptase", "inhibitors", "as", "initial", "therapy", "(", "CPCRA", "058", "FIRST", "Study", ")", ":", "a", "long", "-", "term", "randomised", "trial", ".", "BACKGROUND", "Long", "-", "term", "data", "from", "randomised", "trials", "on", "the", "consequences", "of", "treatment", "with", "a", "protease", "inhibitor", "(", "PI", ")", ",", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", ",", "or", "both", "are", "lacking", ".", "Here", ",", "we", "report", "results", "from", "the", "FIRST", "trial", ",", "which", "compared", "initial", "treatment", "strategies", "for", "clinical", ",", "immunological", ",", "and", "virological", "outcomes", ".", "METHODS", "Between", "1999", "and", "2002", ",", "1397", "antiretroviral", "-", "treatment", "-", "naive", "patients", ",", "presenting", "at", "18", "clinical", "trial", "units", "with", "80", "research", "sites", "in", "the", "USA", ",", "were", "randomly", "assigned", "in", "a", "ratio", "of", "1:1:1", "to", "a", "protease", "inhibitor", "(", "PI", ")", "strategy", "(", "PI", "plus", "nucleoside", "reverse", "transcriptase", "inhibitor", "[", "NRTI", "]", ";", "n=470", ")", ",", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", "strategy", "(", "NNRTI", "plus", "NRTI", ";", "n=463", ")", ",", "or", "a", "three", "-", "class", "strategy", "(", "PI", "plus", "NNRTI", "plus", "NRTI", ";", "n=464", ")", ".", "Primary", "endpoints", "were", "a", "composite", "of", "an", "AIDS", "-", "defining", "event", ",", "death", ",", "or", "CD4", "cell", "count", "decline", "to", "less", "than", "200", "cells", "per", "mm3", "for", "the", "PI", "versus", "NNRTI", "comparison", ",", "and", "average", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "comparison", ".", "Analyses", "were", "by", "intention", "-", "to", "-", "treat", ".", "This", "study", "is", "registered", "ClinicalTrials.gov", ",", "number", "NCT00000922", ".", "FINDINGS", "1397", "patients", "were", "assessed", "for", "the", "composite", "endpoint", ".", "A", "total", "of", "388", "participants", "developed", "the", "composite", "endpoint", ",", "302", "developed", "AIDS", "or", "died", ",", "and", "188", "died", ".", "NNRTI", "versus", "PI", "hazard", "ratios", "(", "HRs", ")", "for", "the", "composite", "endpoint", ",", "for", "AIDS", "or", "death", ",", "for", "death", ",", "and", "for", "virological", "failure", "were", "1.02", "(", "95", "%", "CI", "0.79", "-", "1.31", ")", ",", "1.07", "(", "0.80", "-", "1.41", ")", ",", "0.95", "(", "0.66", "-", "1.37", ")", ",", "and", "0.66", "(", "0.56", "-", "0.78", ")", ",", "respectively", ".", "1196", "patients", "were", "assessed", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "primary", "endpoint", ".", "Mean", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "was", "+234", "cells", "per", "mm3", "and", "+227", "cells", "per", "mm3", "for", "the", "three", "-", "class", "and", "the", "combined", "two", "-", "class", "strategies", "(", "p=0.62", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "and", "virological", "failure", "were", "1.15", "(", "0.91", "-", "1.45", ")", "and", "0.87", "(", "0.75", "-", "1.00", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "were", "similar", "for", "participants", "with", "baseline", "CD4", "cell", "counts", "of", "200", "cells", "per", "mm3", "or", "less", "and", "of", "more", "than", "200", "cells", "per", "mm3", "(", "p=0.38", "for", "interaction", ")", ",", "and", "for", "participants", "with", "baseline", "HIV", "RNA", "concentrations", "less", "than", "100", "000", "copies", "per", "mL", "and", "100,000", "copies", "per", "mL", "or", "more", "(", "p=0.26", "for", "interaction", ")", ".", "Participants", "assigned", "the", "three", "-", "class", "strategy", "were", "significantly", "more", "likely", "to", "discontinue", "treatment", "because", "of", "toxic", "effects", "than", "were", "those", "assigned", "to", "the", "two", "-", "class", "strategies", "(", "HR", "1.58", ";", "p", "<", "0.0001", ")", ".", "INTERPRETATION", "Initial", "treatment", "with", "either", "an", "NNRTI", "-", "based", "regimen", "or", "a", "PI", "-", "based", "regimen", ",", "but", "not", "both", "together", ",", "is", "a", "good", "strategy", "for", "long", "-", "term", "antiretroviral", "management", "in", "treatment", "-", "naive", "patients", "with", "HIV", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Outcome_Mortality", "Outcome_Adverse-effects", "Participant_Sample-size" ]

non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors is a Intervention_Pharmacological, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . is a Intervention_Pharmacological, 1397 is a Participant_Sample-size, antiretroviral - treatment - naive is a Participant_Condition, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; is a Intervention_Pharmacological, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; is a Intervention_Pharmacological, or a three - class strategy ( PI plus NNRTI plus NRTI ; is a Intervention_Pharmacological, AIDS - defining event is a Outcome_Physical, death is a Outcome_Mortality, CD4 cell count decline is a Outcome_Physical, change in CD4 cell count is a Outcome_Physical, composite endpoint is a Outcome_Other, 388 is a Participant_Sample-size, 302 is a Participant_Sample-size, 188 is a Participant_Sample-size, HRs is a Outcome_Other, AIDS or death is a Outcome_Mortality, virological failure is a Outcome_Physical, Mean change in CD4 cell count is a Outcome_Physical, HIV is a Participant_Condition, discontinue treatment is a Outcome_Other, toxic effects is a Outcome_Adverse-effects, NNRTI - based regimen is a Intervention_Pharmacological, PI - based regimen is a Intervention_Pharmacological

29145_task1

Sentence: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV . Instructions: please typing these entity words according to sentence: non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking ., 1397, antiretroviral - treatment - naive, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ;, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ;, or a three - class strategy ( PI plus NNRTI plus NRTI ;, AIDS - defining event, death, CD4 cell count decline, change in CD4 cell count, composite endpoint, 388, 302, 188, HRs, AIDS or death, virological failure, Mean change in CD4 cell count, HIV, discontinue treatment, toxic effects, NNRTI - based regimen, PI - based regimen Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV .

[ "A", "comparison", "of", "three", "highly", "active", "antiretroviral", "treatment", "strategies", "consisting", "of", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitors", ",", "protease", "inhibitors", ",", "or", "both", "in", "the", "presence", "of", "nucleoside", "reverse", "transcriptase", "inhibitors", "as", "initial", "therapy", "(", "CPCRA", "058", "FIRST", "Study", ")", ":", "a", "long", "-", "term", "randomised", "trial", ".", "BACKGROUND", "Long", "-", "term", "data", "from", "randomised", "trials", "on", "the", "consequences", "of", "treatment", "with", "a", "protease", "inhibitor", "(", "PI", ")", ",", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", ",", "or", "both", "are", "lacking", ".", "Here", ",", "we", "report", "results", "from", "the", "FIRST", "trial", ",", "which", "compared", "initial", "treatment", "strategies", "for", "clinical", ",", "immunological", ",", "and", "virological", "outcomes", ".", "METHODS", "Between", "1999", "and", "2002", ",", "1397", "antiretroviral", "-", "treatment", "-", "naive", "patients", ",", "presenting", "at", "18", "clinical", "trial", "units", "with", "80", "research", "sites", "in", "the", "USA", ",", "were", "randomly", "assigned", "in", "a", "ratio", "of", "1:1:1", "to", "a", "protease", "inhibitor", "(", "PI", ")", "strategy", "(", "PI", "plus", "nucleoside", "reverse", "transcriptase", "inhibitor", "[", "NRTI", "]", ";", "n=470", ")", ",", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", "strategy", "(", "NNRTI", "plus", "NRTI", ";", "n=463", ")", ",", "or", "a", "three", "-", "class", "strategy", "(", "PI", "plus", "NNRTI", "plus", "NRTI", ";", "n=464", ")", ".", "Primary", "endpoints", "were", "a", "composite", "of", "an", "AIDS", "-", "defining", "event", ",", "death", ",", "or", "CD4", "cell", "count", "decline", "to", "less", "than", "200", "cells", "per", "mm3", "for", "the", "PI", "versus", "NNRTI", "comparison", ",", "and", "average", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "comparison", ".", "Analyses", "were", "by", "intention", "-", "to", "-", "treat", ".", "This", "study", "is", "registered", "ClinicalTrials.gov", ",", "number", "NCT00000922", ".", "FINDINGS", "1397", "patients", "were", "assessed", "for", "the", "composite", "endpoint", ".", "A", "total", "of", "388", "participants", "developed", "the", "composite", "endpoint", ",", "302", "developed", "AIDS", "or", "died", ",", "and", "188", "died", ".", "NNRTI", "versus", "PI", "hazard", "ratios", "(", "HRs", ")", "for", "the", "composite", "endpoint", ",", "for", "AIDS", "or", "death", ",", "for", "death", ",", "and", "for", "virological", "failure", "were", "1.02", "(", "95", "%", "CI", "0.79", "-", "1.31", ")", ",", "1.07", "(", "0.80", "-", "1.41", ")", ",", "0.95", "(", "0.66", "-", "1.37", ")", ",", "and", "0.66", "(", "0.56", "-", "0.78", ")", ",", "respectively", ".", "1196", "patients", "were", "assessed", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "primary", "endpoint", ".", "Mean", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "was", "+234", "cells", "per", "mm3", "and", "+227", "cells", "per", "mm3", "for", "the", "three", "-", "class", "and", "the", "combined", "two", "-", "class", "strategies", "(", "p=0.62", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "and", "virological", "failure", "were", "1.15", "(", "0.91", "-", "1.45", ")", "and", "0.87", "(", "0.75", "-", "1.00", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "were", "similar", "for", "participants", "with", "baseline", "CD4", "cell", "counts", "of", "200", "cells", "per", "mm3", "or", "less", "and", "of", "more", "than", "200", "cells", "per", "mm3", "(", "p=0.38", "for", "interaction", ")", ",", "and", "for", "participants", "with", "baseline", "HIV", "RNA", "concentrations", "less", "than", "100", "000", "copies", "per", "mL", "and", "100,000", "copies", "per", "mL", "or", "more", "(", "p=0.26", "for", "interaction", ")", ".", "Participants", "assigned", "the", "three", "-", "class", "strategy", "were", "significantly", "more", "likely", "to", "discontinue", "treatment", "because", "of", "toxic", "effects", "than", "were", "those", "assigned", "to", "the", "two", "-", "class", "strategies", "(", "HR", "1.58", ";", "p", "<", "0.0001", ")", ".", "INTERPRETATION", "Initial", "treatment", "with", "either", "an", "NNRTI", "-", "based", "regimen", "or", "a", "PI", "-", "based", "regimen", ",", "but", "not", "both", "together", ",", "is", "a", "good", "strategy", "for", "long", "-", "term", "antiretroviral", "management", "in", "treatment", "-", "naive", "patients", "with", "HIV", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Outcome_Mortality", "Outcome_Adverse-effects", "Participant_Sample-size" ]

non - nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors, protease inhibitor ( PI ) , non - nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking ., 1397, antiretroviral - treatment - naive, protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ;, a non - nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ;, or a three - class strategy ( PI plus NNRTI plus NRTI ;, AIDS - defining event, death, CD4 cell count decline, change in CD4 cell count, composite endpoint, 388, 302, 188, HRs, AIDS or death, virological failure, Mean change in CD4 cell count, HIV, discontinue treatment, toxic effects, NNRTI - based regimen, PI - based regimen

29145_task2

Sentence: A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors , protease inhibitors , or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy ( CPCRA 058 FIRST Study ) : a long-term randomised trial . BACKGROUND Long-term data from randomised trials on the consequences of treatment with a protease inhibitor ( PI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , or both are lacking . Here , we report results from the FIRST trial , which compared initial treatment strategies for clinical , immunological , and virological outcomes . METHODS Between 1999 and 2002 , 1397 antiretroviral-treatment-naive patients , presenting at 18 clinical trial units with 80 research sites in the USA , were randomly assigned in a ratio of 1:1:1 to a protease inhibitor ( PI ) strategy ( PI plus nucleoside reverse transcriptase inhibitor [ NRTI ] ; n=470 ) , a non-nucleoside reverse transcriptase inhibitor ( NNRTI ) strategy ( NNRTI plus NRTI ; n=463 ) , or a three-class strategy ( PI plus NNRTI plus NRTI ; n=464 ) . Primary endpoints were a composite of an AIDS-defining event , death , or CD4 cell count decline to less than 200 cells per mm3 for the PI versus NNRTI comparison , and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison . Analyses were by intention-to-treat . This study is registered ClinicalTrials.gov , number NCT00000922 . FINDINGS 1397 patients were assessed for the composite endpoint . A total of 388 participants developed the composite endpoint , 302 developed AIDS or died , and 188 died . NNRTI versus PI hazard ratios ( HRs ) for the composite endpoint , for AIDS or death , for death , and for virological failure were 1.02 ( 95 % CI 0.79-1.31 ) , 1.07 ( 0.80-1.41 ) , 0.95 ( 0.66-1.37 ) , and 0.66 ( 0.56-0.78 ) , respectively . 1196 patients were assessed for the three-class versus combined two-class primary endpoint . Mean change in CD4 cell count at or after 32 months was +234 cells per mm3 and +227 cells per mm3 for the three-class and the combined two-class strategies ( p=0.62 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death and virological failure were 1.15 ( 0.91-1.45 ) and 0.87 ( 0.75-1.00 ) , respectively . HRs ( three-class vs combined two-class ) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm3 ( p=0.38 for interaction ) , and for participants with baseline HIV RNA concentrations less than 100 000 copies per mL and 100,000 copies per mL or more ( p=0.26 for interaction ) . Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies ( HR 1.58 ; p < 0.0001 ) . INTERPRETATION Initial treatment with either an NNRTI-based regimen or a PI-based regimen , but not both together , is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV .

[ "A", "comparison", "of", "three", "highly", "active", "antiretroviral", "treatment", "strategies", "consisting", "of", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitors", ",", "protease", "inhibitors", ",", "or", "both", "in", "the", "presence", "of", "nucleoside", "reverse", "transcriptase", "inhibitors", "as", "initial", "therapy", "(", "CPCRA", "058", "FIRST", "Study", ")", ":", "a", "long", "-", "term", "randomised", "trial", ".", "BACKGROUND", "Long", "-", "term", "data", "from", "randomised", "trials", "on", "the", "consequences", "of", "treatment", "with", "a", "protease", "inhibitor", "(", "PI", ")", ",", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", ",", "or", "both", "are", "lacking", ".", "Here", ",", "we", "report", "results", "from", "the", "FIRST", "trial", ",", "which", "compared", "initial", "treatment", "strategies", "for", "clinical", ",", "immunological", ",", "and", "virological", "outcomes", ".", "METHODS", "Between", "1999", "and", "2002", ",", "1397", "antiretroviral", "-", "treatment", "-", "naive", "patients", ",", "presenting", "at", "18", "clinical", "trial", "units", "with", "80", "research", "sites", "in", "the", "USA", ",", "were", "randomly", "assigned", "in", "a", "ratio", "of", "1:1:1", "to", "a", "protease", "inhibitor", "(", "PI", ")", "strategy", "(", "PI", "plus", "nucleoside", "reverse", "transcriptase", "inhibitor", "[", "NRTI", "]", ";", "n=470", ")", ",", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "(", "NNRTI", ")", "strategy", "(", "NNRTI", "plus", "NRTI", ";", "n=463", ")", ",", "or", "a", "three", "-", "class", "strategy", "(", "PI", "plus", "NNRTI", "plus", "NRTI", ";", "n=464", ")", ".", "Primary", "endpoints", "were", "a", "composite", "of", "an", "AIDS", "-", "defining", "event", ",", "death", ",", "or", "CD4", "cell", "count", "decline", "to", "less", "than", "200", "cells", "per", "mm3", "for", "the", "PI", "versus", "NNRTI", "comparison", ",", "and", "average", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "comparison", ".", "Analyses", "were", "by", "intention", "-", "to", "-", "treat", ".", "This", "study", "is", "registered", "ClinicalTrials.gov", ",", "number", "NCT00000922", ".", "FINDINGS", "1397", "patients", "were", "assessed", "for", "the", "composite", "endpoint", ".", "A", "total", "of", "388", "participants", "developed", "the", "composite", "endpoint", ",", "302", "developed", "AIDS", "or", "died", ",", "and", "188", "died", ".", "NNRTI", "versus", "PI", "hazard", "ratios", "(", "HRs", ")", "for", "the", "composite", "endpoint", ",", "for", "AIDS", "or", "death", ",", "for", "death", ",", "and", "for", "virological", "failure", "were", "1.02", "(", "95", "%", "CI", "0.79", "-", "1.31", ")", ",", "1.07", "(", "0.80", "-", "1.41", ")", ",", "0.95", "(", "0.66", "-", "1.37", ")", ",", "and", "0.66", "(", "0.56", "-", "0.78", ")", ",", "respectively", ".", "1196", "patients", "were", "assessed", "for", "the", "three", "-", "class", "versus", "combined", "two", "-", "class", "primary", "endpoint", ".", "Mean", "change", "in", "CD4", "cell", "count", "at", "or", "after", "32", "months", "was", "+234", "cells", "per", "mm3", "and", "+227", "cells", "per", "mm3", "for", "the", "three", "-", "class", "and", "the", "combined", "two", "-", "class", "strategies", "(", "p=0.62", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "and", "virological", "failure", "were", "1.15", "(", "0.91", "-", "1.45", ")", "and", "0.87", "(", "0.75", "-", "1.00", ")", ",", "respectively", ".", "HRs", "(", "three", "-", "class", "vs", "combined", "two", "-", "class", ")", "for", "AIDS", "or", "death", "were", "similar", "for", "participants", "with", "baseline", "CD4", "cell", "counts", "of", "200", "cells", "per", "mm3", "or", "less", "and", "of", "more", "than", "200", "cells", "per", "mm3", "(", "p=0.38", "for", "interaction", ")", ",", "and", "for", "participants", "with", "baseline", "HIV", "RNA", "concentrations", "less", "than", "100", "000", "copies", "per", "mL", "and", "100,000", "copies", "per", "mL", "or", "more", "(", "p=0.26", "for", "interaction", ")", ".", "Participants", "assigned", "the", "three", "-", "class", "strategy", "were", "significantly", "more", "likely", "to", "discontinue", "treatment", "because", "of", "toxic", "effects", "than", "were", "those", "assigned", "to", "the", "two", "-", "class", "strategies", "(", "HR", "1.58", ";", "p", "<", "0.0001", ")", ".", "INTERPRETATION", "Initial", "treatment", "with", "either", "an", "NNRTI", "-", "based", "regimen", "or", "a", "PI", "-", "based", "regimen", ",", "but", "not", "both", "together", ",", "is", "a", "good", "strategy", "for", "long", "-", "term", "antiretroviral", "management", "in", "treatment", "-", "naive", "patients", "with", "HIV", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Other", "Outcome_Mortality", "Outcome_Adverse-effects", "Participant_Sample-size" ]

dysgenesis is an umlsterm, oligohydramnios is an umlsterm, congenital is an umlsterm, anuria is an umlsterm, stillbirth is an umlsterm, death is an umlsterm, respiratory failure is an umlsterm, diagnosis is an umlsterm, histology is an umlsterm, proximal tubule is an umlsterm, family is an umlsterm, consanguinity is an umlsterm, Lectin is an umlsterm, proximal tubule is an umlsterm, findings is an umlsterm, vein thrombosis is an umlsterm, morphological is an umlsterm, disorder is an umlsterm, pathogenesis is an umlsterm

DerPathologe.50160143.eng.abstr_task0

Sentence: Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed .

[ "Renal", "tubular", "dysgenesis", "is", "a", "rarely", "recognized", "condition", "characterized", "by", "oligohydramnios", ",", "Potter", "'s", "sequence", "and", "congenital", "anuria", "leading", "to", "stillbirth", "or", "neonatal", "death", "from", "respiratory", "failure", ".", "It", "is", "thought", "to", "be", "inherited", "in", "an", "autosomal", "recessive", "manner", ".", "Definitive", "diagnosis", "is", "based", "on", "renal", "histology", ",", "revealing", "the", "lack", "of", "proximal", "tubule", "differentiation", ".", "Two", "additional", "cases", "of", "affected", "sibs", "in", "a", "family", "with", "parental", "consanguinity", "are", "reported", ".", "Lectin", "and", "immunohistochemical", "studies", "confirmed", "structural", "and", "functional", "immaturity", "of", "the", "proximal", "tubule", ".", "Further", "findings", "include", "bilateral", "renal", "vein", "thrombosis", ".", "The", "clinical", "and", "morphological", "parameters", "defining", "this", "disorder", "and", "the", "possible", "mechanisms", "of", "pathogenesis", "are", "discussed", "." ]

[ "umlsterm" ]

dysgenesis is an umlsterm, oligohydramnios is an umlsterm, congenital is an umlsterm, anuria is an umlsterm, stillbirth is an umlsterm, death is an umlsterm, respiratory failure is an umlsterm, diagnosis is an umlsterm, histology is an umlsterm, proximal tubule is an umlsterm, family is an umlsterm, consanguinity is an umlsterm, Lectin is an umlsterm, proximal tubule is an umlsterm, findings is an umlsterm, vein thrombosis is an umlsterm, morphological is an umlsterm, disorder is an umlsterm, pathogenesis is an umlsterm

DerPathologe.50160143.eng.abstr_task1

Sentence: Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed . Instructions: please typing these entity words according to sentence: dysgenesis, oligohydramnios, congenital, anuria, stillbirth, death, respiratory failure, diagnosis, histology, proximal tubule, family, consanguinity, Lectin, proximal tubule, findings, vein thrombosis, morphological, disorder, pathogenesis Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed .

[ "Renal", "tubular", "dysgenesis", "is", "a", "rarely", "recognized", "condition", "characterized", "by", "oligohydramnios", ",", "Potter", "'s", "sequence", "and", "congenital", "anuria", "leading", "to", "stillbirth", "or", "neonatal", "death", "from", "respiratory", "failure", ".", "It", "is", "thought", "to", "be", "inherited", "in", "an", "autosomal", "recessive", "manner", ".", "Definitive", "diagnosis", "is", "based", "on", "renal", "histology", ",", "revealing", "the", "lack", "of", "proximal", "tubule", "differentiation", ".", "Two", "additional", "cases", "of", "affected", "sibs", "in", "a", "family", "with", "parental", "consanguinity", "are", "reported", ".", "Lectin", "and", "immunohistochemical", "studies", "confirmed", "structural", "and", "functional", "immaturity", "of", "the", "proximal", "tubule", ".", "Further", "findings", "include", "bilateral", "renal", "vein", "thrombosis", ".", "The", "clinical", "and", "morphological", "parameters", "defining", "this", "disorder", "and", "the", "possible", "mechanisms", "of", "pathogenesis", "are", "discussed", "." ]

[ "umlsterm" ]

dysgenesis, oligohydramnios, congenital, anuria, stillbirth, death, respiratory failure, diagnosis, histology, proximal tubule, family, consanguinity, Lectin, proximal tubule, findings, vein thrombosis, morphological, disorder, pathogenesis

DerPathologe.50160143.eng.abstr_task2

Sentence: Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Renal tubular dysgenesis is a rarely recognized condition characterized by oligohydramnios , Potter's sequence and congenital anuria leading to stillbirth or neonatal death from respiratory failure . It is thought to be inherited in an autosomal recessive manner . Definitive diagnosis is based on renal histology , revealing the lack of proximal tubule differentiation . Two additional cases of affected sibs in a family with parental consanguinity are reported . Lectin and immunohistochemical studies confirmed structural and functional immaturity of the proximal tubule . Further findings include bilateral renal vein thrombosis . The clinical and morphological parameters defining this disorder and the possible mechanisms of pathogenesis are discussed .

[ "Renal", "tubular", "dysgenesis", "is", "a", "rarely", "recognized", "condition", "characterized", "by", "oligohydramnios", ",", "Potter", "'s", "sequence", "and", "congenital", "anuria", "leading", "to", "stillbirth", "or", "neonatal", "death", "from", "respiratory", "failure", ".", "It", "is", "thought", "to", "be", "inherited", "in", "an", "autosomal", "recessive", "manner", ".", "Definitive", "diagnosis", "is", "based", "on", "renal", "histology", ",", "revealing", "the", "lack", "of", "proximal", "tubule", "differentiation", ".", "Two", "additional", "cases", "of", "affected", "sibs", "in", "a", "family", "with", "parental", "consanguinity", "are", "reported", ".", "Lectin", "and", "immunohistochemical", "studies", "confirmed", "structural", "and", "functional", "immaturity", "of", "the", "proximal", "tubule", ".", "Further", "findings", "include", "bilateral", "renal", "vein", "thrombosis", ".", "The", "clinical", "and", "morphological", "parameters", "defining", "this", "disorder", "and", "the", "possible", "mechanisms", "of", "pathogenesis", "are", "discussed", "." ]

[ "umlsterm" ]

limb is an umlsterm, amputation is an umlsterm, emergency service is an umlsterm, personnel is an umlsterm, treatment is an umlsterm, limbs is an umlsterm, replantation is an umlsterm, prosthesis is an umlsterm, functions is an umlsterm, limb is an umlsterm

Notfall+Rettungsmedizin.90020141.eng.abstr_task0

Sentence: Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting .

[ "Prehospital", "management", "of", "the", "acute", "limb", "amputation", "places", "great", "demands", "on", "the", "emergency", "service", "personnel", ".", "The", "initial", "treatment", "of", "amputated", "limbs", "often", "determines", "the", "success", "of", "later", "clinical", "attempts", "of", "replantation", ".", "So", "far", "no", "kind", "of", "prosthesis", "could", "ever", "take", "the", "place", "and", "the", "original", "biomechanical", "functions", "of", "the", "original", "limb", "in", "the", "prehospital", "setting", "." ]

[ "umlsterm" ]

limb is an umlsterm, amputation is an umlsterm, emergency service is an umlsterm, personnel is an umlsterm, treatment is an umlsterm, limbs is an umlsterm, replantation is an umlsterm, prosthesis is an umlsterm, functions is an umlsterm, limb is an umlsterm

Notfall+Rettungsmedizin.90020141.eng.abstr_task1

Sentence: Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting . Instructions: please typing these entity words according to sentence: limb, amputation, emergency service, personnel, treatment, limbs, replantation, prosthesis, functions, limb Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting .

[ "Prehospital", "management", "of", "the", "acute", "limb", "amputation", "places", "great", "demands", "on", "the", "emergency", "service", "personnel", ".", "The", "initial", "treatment", "of", "amputated", "limbs", "often", "determines", "the", "success", "of", "later", "clinical", "attempts", "of", "replantation", ".", "So", "far", "no", "kind", "of", "prosthesis", "could", "ever", "take", "the", "place", "and", "the", "original", "biomechanical", "functions", "of", "the", "original", "limb", "in", "the", "prehospital", "setting", "." ]

[ "umlsterm" ]

limb, amputation, emergency service, personnel, treatment, limbs, replantation, prosthesis, functions, limb

Notfall+Rettungsmedizin.90020141.eng.abstr_task2

Sentence: Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Prehospital management of the acute limb amputation places great demands on the emergency service personnel . The initial treatment of amputated limbs often determines the success of later clinical attempts of replantation . So far no kind of prosthesis could ever take the place and the original biomechanical functions of the original limb in the prehospital setting .

[ "Prehospital", "management", "of", "the", "acute", "limb", "amputation", "places", "great", "demands", "on", "the", "emergency", "service", "personnel", ".", "The", "initial", "treatment", "of", "amputated", "limbs", "often", "determines", "the", "success", "of", "later", "clinical", "attempts", "of", "replantation", ".", "So", "far", "no", "kind", "of", "prosthesis", "could", "ever", "take", "the", "place", "and", "the", "original", "biomechanical", "functions", "of", "the", "original", "limb", "in", "the", "prehospital", "setting", "." ]

[ "umlsterm" ]

CpG is a compound, ERalpha is a protein

DS.d1277_task0

Sentence: In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O" ]

In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e.

[ "In", "the", "present", "study", ",", "the", "mRNA", "expression", "and", "promoter", "CpG", "methylation", "of", "ERalpha", "isoforms", "(", "i.e", "." ]

[ "protein", "compound" ]

CpG is a compound, ERalpha is a protein

DS.d1277_task1

Sentence: In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e. Instructions: please typing these entity words according to sentence: CpG, ERalpha Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O" ]

In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e.

[ "In", "the", "present", "study", ",", "the", "mRNA", "expression", "and", "promoter", "CpG", "methylation", "of", "ERalpha", "isoforms", "(", "i.e", "." ]

[ "protein", "compound" ]

CpG, ERalpha

DS.d1277_task2

Sentence: In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "B-protein", "O", "O", "O", "O" ]

In the present study, the mRNA expression and promoter CpG methylation of ERalpha isoforms (i.e.

[ "In", "the", "present", "study", ",", "the", "mRNA", "expression", "and", "promoter", "CpG", "methylation", "of", "ERalpha", "isoforms", "(", "i.e", "." ]

[ "protein", "compound" ]

Dysphagia is an umlsterm, surgical is an umlsterm, oral cavity is an umlsterm, hypopharynx is an umlsterm, postoperative is an umlsterm, Videofluoroscopy is an umlsterm, visualization is an umlsterm, deglutition is an umlsterm, morphology is an umlsterm, videofluoroscopy is an umlsterm, therapeutic is an umlsterm, pathology is an umlsterm, deglutition is an umlsterm, patients is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, hypopharynx is an umlsterm, deglutition is an umlsterm, deglutition is an umlsterm

DerRadiologe.80380117.eng.abstr_task0

Sentence: Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases .

[ "Dysphagia", "is", "a", "common", "complaint", "following", "surgical", "intervention", "in", "the", "oral", "cavity", "and", "hypopharynx", ",", "often", "leading", "to", "prolonged", "postoperative", "recovery", ".", "Videofluoroscopy", "allows", "detailed", "visualization", "of", "deglutition", ",", "demonstrating", "the", "morphology", "as", "well", "as", "the", "functional", "aspects", ".", "Therefore", ",", "videofluoroscopy", "provides", "the", "basis", "for", "further", "therapeutic", "management", ".", "We", "discuss", "the", "pathology", "of", "deglutition", "in", "19", "patients", "recovering", "from", "tumor", "surgery", "of", "the", "oro-", "and", "hypopharynx", ".", "In", "most", "cases", "the", "results", "demonstrated", "severe", "impairment", "of", "both", "the", "oral", "and", "pharyngeal", "phase", "of", "deglutition", ".", "Our", "data", "emphasize", "the", "importance", "of", "the", "oral", "phase", "of", "deglutition", "for", "preparation", "and", "initiation", "of", "the", "following", "phases", "." ]

[ "umlsterm" ]

Dysphagia is an umlsterm, surgical is an umlsterm, oral cavity is an umlsterm, hypopharynx is an umlsterm, postoperative is an umlsterm, Videofluoroscopy is an umlsterm, visualization is an umlsterm, deglutition is an umlsterm, morphology is an umlsterm, videofluoroscopy is an umlsterm, therapeutic is an umlsterm, pathology is an umlsterm, deglutition is an umlsterm, patients is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, hypopharynx is an umlsterm, deglutition is an umlsterm, deglutition is an umlsterm

DerRadiologe.80380117.eng.abstr_task1

Sentence: Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases . Instructions: please typing these entity words according to sentence: Dysphagia, surgical, oral cavity, hypopharynx, postoperative, Videofluoroscopy, visualization, deglutition, morphology, videofluoroscopy, therapeutic, pathology, deglutition, patients, tumor, surgery, hypopharynx, deglutition, deglutition Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases .

[ "Dysphagia", "is", "a", "common", "complaint", "following", "surgical", "intervention", "in", "the", "oral", "cavity", "and", "hypopharynx", ",", "often", "leading", "to", "prolonged", "postoperative", "recovery", ".", "Videofluoroscopy", "allows", "detailed", "visualization", "of", "deglutition", ",", "demonstrating", "the", "morphology", "as", "well", "as", "the", "functional", "aspects", ".", "Therefore", ",", "videofluoroscopy", "provides", "the", "basis", "for", "further", "therapeutic", "management", ".", "We", "discuss", "the", "pathology", "of", "deglutition", "in", "19", "patients", "recovering", "from", "tumor", "surgery", "of", "the", "oro-", "and", "hypopharynx", ".", "In", "most", "cases", "the", "results", "demonstrated", "severe", "impairment", "of", "both", "the", "oral", "and", "pharyngeal", "phase", "of", "deglutition", ".", "Our", "data", "emphasize", "the", "importance", "of", "the", "oral", "phase", "of", "deglutition", "for", "preparation", "and", "initiation", "of", "the", "following", "phases", "." ]

[ "umlsterm" ]

Dysphagia, surgical, oral cavity, hypopharynx, postoperative, Videofluoroscopy, visualization, deglutition, morphology, videofluoroscopy, therapeutic, pathology, deglutition, patients, tumor, surgery, hypopharynx, deglutition, deglutition

DerRadiologe.80380117.eng.abstr_task2

Sentence: Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Dysphagia is a common complaint following surgical intervention in the oral cavity and hypopharynx , often leading to prolonged postoperative recovery . Videofluoroscopy allows detailed visualization of deglutition , demonstrating the morphology as well as the functional aspects . Therefore , videofluoroscopy provides the basis for further therapeutic management . We discuss the pathology of deglutition in 19 patients recovering from tumor surgery of the oro- and hypopharynx . In most cases the results demonstrated severe impairment of both the oral and pharyngeal phase of deglutition . Our data emphasize the importance of the oral phase of deglutition for preparation and initiation of the following phases .

[ "Dysphagia", "is", "a", "common", "complaint", "following", "surgical", "intervention", "in", "the", "oral", "cavity", "and", "hypopharynx", ",", "often", "leading", "to", "prolonged", "postoperative", "recovery", ".", "Videofluoroscopy", "allows", "detailed", "visualization", "of", "deglutition", ",", "demonstrating", "the", "morphology", "as", "well", "as", "the", "functional", "aspects", ".", "Therefore", ",", "videofluoroscopy", "provides", "the", "basis", "for", "further", "therapeutic", "management", ".", "We", "discuss", "the", "pathology", "of", "deglutition", "in", "19", "patients", "recovering", "from", "tumor", "surgery", "of", "the", "oro-", "and", "hypopharynx", ".", "In", "most", "cases", "the", "results", "demonstrated", "severe", "impairment", "of", "both", "the", "oral", "and", "pharyngeal", "phase", "of", "deglutition", ".", "Our", "data", "emphasize", "the", "importance", "of", "the", "oral", "phase", "of", "deglutition", "for", "preparation", "and", "initiation", "of", "the", "following", "phases", "." ]

[ "umlsterm" ]

interferon - gamma is a protein_molecule, gene expression is an other_name

22106_task0

Sentence: Regulation of interferon-gamma gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, protein_molecule

[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "B-other_name", "I-other_name", "O" ]

Regulation of interferon-gamma gene expression.

[ "Regulation", "of", "interferon", "-", "gamma", "gene", "expression", "." ]

[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "protein_N/A", "RNA_molecule", "DNA_domain_or_region", "body_part" ]

interferon - gamma is a protein_molecule, gene expression is an other_name

22106_task1

Sentence: Regulation of interferon-gamma gene expression. Instructions: please typing these entity words according to sentence: interferon - gamma, gene expression Options: other_name, protein_molecule

[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "B-other_name", "I-other_name", "O" ]

Regulation of interferon-gamma gene expression.

[ "Regulation", "of", "interferon", "-", "gamma", "gene", "expression", "." ]

[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "protein_N/A", "RNA_molecule", "DNA_domain_or_region", "body_part" ]

interferon - gamma, gene expression

22106_task2

Sentence: Regulation of interferon-gamma gene expression. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "B-other_name", "I-other_name", "O" ]

Regulation of interferon-gamma gene expression.

[ "Regulation", "of", "interferon", "-", "gamma", "gene", "expression", "." ]

[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "protein_N/A", "RNA_molecule", "DNA_domain_or_region", "body_part" ]

Histamine is an other_organic_compound, c - fos is a DNA_domain_or_region, cyclic AMP production is an other_name, H2 receptor is a protein_complex, human promonocytic cell line U937 is a cell_line

61791_task0

Sentence: Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, other_name, cell_line, DNA_domain_or_region, protein_complex

[ "B-other_organic_compound", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_complex", "I-protein_complex", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937.

[ "Histamine", "modulates", "the", "expression", "of", "c", "-", "fos", "through", "cyclic", "AMP", "production", "via", "the", "H2", "receptor", "in", "the", "human", "promonocytic", "cell", "line", "U937", "." ]

[ "protein_family_or_group", "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region)", "other_name", "other_organic_compound", "protein_molecule", "", "nucleotide", "DNA_family_or_group", "protein_complex", "RNA_molecule", "DNA_domain_or_region" ]

Histamine is an other_organic_compound, c - fos is a DNA_domain_or_region, cyclic AMP production is an other_name, H2 receptor is a protein_complex, human promonocytic cell line U937 is a cell_line

61791_task1

Sentence: Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. Instructions: please typing these entity words according to sentence: Histamine, c - fos, cyclic AMP production, H2 receptor, human promonocytic cell line U937 Options: other_organic_compound, other_name, cell_line, DNA_domain_or_region, protein_complex

[ "B-other_organic_compound", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_complex", "I-protein_complex", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937.

[ "Histamine", "modulates", "the", "expression", "of", "c", "-", "fos", "through", "cyclic", "AMP", "production", "via", "the", "H2", "receptor", "in", "the", "human", "promonocytic", "cell", "line", "U937", "." ]

[ "protein_family_or_group", "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region)", "other_name", "other_organic_compound", "protein_molecule", "", "nucleotide", "DNA_family_or_group", "protein_complex", "RNA_molecule", "DNA_domain_or_region" ]

Histamine, c - fos, cyclic AMP production, H2 receptor, human promonocytic cell line U937

61791_task2

Sentence: Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. Instructions: please extract entity words from the input sentence

[ "B-other_organic_compound", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_complex", "I-protein_complex", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937.

[ "Histamine", "modulates", "the", "expression", "of", "c", "-", "fos", "through", "cyclic", "AMP", "production", "via", "the", "H2", "receptor", "in", "the", "human", "promonocytic", "cell", "line", "U937", "." ]

[ "protein_family_or_group", "cell_line", "(AND DNA_domain_or_region DNA_domain_or_region)", "other_name", "other_organic_compound", "protein_molecule", "", "nucleotide", "DNA_family_or_group", "protein_complex", "RNA_molecule", "DNA_domain_or_region" ]

FGEYRSLESDNEE is a peptide, TGN38 is a protein, AP-2 is a protein-complex

1.0alpha7.train.1235_task0

Sentence: We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: peptide, protein, protein-complex

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-peptide", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b).

[ "We", "have", "shown", "previously", ",", "using", "an", "in", "vitro", "peptide", "competition", "assay", ",", "that", "the", "peptide", "FGEYRSLESDNEE", "blocks", "binding", "of", "a", "biotin", "-", "labeled", "TGN38", "peptide", "to", "AP-2", "purified", "from", "rat", "brain", "(", "Kamiguchi", "et", "al", ".", ",", "1998b", ")", "." ]

[ "peptide", "protein", "protein-complex" ]

FGEYRSLESDNEE is a peptide, TGN38 is a protein, AP-2 is a protein-complex

1.0alpha7.train.1235_task1

Sentence: We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b). Instructions: please typing these entity words according to sentence: FGEYRSLESDNEE, TGN38, AP-2 Options: peptide, protein, protein-complex

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-peptide", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b).

[ "We", "have", "shown", "previously", ",", "using", "an", "in", "vitro", "peptide", "competition", "assay", ",", "that", "the", "peptide", "FGEYRSLESDNEE", "blocks", "binding", "of", "a", "biotin", "-", "labeled", "TGN38", "peptide", "to", "AP-2", "purified", "from", "rat", "brain", "(", "Kamiguchi", "et", "al", ".", ",", "1998b", ")", "." ]

[ "peptide", "protein", "protein-complex" ]

FGEYRSLESDNEE, TGN38, AP-2

1.0alpha7.train.1235_task2

Sentence: We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-peptide", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We have shown previously, using an in vitro peptide competition assay, that the peptide FGEYRSLESDNEE blocks binding of a biotin-labeled TGN38 peptide to AP-2 purified from rat brain (Kamiguchi et al., 1998b).

[ "We", "have", "shown", "previously", ",", "using", "an", "in", "vitro", "peptide", "competition", "assay", ",", "that", "the", "peptide", "FGEYRSLESDNEE", "blocks", "binding", "of", "a", "biotin", "-", "labeled", "TGN38", "peptide", "to", "AP-2", "purified", "from", "rat", "brain", "(", "Kamiguchi", "et", "al", ".", ",", "1998b", ")", "." ]

[ "peptide", "protein", "protein-complex" ]

aim is an umlsterm, techniques is an umlsterm, cataract surgery is an umlsterm, postoperative is an umlsterm, astigmatism is an umlsterm, visual acuity is an umlsterm

DerOpthalmologe.80950427.eng.abstr_task0

Sentence: Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity .

[ "Purpose", ":", "The", "aim", "was", "to", "compare", "the", "different", "techniques", "of", "cataract", "surgery", "regarding", "early", "postoperative", "astigmatism", "and", "visual", "acuity", "." ]

[ "umlsterm" ]

aim is an umlsterm, techniques is an umlsterm, cataract surgery is an umlsterm, postoperative is an umlsterm, astigmatism is an umlsterm, visual acuity is an umlsterm

DerOpthalmologe.80950427.eng.abstr_task1

Sentence: Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity . Instructions: please typing these entity words according to sentence: aim, techniques, cataract surgery, postoperative, astigmatism, visual acuity Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity .

[ "Purpose", ":", "The", "aim", "was", "to", "compare", "the", "different", "techniques", "of", "cataract", "surgery", "regarding", "early", "postoperative", "astigmatism", "and", "visual", "acuity", "." ]

[ "umlsterm" ]

aim, techniques, cataract surgery, postoperative, astigmatism, visual acuity

DerOpthalmologe.80950427.eng.abstr_task2

Sentence: Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

Purpose : The aim was to compare the different techniques of cataract surgery regarding early postoperative astigmatism and visual acuity .

[ "Purpose", ":", "The", "aim", "was", "to", "compare", "the", "different", "techniques", "of", "cataract", "surgery", "regarding", "early", "postoperative", "astigmatism", "and", "visual", "acuity", "." ]

[ "umlsterm" ]

Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural is a MORFOLOGIA_NEOPLASIA, afectación meníngea is a MORFOLOGIA_NEOPLASIA, angiomiolipoma is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, lesiones intraparenquimatosas is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma seroso G3 is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, masa residual retroperitoneal is a MORFOLOGIA_NEOPLASIA, masa mesentérica is a MORFOLOGIA_NEOPLASIA, implante tumoral is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA

205_task0

Sentence: Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. ** HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. ** 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. ** HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. ** 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16).

[ "Anamnesis", "\n", "Mujer", "68", "años", ".", "\n", "-", "Alergia", "a", "amoxicilina", "y", "moxifloxacino", "(", "con", "estudio", "por", "alergología", ")", ".", "\n", "-", "No", "hábitos", "tóxicos", ".", "\n", "-", "No", "factores", "de", "riesgo", "cardiovascular", ".", "\n\n", "-", "Hipotiroidismo", ".", "\n", "-", "Antecedentes", "quirúrgicos", ":", "histerectomía", "sin", "anexectomía", "con", "41", "años", ".", "\n", "-", "Tratamiento", "habitual", ":", "Levotiroxina", ",", "Guayana", "en", "comprimidos", ".", "\n\n", "*", "*", "HISTORIA", "ONCOLÓGICA", ":", "\n", "-", "Diagnóstico", "en", "Mayo/2015", "de", "Adenocarcinoma", "seroso", "de", "ovario", "G3", "estadio", "IV", "por", "afectación", "pleural", ".", "Inicia", "tratamiento", "con", "quimioterapia", "(", "QT", ")", "según", "esquema", "Carboplatino", "(", "AUC", "5", "cada", "3", "semanas", ")", "-", "Paclitaxel", "(", "175", "mg", "/", "m2", "cada", "3", "semanas", ")", "-", "Bevacizumab", "(", "15", "mg", "/", "kg", ")", ",", "del", "que", "recibe", "un", "total", "de", "4", "ciclos", ",", "último", "el", "07/08/15", "con", "reducción", "10", "%", "en", "4º", "ciclo", "por", "astenia", "G3", ".", "Respuesta", "parcial", "bioquímica", "(", "descenso", "importante", "del", "Ca", "125", ")", "y", "por", "imagen", ".", "\n\n", "*", "*", "22/08/16", ":", "Paciente", "con", "clínica", "de", "1", "mes", "aproximadamente", "de", "duración", "(", "tras", "3º", "ciclo", "de", "QT", "el", "14/07/15", ")", "consistente", "en", "cuadro", "de", "desorientación", ".", "Tras", "4º", "ciclo", "de", "QT", "el", "07/08/15", ",", "con", "mala", "tolerancia", "al", "mismo", ",", "presenta", "empeoramiento", "del", "cuadro", "neurológico", "con", "crisis", "convulsiva", "el", "22/08/15", "por", "lo", "que", "es", "traída", "a", "urgencias", "por", "sus", "familiares", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "118", "mEq", "/", "L.", "Se", "realiza", "TAC", "craneal", "sin", "hallazgos", "patológicos", "y", "sin", "hacer", "referencia", "a", "existencia", "de", "edema", "cerebral", ",", "y", "se", "inicia", "correción", "hidroelectrolítica", "con", "mejoria", "rápida", "del", "cuadro", ",", "aunque", "no", "resolución", "completa", ".", "Es", "dada", "de", "alta", "tras", "24", "horas", "en", "observación", "y", "con", "cifra", "de", "Na", "133", "mEq", "/", "L.", "\n", "El", "28/08/15", "en", "valorada", "en", "hospital", "de", "día", "de", "Oncología", "para", "5º", "cliclo", ",", "que", "se", "suspende", "por", "persitencia", "de", "cuadro", "neurológico", "a", "pesar", "de", "Na", "corregido", "(", "134", "mEq", "/", "L", ")", ",", "mala", "tolerancia", "al", "4º", "ciclo", "y", "episodio", "de", "fiebre", "puntual", "el", "26/08/15", "secundario", "a", "fístula", "perianal", "en", "tratamiento", "con", "Eritromicina", ".", "En", "dicha", "consulta", ",", "debido", "a", "persistencia", "del", "cuadro", "neurologico", ",", "se", "solicita", "RMN", "craneal", "a", "fin", "de", "descartar", "afectación", "meníngea", "que", "pudiera", "explicar", "el", "cuadro", ".", "\n", "El", "31/08/16", "consulta", "nuevamente", "en", "urgencias", "por", "episodio", "convulsivo", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "112", "mEq", "/", "L", ",", "por", "lo", "que", "se", "inicia", "corrección", "de", "la", "misma", "con", "mejoría", "rápida", "del", "cuadro", "en", "24", "horas", "y", "posteriormente", "trasladada", "a", "planta", "de", "Oncología", "para", "continuidad", "de", "cuidados", ".", "\n\n", "Exploración", "física", "\n", "AL", "INGRESO", "EN", "ONCOLOGÍA", "MÉDICA", "\n", "PS", "4", ".", "Glasgow", "11", "(", "apertura", "espontánea", "de", "ojos", ",", "retira", "al", "dolor", ",", "no", "obedece", "órdenes", ",", "lenguaje", "incomprensible", ")", ".", "\n", "Pupilas", "isocóricas", "normorreactivas", ".", "Moviliza", "4", "miembros", ".", "\n", "Auscultación", "Cardio", "-", "Respiratoria", ":", "Normal", ".", "Abdomen", "normal", ".", "\n", "Miembros", "Inferiores", "sin", "edema", "ni", "signos", "Trombosis", "Venosa", "Profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "PRUEBAS", "DE", "LABORATORIO", "\n\n", "-", "Analítica", "31/08/15", ":", "\n", "*", "Hemograma", ":", "Hb", "99", "g", "/", "l", ",", "resto", "normal", ".", "\n", "*", "BioquÍmica", "sérica", ":", "Na", "112", "mEq", "/", "L", ",", "K", "3.2", "mEq", "/", "L", ",", "resto", "normal", ".", "\n", "*", "Coagulación", ":", "Normal", ".", "\n", "-", "Gasometría", "Venosa", "31/05/15", ":", "EVOLUCIÓN", ".", "\n", "*", "Na", ":", "111", "(", "15.00pm", ")", "-", ">", "113", "(", "16.00pm", ")", "-", ">", "116", "(", "17.00pm", ")", "-", ">", "116", "(", "18.45pm", ")", "\n", "*", "Osm", ":", "229", "-", ">", "233", "-", ">", "237-", ">", "237", ".", "\n", "-", "IONES", "ORINA", ":", "Na", "110", "mEq", "/", "L", "(", "elevado", ")", ",", "K", "10", "mEq", "/", "L.", "Proteinuria", ".", "\n", "-", "Marcadores", "tumorales", "01/09/16", ":", "CEA", "5,1", "ng", "/", "ml", "(", "descenso", ",", "al", "diagnóstico", "de", "7.9", "ng", "/", "ml", ")", ".", "CA", "125", "977", "U", "/", "ml", "(", "franco", "descenso", ",", "al", "diagnóstico", "de", "46852", "U", "/", "ml", ")", ".", "\n", "-", "Analítica", "10/09/16", "(", "PREVIA", "AL", "ALTA", "):", "\n", "*", "Bioquímica", ":", "Urea", "45", "mg", "/", "dl", ",", "proteinas", "totales", "6", "gr", "/", "dl", ",", "fósforo", "inorgánico", "2,55", "mg", "/", "dl", ".", "Sodio", "normal", "(", "139", "mEq", "/", "L", ")", ".", "\n", "*", "Hemograma", ":", "Hemoglobina", "98", "gr", "/", "L.", "Series", "blanca", "y", "paquetaria", "normales", ".", "\n\n", "PRUEBAS", "IMAGEN", "\n", "-", "TAC", "de", "tórax", "y", "abdomen", "(", "3/09/2015", ")", ".", "Nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "sin", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "pleural", ".", "Han", "desaparecido", "los", "engrosamientos", "pleurales", ".", "En", "hígado", "sigue", "apreciándose", "pequeño", "nódulo", "de", "8", "mm", "en", "periferia", "subdiafragmática", "del", "segmento", "VIII", "de", "contenido", "predominantemente", "graso", "(", "angiomiolipoma", "hepático", "?", ")", ".", "Pequeña", "lesión", "focal", "hipodensa", "en", "periferia", "del", "segmento", "VII", "de", "6", "mm", "de", "diámetro", ",", "indeterminada", ".", "Masa", "mesentérica", "de", "72", "x", "27", "x", "34", "mm", "de", "mayor", "tamaño", "que", "en", "la", "TC", "previa", ",", "con", "cápsula", "periférica", "bien", "definida", "y", "con", "contenido", "interno", "graso", "con", "polos", "sólidos", "de", "aspecto", "tumoral", "y", "de", "extirpe", "histológica", "diferente", "al", "tumor", "ovárico", ".", "Persisten", "masas", "tumorales", "pélvicas", "que", "rodean", "el", "rectosigma", ",", "útero", "y", "ocupan", "ambas", "fosas", "anexiales", "que", "se", "han", "reducido", "notablemente", "de", "tamaño", "respecto", "a", "la", "TC", "previa", ".", "Ha", "desaparecido", "la", "ascitis", ".", "Con", "ventana", "de", "hueso", "no", "se", "han", "apreciado", "imágenes", "sugestivas", "enfermedad", "metastásica", "ósea", ".", "\n\n", "-", "RM", "cerebral", "(", "7/09/2015", ")", ".", "No", "existen", "lesiones", "intraparenquimatosas", "ni", "que", "afecten", "a", "las", "meninges", ".", "\n\n", "INTERVENCIONISMO", "\n\n", "-", "Anatomía", "patológica", "biopsia", "core", "masa", "abdominal", "residual", "(", "con", "control", "ecográfico", ")", "11/09/16", ":", "\n", "BIOPSIA", "INSUFICIENTE", "PARA", "DIAGNÓSTICO", "CONSTITUIDA", "POR", "TEJIDO", "FIBROADIPOSO", ",", "CON", "PRESENCIA", "DE", "MACRÓFAGOS", "Y", "CAMBIOS", "INFLAMATORIOS", ".", "Comentario", ":", "No", "se", "han", "identificado", "signos", "morfológicos", "de", "malignidad", ".", "\n\n", "Diagnóstico", "\n", "-", "INGRESO", "EN", "PLANTA", "POR", ":", "\n", "1", ".", "Hiponatremia", "profunda", ",", "sintomáticamente", "severa", "y", "de", "carácter", "crónico", "y", "dos", "episodios", "graves", "documentados", "de", "somnolencia", ",", "confusión", "y", "convulsiones", ",", "por", "probable", "SIADH", "asociado", "a", "carboplatino", ".", "\n", "2", ".", "Proteinuria", "y", "tendencia", "a", "la", "hipertensión", "arterial", "seguramente", "secundaria", "a", "toxicidad", "por", "Bevacizumab", ".", "\n", "3", ".", "Masa", "abdominal", "de", "unos", "8", "-", "9", "cms", "de", "densidad", "grasa", "en", "raíz", "de", "mesenterio", "que", "ha", "crecido", "de", "forma", "aislada", "y", "que", "parece", "de", "etiología", "diferente", "al", "adenocarcinoma", "diagnosticado", "previamente", ".", "\n", "-", "PATOLOGÍA", "BASAL", ":", "Adenocarcinoma", "seroso", "G3", "de", "ovario", "estadio", "IV", "en", "RP", "tras", "4", "ciclos", "de", "Carbo", "-", "Taxol", "-", "Beva", "(", "corroborada", "en", "TAC", "de", "reevaluación", "y", "con", "descenso", "muy", "importante", "de", "marcadores", "séricos", ")", ".", "\n\n", "Tratamiento", "\n", "TRATAMIENTO", "AL", "ALTA", "DE", "PLANTA", "\n", "-", "Dieta", "normal", ".", "\n", "-", "Retirada", "de", "tratamiento", "de", "primera", "línea", "con", "Carbo", "-", "Paclitaxel", "-", "Bevacizumab", ".", "\n", "-", "Ingesta", "de", "líquidos", "sin", "restricciones", "(", "no", "tomar", "mas", "de", "2", "litros", "diarios", ")", "\n", "-", "Tratamiento", "hipotensor", "con", "Losartán", "50", ":", "1", "-", "0", "-", "0", "y", "si", "presiste", "TA", "elevadas", "(", ">", "160/80", "mmHg", ")", ",", "añadir", "manidipino", "10", ":", "0", "-", "0", "-", "1", ".", "\n", "-", "Omeprazol", "20", "mgrs", "al", "día", "vía", "oral", ".", "\n", "-", "Dexametasona", "4", "mgrs", "cada", "12", "horas", "vía", "oral", ".", "Seguir", "pauta", "descendente", ".", "\n", "-", "Lorazepam", "2", "mgrs", "por", "las", "noches", ".", "\n", "-", "Levotiroxina", "50", "mcgrs", "al", "día", "(", "por", "las", "mañans", ")", ".", "\n", "-", "No", "precisa", "tratamiento", "con", "Tolvaptán", ".", "\n\n", "Evolución", "\n", "La", "evolución", "de", "la", "paciente", "durante", "el", "ingreso", "fue", ",", "al", "principio", ",", "bastante", "tórpida", "por", "persistencia", "del", "estado", "de", "sopor", "y", "de", "bajo", "nivel", "de", "conciencia", "y", "por", "presentar", "episodios", "de", "agitación", "intermitentes", "a", "pesar", "de", "la", "normalización", "progresiva", "y", "lenta", "de", "los", "nivels", "de", "sodio", "sérico", ".", "Si", "bien", "lo", "anterior", ",", "no", "presentó", "en", "más", "ocasiones", "crisis", "convulsivas", ",", "manteniéndose", "en", "todo", "momento", "afebril", "y", "sin", "otros", "déficits", "neurológicos", ".", "Además", "poliuria", "con", "natriuresis", "normal", "y", "con", "creatinina", "sérica", "y", "ácido", "úrico", "normales", ".", "Por", "fin", ",", "tras", "elevación", "de", "la", "osmolalidad", "plasmática", "progresiva", "y", "tratamiento", "con", "dosis", "moderadas", "de", "dexametasona", "además", "de", "restricción", "de", "aporte", "liquidos", ",", "mejoró", "de", "forma", "ostensible", "a", "nivel", "neurológico", ",", "permaneciendo", "en", "los", "últimos", "días", "del", "ingreso", "consciente", "y", "cada", "vez", "más", "orientada", "y", "alerta", ",", "mejorando", "progresivamene", "su", "estado", "general", ".", "No", "obstante", ",", "durante", "su", "ingreso", "se", "ha", "objetivado", "de", "forma", "progresiva", "tendencia", "a", "la", "hipertensió", "arterial", "ademá", "de", "proteinuria", "discreta", ",", "siendo", "bien", "controladas", "con", "Losartán", ".", "Al", "alta", "de", "con", "sodio", "plasmático", "normal", "y", "con", "estado", "general", "conservado", ",", "afebril", "y", "tolerando", "dieta", "oral", "ademas", "de", "ausenxcia", "de", "deficits", "neurologicos", ".", "\n", "En", "cuanto", "a", "la", "causa", "de", "la", "hiponatremia", ",", "la", "pacinete", "fue", "valorado", "por", "Nefrología", "(", "continúa", "en", "sus", "consultas", ")", ",", "siendo", "diagnosticada", "de", "SIADH", "en", "relación", "a", "Carboplatino", "(", "diagnóstico", "de", "exclusión", ")", "vs", "SIADH", "como", "síndrome", "paraneoplásico", "en", "relación", "al", "tumor", ".", "Inicia", "nueva", "línea", "de", "QT", "con", "adriamicina", "liposomal", "en", "Noviembre/15", "(", "recibe", "únicamente", "1", "ciclo", ")", ".", "Dado", "que", "el", "SIADH", "se", "relaciona", "poco", "con", "un", "adenocarcinoma", "de", "pulmón", ",", "se", "decidió", "tomar", "muestra", "de", "la", "masa", "residual", "retroperitoneal", "(", "dado", "que", "parecía", "de", "una", "estirpe", "diferente", ")", ",", "por", "lo", "que", "la", "paciente", "se", "comentó", "en", "Comité", "de", "Tumores", ".", "Se", "decide", "resección", "de", "la", "masa", ":", "Intervención", "Quirúrgica", "(", "Enero/16", "):", "exéresis", "de", "la", "masa", "mesentérica", ",", "ooforectomía", "bilateral", ",", "omentectomía", "con", "implante", "tumoral", "peritoneal", ".", "\n", "Anatomía", "patológica", "de", "adenocarcinoma", "de", "origen", "ovárico", ".", "Posteriormente", "continúa", "con", "QT", "basada", "en", "adriamicina", "liposomal", ",", "y", "recibe", "un", "total", "de", "3", "ciclos", "(", "contando", "con", "el", "previo", "a", "la", "cirugía", ")", ",", "decidiéndose", "STOP", "en", "Abril/15", "por", "astenia", "importante", ".", "En", "la", "reevaluación", "de", "Mayo/15", "se", "objetiva", "respuesta", "completa", "por", "imagen", "y", "por", "marcadores", ".", "Desde", "la", "retirada", "del", "carboplatino", ",", "no", "ha", "vuelto", "a", "presentar", "hiponatremia", ".", "\n", "-", "TC", "tórax", "-", "abdomen", "Mayo/15", ":", "Tórax", ":", "Persiste", "nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "estable", "respecto", "al", "estudios", "previos", ",", "asi", "como", "en", "segmento", "laterobasal", "del", "LID", ",", "sin", "cambios", "también", ".", "No", "hay", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "ni", "engrosamiento", "pleural", ".", "Múltiples", "nódulos", "calcificados", "en", "ambas", "mamas", ".", "Resto", "del", "tórax", "sin", "hallazgos", "de", "interés", ".", "Abdomen", ":", "Hígado", "de", "tamaño", "normal", "y", "contorno", "liso", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "pequeño", "tamaño", "ya", "conocida", ".", "Vía", "biliar", "intra", "y", "extrahepática", "de", "calibre", "normal", ".", "Vesícula", "biliar", "sin", "alteraciones", ".", "\n", "Bazo", ",", "pancreas", ",", "adrenales", "y", "riñones", "sin", "hallazgos", "de", "interés", ".", "Estómago", ",", "asas", "de", "intestino", "delgado", "y", "colon", "sin", "dilataciones", "ni", "engrosamientos", "murales", ".", "\n", "Vejiga", "urinaria", "bien", "replecionada", "sin", "engrosamiento", "de", "la", "pared", ".", "Histerectomizada", "con", "doble", "anexectomía", ",", "sin", "imágenes", "de", "recidiva", ".", "Resto", "del", "abdomen", "sin", "hallazgos", "de", "interés", ".", "Conclusión", ":", "Nódulos", "pulmonares", "estables", ".", "Nódulos", "mamarios", "calcificados", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "estable", ".", "Ausencia", "quirúrgica", "de", "genitales", "internos", ".", "\n", "-", "Evolución", "de", "Ca", "125", ":", "46852", "U", "/", "ml", "(", "diagnóstico", ")", "--", ">", "19.4", "U", "/", "ml", "(", "Mayo/16", ")", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural is a MORFOLOGIA_NEOPLASIA, afectación meníngea is a MORFOLOGIA_NEOPLASIA, angiomiolipoma is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, lesiones intraparenquimatosas is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma seroso G3 is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, masa residual retroperitoneal is a MORFOLOGIA_NEOPLASIA, masa mesentérica is a MORFOLOGIA_NEOPLASIA, implante tumoral is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA

205_task1

Sentence: Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. ** HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. ** 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16). Instructions: please typing these entity words according to sentence: Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural, afectación meníngea, angiomiolipoma, tumoral, tumor, tumorales, metastásica, lesiones intraparenquimatosas, malignidad, adenocarcinoma, Adenocarcinoma seroso G3, tumor, adenocarcinoma, masa residual retroperitoneal, masa mesentérica, implante tumoral, adenocarcinoma Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. ** HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. ** 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16).

[ "Anamnesis", "\n", "Mujer", "68", "años", ".", "\n", "-", "Alergia", "a", "amoxicilina", "y", "moxifloxacino", "(", "con", "estudio", "por", "alergología", ")", ".", "\n", "-", "No", "hábitos", "tóxicos", ".", "\n", "-", "No", "factores", "de", "riesgo", "cardiovascular", ".", "\n\n", "-", "Hipotiroidismo", ".", "\n", "-", "Antecedentes", "quirúrgicos", ":", "histerectomía", "sin", "anexectomía", "con", "41", "años", ".", "\n", "-", "Tratamiento", "habitual", ":", "Levotiroxina", ",", "Guayana", "en", "comprimidos", ".", "\n\n", "*", "*", "HISTORIA", "ONCOLÓGICA", ":", "\n", "-", "Diagnóstico", "en", "Mayo/2015", "de", "Adenocarcinoma", "seroso", "de", "ovario", "G3", "estadio", "IV", "por", "afectación", "pleural", ".", "Inicia", "tratamiento", "con", "quimioterapia", "(", "QT", ")", "según", "esquema", "Carboplatino", "(", "AUC", "5", "cada", "3", "semanas", ")", "-", "Paclitaxel", "(", "175", "mg", "/", "m2", "cada", "3", "semanas", ")", "-", "Bevacizumab", "(", "15", "mg", "/", "kg", ")", ",", "del", "que", "recibe", "un", "total", "de", "4", "ciclos", ",", "último", "el", "07/08/15", "con", "reducción", "10", "%", "en", "4º", "ciclo", "por", "astenia", "G3", ".", "Respuesta", "parcial", "bioquímica", "(", "descenso", "importante", "del", "Ca", "125", ")", "y", "por", "imagen", ".", "\n\n", "*", "*", "22/08/16", ":", "Paciente", "con", "clínica", "de", "1", "mes", "aproximadamente", "de", "duración", "(", "tras", "3º", "ciclo", "de", "QT", "el", "14/07/15", ")", "consistente", "en", "cuadro", "de", "desorientación", ".", "Tras", "4º", "ciclo", "de", "QT", "el", "07/08/15", ",", "con", "mala", "tolerancia", "al", "mismo", ",", "presenta", "empeoramiento", "del", "cuadro", "neurológico", "con", "crisis", "convulsiva", "el", "22/08/15", "por", "lo", "que", "es", "traída", "a", "urgencias", "por", "sus", "familiares", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "118", "mEq", "/", "L.", "Se", "realiza", "TAC", "craneal", "sin", "hallazgos", "patológicos", "y", "sin", "hacer", "referencia", "a", "existencia", "de", "edema", "cerebral", ",", "y", "se", "inicia", "correción", "hidroelectrolítica", "con", "mejoria", "rápida", "del", "cuadro", ",", "aunque", "no", "resolución", "completa", ".", "Es", "dada", "de", "alta", "tras", "24", "horas", "en", "observación", "y", "con", "cifra", "de", "Na", "133", "mEq", "/", "L.", "\n", "El", "28/08/15", "en", "valorada", "en", "hospital", "de", "día", "de", "Oncología", "para", "5º", "cliclo", ",", "que", "se", "suspende", "por", "persitencia", "de", "cuadro", "neurológico", "a", "pesar", "de", "Na", "corregido", "(", "134", "mEq", "/", "L", ")", ",", "mala", "tolerancia", "al", "4º", "ciclo", "y", "episodio", "de", "fiebre", "puntual", "el", "26/08/15", "secundario", "a", "fístula", "perianal", "en", "tratamiento", "con", "Eritromicina", ".", "En", "dicha", "consulta", ",", "debido", "a", "persistencia", "del", "cuadro", "neurologico", ",", "se", "solicita", "RMN", "craneal", "a", "fin", "de", "descartar", "afectación", "meníngea", "que", "pudiera", "explicar", "el", "cuadro", ".", "\n", "El", "31/08/16", "consulta", "nuevamente", "en", "urgencias", "por", "episodio", "convulsivo", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "112", "mEq", "/", "L", ",", "por", "lo", "que", "se", "inicia", "corrección", "de", "la", "misma", "con", "mejoría", "rápida", "del", "cuadro", "en", "24", "horas", "y", "posteriormente", "trasladada", "a", "planta", "de", "Oncología", "para", "continuidad", "de", "cuidados", ".", "\n\n", "Exploración", "física", "\n", "AL", "INGRESO", "EN", "ONCOLOGÍA", "MÉDICA", "\n", "PS", "4", ".", "Glasgow", "11", "(", "apertura", "espontánea", "de", "ojos", ",", "retira", "al", "dolor", ",", "no", "obedece", "órdenes", ",", "lenguaje", "incomprensible", ")", ".", "\n", "Pupilas", "isocóricas", "normorreactivas", ".", "Moviliza", "4", "miembros", ".", "\n", "Auscultación", "Cardio", "-", "Respiratoria", ":", "Normal", ".", "Abdomen", "normal", ".", "\n", "Miembros", "Inferiores", "sin", "edema", "ni", "signos", "Trombosis", "Venosa", "Profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "PRUEBAS", "DE", "LABORATORIO", "\n\n", "-", "Analítica", "31/08/15", ":", "\n", "*", "Hemograma", ":", "Hb", "99", "g", "/", "l", ",", "resto", "normal", ".", "\n", "*", "BioquÍmica", "sérica", ":", "Na", "112", "mEq", "/", "L", ",", "K", "3.2", "mEq", "/", "L", ",", "resto", "normal", ".", "\n", "*", "Coagulación", ":", "Normal", ".", "\n", "-", "Gasometría", "Venosa", "31/05/15", ":", "EVOLUCIÓN", ".", "\n", "*", "Na", ":", "111", "(", "15.00pm", ")", "-", ">", "113", "(", "16.00pm", ")", "-", ">", "116", "(", "17.00pm", ")", "-", ">", "116", "(", "18.45pm", ")", "\n", "*", "Osm", ":", "229", "-", ">", "233", "-", ">", "237-", ">", "237", ".", "\n", "-", "IONES", "ORINA", ":", "Na", "110", "mEq", "/", "L", "(", "elevado", ")", ",", "K", "10", "mEq", "/", "L.", "Proteinuria", ".", "\n", "-", "Marcadores", "tumorales", "01/09/16", ":", "CEA", "5,1", "ng", "/", "ml", "(", "descenso", ",", "al", "diagnóstico", "de", "7.9", "ng", "/", "ml", ")", ".", "CA", "125", "977", "U", "/", "ml", "(", "franco", "descenso", ",", "al", "diagnóstico", "de", "46852", "U", "/", "ml", ")", ".", "\n", "-", "Analítica", "10/09/16", "(", "PREVIA", "AL", "ALTA", "):", "\n", "*", "Bioquímica", ":", "Urea", "45", "mg", "/", "dl", ",", "proteinas", "totales", "6", "gr", "/", "dl", ",", "fósforo", "inorgánico", "2,55", "mg", "/", "dl", ".", "Sodio", "normal", "(", "139", "mEq", "/", "L", ")", ".", "\n", "*", "Hemograma", ":", "Hemoglobina", "98", "gr", "/", "L.", "Series", "blanca", "y", "paquetaria", "normales", ".", "\n\n", "PRUEBAS", "IMAGEN", "\n", "-", "TAC", "de", "tórax", "y", "abdomen", "(", "3/09/2015", ")", ".", "Nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "sin", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "pleural", ".", "Han", "desaparecido", "los", "engrosamientos", "pleurales", ".", "En", "hígado", "sigue", "apreciándose", "pequeño", "nódulo", "de", "8", "mm", "en", "periferia", "subdiafragmática", "del", "segmento", "VIII", "de", "contenido", "predominantemente", "graso", "(", "angiomiolipoma", "hepático", "?", ")", ".", "Pequeña", "lesión", "focal", "hipodensa", "en", "periferia", "del", "segmento", "VII", "de", "6", "mm", "de", "diámetro", ",", "indeterminada", ".", "Masa", "mesentérica", "de", "72", "x", "27", "x", "34", "mm", "de", "mayor", "tamaño", "que", "en", "la", "TC", "previa", ",", "con", "cápsula", "periférica", "bien", "definida", "y", "con", "contenido", "interno", "graso", "con", "polos", "sólidos", "de", "aspecto", "tumoral", "y", "de", "extirpe", "histológica", "diferente", "al", "tumor", "ovárico", ".", "Persisten", "masas", "tumorales", "pélvicas", "que", "rodean", "el", "rectosigma", ",", "útero", "y", "ocupan", "ambas", "fosas", "anexiales", "que", "se", "han", "reducido", "notablemente", "de", "tamaño", "respecto", "a", "la", "TC", "previa", ".", "Ha", "desaparecido", "la", "ascitis", ".", "Con", "ventana", "de", "hueso", "no", "se", "han", "apreciado", "imágenes", "sugestivas", "enfermedad", "metastásica", "ósea", ".", "\n\n", "-", "RM", "cerebral", "(", "7/09/2015", ")", ".", "No", "existen", "lesiones", "intraparenquimatosas", "ni", "que", "afecten", "a", "las", "meninges", ".", "\n\n", "INTERVENCIONISMO", "\n\n", "-", "Anatomía", "patológica", "biopsia", "core", "masa", "abdominal", "residual", "(", "con", "control", "ecográfico", ")", "11/09/16", ":", "\n", "BIOPSIA", "INSUFICIENTE", "PARA", "DIAGNÓSTICO", "CONSTITUIDA", "POR", "TEJIDO", "FIBROADIPOSO", ",", "CON", "PRESENCIA", "DE", "MACRÓFAGOS", "Y", "CAMBIOS", "INFLAMATORIOS", ".", "Comentario", ":", "No", "se", "han", "identificado", "signos", "morfológicos", "de", "malignidad", ".", "\n\n", "Diagnóstico", "\n", "-", "INGRESO", "EN", "PLANTA", "POR", ":", "\n", "1", ".", "Hiponatremia", "profunda", ",", "sintomáticamente", "severa", "y", "de", "carácter", "crónico", "y", "dos", "episodios", "graves", "documentados", "de", "somnolencia", ",", "confusión", "y", "convulsiones", ",", "por", "probable", "SIADH", "asociado", "a", "carboplatino", ".", "\n", "2", ".", "Proteinuria", "y", "tendencia", "a", "la", "hipertensión", "arterial", "seguramente", "secundaria", "a", "toxicidad", "por", "Bevacizumab", ".", "\n", "3", ".", "Masa", "abdominal", "de", "unos", "8", "-", "9", "cms", "de", "densidad", "grasa", "en", "raíz", "de", "mesenterio", "que", "ha", "crecido", "de", "forma", "aislada", "y", "que", "parece", "de", "etiología", "diferente", "al", "adenocarcinoma", "diagnosticado", "previamente", ".", "\n", "-", "PATOLOGÍA", "BASAL", ":", "Adenocarcinoma", "seroso", "G3", "de", "ovario", "estadio", "IV", "en", "RP", "tras", "4", "ciclos", "de", "Carbo", "-", "Taxol", "-", "Beva", "(", "corroborada", "en", "TAC", "de", "reevaluación", "y", "con", "descenso", "muy", "importante", "de", "marcadores", "séricos", ")", ".", "\n\n", "Tratamiento", "\n", "TRATAMIENTO", "AL", "ALTA", "DE", "PLANTA", "\n", "-", "Dieta", "normal", ".", "\n", "-", "Retirada", "de", "tratamiento", "de", "primera", "línea", "con", "Carbo", "-", "Paclitaxel", "-", "Bevacizumab", ".", "\n", "-", "Ingesta", "de", "líquidos", "sin", "restricciones", "(", "no", "tomar", "mas", "de", "2", "litros", "diarios", ")", "\n", "-", "Tratamiento", "hipotensor", "con", "Losartán", "50", ":", "1", "-", "0", "-", "0", "y", "si", "presiste", "TA", "elevadas", "(", ">", "160/80", "mmHg", ")", ",", "añadir", "manidipino", "10", ":", "0", "-", "0", "-", "1", ".", "\n", "-", "Omeprazol", "20", "mgrs", "al", "día", "vía", "oral", ".", "\n", "-", "Dexametasona", "4", "mgrs", "cada", "12", "horas", "vía", "oral", ".", "Seguir", "pauta", "descendente", ".", "\n", "-", "Lorazepam", "2", "mgrs", "por", "las", "noches", ".", "\n", "-", "Levotiroxina", "50", "mcgrs", "al", "día", "(", "por", "las", "mañans", ")", ".", "\n", "-", "No", "precisa", "tratamiento", "con", "Tolvaptán", ".", "\n\n", "Evolución", "\n", "La", "evolución", "de", "la", "paciente", "durante", "el", "ingreso", "fue", ",", "al", "principio", ",", "bastante", "tórpida", "por", "persistencia", "del", "estado", "de", "sopor", "y", "de", "bajo", "nivel", "de", "conciencia", "y", "por", "presentar", "episodios", "de", "agitación", "intermitentes", "a", "pesar", "de", "la", "normalización", "progresiva", "y", "lenta", "de", "los", "nivels", "de", "sodio", "sérico", ".", "Si", "bien", "lo", "anterior", ",", "no", "presentó", "en", "más", "ocasiones", "crisis", "convulsivas", ",", "manteniéndose", "en", "todo", "momento", "afebril", "y", "sin", "otros", "déficits", "neurológicos", ".", "Además", "poliuria", "con", "natriuresis", "normal", "y", "con", "creatinina", "sérica", "y", "ácido", "úrico", "normales", ".", "Por", "fin", ",", "tras", "elevación", "de", "la", "osmolalidad", "plasmática", "progresiva", "y", "tratamiento", "con", "dosis", "moderadas", "de", "dexametasona", "además", "de", "restricción", "de", "aporte", "liquidos", ",", "mejoró", "de", "forma", "ostensible", "a", "nivel", "neurológico", ",", "permaneciendo", "en", "los", "últimos", "días", "del", "ingreso", "consciente", "y", "cada", "vez", "más", "orientada", "y", "alerta", ",", "mejorando", "progresivamene", "su", "estado", "general", ".", "No", "obstante", ",", "durante", "su", "ingreso", "se", "ha", "objetivado", "de", "forma", "progresiva", "tendencia", "a", "la", "hipertensió", "arterial", "ademá", "de", "proteinuria", "discreta", ",", "siendo", "bien", "controladas", "con", "Losartán", ".", "Al", "alta", "de", "con", "sodio", "plasmático", "normal", "y", "con", "estado", "general", "conservado", ",", "afebril", "y", "tolerando", "dieta", "oral", "ademas", "de", "ausenxcia", "de", "deficits", "neurologicos", ".", "\n", "En", "cuanto", "a", "la", "causa", "de", "la", "hiponatremia", ",", "la", "pacinete", "fue", "valorado", "por", "Nefrología", "(", "continúa", "en", "sus", "consultas", ")", ",", "siendo", "diagnosticada", "de", "SIADH", "en", "relación", "a", "Carboplatino", "(", "diagnóstico", "de", "exclusión", ")", "vs", "SIADH", "como", "síndrome", "paraneoplásico", "en", "relación", "al", "tumor", ".", "Inicia", "nueva", "línea", "de", "QT", "con", "adriamicina", "liposomal", "en", "Noviembre/15", "(", "recibe", "únicamente", "1", "ciclo", ")", ".", "Dado", "que", "el", "SIADH", "se", "relaciona", "poco", "con", "un", "adenocarcinoma", "de", "pulmón", ",", "se", "decidió", "tomar", "muestra", "de", "la", "masa", "residual", "retroperitoneal", "(", "dado", "que", "parecía", "de", "una", "estirpe", "diferente", ")", ",", "por", "lo", "que", "la", "paciente", "se", "comentó", "en", "Comité", "de", "Tumores", ".", "Se", "decide", "resección", "de", "la", "masa", ":", "Intervención", "Quirúrgica", "(", "Enero/16", "):", "exéresis", "de", "la", "masa", "mesentérica", ",", "ooforectomía", "bilateral", ",", "omentectomía", "con", "implante", "tumoral", "peritoneal", ".", "\n", "Anatomía", "patológica", "de", "adenocarcinoma", "de", "origen", "ovárico", ".", "Posteriormente", "continúa", "con", "QT", "basada", "en", "adriamicina", "liposomal", ",", "y", "recibe", "un", "total", "de", "3", "ciclos", "(", "contando", "con", "el", "previo", "a", "la", "cirugía", ")", ",", "decidiéndose", "STOP", "en", "Abril/15", "por", "astenia", "importante", ".", "En", "la", "reevaluación", "de", "Mayo/15", "se", "objetiva", "respuesta", "completa", "por", "imagen", "y", "por", "marcadores", ".", "Desde", "la", "retirada", "del", "carboplatino", ",", "no", "ha", "vuelto", "a", "presentar", "hiponatremia", ".", "\n", "-", "TC", "tórax", "-", "abdomen", "Mayo/15", ":", "Tórax", ":", "Persiste", "nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "estable", "respecto", "al", "estudios", "previos", ",", "asi", "como", "en", "segmento", "laterobasal", "del", "LID", ",", "sin", "cambios", "también", ".", "No", "hay", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "ni", "engrosamiento", "pleural", ".", "Múltiples", "nódulos", "calcificados", "en", "ambas", "mamas", ".", "Resto", "del", "tórax", "sin", "hallazgos", "de", "interés", ".", "Abdomen", ":", "Hígado", "de", "tamaño", "normal", "y", "contorno", "liso", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "pequeño", "tamaño", "ya", "conocida", ".", "Vía", "biliar", "intra", "y", "extrahepática", "de", "calibre", "normal", ".", "Vesícula", "biliar", "sin", "alteraciones", ".", "\n", "Bazo", ",", "pancreas", ",", "adrenales", "y", "riñones", "sin", "hallazgos", "de", "interés", ".", "Estómago", ",", "asas", "de", "intestino", "delgado", "y", "colon", "sin", "dilataciones", "ni", "engrosamientos", "murales", ".", "\n", "Vejiga", "urinaria", "bien", "replecionada", "sin", "engrosamiento", "de", "la", "pared", ".", "Histerectomizada", "con", "doble", "anexectomía", ",", "sin", "imágenes", "de", "recidiva", ".", "Resto", "del", "abdomen", "sin", "hallazgos", "de", "interés", ".", "Conclusión", ":", "Nódulos", "pulmonares", "estables", ".", "Nódulos", "mamarios", "calcificados", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "estable", ".", "Ausencia", "quirúrgica", "de", "genitales", "internos", ".", "\n", "-", "Evolución", "de", "Ca", "125", ":", "46852", "U", "/", "ml", "(", "diagnóstico", ")", "--", ">", "19.4", "U", "/", "ml", "(", "Mayo/16", ")", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural, afectación meníngea, angiomiolipoma, tumoral, tumor, tumorales, metastásica, lesiones intraparenquimatosas, malignidad, adenocarcinoma, Adenocarcinoma seroso G3, tumor, adenocarcinoma, masa residual retroperitoneal, masa mesentérica, implante tumoral, adenocarcinoma

205_task2

Sentence: Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. ** HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. ** 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Mujer 68 años. - Alergia a amoxicilina y moxifloxacino (con estudio por alergología). - No hábitos tóxicos. - No factores de riesgo cardiovascular. - Hipotiroidismo. - Antecedentes quirúrgicos: histerectomía sin anexectomía con 41 años. - Tratamiento habitual: Levotiroxina, Guayana en comprimidos. ** HISTORIA ONCOLÓGICA: - Diagnóstico en Mayo/2015 de Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural. Inicia tratamiento con quimioterapia (QT) según esquema Carboplatino (AUC 5 cada 3 semanas) - Paclitaxel (175 mg/m2 cada 3 semanas) - Bevacizumab (15 mg/kg), del que recibe un total de 4 ciclos, último el 07/08/15 con reducción 10% en 4º ciclo por astenia G3. Respuesta parcial bioquímica (descenso importante del Ca 125) y por imagen. ** 22/08/16: Paciente con clínica de 1 mes aproximadamente de duración (tras 3º ciclo de QT el 14/07/15) consistente en cuadro de desorientación. Tras 4º ciclo de QT el 07/08/15, con mala tolerancia al mismo, presenta empeoramiento del cuadro neurológico con crisis convulsiva el 22/08/15 por lo que es traída a urgencias por sus familiares, objetivándose en analítica hiponatremia con Na 118 mEq/L. Se realiza TAC craneal sin hallazgos patológicos y sin hacer referencia a existencia de edema cerebral, y se inicia correción hidroelectrolítica con mejoria rápida del cuadro, aunque no resolución completa. Es dada de alta tras 24 horas en observación y con cifra de Na 133 mEq/L. El 28/08/15 en valorada en hospital de día de Oncología para 5º cliclo, que se suspende por persitencia de cuadro neurológico a pesar de Na corregido (134 mEq/L), mala tolerancia al 4º ciclo y episodio de fiebre puntual el 26/08/15 secundario a fístula perianal en tratamiento con Eritromicina. En dicha consulta, debido a persistencia del cuadro neurologico, se solicita RMN craneal a fin de descartar afectación meníngea que pudiera explicar el cuadro. El 31/08/16 consulta nuevamente en urgencias por episodio convulsivo, objetivándose en analítica hiponatremia con Na 112 mEq/L, por lo que se inicia corrección de la misma con mejoría rápida del cuadro en 24 horas y posteriormente trasladada a planta de Oncología para continuidad de cuidados. Exploración física AL INGRESO EN ONCOLOGÍA MÉDICA PS 4. Glasgow 11 (apertura espontánea de ojos, retira al dolor, no obedece órdenes, lenguaje incomprensible). Pupilas isocóricas normorreactivas. Moviliza 4 miembros. Auscultación Cardio-Respiratoria: Normal. Abdomen normal. Miembros Inferiores sin edema ni signos Trombosis Venosa Profunda. Pruebas complementarias PRUEBAS DE LABORATORIO - Analítica 31/08/15: * Hemograma: Hb 99 g/l, resto normal. * BioquÍmica sérica: Na 112 mEq/L, K 3.2 mEq/L, resto normal. * Coagulación: Normal. - Gasometría Venosa 31/05/15: EVOLUCIÓN. * Na: 111 (15.00pm) -> 113 (16.00pm) -> 116 (17.00pm) -> 116 (18.45pm) * Osm: 229 -> 233 -> 237- >237. - IONES ORINA: Na 110 mEq/L (elevado), K 10 mEq/L. Proteinuria. - Marcadores tumorales 01/09/16: CEA 5,1 ng/ml (descenso, al diagnóstico de 7.9 ng/ml). CA 125 977 U/ml (franco descenso, al diagnóstico de 46852 U/ml). - Analítica 10/09/16 (PREVIA AL ALTA): * Bioquímica: Urea 45 mg/dl, proteinas totales 6 gr/dl, fósforo inorgánico 2,55 mg/dl. Sodio normal (139 mEq/L). * Hemograma: Hemoglobina 98 gr/L. Series blanca y paquetaria normales. PRUEBAS IMAGEN - TAC de tórax y abdomen (3/09/2015). Nódulo pulmonar milimétrico en segmento apicoposterior de LSI, sin aparición de nuevos nódulos. No hay derrame pleural. Han desaparecido los engrosamientos pleurales. En hígado sigue apreciándose pequeño nódulo de 8 mm en periferia subdiafragmática del segmento VIII de contenido predominantemente graso (angiomiolipoma hepático?). Pequeña lesión focal hipodensa en periferia del segmento VII de 6 mm de diámetro, indeterminada. Masa mesentérica de 72 x 27 x 34 mm de mayor tamaño que en la TC previa, con cápsula periférica bien definida y con contenido interno graso con polos sólidos de aspecto tumoral y de extirpe histológica diferente al tumor ovárico. Persisten masas tumorales pélvicas que rodean el rectosigma, útero y ocupan ambas fosas anexiales que se han reducido notablemente de tamaño respecto a la TC previa. Ha desaparecido la ascitis. Con ventana de hueso no se han apreciado imágenes sugestivas enfermedad metastásica ósea. - RM cerebral (7/09/2015). No existen lesiones intraparenquimatosas ni que afecten a las meninges. INTERVENCIONISMO - Anatomía patológica biopsia core masa abdominal residual (con control ecográfico) 11/09/16: BIOPSIA INSUFICIENTE PARA DIAGNÓSTICO CONSTITUIDA POR TEJIDO FIBROADIPOSO, CON PRESENCIA DE MACRÓFAGOS Y CAMBIOS INFLAMATORIOS. Comentario: No se han identificado signos morfológicos de malignidad. Diagnóstico - INGRESO EN PLANTA POR: 1. Hiponatremia profunda, sintomáticamente severa y de carácter crónico y dos episodios graves documentados de somnolencia, confusión y convulsiones, por probable SIADH asociado a carboplatino. 2. Proteinuria y tendencia a la hipertensión arterial seguramente secundaria a toxicidad por Bevacizumab. 3. Masa abdominal de unos 8-9 cms de densidad grasa en raíz de mesenterio que ha crecido de forma aislada y que parece de etiología diferente al adenocarcinoma diagnosticado previamente. - PATOLOGÍA BASAL: Adenocarcinoma seroso G3 de ovario estadio IV en RP tras 4 ciclos de Carbo-Taxol-Beva (corroborada en TAC de reevaluación y con descenso muy importante de marcadores séricos). Tratamiento TRATAMIENTO AL ALTA DE PLANTA - Dieta normal. - Retirada de tratamiento de primera línea con Carbo-Paclitaxel-Bevacizumab. - Ingesta de líquidos sin restricciones (no tomar mas de 2 litros diarios) - Tratamiento hipotensor con Losartán 50: 1-0-0 y si presiste TA elevadas (> 160/80 mmHg), añadir manidipino 10: 0-0-1. - Omeprazol 20 mgrs al día vía oral. - Dexametasona 4 mgrs cada 12 horas vía oral. Seguir pauta descendente. - Lorazepam 2 mgrs por las noches. - Levotiroxina 50 mcgrs al día (por las mañans). - No precisa tratamiento con Tolvaptán. Evolución La evolución de la paciente durante el ingreso fue, al principio, bastante tórpida por persistencia del estado de sopor y de bajo nivel de conciencia y por presentar episodios de agitación intermitentes a pesar de la normalización progresiva y lenta de los nivels de sodio sérico. Si bien lo anterior, no presentó en más ocasiones crisis convulsivas, manteniéndose en todo momento afebril y sin otros déficits neurológicos. Además poliuria con natriuresis normal y con creatinina sérica y ácido úrico normales. Por fin, tras elevación de la osmolalidad plasmática progresiva y tratamiento con dosis moderadas de dexametasona además de restricción de aporte liquidos, mejoró de forma ostensible a nivel neurológico, permaneciendo en los últimos días del ingreso consciente y cada vez más orientada y alerta, mejorando progresivamene su estado general. No obstante, durante su ingreso se ha objetivado de forma progresiva tendencia a la hipertensió arterial ademá de proteinuria discreta, siendo bien controladas con Losartán. Al alta de con sodio plasmático normal y con estado general conservado, afebril y tolerando dieta oral ademas de ausenxcia de deficits neurologicos. En cuanto a la causa de la hiponatremia, la pacinete fue valorado por Nefrología (continúa en sus consultas), siendo diagnosticada de SIADH en relación a Carboplatino (diagnóstico de exclusión) vs SIADH como síndrome paraneoplásico en relación al tumor. Inicia nueva línea de QT con adriamicina liposomal en Noviembre/15 (recibe únicamente 1 ciclo). Dado que el SIADH se relaciona poco con un adenocarcinoma de pulmón, se decidió tomar muestra de la masa residual retroperitoneal (dado que parecía de una estirpe diferente), por lo que la paciente se comentó en Comité de Tumores. Se decide resección de la masa: Intervención Quirúrgica (Enero/16): exéresis de la masa mesentérica, ooforectomía bilateral, omentectomía con implante tumoral peritoneal. Anatomía patológica de adenocarcinoma de origen ovárico. Posteriormente continúa con QT basada en adriamicina liposomal, y recibe un total de 3 ciclos (contando con el previo a la cirugía), decidiéndose STOP en Abril/15 por astenia importante. En la reevaluación de Mayo/15 se objetiva respuesta completa por imagen y por marcadores. Desde la retirada del carboplatino, no ha vuelto a presentar hiponatremia. - TC tórax-abdomen Mayo/15: Tórax: Persiste nódulo pulmonar milimétrico en segmento apicoposterior de LSI, estable respecto al estudios previos, asi como en segmento laterobasal del LID, sin cambios también. No hay aparición de nuevos nódulos. No hay derrame ni engrosamiento pleural. Múltiples nódulos calcificados en ambas mamas. Resto del tórax sin hallazgos de interés. Abdomen: Hígado de tamaño normal y contorno liso. LOE hepática de aspecto benigno y pequeño tamaño ya conocida. Vía biliar intra y extrahepática de calibre normal. Vesícula biliar sin alteraciones. Bazo, pancreas, adrenales y riñones sin hallazgos de interés. Estómago, asas de intestino delgado y colon sin dilataciones ni engrosamientos murales. Vejiga urinaria bien replecionada sin engrosamiento de la pared. Histerectomizada con doble anexectomía, sin imágenes de recidiva. Resto del abdomen sin hallazgos de interés. Conclusión: Nódulos pulmonares estables. Nódulos mamarios calcificados. LOE hepática de aspecto benigno y estable. Ausencia quirúrgica de genitales internos. - Evolución de Ca 125: 46852 U/ml (diagnóstico) --> 19.4 U/ml (Mayo/16).

[ "Anamnesis", "\n", "Mujer", "68", "años", ".", "\n", "-", "Alergia", "a", "amoxicilina", "y", "moxifloxacino", "(", "con", "estudio", "por", "alergología", ")", ".", "\n", "-", "No", "hábitos", "tóxicos", ".", "\n", "-", "No", "factores", "de", "riesgo", "cardiovascular", ".", "\n\n", "-", "Hipotiroidismo", ".", "\n", "-", "Antecedentes", "quirúrgicos", ":", "histerectomía", "sin", "anexectomía", "con", "41", "años", ".", "\n", "-", "Tratamiento", "habitual", ":", "Levotiroxina", ",", "Guayana", "en", "comprimidos", ".", "\n\n", "*", "*", "HISTORIA", "ONCOLÓGICA", ":", "\n", "-", "Diagnóstico", "en", "Mayo/2015", "de", "Adenocarcinoma", "seroso", "de", "ovario", "G3", "estadio", "IV", "por", "afectación", "pleural", ".", "Inicia", "tratamiento", "con", "quimioterapia", "(", "QT", ")", "según", "esquema", "Carboplatino", "(", "AUC", "5", "cada", "3", "semanas", ")", "-", "Paclitaxel", "(", "175", "mg", "/", "m2", "cada", "3", "semanas", ")", "-", "Bevacizumab", "(", "15", "mg", "/", "kg", ")", ",", "del", "que", "recibe", "un", "total", "de", "4", "ciclos", ",", "último", "el", "07/08/15", "con", "reducción", "10", "%", "en", "4º", "ciclo", "por", "astenia", "G3", ".", "Respuesta", "parcial", "bioquímica", "(", "descenso", "importante", "del", "Ca", "125", ")", "y", "por", "imagen", ".", "\n\n", "*", "*", "22/08/16", ":", "Paciente", "con", "clínica", "de", "1", "mes", "aproximadamente", "de", "duración", "(", "tras", "3º", "ciclo", "de", "QT", "el", "14/07/15", ")", "consistente", "en", "cuadro", "de", "desorientación", ".", "Tras", "4º", "ciclo", "de", "QT", "el", "07/08/15", ",", "con", "mala", "tolerancia", "al", "mismo", ",", "presenta", "empeoramiento", "del", "cuadro", "neurológico", "con", "crisis", "convulsiva", "el", "22/08/15", "por", "lo", "que", "es", "traída", "a", "urgencias", "por", "sus", "familiares", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "118", "mEq", "/", "L.", "Se", "realiza", "TAC", "craneal", "sin", "hallazgos", "patológicos", "y", "sin", "hacer", "referencia", "a", "existencia", "de", "edema", "cerebral", ",", "y", "se", "inicia", "correción", "hidroelectrolítica", "con", "mejoria", "rápida", "del", "cuadro", ",", "aunque", "no", "resolución", "completa", ".", "Es", "dada", "de", "alta", "tras", "24", "horas", "en", "observación", "y", "con", "cifra", "de", "Na", "133", "mEq", "/", "L.", "\n", "El", "28/08/15", "en", "valorada", "en", "hospital", "de", "día", "de", "Oncología", "para", "5º", "cliclo", ",", "que", "se", "suspende", "por", "persitencia", "de", "cuadro", "neurológico", "a", "pesar", "de", "Na", "corregido", "(", "134", "mEq", "/", "L", ")", ",", "mala", "tolerancia", "al", "4º", "ciclo", "y", "episodio", "de", "fiebre", "puntual", "el", "26/08/15", "secundario", "a", "fístula", "perianal", "en", "tratamiento", "con", "Eritromicina", ".", "En", "dicha", "consulta", ",", "debido", "a", "persistencia", "del", "cuadro", "neurologico", ",", "se", "solicita", "RMN", "craneal", "a", "fin", "de", "descartar", "afectación", "meníngea", "que", "pudiera", "explicar", "el", "cuadro", ".", "\n", "El", "31/08/16", "consulta", "nuevamente", "en", "urgencias", "por", "episodio", "convulsivo", ",", "objetivándose", "en", "analítica", "hiponatremia", "con", "Na", "112", "mEq", "/", "L", ",", "por", "lo", "que", "se", "inicia", "corrección", "de", "la", "misma", "con", "mejoría", "rápida", "del", "cuadro", "en", "24", "horas", "y", "posteriormente", "trasladada", "a", "planta", "de", "Oncología", "para", "continuidad", "de", "cuidados", ".", "\n\n", "Exploración", "física", "\n", "AL", "INGRESO", "EN", "ONCOLOGÍA", "MÉDICA", "\n", "PS", "4", ".", "Glasgow", "11", "(", "apertura", "espontánea", "de", "ojos", ",", "retira", "al", "dolor", ",", "no", "obedece", "órdenes", ",", "lenguaje", "incomprensible", ")", ".", "\n", "Pupilas", "isocóricas", "normorreactivas", ".", "Moviliza", "4", "miembros", ".", "\n", "Auscultación", "Cardio", "-", "Respiratoria", ":", "Normal", ".", "Abdomen", "normal", ".", "\n", "Miembros", "Inferiores", "sin", "edema", "ni", "signos", "Trombosis", "Venosa", "Profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "PRUEBAS", "DE", "LABORATORIO", "\n\n", "-", "Analítica", "31/08/15", ":", "\n", "*", "Hemograma", ":", "Hb", "99", "g", "/", "l", ",", "resto", "normal", ".", "\n", "*", "BioquÍmica", "sérica", ":", "Na", "112", "mEq", "/", "L", ",", "K", "3.2", "mEq", "/", "L", ",", "resto", "normal", ".", "\n", "*", "Coagulación", ":", "Normal", ".", "\n", "-", "Gasometría", "Venosa", "31/05/15", ":", "EVOLUCIÓN", ".", "\n", "*", "Na", ":", "111", "(", "15.00pm", ")", "-", ">", "113", "(", "16.00pm", ")", "-", ">", "116", "(", "17.00pm", ")", "-", ">", "116", "(", "18.45pm", ")", "\n", "*", "Osm", ":", "229", "-", ">", "233", "-", ">", "237-", ">", "237", ".", "\n", "-", "IONES", "ORINA", ":", "Na", "110", "mEq", "/", "L", "(", "elevado", ")", ",", "K", "10", "mEq", "/", "L.", "Proteinuria", ".", "\n", "-", "Marcadores", "tumorales", "01/09/16", ":", "CEA", "5,1", "ng", "/", "ml", "(", "descenso", ",", "al", "diagnóstico", "de", "7.9", "ng", "/", "ml", ")", ".", "CA", "125", "977", "U", "/", "ml", "(", "franco", "descenso", ",", "al", "diagnóstico", "de", "46852", "U", "/", "ml", ")", ".", "\n", "-", "Analítica", "10/09/16", "(", "PREVIA", "AL", "ALTA", "):", "\n", "*", "Bioquímica", ":", "Urea", "45", "mg", "/", "dl", ",", "proteinas", "totales", "6", "gr", "/", "dl", ",", "fósforo", "inorgánico", "2,55", "mg", "/", "dl", ".", "Sodio", "normal", "(", "139", "mEq", "/", "L", ")", ".", "\n", "*", "Hemograma", ":", "Hemoglobina", "98", "gr", "/", "L.", "Series", "blanca", "y", "paquetaria", "normales", ".", "\n\n", "PRUEBAS", "IMAGEN", "\n", "-", "TAC", "de", "tórax", "y", "abdomen", "(", "3/09/2015", ")", ".", "Nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "sin", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "pleural", ".", "Han", "desaparecido", "los", "engrosamientos", "pleurales", ".", "En", "hígado", "sigue", "apreciándose", "pequeño", "nódulo", "de", "8", "mm", "en", "periferia", "subdiafragmática", "del", "segmento", "VIII", "de", "contenido", "predominantemente", "graso", "(", "angiomiolipoma", "hepático", "?", ")", ".", "Pequeña", "lesión", "focal", "hipodensa", "en", "periferia", "del", "segmento", "VII", "de", "6", "mm", "de", "diámetro", ",", "indeterminada", ".", "Masa", "mesentérica", "de", "72", "x", "27", "x", "34", "mm", "de", "mayor", "tamaño", "que", "en", "la", "TC", "previa", ",", "con", "cápsula", "periférica", "bien", "definida", "y", "con", "contenido", "interno", "graso", "con", "polos", "sólidos", "de", "aspecto", "tumoral", "y", "de", "extirpe", "histológica", "diferente", "al", "tumor", "ovárico", ".", "Persisten", "masas", "tumorales", "pélvicas", "que", "rodean", "el", "rectosigma", ",", "útero", "y", "ocupan", "ambas", "fosas", "anexiales", "que", "se", "han", "reducido", "notablemente", "de", "tamaño", "respecto", "a", "la", "TC", "previa", ".", "Ha", "desaparecido", "la", "ascitis", ".", "Con", "ventana", "de", "hueso", "no", "se", "han", "apreciado", "imágenes", "sugestivas", "enfermedad", "metastásica", "ósea", ".", "\n\n", "-", "RM", "cerebral", "(", "7/09/2015", ")", ".", "No", "existen", "lesiones", "intraparenquimatosas", "ni", "que", "afecten", "a", "las", "meninges", ".", "\n\n", "INTERVENCIONISMO", "\n\n", "-", "Anatomía", "patológica", "biopsia", "core", "masa", "abdominal", "residual", "(", "con", "control", "ecográfico", ")", "11/09/16", ":", "\n", "BIOPSIA", "INSUFICIENTE", "PARA", "DIAGNÓSTICO", "CONSTITUIDA", "POR", "TEJIDO", "FIBROADIPOSO", ",", "CON", "PRESENCIA", "DE", "MACRÓFAGOS", "Y", "CAMBIOS", "INFLAMATORIOS", ".", "Comentario", ":", "No", "se", "han", "identificado", "signos", "morfológicos", "de", "malignidad", ".", "\n\n", "Diagnóstico", "\n", "-", "INGRESO", "EN", "PLANTA", "POR", ":", "\n", "1", ".", "Hiponatremia", "profunda", ",", "sintomáticamente", "severa", "y", "de", "carácter", "crónico", "y", "dos", "episodios", "graves", "documentados", "de", "somnolencia", ",", "confusión", "y", "convulsiones", ",", "por", "probable", "SIADH", "asociado", "a", "carboplatino", ".", "\n", "2", ".", "Proteinuria", "y", "tendencia", "a", "la", "hipertensión", "arterial", "seguramente", "secundaria", "a", "toxicidad", "por", "Bevacizumab", ".", "\n", "3", ".", "Masa", "abdominal", "de", "unos", "8", "-", "9", "cms", "de", "densidad", "grasa", "en", "raíz", "de", "mesenterio", "que", "ha", "crecido", "de", "forma", "aislada", "y", "que", "parece", "de", "etiología", "diferente", "al", "adenocarcinoma", "diagnosticado", "previamente", ".", "\n", "-", "PATOLOGÍA", "BASAL", ":", "Adenocarcinoma", "seroso", "G3", "de", "ovario", "estadio", "IV", "en", "RP", "tras", "4", "ciclos", "de", "Carbo", "-", "Taxol", "-", "Beva", "(", "corroborada", "en", "TAC", "de", "reevaluación", "y", "con", "descenso", "muy", "importante", "de", "marcadores", "séricos", ")", ".", "\n\n", "Tratamiento", "\n", "TRATAMIENTO", "AL", "ALTA", "DE", "PLANTA", "\n", "-", "Dieta", "normal", ".", "\n", "-", "Retirada", "de", "tratamiento", "de", "primera", "línea", "con", "Carbo", "-", "Paclitaxel", "-", "Bevacizumab", ".", "\n", "-", "Ingesta", "de", "líquidos", "sin", "restricciones", "(", "no", "tomar", "mas", "de", "2", "litros", "diarios", ")", "\n", "-", "Tratamiento", "hipotensor", "con", "Losartán", "50", ":", "1", "-", "0", "-", "0", "y", "si", "presiste", "TA", "elevadas", "(", ">", "160/80", "mmHg", ")", ",", "añadir", "manidipino", "10", ":", "0", "-", "0", "-", "1", ".", "\n", "-", "Omeprazol", "20", "mgrs", "al", "día", "vía", "oral", ".", "\n", "-", "Dexametasona", "4", "mgrs", "cada", "12", "horas", "vía", "oral", ".", "Seguir", "pauta", "descendente", ".", "\n", "-", "Lorazepam", "2", "mgrs", "por", "las", "noches", ".", "\n", "-", "Levotiroxina", "50", "mcgrs", "al", "día", "(", "por", "las", "mañans", ")", ".", "\n", "-", "No", "precisa", "tratamiento", "con", "Tolvaptán", ".", "\n\n", "Evolución", "\n", "La", "evolución", "de", "la", "paciente", "durante", "el", "ingreso", "fue", ",", "al", "principio", ",", "bastante", "tórpida", "por", "persistencia", "del", "estado", "de", "sopor", "y", "de", "bajo", "nivel", "de", "conciencia", "y", "por", "presentar", "episodios", "de", "agitación", "intermitentes", "a", "pesar", "de", "la", "normalización", "progresiva", "y", "lenta", "de", "los", "nivels", "de", "sodio", "sérico", ".", "Si", "bien", "lo", "anterior", ",", "no", "presentó", "en", "más", "ocasiones", "crisis", "convulsivas", ",", "manteniéndose", "en", "todo", "momento", "afebril", "y", "sin", "otros", "déficits", "neurológicos", ".", "Además", "poliuria", "con", "natriuresis", "normal", "y", "con", "creatinina", "sérica", "y", "ácido", "úrico", "normales", ".", "Por", "fin", ",", "tras", "elevación", "de", "la", "osmolalidad", "plasmática", "progresiva", "y", "tratamiento", "con", "dosis", "moderadas", "de", "dexametasona", "además", "de", "restricción", "de", "aporte", "liquidos", ",", "mejoró", "de", "forma", "ostensible", "a", "nivel", "neurológico", ",", "permaneciendo", "en", "los", "últimos", "días", "del", "ingreso", "consciente", "y", "cada", "vez", "más", "orientada", "y", "alerta", ",", "mejorando", "progresivamene", "su", "estado", "general", ".", "No", "obstante", ",", "durante", "su", "ingreso", "se", "ha", "objetivado", "de", "forma", "progresiva", "tendencia", "a", "la", "hipertensió", "arterial", "ademá", "de", "proteinuria", "discreta", ",", "siendo", "bien", "controladas", "con", "Losartán", ".", "Al", "alta", "de", "con", "sodio", "plasmático", "normal", "y", "con", "estado", "general", "conservado", ",", "afebril", "y", "tolerando", "dieta", "oral", "ademas", "de", "ausenxcia", "de", "deficits", "neurologicos", ".", "\n", "En", "cuanto", "a", "la", "causa", "de", "la", "hiponatremia", ",", "la", "pacinete", "fue", "valorado", "por", "Nefrología", "(", "continúa", "en", "sus", "consultas", ")", ",", "siendo", "diagnosticada", "de", "SIADH", "en", "relación", "a", "Carboplatino", "(", "diagnóstico", "de", "exclusión", ")", "vs", "SIADH", "como", "síndrome", "paraneoplásico", "en", "relación", "al", "tumor", ".", "Inicia", "nueva", "línea", "de", "QT", "con", "adriamicina", "liposomal", "en", "Noviembre/15", "(", "recibe", "únicamente", "1", "ciclo", ")", ".", "Dado", "que", "el", "SIADH", "se", "relaciona", "poco", "con", "un", "adenocarcinoma", "de", "pulmón", ",", "se", "decidió", "tomar", "muestra", "de", "la", "masa", "residual", "retroperitoneal", "(", "dado", "que", "parecía", "de", "una", "estirpe", "diferente", ")", ",", "por", "lo", "que", "la", "paciente", "se", "comentó", "en", "Comité", "de", "Tumores", ".", "Se", "decide", "resección", "de", "la", "masa", ":", "Intervención", "Quirúrgica", "(", "Enero/16", "):", "exéresis", "de", "la", "masa", "mesentérica", ",", "ooforectomía", "bilateral", ",", "omentectomía", "con", "implante", "tumoral", "peritoneal", ".", "\n", "Anatomía", "patológica", "de", "adenocarcinoma", "de", "origen", "ovárico", ".", "Posteriormente", "continúa", "con", "QT", "basada", "en", "adriamicina", "liposomal", ",", "y", "recibe", "un", "total", "de", "3", "ciclos", "(", "contando", "con", "el", "previo", "a", "la", "cirugía", ")", ",", "decidiéndose", "STOP", "en", "Abril/15", "por", "astenia", "importante", ".", "En", "la", "reevaluación", "de", "Mayo/15", "se", "objetiva", "respuesta", "completa", "por", "imagen", "y", "por", "marcadores", ".", "Desde", "la", "retirada", "del", "carboplatino", ",", "no", "ha", "vuelto", "a", "presentar", "hiponatremia", ".", "\n", "-", "TC", "tórax", "-", "abdomen", "Mayo/15", ":", "Tórax", ":", "Persiste", "nódulo", "pulmonar", "milimétrico", "en", "segmento", "apicoposterior", "de", "LSI", ",", "estable", "respecto", "al", "estudios", "previos", ",", "asi", "como", "en", "segmento", "laterobasal", "del", "LID", ",", "sin", "cambios", "también", ".", "No", "hay", "aparición", "de", "nuevos", "nódulos", ".", "No", "hay", "derrame", "ni", "engrosamiento", "pleural", ".", "Múltiples", "nódulos", "calcificados", "en", "ambas", "mamas", ".", "Resto", "del", "tórax", "sin", "hallazgos", "de", "interés", ".", "Abdomen", ":", "Hígado", "de", "tamaño", "normal", "y", "contorno", "liso", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "pequeño", "tamaño", "ya", "conocida", ".", "Vía", "biliar", "intra", "y", "extrahepática", "de", "calibre", "normal", ".", "Vesícula", "biliar", "sin", "alteraciones", ".", "\n", "Bazo", ",", "pancreas", ",", "adrenales", "y", "riñones", "sin", "hallazgos", "de", "interés", ".", "Estómago", ",", "asas", "de", "intestino", "delgado", "y", "colon", "sin", "dilataciones", "ni", "engrosamientos", "murales", ".", "\n", "Vejiga", "urinaria", "bien", "replecionada", "sin", "engrosamiento", "de", "la", "pared", ".", "Histerectomizada", "con", "doble", "anexectomía", ",", "sin", "imágenes", "de", "recidiva", ".", "Resto", "del", "abdomen", "sin", "hallazgos", "de", "interés", ".", "Conclusión", ":", "Nódulos", "pulmonares", "estables", ".", "Nódulos", "mamarios", "calcificados", ".", "LOE", "hepática", "de", "aspecto", "benigno", "y", "estable", ".", "Ausencia", "quirúrgica", "de", "genitales", "internos", ".", "\n", "-", "Evolución", "de", "Ca", "125", ":", "46852", "U", "/", "ml", "(", "diagnóstico", ")", "--", ">", "19.4", "U", "/", "ml", "(", "Mayo/16", ")", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

dasatinib is a CHEMICAL, BMS-354825 is a CHEMICAL, kinase is a GENE-N, SRC is a GENE-Y, BCR is a GENE-Y, ABL is a GENE-Y

17429625_task0

Sentence: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O" ]

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

[ "Preclinical", "pharmacokinetics", "and", "in", "vitro", "metabolism", "of", "dasatinib", "(", "BMS-354825", "):", "a", "potent", "oral", "multi", "-", "targeted", "kinase", "inhibitor", "against", "SRC", "and", "BCR", "-", "ABL", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

dasatinib is a CHEMICAL, BMS-354825 is a CHEMICAL, kinase is a GENE-N, SRC is a GENE-Y, BCR is a GENE-Y, ABL is a GENE-Y

17429625_task1

Sentence: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Instructions: please typing these entity words according to sentence: dasatinib, BMS-354825, kinase, SRC, BCR, ABL Options: GENE-Y, GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O" ]

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

[ "Preclinical", "pharmacokinetics", "and", "in", "vitro", "metabolism", "of", "dasatinib", "(", "BMS-354825", "):", "a", "potent", "oral", "multi", "-", "targeted", "kinase", "inhibitor", "against", "SRC", "and", "BCR", "-", "ABL", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

dasatinib, BMS-354825, kinase, SRC, BCR, ABL

17429625_task2

Sentence: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O" ]

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

[ "Preclinical", "pharmacokinetics", "and", "in", "vitro", "metabolism", "of", "dasatinib", "(", "BMS-354825", "):", "a", "potent", "oral", "multi", "-", "targeted", "kinase", "inhibitor", "against", "SRC", "and", "BCR", "-", "ABL", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Rel / NF - kappaB is a Protein, Notch is a Protein, Jagged1 is a Ligand, ligand is a Ligand, Notch receptors is a Protein, Jagged1 is a Ligand, DSL family is a Ligand, ligands is a Ligand, Notch receptors is a Protein, cell lineages is a Cell, transcription factors is a TranscriptionFactor, Jagged1 is a Ligand, Rel / NF - kappaB is a Protein, gene is a Gene, c - Rel is a Protein, RelA is a Protein, jagged1 is a Ligand, jagged1 is a Ligand, transcripts is a Transcript, NF - kappaB is a Protein, dominant mutant is a MutantProtein, IkappaBalpha is a Protein, Cell surface is a CellComponent, Jagged1 is a Ligand, c - Rel is a Protein, cell is a Cell, lymphocytes is a Cell, Notch1 / TAN-1 receptor is a Protein, Notch is a Protein, HES-1 is a Protein, transcripts is a Transcript, T cells is a Cell, CD23 is a Protein, transcripts is a Transcript, B cells is a Cell, Rel / NF - kappaB is a Protein, Jagged1 is a Ligand, splenic is a Tissue, B cells is a Cell, c - Rel is a Protein, c - Rel is a Protein, Notch is a Protein, jagged1 is a Ligand, Jagged1 is a Ligand, B - cell is a Cell, Notch is a Protein, NF - kappaB is a Protein

50_task0

Sentence: Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, TranscriptionFactor, CellComponent, Gene, Transcript, Ligand, MutantProtein, Protein, Cell

[ "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "B-Ligand", "O", "O", "O", "B-Ligand", "I-Ligand", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Gene", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "B-Transcript", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "B-Cell", "I-Cell", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system.

[ "Rel", "/", "NF", "-", "kappaB", "can", "trigger", "the", "Notch", "signaling", "pathway", "by", "inducing", "the", "expression", "of", "Jagged1", ",", "a", "ligand", "for", "Notch", "receptors", ".", "Jagged1", "belongs", "to", "the", "DSL", "family", "of", "ligands", "for", "Notch", "receptors", "that", "control", "the", "proliferation", "and", "differentiation", "of", "various", "cell", "lineages", ".", "However", ",", "little", "is", "known", "about", "the", "transcription", "factors", "that", "regulate", "its", "expression", ".", "Here", ",", "we", "show", "that", "Jagged1", "is", "a", "Rel", "/", "NF", "-", "kappaB", "-", "responsive", "gene", ".", "Both", "c", "-", "Rel", "and", "RelA", "induced", "jagged1", "gene", "expression", ",", "whereas", "a", "mutant", "defective", "for", "transactivation", "did", "not", ".", "Importantly", ",", "jagged1", "transcripts", "were", "also", "upregulated", "by", "endogenous", "NF", "-", "kappaB", "activation", "and", "this", "effect", "was", "inhibited", "by", "a", "dominant", "mutant", "of", "IkappaBalpha", ",", "a", "physiological", "inhibitor", "of", "NF", "-", "kappaB.", "Cell", "surface", "expression", "of", "Jagged1", "in", "c", "-", "Rel", "-", "expressing", "cell", "monolayers", "led", "to", "a", "functional", "interaction", "with", "lymphocytes", "expressing", "the", "Notch1", "/", "TAN-1", "receptor", ".", "This", "correlated", "with", "the", "initiation", "of", "signaling", "downstream", "of", "Notch", ",", "as", "evidenced", "by", "increased", "levels", "of", "HES-1", "transcripts", "in", "co", "-", "cultivated", "T", "cells", "and", "of", "CD23", "transcripts", "in", "co", "-", "cultivated", "B", "cells", ".", "Consistent", "with", "its", "Rel", "/", "NF", "-", "kappaB", "-", "dependent", "induction", ",", "Jagged1", "was", "found", "to", "be", "highly", "expressed", "in", "splenic", "B", "cells", "where", "c", "-", "Rel", "is", "expressed", "constitutively", ".", "These", "results", "demonstrate", "that", "c", "-", "Rel", "can", "trigger", "the", "Notch", "signaling", "pathway", "in", "neighboring", "cells", "by", "inducing", "jagged1", "gene", "expression", ",", "and", "suggest", "a", "role", "for", "Jagged1", "in", "B", "-", "cell", "activation", ",", "differentiation", "or", "function", ".", "These", "findings", "also", "highlight", "the", "potential", "for", "an", "interplay", "between", "the", "Notch", "and", "NF", "-", "kappaB", "signaling", "pathways", "in", "the", "immune", "system", ".", "\n" ]

[ "TranscriptionFactor", "Protein", "MutantProtein", "Cell", "CellComponent", "Transcript", "Ligand", "Tissue", "Gene" ]

Rel / NF - kappaB is a Protein, Notch is a Protein, Jagged1 is a Ligand, ligand is a Ligand, Notch receptors is a Protein, Jagged1 is a Ligand, DSL family is a Ligand, ligands is a Ligand, Notch receptors is a Protein, cell lineages is a Cell, transcription factors is a TranscriptionFactor, Jagged1 is a Ligand, Rel / NF - kappaB is a Protein, gene is a Gene, c - Rel is a Protein, RelA is a Protein, jagged1 is a Ligand, jagged1 is a Ligand, transcripts is a Transcript, NF - kappaB is a Protein, dominant mutant is a MutantProtein, IkappaBalpha is a Protein, Cell surface is a CellComponent, Jagged1 is a Ligand, c - Rel is a Protein, cell is a Cell, lymphocytes is a Cell, Notch1 / TAN-1 receptor is a Protein, Notch is a Protein, HES-1 is a Protein, transcripts is a Transcript, T cells is a Cell, CD23 is a Protein, transcripts is a Transcript, B cells is a Cell, Rel / NF - kappaB is a Protein, Jagged1 is a Ligand, splenic is a Tissue, B cells is a Cell, c - Rel is a Protein, c - Rel is a Protein, Notch is a Protein, jagged1 is a Ligand, Jagged1 is a Ligand, B - cell is a Cell, Notch is a Protein, NF - kappaB is a Protein

50_task1

Sentence: Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system. Instructions: please typing these entity words according to sentence: Rel / NF - kappaB, Notch, Jagged1, ligand, Notch receptors, Jagged1, DSL family, ligands, Notch receptors, cell lineages, transcription factors, Jagged1, Rel / NF - kappaB, gene, c - Rel, RelA, jagged1, jagged1, transcripts, NF - kappaB, dominant mutant, IkappaBalpha, Cell surface, Jagged1, c - Rel, cell, lymphocytes, Notch1 / TAN-1 receptor, Notch, HES-1, transcripts, T cells, CD23, transcripts, B cells, Rel / NF - kappaB, Jagged1, splenic, B cells, c - Rel, c - Rel, Notch, jagged1, Jagged1, B - cell, Notch, NF - kappaB Options: Tissue, TranscriptionFactor, CellComponent, Gene, Transcript, Ligand, MutantProtein, Protein, Cell

[ "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "B-Ligand", "O", "O", "O", "B-Ligand", "I-Ligand", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Gene", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "B-Transcript", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "B-Cell", "I-Cell", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system.

[ "Rel", "/", "NF", "-", "kappaB", "can", "trigger", "the", "Notch", "signaling", "pathway", "by", "inducing", "the", "expression", "of", "Jagged1", ",", "a", "ligand", "for", "Notch", "receptors", ".", "Jagged1", "belongs", "to", "the", "DSL", "family", "of", "ligands", "for", "Notch", "receptors", "that", "control", "the", "proliferation", "and", "differentiation", "of", "various", "cell", "lineages", ".", "However", ",", "little", "is", "known", "about", "the", "transcription", "factors", "that", "regulate", "its", "expression", ".", "Here", ",", "we", "show", "that", "Jagged1", "is", "a", "Rel", "/", "NF", "-", "kappaB", "-", "responsive", "gene", ".", "Both", "c", "-", "Rel", "and", "RelA", "induced", "jagged1", "gene", "expression", ",", "whereas", "a", "mutant", "defective", "for", "transactivation", "did", "not", ".", "Importantly", ",", "jagged1", "transcripts", "were", "also", "upregulated", "by", "endogenous", "NF", "-", "kappaB", "activation", "and", "this", "effect", "was", "inhibited", "by", "a", "dominant", "mutant", "of", "IkappaBalpha", ",", "a", "physiological", "inhibitor", "of", "NF", "-", "kappaB.", "Cell", "surface", "expression", "of", "Jagged1", "in", "c", "-", "Rel", "-", "expressing", "cell", "monolayers", "led", "to", "a", "functional", "interaction", "with", "lymphocytes", "expressing", "the", "Notch1", "/", "TAN-1", "receptor", ".", "This", "correlated", "with", "the", "initiation", "of", "signaling", "downstream", "of", "Notch", ",", "as", "evidenced", "by", "increased", "levels", "of", "HES-1", "transcripts", "in", "co", "-", "cultivated", "T", "cells", "and", "of", "CD23", "transcripts", "in", "co", "-", "cultivated", "B", "cells", ".", "Consistent", "with", "its", "Rel", "/", "NF", "-", "kappaB", "-", "dependent", "induction", ",", "Jagged1", "was", "found", "to", "be", "highly", "expressed", "in", "splenic", "B", "cells", "where", "c", "-", "Rel", "is", "expressed", "constitutively", ".", "These", "results", "demonstrate", "that", "c", "-", "Rel", "can", "trigger", "the", "Notch", "signaling", "pathway", "in", "neighboring", "cells", "by", "inducing", "jagged1", "gene", "expression", ",", "and", "suggest", "a", "role", "for", "Jagged1", "in", "B", "-", "cell", "activation", ",", "differentiation", "or", "function", ".", "These", "findings", "also", "highlight", "the", "potential", "for", "an", "interplay", "between", "the", "Notch", "and", "NF", "-", "kappaB", "signaling", "pathways", "in", "the", "immune", "system", ".", "\n" ]

[ "TranscriptionFactor", "Protein", "MutantProtein", "Cell", "CellComponent", "Transcript", "Ligand", "Tissue", "Gene" ]

Rel / NF - kappaB, Notch, Jagged1, ligand, Notch receptors, Jagged1, DSL family, ligands, Notch receptors, cell lineages, transcription factors, Jagged1, Rel / NF - kappaB, gene, c - Rel, RelA, jagged1, jagged1, transcripts, NF - kappaB, dominant mutant, IkappaBalpha, Cell surface, Jagged1, c - Rel, cell, lymphocytes, Notch1 / TAN-1 receptor, Notch, HES-1, transcripts, T cells, CD23, transcripts, B cells, Rel / NF - kappaB, Jagged1, splenic, B cells, c - Rel, c - Rel, Notch, jagged1, Jagged1, B - cell, Notch, NF - kappaB

50_task2

Sentence: Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system. Instructions: please extract entity words from the input sentence

[ "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "B-Ligand", "O", "O", "O", "B-Ligand", "I-Ligand", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Gene", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "B-Transcript", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-MutantProtein", "I-MutantProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellComponent", "I-CellComponent", "O", "O", "B-Ligand", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Protein", "B-Transcript", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "B-Cell", "I-Cell", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "O", "O", "O", "O", "O", "O", "O", "B-Ligand", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages. However, little is known about the transcription factors that regulate its expression. Here, we show that Jagged1 is a Rel/NF-kappaB-responsive gene. Both c-Rel and RelA induced jagged1 gene expression, whereas a mutant defective for transactivation did not. Importantly, jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of IkappaBalpha, a physiological inhibitor of NF-kappaB. Cell surface expression of Jagged1 in c-Rel-expressing cell monolayers led to a functional interaction with lymphocytes expressing the Notch1/TAN-1 receptor. This correlated with the initiation of signaling downstream of Notch, as evidenced by increased levels of HES-1 transcripts in co-cultivated T cells and of CD23 transcripts in co-cultivated B cells. Consistent with its Rel/NF-kappaB-dependent induction, Jagged1 was found to be highly expressed in splenic B cells where c-Rel is expressed constitutively. These results demonstrate that c-Rel can trigger the Notch signaling pathway in neighboring cells by inducing jagged1 gene expression, and suggest a role for Jagged1 in B-cell activation, differentiation or function. These findings also highlight the potential for an interplay between the Notch and NF-kappaB signaling pathways in the immune system.

[ "Rel", "/", "NF", "-", "kappaB", "can", "trigger", "the", "Notch", "signaling", "pathway", "by", "inducing", "the", "expression", "of", "Jagged1", ",", "a", "ligand", "for", "Notch", "receptors", ".", "Jagged1", "belongs", "to", "the", "DSL", "family", "of", "ligands", "for", "Notch", "receptors", "that", "control", "the", "proliferation", "and", "differentiation", "of", "various", "cell", "lineages", ".", "However", ",", "little", "is", "known", "about", "the", "transcription", "factors", "that", "regulate", "its", "expression", ".", "Here", ",", "we", "show", "that", "Jagged1", "is", "a", "Rel", "/", "NF", "-", "kappaB", "-", "responsive", "gene", ".", "Both", "c", "-", "Rel", "and", "RelA", "induced", "jagged1", "gene", "expression", ",", "whereas", "a", "mutant", "defective", "for", "transactivation", "did", "not", ".", "Importantly", ",", "jagged1", "transcripts", "were", "also", "upregulated", "by", "endogenous", "NF", "-", "kappaB", "activation", "and", "this", "effect", "was", "inhibited", "by", "a", "dominant", "mutant", "of", "IkappaBalpha", ",", "a", "physiological", "inhibitor", "of", "NF", "-", "kappaB.", "Cell", "surface", "expression", "of", "Jagged1", "in", "c", "-", "Rel", "-", "expressing", "cell", "monolayers", "led", "to", "a", "functional", "interaction", "with", "lymphocytes", "expressing", "the", "Notch1", "/", "TAN-1", "receptor", ".", "This", "correlated", "with", "the", "initiation", "of", "signaling", "downstream", "of", "Notch", ",", "as", "evidenced", "by", "increased", "levels", "of", "HES-1", "transcripts", "in", "co", "-", "cultivated", "T", "cells", "and", "of", "CD23", "transcripts", "in", "co", "-", "cultivated", "B", "cells", ".", "Consistent", "with", "its", "Rel", "/", "NF", "-", "kappaB", "-", "dependent", "induction", ",", "Jagged1", "was", "found", "to", "be", "highly", "expressed", "in", "splenic", "B", "cells", "where", "c", "-", "Rel", "is", "expressed", "constitutively", ".", "These", "results", "demonstrate", "that", "c", "-", "Rel", "can", "trigger", "the", "Notch", "signaling", "pathway", "in", "neighboring", "cells", "by", "inducing", "jagged1", "gene", "expression", ",", "and", "suggest", "a", "role", "for", "Jagged1", "in", "B", "-", "cell", "activation", ",", "differentiation", "or", "function", ".", "These", "findings", "also", "highlight", "the", "potential", "for", "an", "interplay", "between", "the", "Notch", "and", "NF", "-", "kappaB", "signaling", "pathways", "in", "the", "immune", "system", ".", "\n" ]

[ "TranscriptionFactor", "Protein", "MutantProtein", "Cell", "CellComponent", "Transcript", "Ligand", "Tissue", "Gene" ]

old is an umlsterm, adult is an umlsterm, man is an umlsterm, rheumatoid factor is an umlsterm, person is an umlsterm, Africa is an umlsterm, history is an umlsterm, laboratory is an umlsterm, diseases is an umlsterm, person is an umlsterm, risk factors is an umlsterm, rheumatic diseases is an umlsterm, future is an umlsterm, rheumatoid factor is an umlsterm, immunizations is an umlsterm, rheumatoid factor is an umlsterm, risk factors is an umlsterm

ZfuerRheumatologie.00590086.eng.abstr_task0

Sentence: A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed .

[ "A", "forty", "year", "old", "healthy", "adult", "man", "was", "admitted", "to", "our", "out", "-", "patient", "department", "because", "of", "a", "highly", "elevanted", "rheumatoid", "factor", ".", "Since", "the", "person", "was", "planning", "an", "extended", "stay", "in", "Africa", ",", "we", "performed", "an", "extensive", "history", ",", "clinical", "and", "laboratory", "examination", "to", "rule", "out", "oligosymptomatic", "inflammatory", "diseases", ".", "We", "further", "analyzed", "if", "the", "person", "presented", "genetic", "risk", "factors", "to", "develop", "rheumatic", "diseases", "in", "the", "future", "or", "if", "the", "presence", "of", "the", "rheumatoid", "factor", "could", "be", "a", "reaction", "to", "multiple", "immunizations", ".", "Possible", "explanations", "for", "an", "elevated", "rheumatoid", "factor", "including", "the", "genetic", "risk", "factors", "are", "discussed", "." ]

[ "umlsterm" ]

old is an umlsterm, adult is an umlsterm, man is an umlsterm, rheumatoid factor is an umlsterm, person is an umlsterm, Africa is an umlsterm, history is an umlsterm, laboratory is an umlsterm, diseases is an umlsterm, person is an umlsterm, risk factors is an umlsterm, rheumatic diseases is an umlsterm, future is an umlsterm, rheumatoid factor is an umlsterm, immunizations is an umlsterm, rheumatoid factor is an umlsterm, risk factors is an umlsterm

ZfuerRheumatologie.00590086.eng.abstr_task1

Sentence: A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed . Instructions: please typing these entity words according to sentence: old, adult, man, rheumatoid factor, person, Africa, history, laboratory, diseases, person, risk factors, rheumatic diseases, future, rheumatoid factor, immunizations, rheumatoid factor, risk factors Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed .

[ "A", "forty", "year", "old", "healthy", "adult", "man", "was", "admitted", "to", "our", "out", "-", "patient", "department", "because", "of", "a", "highly", "elevanted", "rheumatoid", "factor", ".", "Since", "the", "person", "was", "planning", "an", "extended", "stay", "in", "Africa", ",", "we", "performed", "an", "extensive", "history", ",", "clinical", "and", "laboratory", "examination", "to", "rule", "out", "oligosymptomatic", "inflammatory", "diseases", ".", "We", "further", "analyzed", "if", "the", "person", "presented", "genetic", "risk", "factors", "to", "develop", "rheumatic", "diseases", "in", "the", "future", "or", "if", "the", "presence", "of", "the", "rheumatoid", "factor", "could", "be", "a", "reaction", "to", "multiple", "immunizations", ".", "Possible", "explanations", "for", "an", "elevated", "rheumatoid", "factor", "including", "the", "genetic", "risk", "factors", "are", "discussed", "." ]

[ "umlsterm" ]

old, adult, man, rheumatoid factor, person, Africa, history, laboratory, diseases, person, risk factors, rheumatic diseases, future, rheumatoid factor, immunizations, rheumatoid factor, risk factors

ZfuerRheumatologie.00590086.eng.abstr_task2

Sentence: A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

A forty year old healthy adult man was admitted to our out-patient department because of a highly elevanted rheumatoid factor . Since the person was planning an extended stay in Africa , we performed an extensive history , clinical and laboratory examination to rule out oligosymptomatic inflammatory diseases . We further analyzed if the person presented genetic risk factors to develop rheumatic diseases in the future or if the presence of the rheumatoid factor could be a reaction to multiple immunizations . Possible explanations for an elevated rheumatoid factor including the genetic risk factors are discussed .

[ "A", "forty", "year", "old", "healthy", "adult", "man", "was", "admitted", "to", "our", "out", "-", "patient", "department", "because", "of", "a", "highly", "elevanted", "rheumatoid", "factor", ".", "Since", "the", "person", "was", "planning", "an", "extended", "stay", "in", "Africa", ",", "we", "performed", "an", "extensive", "history", ",", "clinical", "and", "laboratory", "examination", "to", "rule", "out", "oligosymptomatic", "inflammatory", "diseases", ".", "We", "further", "analyzed", "if", "the", "person", "presented", "genetic", "risk", "factors", "to", "develop", "rheumatic", "diseases", "in", "the", "future", "or", "if", "the", "presence", "of", "the", "rheumatoid", "factor", "could", "be", "a", "reaction", "to", "multiple", "immunizations", ".", "Possible", "explanations", "for", "an", "elevated", "rheumatoid", "factor", "including", "the", "genetic", "risk", "factors", "are", "discussed", "." ]

[ "umlsterm" ]

Fazialisparese is an umlsterm, Goldimplantate is an umlsterm, Platinimplantaten is an umlsterm

DerOpthalmologe.70940600.ger.abstr_task0

Sentence: Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen .

[ "Zur", "Verbesserung", "des", "Lidschlusses", "bei", "Lagophthalmus", "aufgrund", "einer", "Fazialisparese", "werden", "zur", "Lidbeschwerung", "haeufig", "Goldimplantate", "eingesetzt", ".", "Die", "Vertraeglichkeit", "des", "implantierten", "Materials", "entspricht", "nicht", "immer", "den", "Erwartungen", ".", "Wir", "untersuchten", "daher", ",", "ob", "mit", "den", "sehr", "gut", "vertraeglichen", "Platinimplantaten", "bessere", "Ergebnisse", "erzielt", "werden", "koennen", "." ]

[ "umlsterm" ]

Fazialisparese is an umlsterm, Goldimplantate is an umlsterm, Platinimplantaten is an umlsterm

DerOpthalmologe.70940600.ger.abstr_task1

Sentence: Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen . Instructions: please typing these entity words according to sentence: Fazialisparese, Goldimplantate, Platinimplantaten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen .

[ "Zur", "Verbesserung", "des", "Lidschlusses", "bei", "Lagophthalmus", "aufgrund", "einer", "Fazialisparese", "werden", "zur", "Lidbeschwerung", "haeufig", "Goldimplantate", "eingesetzt", ".", "Die", "Vertraeglichkeit", "des", "implantierten", "Materials", "entspricht", "nicht", "immer", "den", "Erwartungen", ".", "Wir", "untersuchten", "daher", ",", "ob", "mit", "den", "sehr", "gut", "vertraeglichen", "Platinimplantaten", "bessere", "Ergebnisse", "erzielt", "werden", "koennen", "." ]

[ "umlsterm" ]

Fazialisparese, Goldimplantate, Platinimplantaten

DerOpthalmologe.70940600.ger.abstr_task2

Sentence: Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Zur Verbesserung des Lidschlusses bei Lagophthalmus aufgrund einer Fazialisparese werden zur Lidbeschwerung haeufig Goldimplantate eingesetzt . Die Vertraeglichkeit des implantierten Materials entspricht nicht immer den Erwartungen . Wir untersuchten daher , ob mit den sehr gut vertraeglichen Platinimplantaten bessere Ergebnisse erzielt werden koennen .

[ "Zur", "Verbesserung", "des", "Lidschlusses", "bei", "Lagophthalmus", "aufgrund", "einer", "Fazialisparese", "werden", "zur", "Lidbeschwerung", "haeufig", "Goldimplantate", "eingesetzt", ".", "Die", "Vertraeglichkeit", "des", "implantierten", "Materials", "entspricht", "nicht", "immer", "den", "Erwartungen", ".", "Wir", "untersuchten", "daher", ",", "ob", "mit", "den", "sehr", "gut", "vertraeglichen", "Platinimplantaten", "bessere", "Ergebnisse", "erzielt", "werden", "koennen", "." ]

[ "umlsterm" ]

Pyoderma is an umlsterm, skin ulceration is an umlsterm, aetiology is an umlsterm, trauma is an umlsterm, standards is an umlsterm, treatment is an umlsterm, pyoderma is an umlsterm, diseases is an umlsterm, drug is an umlsterm, side effects is an umlsterm, therapy is an umlsterm, Immunosuppressive is an umlsterm, patient is an umlsterm, pyoderma is an umlsterm, operation is an umlsterm, combination therapy is an umlsterm, intravenous immunoglobulins is an umlsterm, corticosteroids is an umlsterm, disease is an umlsterm

DerHautarzt.90500879.eng.abstr_task0

Sentence: Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days .

[ "Pyoderma", "gangraenosum", "is", "a", "rare", ",", "chronic", "type", "of", "skin", "ulceration", "of", "unknown", "aetiology", ".", "It", "occasionally", "appears", "following", "trauma", ".", "There", "are", "no", "set", "standards", "for", "the", "treatment", "of", "pyoderma", "gangraenosum", ".", "It", "is", "essential", "to", "consider", "acuteness", "of", "progression", "as", "well", "as", "underlying", "systemic", "diseases", "and", "possible", "drug", "side", "effects", "before", "initiating", "a", "therapy", ".", "Immunosuppressive", "as", "well", "as", "immunomodulating", "agents", "are", "most", "often", "used", ",", "with", "varying", "degrees", "of", "success", ".", "We", "report", "a", "45-year", "-", "old", "patient", "who", "suffered", "from", "an", "extensive", "posttraumatic", "pyoderma", "gangraenosum", "after", "cardiac", "bypass", "operation", ".", "With", "short", "-", "term", "combination", "therapy", "consisting", "of", "high", "dose", "intravenous", "immunoglobulins", "and", "systemic", "corticosteroids", ",", "the", "progression", "of", "the", "disease", "could", "be", "stopped", "within", "a", "few", "days", "." ]

[ "umlsterm" ]

Pyoderma is an umlsterm, skin ulceration is an umlsterm, aetiology is an umlsterm, trauma is an umlsterm, standards is an umlsterm, treatment is an umlsterm, pyoderma is an umlsterm, diseases is an umlsterm, drug is an umlsterm, side effects is an umlsterm, therapy is an umlsterm, Immunosuppressive is an umlsterm, patient is an umlsterm, pyoderma is an umlsterm, operation is an umlsterm, combination therapy is an umlsterm, intravenous immunoglobulins is an umlsterm, corticosteroids is an umlsterm, disease is an umlsterm

DerHautarzt.90500879.eng.abstr_task1

Sentence: Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days . Instructions: please typing these entity words according to sentence: Pyoderma, skin ulceration, aetiology, trauma, standards, treatment, pyoderma, diseases, drug, side effects, therapy, Immunosuppressive, patient, pyoderma, operation, combination therapy, intravenous immunoglobulins, corticosteroids, disease Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days .

[ "Pyoderma", "gangraenosum", "is", "a", "rare", ",", "chronic", "type", "of", "skin", "ulceration", "of", "unknown", "aetiology", ".", "It", "occasionally", "appears", "following", "trauma", ".", "There", "are", "no", "set", "standards", "for", "the", "treatment", "of", "pyoderma", "gangraenosum", ".", "It", "is", "essential", "to", "consider", "acuteness", "of", "progression", "as", "well", "as", "underlying", "systemic", "diseases", "and", "possible", "drug", "side", "effects", "before", "initiating", "a", "therapy", ".", "Immunosuppressive", "as", "well", "as", "immunomodulating", "agents", "are", "most", "often", "used", ",", "with", "varying", "degrees", "of", "success", ".", "We", "report", "a", "45-year", "-", "old", "patient", "who", "suffered", "from", "an", "extensive", "posttraumatic", "pyoderma", "gangraenosum", "after", "cardiac", "bypass", "operation", ".", "With", "short", "-", "term", "combination", "therapy", "consisting", "of", "high", "dose", "intravenous", "immunoglobulins", "and", "systemic", "corticosteroids", ",", "the", "progression", "of", "the", "disease", "could", "be", "stopped", "within", "a", "few", "days", "." ]

[ "umlsterm" ]

Pyoderma, skin ulceration, aetiology, trauma, standards, treatment, pyoderma, diseases, drug, side effects, therapy, Immunosuppressive, patient, pyoderma, operation, combination therapy, intravenous immunoglobulins, corticosteroids, disease

DerHautarzt.90500879.eng.abstr_task2

Sentence: Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pyoderma gangraenosum is a rare , chronic type of skin ulceration of unknown aetiology . It occasionally appears following trauma . There are no set standards for the treatment of pyoderma gangraenosum . It is essential to consider acuteness of progression as well as underlying systemic diseases and possible drug side effects before initiating a therapy . Immunosuppressive as well as immunomodulating agents are most often used , with varying degrees of success . We report a 45-year-old patient who suffered from an extensive posttraumatic pyoderma gangraenosum after cardiac bypass operation . With short-term combination therapy consisting of high dose intravenous immunoglobulins and systemic corticosteroids , the progression of the disease could be stopped within a few days .

[ "Pyoderma", "gangraenosum", "is", "a", "rare", ",", "chronic", "type", "of", "skin", "ulceration", "of", "unknown", "aetiology", ".", "It", "occasionally", "appears", "following", "trauma", ".", "There", "are", "no", "set", "standards", "for", "the", "treatment", "of", "pyoderma", "gangraenosum", ".", "It", "is", "essential", "to", "consider", "acuteness", "of", "progression", "as", "well", "as", "underlying", "systemic", "diseases", "and", "possible", "drug", "side", "effects", "before", "initiating", "a", "therapy", ".", "Immunosuppressive", "as", "well", "as", "immunomodulating", "agents", "are", "most", "often", "used", ",", "with", "varying", "degrees", "of", "success", ".", "We", "report", "a", "45-year", "-", "old", "patient", "who", "suffered", "from", "an", "extensive", "posttraumatic", "pyoderma", "gangraenosum", "after", "cardiac", "bypass", "operation", ".", "With", "short", "-", "term", "combination", "therapy", "consisting", "of", "high", "dose", "intravenous", "immunoglobulins", "and", "systemic", "corticosteroids", ",", "the", "progression", "of", "the", "disease", "could", "be", "stopped", "within", "a", "few", "days", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Parakeratosis variegata is an umlsterm, Pityriasis lichenoides is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm, Analysen is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm

DerHautarzt.50460498.ger.abstr_task0

Sentence: Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O" ]

Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps .

[ "Es", "wird", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "dem", "seltenen", "Krankheitsbild", "einer", "Parakeratosis", "variegata", "berichtet", ",", "die", "nach", "einem", "Zeitraum", "von", "4", "Jahren", "nach", "einer", "Pityriasis", "lichenoides", "et", "varioliformis", "acuta", "auftrat", ".", "Um", "einem", "moeglichen", "pathogenetischen", "Bezug", "dieser", "Erkrankungen", "aus", "der", "Gruppe", "der", "Parapsoriasisveraenderungen", "untereinander", "und", "bzgl", ".", "ihrer", "Beziehung", "zum", "niedrigmalignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "zu", "untersuchen", ",", "fuehrten", "wir", "histologische", "immunhistochemische", "und", "molekulargenetische", "Analysen", ",", "durch", ".", "Waehrend", "beide", "Erkrankungen", "charakteristische", "histologische", "Veraenderungen", "sowie", "ein", "ueberwiegendes", "lymphozytaeres", "epidermotropes", "T", "-", "Zellinfiltrat", "aufwiesen", ",", "konnte", "ein", "monoklonales", "Rearrangement", "des", "T", "-", "Zell", "-", "Rezeptors", "innerhalb", "beider", "Veraenderungen", "nicht", "gesichert", "werden", ".", "Somit", "interpretieren", "wir", "beide", "Erkrankungen", "als", "eigene", "Entitaeten", "und", "in", "diesem", "Fall", "ohne", "Bezug", "zum", "niedrig", "malignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Parakeratosis variegata is an umlsterm, Pityriasis lichenoides is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm, Analysen is an umlsterm, Non - Hodgkin - Lymphom is an umlsterm

DerHautarzt.50460498.ger.abstr_task1

Sentence: Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps . Instructions: please typing these entity words according to sentence: Patienten, Parakeratosis variegata, Pityriasis lichenoides, Non - Hodgkin - Lymphom, Analysen, Non - Hodgkin - Lymphom Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O" ]

Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps .

[ "Es", "wird", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "dem", "seltenen", "Krankheitsbild", "einer", "Parakeratosis", "variegata", "berichtet", ",", "die", "nach", "einem", "Zeitraum", "von", "4", "Jahren", "nach", "einer", "Pityriasis", "lichenoides", "et", "varioliformis", "acuta", "auftrat", ".", "Um", "einem", "moeglichen", "pathogenetischen", "Bezug", "dieser", "Erkrankungen", "aus", "der", "Gruppe", "der", "Parapsoriasisveraenderungen", "untereinander", "und", "bzgl", ".", "ihrer", "Beziehung", "zum", "niedrigmalignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "zu", "untersuchen", ",", "fuehrten", "wir", "histologische", "immunhistochemische", "und", "molekulargenetische", "Analysen", ",", "durch", ".", "Waehrend", "beide", "Erkrankungen", "charakteristische", "histologische", "Veraenderungen", "sowie", "ein", "ueberwiegendes", "lymphozytaeres", "epidermotropes", "T", "-", "Zellinfiltrat", "aufwiesen", ",", "konnte", "ein", "monoklonales", "Rearrangement", "des", "T", "-", "Zell", "-", "Rezeptors", "innerhalb", "beider", "Veraenderungen", "nicht", "gesichert", "werden", ".", "Somit", "interpretieren", "wir", "beide", "Erkrankungen", "als", "eigene", "Entitaeten", "und", "in", "diesem", "Fall", "ohne", "Bezug", "zum", "niedrig", "malignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "." ]

[ "umlsterm" ]

Patienten, Parakeratosis variegata, Pityriasis lichenoides, Non - Hodgkin - Lymphom, Analysen, Non - Hodgkin - Lymphom

DerHautarzt.50460498.ger.abstr_task2

Sentence: Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O" ]

Es wird ueber einen 34jaehrigen Patienten mit dem seltenen Krankheitsbild einer Parakeratosis variegata berichtet , die nach einem Zeitraum von 4 Jahren nach einer Pityriasis lichenoides et varioliformis acuta auftrat . Um einem moeglichen pathogenetischen Bezug dieser Erkrankungen aus der Gruppe der Parapsoriasisveraenderungen untereinander und bzgl. ihrer Beziehung zum niedrigmalignen Non-Hodgkin-Lymphom des T-Zelltyps zu untersuchen , fuehrten wir histologische immunhistochemische und molekulargenetische Analysen , durch . Waehrend beide Erkrankungen charakteristische histologische Veraenderungen sowie ein ueberwiegendes lymphozytaeres epidermotropes T-Zellinfiltrat aufwiesen , konnte ein monoklonales Rearrangement des T-Zell-Rezeptors innerhalb beider Veraenderungen nicht gesichert werden . Somit interpretieren wir beide Erkrankungen als eigene Entitaeten und in diesem Fall ohne Bezug zum niedrig malignen Non-Hodgkin-Lymphom des T-Zelltyps .

[ "Es", "wird", "ueber", "einen", "34jaehrigen", "Patienten", "mit", "dem", "seltenen", "Krankheitsbild", "einer", "Parakeratosis", "variegata", "berichtet", ",", "die", "nach", "einem", "Zeitraum", "von", "4", "Jahren", "nach", "einer", "Pityriasis", "lichenoides", "et", "varioliformis", "acuta", "auftrat", ".", "Um", "einem", "moeglichen", "pathogenetischen", "Bezug", "dieser", "Erkrankungen", "aus", "der", "Gruppe", "der", "Parapsoriasisveraenderungen", "untereinander", "und", "bzgl", ".", "ihrer", "Beziehung", "zum", "niedrigmalignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "zu", "untersuchen", ",", "fuehrten", "wir", "histologische", "immunhistochemische", "und", "molekulargenetische", "Analysen", ",", "durch", ".", "Waehrend", "beide", "Erkrankungen", "charakteristische", "histologische", "Veraenderungen", "sowie", "ein", "ueberwiegendes", "lymphozytaeres", "epidermotropes", "T", "-", "Zellinfiltrat", "aufwiesen", ",", "konnte", "ein", "monoklonales", "Rearrangement", "des", "T", "-", "Zell", "-", "Rezeptors", "innerhalb", "beider", "Veraenderungen", "nicht", "gesichert", "werden", ".", "Somit", "interpretieren", "wir", "beide", "Erkrankungen", "als", "eigene", "Entitaeten", "und", "in", "diesem", "Fall", "ohne", "Bezug", "zum", "niedrig", "malignen", "Non", "-", "Hodgkin", "-", "Lymphom", "des", "T", "-", "Zelltyps", "." ]

[ "umlsterm" ]

microRNA is a Non-Specific_miRNAs, rat is a Species, traumatic brain injury is a Diseases, microRNA is a Non-Specific_miRNAs, miR-21 is a Specific_miRNAs, TBI is a Diseases

2527_task0

Sentence: Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Specific_miRNAs, Species, Diseases, Non-Specific_miRNAs

[ "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Species", "O", "O", "O", "B-Diseases", "I-Diseases", "I-Diseases", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O", "O", "O" ]

Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.

[ "Our", "microarray", "based", "analysis", "of", "microRNA", "expression", "in", "rat", "cerebral", "cortex", "after", "traumatic", "brain", "injury", "has", "shown", "that", "some", "microRNA", "such", "as", "miR-21", "could", "be", "involved", "in", "the", "intricate", "process", "of", "TBI", "course", ".", " " ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Specific_miRNAs", "Species" ]

microRNA is a Non-Specific_miRNAs, rat is a Species, traumatic brain injury is a Diseases, microRNA is a Non-Specific_miRNAs, miR-21 is a Specific_miRNAs, TBI is a Diseases

2527_task1

Sentence: Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. Instructions: please typing these entity words according to sentence: microRNA, rat, traumatic brain injury, microRNA, miR-21, TBI Options: Specific_miRNAs, Species, Diseases, Non-Specific_miRNAs

[ "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Species", "O", "O", "O", "B-Diseases", "I-Diseases", "I-Diseases", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O", "O", "O" ]

Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.

[ "Our", "microarray", "based", "analysis", "of", "microRNA", "expression", "in", "rat", "cerebral", "cortex", "after", "traumatic", "brain", "injury", "has", "shown", "that", "some", "microRNA", "such", "as", "miR-21", "could", "be", "involved", "in", "the", "intricate", "process", "of", "TBI", "course", ".", " " ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Specific_miRNAs", "Species" ]

microRNA, rat, traumatic brain injury, microRNA, miR-21, TBI

2527_task2

Sentence: Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Species", "O", "O", "O", "B-Diseases", "I-Diseases", "I-Diseases", "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "B-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O", "O", "O" ]

Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.

[ "Our", "microarray", "based", "analysis", "of", "microRNA", "expression", "in", "rat", "cerebral", "cortex", "after", "traumatic", "brain", "injury", "has", "shown", "that", "some", "microRNA", "such", "as", "miR-21", "could", "be", "involved", "in", "the", "intricate", "process", "of", "TBI", "course", ".", " " ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Specific_miRNAs", "Species" ]

Patients is a cohort-patient, Swedish is an ethnicity, Polyposis is a disease, 196 is a size, families is a cohort-patient, FAP is a disease, colorectal is a body-part, adenomas is a disease, FAP is a disease, Sixty - one is a size, families is a cohort-patient, 135 is a size, families is a cohort-patient, living disease - affected member is a cohort-patient, 315 is a size, disease is a disease, patients is a cohort-patient, Sweden is an ethnicity, patients is a cohort-patient, 96 is a size, families is a cohort-patient, mutations is a mutation, APC is a gene, Twenty - four of the remaining 39 is a size, families is a cohort-patient, APC is a gene, mutations is a mutation, 15 is a size, families is a cohort-patient, six of these is a size, patients is a cohort-patient, bi - allelic MUTYH mutations is a mutation, Probands is a cohort-patient, cases is a cohort-patient, family is a cohort-patient, patients is a cohort-patient, FAP is a disease, individuals is a cohort-patient, age of 50 is an age, FAP is a disease, age of 75 is an age, patients is a cohort-patient, index patients is a cohort-patient, families is a cohort-patient, Patients is a cohort-patient, mutation is a mutation, APC is a gene, MUTYH is a gene, DL is a disease, duodenal is a body-part, lesion is a disease, FGP is a disease, fundic gland is a body-part, polyps is a disease, polyps is a disease, polyps is a disease, Patient is a cohort-patient, C896 is a cohort-patient, adenomas is a disease, family history of FAP is a Disorder, Patient is a cohort-patient, C107 is a cohort-patient, her is a gender, intestinal bleeding is a Disorder, age 47 is an age, 10–20 small ( less than 10 mm ) is a Concepts_Ideas, polyps is a disease, colorectal is a body-part, Tubular is a Concepts_Ideas, tubulovillous is a Concepts_Ideas, adenomas is a disease, age 50 is an age, carcinoma is a disease, Dukes A is a Phenomena, valvula Bauhini is a body-part, adenomas is a disease, patient is a cohort-patient

63_task0

Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ethnicity, Concepts_Ideas, Phenomena, disease, mutation, cohort-patient, body-part, gender, Disorder, size, gene, age

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "B-disease", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "B-size", "I-size", "I-size", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-size", "B-disease", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "B-mutation", "O", "O", "B-gene", "O", "O", "B-size", "I-size", "I-size", "I-size", "I-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "O", "O", "B-gene", "O", "B-mutation", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "B-cohort-patient", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "B-cohort-patient", "B-cohort-patient", "O", "B-gender", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "O", "B-age", "I-age", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-body-part", "O", "O", "B-Concepts_Ideas", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "O", "B-age", "I-age", "O", "B-disease", "O", "B-Phenomena", "I-Phenomena", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33].

[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Methods", "\n\n", "Patients", "\n\n", "Between", "1957", "and", "31", "December", "2004", "the", "Swedish", "Polyposis", "Registry", "included", "data", "on", "196", "families", "with", "verified", "FAP", "(", "defined", "as", "more", "than", "100", "colorectal", "adenomas", "or", "if", "less", "with", "a", "family", "history", "of", "FAP", ")", ".", "Sixty", "-", "one", "of", "these", "families", "are", "now", "extinct", "but", "135", "families", "with", "at", "least", "one", "living", "disease", "-", "affected", "member", "remain", ".", "Presently", ",", "315", "disease", "-", "affected", "living", "patients", "are", "included", "in", "the", "registry", ".", "The", "geographical", "catchment", "area", "comprises", "the", "whole", "of", "Sweden", ".", "Details", "of", "how", "patients", "have", "been", "eligible", "for", "accession", "into", "the", "registry", "are", "given", "in", "[", "30", "]", ".", "In", "this", "study", "we", "have", "analyzed", "96", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene", ".", "Twenty", "-", "four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", "families", "remain", "to", "be", "tested", ".", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi", "-", "allelic", "MUTYH", "mutations", "[", "31", "]", ".", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call", "-", "up", "patients", ",", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP", ".", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non", "-", "FAP", "related", "cause", "after", "the", "age", "of", "75", ".", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study", ".", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1", ".", "\n\n", "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH", "\n\n", "Age", ",", "age", "at", "diagnosis", ";", "DL", ",", "duodenal", "lesion", ";", "dom", ",", "dominant", ";", "FGP", ",", "fundic", "gland", "polyps", ";", "NA", ",", "no", "available", "data", ";", "NI", ",", "no", "inheritance", ";", "Number", "of", "polyps", ",", "number", "of", "polyps", "at", "diagnosis", ";", "rec", ",", "recessive", "\n\n", "Patient", "C896", ",", "with", "only", "five", "adenomas", ",", "was", "included", "because", "of", "a", "family", "history", "of", "FAP", ".", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47", ".", "At", "diagnosis", ",", "10–20", "small", "(", "less", "than", "10", "mm", ")", "polyps", "were", "found", "in", "most", "colorectal", "parts", ".", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly", ".", "At", "age", "50", ",", "carcinoma", "(", "Dukes", "A", ")", "was", "diagnosed", "4", "cm", "from", "valvula", "Bauhini", "in", "conjunction", "with", "several", "new", "adenomas", ".", "At", "that", "time", "the", "patient", "underwent", "total", "colectomy", "with", "ileorectal", "anastomosis", "(", "IRA", ")", ".", "\n\n", "DNA", ",", "RNA", "and", "cDNA", "preparation", "\n\n", "Genomic", "DNA", "was", "isolated", "from", "samples", "of", "venous", "blood", ",", "anti", "-", "coagulated", "in", "ethylenediaminetetraacetic", "acid", "(", "EDTA", ")", ".", "DNA", "purification", "was", "performed", "using", "the", "PuregeneR", "DNA", "Isolation", "Kit", "(", "Gentra", "Systems", ",", "Minneapolis", ",", "MN", ")", "according", "to", "the", "manufacturer", "'s", "recommendations", ".", "DNA", "was", "extracted", "from", "paraffin", "-", "embedded", "tissue", "as", "described", "previously", "[", "32", "]", ".", "Histopaque", "(", "Sigma", ",", "St", "Louis", ",", "MO", ")", "or", "Lymphoprep", "(", "Axis", "-", "Shield", "PoC", "AS", ",", "Oslo", ",", "Norway", ")", "was", "used", "for", "purification", "of", "the", "lymphocytes", ",", "and", "total", "RNA", "was", "extracted", "using", "RNA", "-", "Stat", "60", "(", "Tel", "-", "Test", ",", "Friendswood", ",", "TX", ")", ".", "cDNA", "was", "synthesized", "as", "described", "previously", "[", "33", "]", ".", "\n\n" ]

[ "size", "cohort-patient", "Concepts_Ideas", "mutation", "Disorder", "body-part", "disease", "age", "Phenomena", "ethnicity", "gene", "gender" ]

Patients is a cohort-patient, Swedish is an ethnicity, Polyposis is a disease, 196 is a size, families is a cohort-patient, FAP is a disease, colorectal is a body-part, adenomas is a disease, FAP is a disease, Sixty - one is a size, families is a cohort-patient, 135 is a size, families is a cohort-patient, living disease - affected member is a cohort-patient, 315 is a size, disease is a disease, patients is a cohort-patient, Sweden is an ethnicity, patients is a cohort-patient, 96 is a size, families is a cohort-patient, mutations is a mutation, APC is a gene, Twenty - four of the remaining 39 is a size, families is a cohort-patient, APC is a gene, mutations is a mutation, 15 is a size, families is a cohort-patient, six of these is a size, patients is a cohort-patient, bi - allelic MUTYH mutations is a mutation, Probands is a cohort-patient, cases is a cohort-patient, family is a cohort-patient, patients is a cohort-patient, FAP is a disease, individuals is a cohort-patient, age of 50 is an age, FAP is a disease, age of 75 is an age, patients is a cohort-patient, index patients is a cohort-patient, families is a cohort-patient, Patients is a cohort-patient, mutation is a mutation, APC is a gene, MUTYH is a gene, DL is a disease, duodenal is a body-part, lesion is a disease, FGP is a disease, fundic gland is a body-part, polyps is a disease, polyps is a disease, polyps is a disease, Patient is a cohort-patient, C896 is a cohort-patient, adenomas is a disease, family history of FAP is a Disorder, Patient is a cohort-patient, C107 is a cohort-patient, her is a gender, intestinal bleeding is a Disorder, age 47 is an age, 10–20 small ( less than 10 mm ) is a Concepts_Ideas, polyps is a disease, colorectal is a body-part, Tubular is a Concepts_Ideas, tubulovillous is a Concepts_Ideas, adenomas is a disease, age 50 is an age, carcinoma is a disease, Dukes A is a Phenomena, valvula Bauhini is a body-part, adenomas is a disease, patient is a cohort-patient

63_task1

Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33]. Instructions: please typing these entity words according to sentence: Patients, Swedish, Polyposis, 196, families, FAP, colorectal, adenomas, FAP, Sixty - one, families, 135, families, living disease - affected member, 315, disease, patients, Sweden, patients, 96, families, mutations, APC, Twenty - four of the remaining 39, families, APC, mutations, 15, families, six of these, patients, bi - allelic MUTYH mutations, Probands, cases, family, patients, FAP, individuals, age of 50, FAP, age of 75, patients, index patients, families, Patients, mutation, APC, MUTYH, DL, duodenal, lesion, FGP, fundic gland, polyps, polyps, polyps, Patient, C896, adenomas, family history of FAP, Patient, C107, her, intestinal bleeding, age 47, 10–20 small ( less than 10 mm ), polyps, colorectal, Tubular, tubulovillous, adenomas, age 50, carcinoma, Dukes A, valvula Bauhini, adenomas, patient Options: ethnicity, Concepts_Ideas, Phenomena, disease, mutation, cohort-patient, body-part, gender, Disorder, size, gene, age

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "B-disease", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "B-size", "I-size", "I-size", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-size", "B-disease", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "B-mutation", "O", "O", "B-gene", "O", "O", "B-size", "I-size", "I-size", "I-size", "I-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "O", "O", "B-gene", "O", "B-mutation", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "B-cohort-patient", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "B-cohort-patient", "B-cohort-patient", "O", "B-gender", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "O", "B-age", "I-age", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-body-part", "O", "O", "B-Concepts_Ideas", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "O", "B-age", "I-age", "O", "B-disease", "O", "B-Phenomena", "I-Phenomena", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33].

[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Methods", "\n\n", "Patients", "\n\n", "Between", "1957", "and", "31", "December", "2004", "the", "Swedish", "Polyposis", "Registry", "included", "data", "on", "196", "families", "with", "verified", "FAP", "(", "defined", "as", "more", "than", "100", "colorectal", "adenomas", "or", "if", "less", "with", "a", "family", "history", "of", "FAP", ")", ".", "Sixty", "-", "one", "of", "these", "families", "are", "now", "extinct", "but", "135", "families", "with", "at", "least", "one", "living", "disease", "-", "affected", "member", "remain", ".", "Presently", ",", "315", "disease", "-", "affected", "living", "patients", "are", "included", "in", "the", "registry", ".", "The", "geographical", "catchment", "area", "comprises", "the", "whole", "of", "Sweden", ".", "Details", "of", "how", "patients", "have", "been", "eligible", "for", "accession", "into", "the", "registry", "are", "given", "in", "[", "30", "]", ".", "In", "this", "study", "we", "have", "analyzed", "96", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene", ".", "Twenty", "-", "four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", "families", "remain", "to", "be", "tested", ".", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi", "-", "allelic", "MUTYH", "mutations", "[", "31", "]", ".", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call", "-", "up", "patients", ",", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP", ".", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non", "-", "FAP", "related", "cause", "after", "the", "age", "of", "75", ".", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study", ".", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1", ".", "\n\n", "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH", "\n\n", "Age", ",", "age", "at", "diagnosis", ";", "DL", ",", "duodenal", "lesion", ";", "dom", ",", "dominant", ";", "FGP", ",", "fundic", "gland", "polyps", ";", "NA", ",", "no", "available", "data", ";", "NI", ",", "no", "inheritance", ";", "Number", "of", "polyps", ",", "number", "of", "polyps", "at", "diagnosis", ";", "rec", ",", "recessive", "\n\n", "Patient", "C896", ",", "with", "only", "five", "adenomas", ",", "was", "included", "because", "of", "a", "family", "history", "of", "FAP", ".", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47", ".", "At", "diagnosis", ",", "10–20", "small", "(", "less", "than", "10", "mm", ")", "polyps", "were", "found", "in", "most", "colorectal", "parts", ".", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly", ".", "At", "age", "50", ",", "carcinoma", "(", "Dukes", "A", ")", "was", "diagnosed", "4", "cm", "from", "valvula", "Bauhini", "in", "conjunction", "with", "several", "new", "adenomas", ".", "At", "that", "time", "the", "patient", "underwent", "total", "colectomy", "with", "ileorectal", "anastomosis", "(", "IRA", ")", ".", "\n\n", "DNA", ",", "RNA", "and", "cDNA", "preparation", "\n\n", "Genomic", "DNA", "was", "isolated", "from", "samples", "of", "venous", "blood", ",", "anti", "-", "coagulated", "in", "ethylenediaminetetraacetic", "acid", "(", "EDTA", ")", ".", "DNA", "purification", "was", "performed", "using", "the", "PuregeneR", "DNA", "Isolation", "Kit", "(", "Gentra", "Systems", ",", "Minneapolis", ",", "MN", ")", "according", "to", "the", "manufacturer", "'s", "recommendations", ".", "DNA", "was", "extracted", "from", "paraffin", "-", "embedded", "tissue", "as", "described", "previously", "[", "32", "]", ".", "Histopaque", "(", "Sigma", ",", "St", "Louis", ",", "MO", ")", "or", "Lymphoprep", "(", "Axis", "-", "Shield", "PoC", "AS", ",", "Oslo", ",", "Norway", ")", "was", "used", "for", "purification", "of", "the", "lymphocytes", ",", "and", "total", "RNA", "was", "extracted", "using", "RNA", "-", "Stat", "60", "(", "Tel", "-", "Test", ",", "Friendswood", ",", "TX", ")", ".", "cDNA", "was", "synthesized", "as", "described", "previously", "[", "33", "]", ".", "\n\n" ]

[ "size", "cohort-patient", "Concepts_Ideas", "mutation", "Disorder", "body-part", "disease", "age", "Phenomena", "ethnicity", "gene", "gender" ]

Patients, Swedish, Polyposis, 196, families, FAP, colorectal, adenomas, FAP, Sixty - one, families, 135, families, living disease - affected member, 315, disease, patients, Sweden, patients, 96, families, mutations, APC, Twenty - four of the remaining 39, families, APC, mutations, 15, families, six of these, patients, bi - allelic MUTYH mutations, Probands, cases, family, patients, FAP, individuals, age of 50, FAP, age of 75, patients, index patients, families, Patients, mutation, APC, MUTYH, DL, duodenal, lesion, FGP, fundic gland, polyps, polyps, polyps, Patient, C896, adenomas, family history of FAP, Patient, C107, her, intestinal bleeding, age 47, 10–20 small ( less than 10 mm ), polyps, colorectal, Tubular, tubulovillous, adenomas, age 50, carcinoma, Dukes A, valvula Bauhini, adenomas, patient

63_task2

Sentence: ** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33]. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "B-disease", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "B-size", "I-size", "I-size", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-size", "B-disease", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ethnicity", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "B-mutation", "O", "O", "B-gene", "O", "O", "B-size", "I-size", "I-size", "I-size", "I-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "O", "O", "B-gene", "O", "B-mutation", "O", "O", "O", "O", "O", "B-size", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-size", "I-size", "I-size", "B-cohort-patient", "O", "O", "B-mutation", "I-mutation", "I-mutation", "I-mutation", "I-mutation", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "B-age", "I-age", "I-age", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "I-cohort-patient", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "B-disease", "O", "O", "O", "O", "O", "B-disease", "O", "B-body-part", "I-body-part", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "B-cohort-patient", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "I-Disorder", "I-Disorder", "O", "B-cohort-patient", "B-cohort-patient", "O", "B-gender", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "O", "B-age", "I-age", "O", "O", "O", "O", "B-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "I-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "B-body-part", "O", "O", "B-Concepts_Ideas", "O", "B-Concepts_Ideas", "B-disease", "O", "O", "O", "O", "O", "B-age", "I-age", "O", "B-disease", "O", "B-Phenomena", "I-Phenomena", "O", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

** IGNORE LINE ** ** IGNORE LINE ** ** IGNORE LINE ** Methods Patients Between 1957 and 31 December 2004 the Swedish Polyposis Registry included data on 196 families with verified FAP (defined as more than 100 colorectal adenomas or if less with a family history of FAP). Sixty-one of these families are now extinct but 135 families with at least one living disease-affected member remain. Presently, 315 disease-affected living patients are included in the registry. The geographical catchment area comprises the whole of Sweden. Details of how patients have been eligible for accession into the registry are given in [30]. In this study we have analyzed 96 families included in the registry for mutations in the APC gene. Twenty-four of the remaining 39 families have been analyzed for APC gene mutations at other genetic laboratories and 15 families remain to be tested. We have previously reported six of these patients who carried bi-allelic MUTYH mutations [31]. Probands were defined as those diagnosed on the basis of the occurrence of symptoms and irrespective of other cases in the family and call-up patients, as those identified as subjects at risk on the basis of studies of pedigrees and found to have FAP. De novo mutations were defined in those individuals where none of the parents carried the mutation or where the parents had a negative colonoscopy after the age of 50 or died of a non-FAP related cause after the age of 75. All patients have given their consent and the local ethics committees have approved the study. The clinical features of index patients of each of the families analyzed are listed in Additional file 1 and Table 1. Patients without any detected mutation in APC or MUTYH Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive Patient C896, with only five adenomas, was included because of a family history of FAP. Patient C107 underwent her first colonoscopy due to intestinal bleeding at age 47. At diagnosis, 10–20 small (less than 10 mm) polyps were found in most colorectal parts. Tubular and tubulovillous adenomas were removed yearly. At age 50, carcinoma (Dukes A) was diagnosed 4 cm from valvula Bauhini in conjunction with several new adenomas. At that time the patient underwent total colectomy with ileorectal anastomosis (IRA). DNA, RNA and cDNA preparation Genomic DNA was isolated from samples of venous blood, anti-coagulated in ethylenediaminetetraacetic acid (EDTA). DNA purification was performed using the PuregeneR DNA Isolation Kit (Gentra Systems, Minneapolis, MN) according to the manufacturer's recommendations. DNA was extracted from paraffin-embedded tissue as described previously [32]. Histopaque (Sigma, St Louis, MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) was used for purification of the lymphocytes, and total RNA was extracted using RNA-Stat 60 (Tel-Test, Friendswood, TX). cDNA was synthesized as described previously [33].

[ "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "*", "*", "IGNORE", "LINE", "*", "*", "\n", "Methods", "\n\n", "Patients", "\n\n", "Between", "1957", "and", "31", "December", "2004", "the", "Swedish", "Polyposis", "Registry", "included", "data", "on", "196", "families", "with", "verified", "FAP", "(", "defined", "as", "more", "than", "100", "colorectal", "adenomas", "or", "if", "less", "with", "a", "family", "history", "of", "FAP", ")", ".", "Sixty", "-", "one", "of", "these", "families", "are", "now", "extinct", "but", "135", "families", "with", "at", "least", "one", "living", "disease", "-", "affected", "member", "remain", ".", "Presently", ",", "315", "disease", "-", "affected", "living", "patients", "are", "included", "in", "the", "registry", ".", "The", "geographical", "catchment", "area", "comprises", "the", "whole", "of", "Sweden", ".", "Details", "of", "how", "patients", "have", "been", "eligible", "for", "accession", "into", "the", "registry", "are", "given", "in", "[", "30", "]", ".", "In", "this", "study", "we", "have", "analyzed", "96", "families", "included", "in", "the", "registry", "for", "mutations", "in", "the", "APC", "gene", ".", "Twenty", "-", "four", "of", "the", "remaining", "39", "families", "have", "been", "analyzed", "for", "APC", "gene", "mutations", "at", "other", "genetic", "laboratories", "and", "15", "families", "remain", "to", "be", "tested", ".", "We", "have", "previously", "reported", "six", "of", "these", "patients", "who", "carried", "bi", "-", "allelic", "MUTYH", "mutations", "[", "31", "]", ".", "Probands", "were", "defined", "as", "those", "diagnosed", "on", "the", "basis", "of", "the", "occurrence", "of", "symptoms", "and", "irrespective", "of", "other", "cases", "in", "the", "family", "and", "call", "-", "up", "patients", ",", "as", "those", "identified", "as", "subjects", "at", "risk", "on", "the", "basis", "of", "studies", "of", "pedigrees", "and", "found", "to", "have", "FAP", ".", "De", "novo", "mutations", "were", "defined", "in", "those", "individuals", "where", "none", "of", "the", "parents", "carried", "the", "mutation", "or", "where", "the", "parents", "had", "a", "negative", "colonoscopy", "after", "the", "age", "of", "50", "or", "died", "of", "a", "non", "-", "FAP", "related", "cause", "after", "the", "age", "of", "75", ".", "All", "patients", "have", "given", "their", "consent", "and", "the", "local", "ethics", "committees", "have", "approved", "the", "study", ".", "The", "clinical", "features", "of", "index", "patients", "of", "each", "of", "the", "families", "analyzed", "are", "listed", "in", "Additional", "file", "1", "and", "Table", "1", ".", "\n\n", "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH", "\n\n", "Age", ",", "age", "at", "diagnosis", ";", "DL", ",", "duodenal", "lesion", ";", "dom", ",", "dominant", ";", "FGP", ",", "fundic", "gland", "polyps", ";", "NA", ",", "no", "available", "data", ";", "NI", ",", "no", "inheritance", ";", "Number", "of", "polyps", ",", "number", "of", "polyps", "at", "diagnosis", ";", "rec", ",", "recessive", "\n\n", "Patient", "C896", ",", "with", "only", "five", "adenomas", ",", "was", "included", "because", "of", "a", "family", "history", "of", "FAP", ".", "Patient", "C107", "underwent", "her", "first", "colonoscopy", "due", "to", "intestinal", "bleeding", "at", "age", "47", ".", "At", "diagnosis", ",", "10–20", "small", "(", "less", "than", "10", "mm", ")", "polyps", "were", "found", "in", "most", "colorectal", "parts", ".", "Tubular", "and", "tubulovillous", "adenomas", "were", "removed", "yearly", ".", "At", "age", "50", ",", "carcinoma", "(", "Dukes", "A", ")", "was", "diagnosed", "4", "cm", "from", "valvula", "Bauhini", "in", "conjunction", "with", "several", "new", "adenomas", ".", "At", "that", "time", "the", "patient", "underwent", "total", "colectomy", "with", "ileorectal", "anastomosis", "(", "IRA", ")", ".", "\n\n", "DNA", ",", "RNA", "and", "cDNA", "preparation", "\n\n", "Genomic", "DNA", "was", "isolated", "from", "samples", "of", "venous", "blood", ",", "anti", "-", "coagulated", "in", "ethylenediaminetetraacetic", "acid", "(", "EDTA", ")", ".", "DNA", "purification", "was", "performed", "using", "the", "PuregeneR", "DNA", "Isolation", "Kit", "(", "Gentra", "Systems", ",", "Minneapolis", ",", "MN", ")", "according", "to", "the", "manufacturer", "'s", "recommendations", ".", "DNA", "was", "extracted", "from", "paraffin", "-", "embedded", "tissue", "as", "described", "previously", "[", "32", "]", ".", "Histopaque", "(", "Sigma", ",", "St", "Louis", ",", "MO", ")", "or", "Lymphoprep", "(", "Axis", "-", "Shield", "PoC", "AS", ",", "Oslo", ",", "Norway", ")", "was", "used", "for", "purification", "of", "the", "lymphocytes", ",", "and", "total", "RNA", "was", "extracted", "using", "RNA", "-", "Stat", "60", "(", "Tel", "-", "Test", ",", "Friendswood", ",", "TX", ")", ".", "cDNA", "was", "synthesized", "as", "described", "previously", "[", "33", "]", ".", "\n\n" ]

[ "size", "cohort-patient", "Concepts_Ideas", "mutation", "Disorder", "body-part", "disease", "age", "Phenomena", "ethnicity", "gene", "gender" ]

cartoon - based hostile attributional bias measure is a Intervention_Educational, urban African American boys is a Participant_Condition, cartoon - based adaptation is a Intervention_Educational, standard written hostile attributional bias vignette measure is a Outcome_Mental, psychometric properties is a Outcome_Mental, acceptability is a Outcome_Mental, test - retest reliability is a Outcome_Mental

51110_task0

Sentence: Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Participant_Condition, Outcome_Mental

[ "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys .

[ "Preliminary", "examination", "of", "a", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "for", "urban", "African", "American", "boys", ".", "The", "current", "study", "illustrates", "how", "researchers", "developed", "and", "validated", "a", "cartoon", "-", "based", "adaptation", "of", "a", "written", "hostile", "attributional", "bias", "measure", "for", "a", "sample", "of", "urban", ",", "low", "-", "income", ",", "African", "American", "boys", ".", "A", "series", "of", "studies", "were", "conducted", "to", "develop", "cartoon", "illustrations", "to", "accompany", "a", "standard", "written", "hostile", "attributional", "bias", "vignette", "measure", "(", "Study", "1", ")", ",", "to", "determine", "initial", "psychometric", "properties", "(", "Study", "2", ")", "and", "acceptability", "(", "Study", "3", ")", ",", "and", "to", "conduct", "a", "test", "-", "retest", "reliability", "trial", "of", "the", "adapted", "measure", "in", "a", "separate", "sample", "(", "Study", "4", ")", ".", "These", "studies", "utilize", "a", "participatory", "action", "research", "approach", "to", "measurement", "design", "and", "adaptation", ",", "and", "suggest", "that", "collaborations", "between", "researchers", "and", "key", "school", "stakeholders", "can", "lead", "to", "measures", "that", "are", "psychometrically", "strong", ",", "developmentally", "appropriate", ",", "and", "culturally", "sensitive", ".", "In", "addition", ",", "the", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "appears", "to", "have", "promise", "as", "an", "assessment", "and", "/", "or", "outcome", "measure", "for", "aggression", "and", "bullying", "prevention", "programs", "conducted", "with", "urban", "African", "American", "boys", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition" ]

cartoon - based hostile attributional bias measure is a Intervention_Educational, urban African American boys is a Participant_Condition, cartoon - based adaptation is a Intervention_Educational, standard written hostile attributional bias vignette measure is a Outcome_Mental, psychometric properties is a Outcome_Mental, acceptability is a Outcome_Mental, test - retest reliability is a Outcome_Mental

51110_task1

Sentence: Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys . Instructions: please typing these entity words according to sentence: cartoon - based hostile attributional bias measure, urban African American boys, cartoon - based adaptation, standard written hostile attributional bias vignette measure, psychometric properties, acceptability, test - retest reliability Options: Intervention_Educational, Participant_Condition, Outcome_Mental

[ "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys .

[ "Preliminary", "examination", "of", "a", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "for", "urban", "African", "American", "boys", ".", "The", "current", "study", "illustrates", "how", "researchers", "developed", "and", "validated", "a", "cartoon", "-", "based", "adaptation", "of", "a", "written", "hostile", "attributional", "bias", "measure", "for", "a", "sample", "of", "urban", ",", "low", "-", "income", ",", "African", "American", "boys", ".", "A", "series", "of", "studies", "were", "conducted", "to", "develop", "cartoon", "illustrations", "to", "accompany", "a", "standard", "written", "hostile", "attributional", "bias", "vignette", "measure", "(", "Study", "1", ")", ",", "to", "determine", "initial", "psychometric", "properties", "(", "Study", "2", ")", "and", "acceptability", "(", "Study", "3", ")", ",", "and", "to", "conduct", "a", "test", "-", "retest", "reliability", "trial", "of", "the", "adapted", "measure", "in", "a", "separate", "sample", "(", "Study", "4", ")", ".", "These", "studies", "utilize", "a", "participatory", "action", "research", "approach", "to", "measurement", "design", "and", "adaptation", ",", "and", "suggest", "that", "collaborations", "between", "researchers", "and", "key", "school", "stakeholders", "can", "lead", "to", "measures", "that", "are", "psychometrically", "strong", ",", "developmentally", "appropriate", ",", "and", "culturally", "sensitive", ".", "In", "addition", ",", "the", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "appears", "to", "have", "promise", "as", "an", "assessment", "and", "/", "or", "outcome", "measure", "for", "aggression", "and", "bullying", "prevention", "programs", "conducted", "with", "urban", "African", "American", "boys", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition" ]

cartoon - based hostile attributional bias measure, urban African American boys, cartoon - based adaptation, standard written hostile attributional bias vignette measure, psychometric properties, acceptability, test - retest reliability

51110_task2

Sentence: Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Preliminary examination of a cartoon-based hostile attributional bias measure for urban African American boys . The current study illustrates how researchers developed and validated a cartoon-based adaptation of a written hostile attributional bias measure for a sample of urban , low-income , African American boys . A series of studies were conducted to develop cartoon illustrations to accompany a standard written hostile attributional bias vignette measure ( Study 1 ) , to determine initial psychometric properties ( Study 2 ) and acceptability ( Study 3 ) , and to conduct a test-retest reliability trial of the adapted measure in a separate sample ( Study 4 ) . These studies utilize a participatory action research approach to measurement design and adaptation , and suggest that collaborations between researchers and key school stakeholders can lead to measures that are psychometrically strong , developmentally appropriate , and culturally sensitive . In addition , the cartoon-based hostile attributional bias measure appears to have promise as an assessment and/or outcome measure for aggression and bullying prevention programs conducted with urban African American boys .

[ "Preliminary", "examination", "of", "a", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "for", "urban", "African", "American", "boys", ".", "The", "current", "study", "illustrates", "how", "researchers", "developed", "and", "validated", "a", "cartoon", "-", "based", "adaptation", "of", "a", "written", "hostile", "attributional", "bias", "measure", "for", "a", "sample", "of", "urban", ",", "low", "-", "income", ",", "African", "American", "boys", ".", "A", "series", "of", "studies", "were", "conducted", "to", "develop", "cartoon", "illustrations", "to", "accompany", "a", "standard", "written", "hostile", "attributional", "bias", "vignette", "measure", "(", "Study", "1", ")", ",", "to", "determine", "initial", "psychometric", "properties", "(", "Study", "2", ")", "and", "acceptability", "(", "Study", "3", ")", ",", "and", "to", "conduct", "a", "test", "-", "retest", "reliability", "trial", "of", "the", "adapted", "measure", "in", "a", "separate", "sample", "(", "Study", "4", ")", ".", "These", "studies", "utilize", "a", "participatory", "action", "research", "approach", "to", "measurement", "design", "and", "adaptation", ",", "and", "suggest", "that", "collaborations", "between", "researchers", "and", "key", "school", "stakeholders", "can", "lead", "to", "measures", "that", "are", "psychometrically", "strong", ",", "developmentally", "appropriate", ",", "and", "culturally", "sensitive", ".", "In", "addition", ",", "the", "cartoon", "-", "based", "hostile", "attributional", "bias", "measure", "appears", "to", "have", "promise", "as", "an", "assessment", "and", "/", "or", "outcome", "measure", "for", "aggression", "and", "bullying", "prevention", "programs", "conducted", "with", "urban", "African", "American", "boys", "." ]

[ "Outcome_Mental", "Intervention_Educational", "Participant_Condition" ]

octreotide is a Intervention_Pharmacological, prochlorperazine is a Intervention_Pharmacological, migraine headache is a Outcome_Physical, octreotide ( OC ) is a Intervention_Pharmacological, prochlorperazine . is a Intervention_Pharmacological, median visual analog scale scores is a Outcome_Physical, pain is a Outcome_Pain, Restlessness consistent with akathisia is a Outcome_Physical, rescue medication is a Outcome_Physical, headache recurrence is a Outcome_Physical, clinical success rate is a Outcome_Other, restlessness is a Outcome_Physical, sedation is a Outcome_Pain

39965_task0

Sentence: Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Pain, Outcome_Other, Intervention_Pharmacological, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Pain", "O" ]

Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation .

[ "Randomized", "evaluation", "of", "octreotide", "vs", "prochlorperazine", "for", "ED", "treatment", "of", "migraine", "headache", ".", "UNLABELLED", "Patients", "with", "headaches", "account", "for", "approximately", "2", "%", "of", "all", "ED", "visits", ",", "with", "migraines", "being", "the", "most", "common", "defined", "primary", "headache", "syndrome", ".", "Our", "goals", "were", "to", "evaluate", "the", "efficacy", "of", "intravenous", "octreotide", "(", "OC", ")", "for", "the", "treatment", "of", "migraines", ",", "when", "compared", "to", "standard", "therapy", "with", "prochlorperazine", ".", "METHODS", "The", "study", "was", "conducted", "as", "a", "double", "-", "blinded", ",", "randomized", "controlled", "trial", ".", "Each", "subject", "received", "either", "100", "microg", "of", "octreotide", "or", "10", "mg", "of", "prochlorperazine", "intravenously", "for", "a", "2-minute", "period", ".", "RESULTS", "Comparison", "of", "the", "change", "in", "median", "visual", "analog", "scale", "scores", "for", "60", "minutes", "demonstrated", "that", "octreotide", "was", "less", "effective", "at", "reducing", "pain", "(", "P", "=", ".03", ")", "and", "producing", "clinical", "success", "(", "P", "<", ".01", ")", ".", "Restlessness", "consistent", "with", "akathisia", "was", "noted", "by", "35", "%", "of", "the", "PC", "group", "and", "8", "%", "of", "the", "OC", "group", "(", "P", "<", ".01", ")", ".", "At", "60", "minutes", ",", "rescue", "medication", "was", "required", "by", "48", "%", "of", "the", "patients", "in", "the", "OC", "group", ",", "whereas", "10", "%", "of", "the", "PC", "group", "required", "such", "therapy", "(", "P", "<", ".01", ")", ".", "All", "44", "patients", "were", "contacted", "for", "follow", "-", "up", "at", "48", "to", "72", "hours", "after", "enrollment", ".", "At", "that", "time", ",", "10", "%", "of", "the", "prochlorperazine", "and", "25", "%", "of", "the", "octreotide", "patients", "had", "experienced", "some", "headache", "recurrence", "(", "P", "=", ".1", ")", ".", "CONCLUSION", "Prochlorperazine", "was", "statistically", "superior", "to", "octreotide", "in", "clinical", "success", "rate", "and", "decrease", "in", "pain", "in", "migraine", "patients", "but", "caused", "more", "restlessness", "and", "sedation", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Pain" ]

octreotide is a Intervention_Pharmacological, prochlorperazine is a Intervention_Pharmacological, migraine headache is a Outcome_Physical, octreotide ( OC ) is a Intervention_Pharmacological, prochlorperazine . is a Intervention_Pharmacological, median visual analog scale scores is a Outcome_Physical, pain is a Outcome_Pain, Restlessness consistent with akathisia is a Outcome_Physical, rescue medication is a Outcome_Physical, headache recurrence is a Outcome_Physical, clinical success rate is a Outcome_Other, restlessness is a Outcome_Physical, sedation is a Outcome_Pain

39965_task1

Sentence: Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation . Instructions: please typing these entity words according to sentence: octreotide, prochlorperazine, migraine headache, octreotide ( OC ), prochlorperazine ., median visual analog scale scores, pain, Restlessness consistent with akathisia, rescue medication, headache recurrence, clinical success rate, restlessness, sedation Options: Outcome_Pain, Outcome_Other, Intervention_Pharmacological, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Pain", "O" ]

Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation .

[ "Randomized", "evaluation", "of", "octreotide", "vs", "prochlorperazine", "for", "ED", "treatment", "of", "migraine", "headache", ".", "UNLABELLED", "Patients", "with", "headaches", "account", "for", "approximately", "2", "%", "of", "all", "ED", "visits", ",", "with", "migraines", "being", "the", "most", "common", "defined", "primary", "headache", "syndrome", ".", "Our", "goals", "were", "to", "evaluate", "the", "efficacy", "of", "intravenous", "octreotide", "(", "OC", ")", "for", "the", "treatment", "of", "migraines", ",", "when", "compared", "to", "standard", "therapy", "with", "prochlorperazine", ".", "METHODS", "The", "study", "was", "conducted", "as", "a", "double", "-", "blinded", ",", "randomized", "controlled", "trial", ".", "Each", "subject", "received", "either", "100", "microg", "of", "octreotide", "or", "10", "mg", "of", "prochlorperazine", "intravenously", "for", "a", "2-minute", "period", ".", "RESULTS", "Comparison", "of", "the", "change", "in", "median", "visual", "analog", "scale", "scores", "for", "60", "minutes", "demonstrated", "that", "octreotide", "was", "less", "effective", "at", "reducing", "pain", "(", "P", "=", ".03", ")", "and", "producing", "clinical", "success", "(", "P", "<", ".01", ")", ".", "Restlessness", "consistent", "with", "akathisia", "was", "noted", "by", "35", "%", "of", "the", "PC", "group", "and", "8", "%", "of", "the", "OC", "group", "(", "P", "<", ".01", ")", ".", "At", "60", "minutes", ",", "rescue", "medication", "was", "required", "by", "48", "%", "of", "the", "patients", "in", "the", "OC", "group", ",", "whereas", "10", "%", "of", "the", "PC", "group", "required", "such", "therapy", "(", "P", "<", ".01", ")", ".", "All", "44", "patients", "were", "contacted", "for", "follow", "-", "up", "at", "48", "to", "72", "hours", "after", "enrollment", ".", "At", "that", "time", ",", "10", "%", "of", "the", "prochlorperazine", "and", "25", "%", "of", "the", "octreotide", "patients", "had", "experienced", "some", "headache", "recurrence", "(", "P", "=", ".1", ")", ".", "CONCLUSION", "Prochlorperazine", "was", "statistically", "superior", "to", "octreotide", "in", "clinical", "success", "rate", "and", "decrease", "in", "pain", "in", "migraine", "patients", "but", "caused", "more", "restlessness", "and", "sedation", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Pain" ]

octreotide, prochlorperazine, migraine headache, octreotide ( OC ), prochlorperazine ., median visual analog scale scores, pain, Restlessness consistent with akathisia, rescue medication, headache recurrence, clinical success rate, restlessness, sedation

39965_task2

Sentence: Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Pain", "O" ]

Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache . UNLABELLED Patients with headaches account for approximately 2 % of all ED visits , with migraines being the most common defined primary headache syndrome . Our goals were to evaluate the efficacy of intravenous octreotide ( OC ) for the treatment of migraines , when compared to standard therapy with prochlorperazine . METHODS The study was conducted as a double-blinded , randomized controlled trial . Each subject received either 100 microg of octreotide or 10 mg of prochlorperazine intravenously for a 2-minute period . RESULTS Comparison of the change in median visual analog scale scores for 60 minutes demonstrated that octreotide was less effective at reducing pain ( P = .03 ) and producing clinical success ( P < .01 ) . Restlessness consistent with akathisia was noted by 35 % of the PC group and 8 % of the OC group ( P < .01 ) . At 60 minutes , rescue medication was required by 48 % of the patients in the OC group , whereas 10 % of the PC group required such therapy ( P < .01 ) . All 44 patients were contacted for follow-up at 48 to 72 hours after enrollment . At that time , 10 % of the prochlorperazine and 25 % of the octreotide patients had experienced some headache recurrence ( P = .1 ) . CONCLUSION Prochlorperazine was statistically superior to octreotide in clinical success rate and decrease in pain in migraine patients but caused more restlessness and sedation .

[ "Randomized", "evaluation", "of", "octreotide", "vs", "prochlorperazine", "for", "ED", "treatment", "of", "migraine", "headache", ".", "UNLABELLED", "Patients", "with", "headaches", "account", "for", "approximately", "2", "%", "of", "all", "ED", "visits", ",", "with", "migraines", "being", "the", "most", "common", "defined", "primary", "headache", "syndrome", ".", "Our", "goals", "were", "to", "evaluate", "the", "efficacy", "of", "intravenous", "octreotide", "(", "OC", ")", "for", "the", "treatment", "of", "migraines", ",", "when", "compared", "to", "standard", "therapy", "with", "prochlorperazine", ".", "METHODS", "The", "study", "was", "conducted", "as", "a", "double", "-", "blinded", ",", "randomized", "controlled", "trial", ".", "Each", "subject", "received", "either", "100", "microg", "of", "octreotide", "or", "10", "mg", "of", "prochlorperazine", "intravenously", "for", "a", "2-minute", "period", ".", "RESULTS", "Comparison", "of", "the", "change", "in", "median", "visual", "analog", "scale", "scores", "for", "60", "minutes", "demonstrated", "that", "octreotide", "was", "less", "effective", "at", "reducing", "pain", "(", "P", "=", ".03", ")", "and", "producing", "clinical", "success", "(", "P", "<", ".01", ")", ".", "Restlessness", "consistent", "with", "akathisia", "was", "noted", "by", "35", "%", "of", "the", "PC", "group", "and", "8", "%", "of", "the", "OC", "group", "(", "P", "<", ".01", ")", ".", "At", "60", "minutes", ",", "rescue", "medication", "was", "required", "by", "48", "%", "of", "the", "patients", "in", "the", "OC", "group", ",", "whereas", "10", "%", "of", "the", "PC", "group", "required", "such", "therapy", "(", "P", "<", ".01", ")", ".", "All", "44", "patients", "were", "contacted", "for", "follow", "-", "up", "at", "48", "to", "72", "hours", "after", "enrollment", ".", "At", "that", "time", ",", "10", "%", "of", "the", "prochlorperazine", "and", "25", "%", "of", "the", "octreotide", "patients", "had", "experienced", "some", "headache", "recurrence", "(", "P", "=", ".1", ")", ".", "CONCLUSION", "Prochlorperazine", "was", "statistically", "superior", "to", "octreotide", "in", "clinical", "success", "rate", "and", "decrease", "in", "pain", "in", "migraine", "patients", "but", "caused", "more", "restlessness", "and", "sedation", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Outcome_Pain" ]

adenoma is an umlsterm, lung is an umlsterm, benign tumor is an umlsterm, epithelial cells is an umlsterm, cells is an umlsterm, findings is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm, lung is an umlsterm, antibodies is an umlsterm, apoprotein is an umlsterm, human is an umlsterm, surfactant is an umlsterm, cells is an umlsterm, macrophages is an umlsterm, tissue is an umlsterm, cells is an umlsterm, findings is an umlsterm, surfactant is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm

DerPathologe.60170150.eng.abstr_task0

Sentence: The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma .

[ "The", "alveolar", "adenoma", "of", "the", "lung", "is", "a", "rare", "benign", "tumor", "in", "which", "the", "normal", "parenchymal", "architectur", "is", "imitated", "by", "a", "proliferation", "of", "both", "the", "alveolar", "epithelial", "cells", "and", "the", "mesenchymal", "septal", "cells", ".", "The", "first", "description", ",", "based", "on", "six", "cases", ",", "was", "published", "in", "1986", "by", "Yousem", "and", "Hochholzer", ".", "From", "their", "ultrastructural", "findings", "they", "presumed", "a", "type", "II", "pneumocytes", "differentiation", "of", "the", "epithelial", "cells", ".", "We", "investigated", "an", "alveolar", "adenoma", "of", "the", "lung", "immunhistochemical", "by", "means", "of", "antibodies", "against", "apoprotein", "B", "and", "C", "of", "human", "surfactant", ".", "Both", "the", "lining", "cells", "and", "the", "macrophages", "in", "the", "alveolar", "-", "like", "spaces", "were", "stained", ".", "The", "septal", "connection", "tissue", "cells", "did", "not", "react", ".", "These", "findings", "confirm", "the", "expression", "of", "surfactant", "constituants", "and", ",", "hence", ",", "the", "differentiation", "into", "type", "II", "pneumocytes", "of", "the", "epithelial", "cells", "of", "the", "alveolar", "adenoma", "." ]

[ "umlsterm" ]

adenoma is an umlsterm, lung is an umlsterm, benign tumor is an umlsterm, epithelial cells is an umlsterm, cells is an umlsterm, findings is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm, lung is an umlsterm, antibodies is an umlsterm, apoprotein is an umlsterm, human is an umlsterm, surfactant is an umlsterm, cells is an umlsterm, macrophages is an umlsterm, tissue is an umlsterm, cells is an umlsterm, findings is an umlsterm, surfactant is an umlsterm, epithelial cells is an umlsterm, adenoma is an umlsterm

DerPathologe.60170150.eng.abstr_task1

Sentence: The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma . Instructions: please typing these entity words according to sentence: adenoma, lung, benign tumor, epithelial cells, cells, findings, epithelial cells, adenoma, lung, antibodies, apoprotein, human, surfactant, cells, macrophages, tissue, cells, findings, surfactant, epithelial cells, adenoma Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma .

[ "The", "alveolar", "adenoma", "of", "the", "lung", "is", "a", "rare", "benign", "tumor", "in", "which", "the", "normal", "parenchymal", "architectur", "is", "imitated", "by", "a", "proliferation", "of", "both", "the", "alveolar", "epithelial", "cells", "and", "the", "mesenchymal", "septal", "cells", ".", "The", "first", "description", ",", "based", "on", "six", "cases", ",", "was", "published", "in", "1986", "by", "Yousem", "and", "Hochholzer", ".", "From", "their", "ultrastructural", "findings", "they", "presumed", "a", "type", "II", "pneumocytes", "differentiation", "of", "the", "epithelial", "cells", ".", "We", "investigated", "an", "alveolar", "adenoma", "of", "the", "lung", "immunhistochemical", "by", "means", "of", "antibodies", "against", "apoprotein", "B", "and", "C", "of", "human", "surfactant", ".", "Both", "the", "lining", "cells", "and", "the", "macrophages", "in", "the", "alveolar", "-", "like", "spaces", "were", "stained", ".", "The", "septal", "connection", "tissue", "cells", "did", "not", "react", ".", "These", "findings", "confirm", "the", "expression", "of", "surfactant", "constituants", "and", ",", "hence", ",", "the", "differentiation", "into", "type", "II", "pneumocytes", "of", "the", "epithelial", "cells", "of", "the", "alveolar", "adenoma", "." ]

[ "umlsterm" ]

adenoma, lung, benign tumor, epithelial cells, cells, findings, epithelial cells, adenoma, lung, antibodies, apoprotein, human, surfactant, cells, macrophages, tissue, cells, findings, surfactant, epithelial cells, adenoma

DerPathologe.60170150.eng.abstr_task2

Sentence: The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

The alveolar adenoma of the lung is a rare benign tumor in which the normal parenchymal architectur is imitated by a proliferation of both the alveolar epithelial cells and the mesenchymal septal cells . The first description , based on six cases , was published in 1986 by Yousem and Hochholzer . From their ultrastructural findings they presumed a type II pneumocytes differentiation of the epithelial cells . We investigated an alveolar adenoma of the lung immunhistochemical by means of antibodies against apoprotein B and C of human surfactant . Both the lining cells and the macrophages in the alveolar-like spaces were stained . The septal connection tissue cells did not react . These findings confirm the expression of surfactant constituants and , hence , the differentiation into type II pneumocytes of the epithelial cells of the alveolar adenoma .

[ "The", "alveolar", "adenoma", "of", "the", "lung", "is", "a", "rare", "benign", "tumor", "in", "which", "the", "normal", "parenchymal", "architectur", "is", "imitated", "by", "a", "proliferation", "of", "both", "the", "alveolar", "epithelial", "cells", "and", "the", "mesenchymal", "septal", "cells", ".", "The", "first", "description", ",", "based", "on", "six", "cases", ",", "was", "published", "in", "1986", "by", "Yousem", "and", "Hochholzer", ".", "From", "their", "ultrastructural", "findings", "they", "presumed", "a", "type", "II", "pneumocytes", "differentiation", "of", "the", "epithelial", "cells", ".", "We", "investigated", "an", "alveolar", "adenoma", "of", "the", "lung", "immunhistochemical", "by", "means", "of", "antibodies", "against", "apoprotein", "B", "and", "C", "of", "human", "surfactant", ".", "Both", "the", "lining", "cells", "and", "the", "macrophages", "in", "the", "alveolar", "-", "like", "spaces", "were", "stained", ".", "The", "septal", "connection", "tissue", "cells", "did", "not", "react", ".", "These", "findings", "confirm", "the", "expression", "of", "surfactant", "constituants", "and", ",", "hence", ",", "the", "differentiation", "into", "type", "II", "pneumocytes", "of", "the", "epithelial", "cells", "of", "the", "alveolar", "adenoma", "." ]

[ "umlsterm" ]

laminin is a Individual_protein, myosin heavy chain is a Individual_protein, MHC is a Individual_protein, alpha - skeletal actin is a Individual_protein

702_task0

Sentence: The effects of two adhesion substrates (serum and laminin) and time in culture on the expression of genes encoding myosin heavy chain (MHC) isoforms and alpha-skeletal actin were analysed in myocytes isolated from adult rat heart and maintained in serum-free culture. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effects of two adhesion substrates (serum and laminin) and time in culture on the expression of genes encoding myosin heavy chain (MHC) isoforms and alpha-skeletal actin were analysed in myocytes isolated from adult rat heart and maintained in serum-free culture.

[ "The", "effects", "of", "two", "adhesion", "substrates", "(", "serum", "and", "laminin", ")", "and", "time", "in", "culture", "on", "the", "expression", "of", "genes", "encoding", "myosin", "heavy", "chain", "(", "MHC", ")", "isoforms", "and", "alpha", "-", "skeletal", "actin", "were", "analysed", "in", "myocytes", "isolated", "from", "adult", "rat", "heart", "and", "maintained", "in", "serum", "-", "free", "culture", "." ]

[ "Individual_protein" ]